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Abstract 
In this research, a series of iridium(III) tetrazolato complexes were synthesised and 
their photophysical and biological properties investigated. Both the cyclometalated 
and the ancillary ligands were systematically modified by substitution of functional 
groups or by increasing the extension of the p conjugation. This approach allowed a 
more systematic rationalisation of the structure-activity relationship, highlighting how 
variations in the chemical structure and charge might influence the biological 
behaviour of these complexes, especially in relation to cellular localisation and 
cytotoxicity. 
A family of cyano and (iso)quinolyl-functionalised iridium(III) tetrazolato 
complexes was firstly investigated. Upon methylation of the tetrazolate ligand, 
positively charged complexes were synthesised from their neutral analogues, allowing 
specific comparison between isostructural complexes with different charge. The 
photophysical analyses were performed in dichloromethane, aqueous and lipophilic 
solvents, revealing a predominantly solvatochromic emission originating from mixed 
metal-to-ligand (MLCT) and ligand-to-ligand (LLCT) charge transfer excited state of 
triplet multiplicity. The behaviour of these complexes was then examined in live cells, 
showing localisation in the endoplasmic reticulum and lipid droplets for the neutral 
species, whereas the majority of the cationic complexes accumulated in mitochondria. 
Interestingly, the cytotoxicity of the charged species was extremely high in comparison 
to their neutral analogues, probably due to a combination of uptake and intracellular 
localisation. The mitochondrial accumulation of one of the methylated complex was 
also evaluated in fresh and fixed muscle tissue samples, extending the application of 
this probe to a field which relies mostly on immunochemistry. 
The amino-functionalised iridium(III) tetrazolato series was then explored. The 
substitution of the nitrile with an amino group on the pyridyl tetrazolate ligand was 
conducted to investigate the protonation/deprotonation properties of these complexes, 
 iii 
aiming to the application in cellular pH-sensing. Lower emission intensity was 
recorded in all the solvents with respect to the previous series, due to the presence of 
a thermally available and dark metal-centred (3MC) excited state. Moreover, solubility 
issues were also encountered. Nevertheless, the pH-sensing activity was recorded in 
organic solvent for one of the complexes, but the same trend was not reproducible in 
aqueous medium. 
The amino complex [Ir(ppy)2(TzPyNH2)] was then combined with different 
fatty acids to form the fatty acid-functionalised iridium(III) family. The degree of 
unsaturation and the length of the fatty acid chains did not affect the photophysical 
properties of these complexes, which exhibit similar emission properties than their 
amino precursor. Moreover the low cytotoxicity and the accumulation of these probes 
in the area surrounding the nucleus was consistent along the whole series, but further 
investigations need to be performed in order to identify the specific stained organelle. 
On the other hand, different mechanisms of uptake were recorded, such as passive 
diffusion and mediated transport. 
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ν Wavenumber 
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λabs Absorption wavelength 
λem Emission wavelength 
λex Excitation wavelength 
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e Molar absorptivity 
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BSA Bovine serum albumin 
bzq Benzo[h]quinoline 
ca. Circa/approximately 
CT Computed tomography 
d Doublet (NMR) 
DCM Dichloromethane 
dec Decomposition 
DMEM Dulbecco’s modified eagle medium 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
EPESS Phosphorescence emission in the solid state 
ER Endoplasmic reticulum 
F2ppy 2-(2,4-difluorophenyl)pyridine 
viii 
FCCP Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
GS Ground state 
HOMO Highest occupied molecular orbital 
IC Internal conversion 
IC50 Half maximal inhibitory concentration 
ICP-MS Inductively coupled plasma mass spectrometry 
IL Intra-ligand 
ILCT Intra-ligand charge transfer 
IR Infrared 
ISC Intersystem crossing 
J Coupling constant (NMR) 
kISC Intersystem crossing rate constant 
knr Non-radiative decay rate constant 
kobs Observed rate constant 
kr Radiative decay rate constant 
LC Ligand-centred 
LEECs Light-emitting electrochemical cells 
LLCT Ligand-to-ligand charge transfer 
LUMO Lowest unoccupied molecular orbital 
Lys. fluid Lysosomal pH= 4.5 fluid solution 
m Multiplet (NMR signal splitting), medium (IR) 
M.P. Melting point 
MC Metal-centred 
MLCT Metal-to-ligand charge transfer 
MLLCT Metal-ligand-to-ligand charge transfer 
MRI Magnetic resonance imaging 
MTS 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium bromide 
MTT 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
NAD(P)H Nicotinamide adenine dinucleotide phosphate (reduced form) 
NIR Near-infrared 
NMR Nuclear magnetic resonance 
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OLEDs Organic light-emitting devices 
PBS Phosphate buffered saline 
PDT Photodynamic therapy 
PEG Polyethylene glycol 
PEI Polyethylenimine 
PET Positron emission tomography 
PeT Photoinduced electron-transfer 
PFA Paraformaldehyde 
phen 1,10-phenanthroline 
ppy 2-phenylpyridine 
pq 2-phenylquinoline 
r.t. Room temperature 
ROS Reactive oxygen species 
RPMI Roswell park memorial institute medium 
s Singlet (NMR signal splitting), sharp (IR) 
S Spin multiplicity 
SPECT Single photon emission computed tomography 
t Triplet (NMR signal splitting) 
TD-DFT Time-dependant density functional theory 
UV Ultraviolet 
Vis Visible 
VR Vibrational relaxation 
w Weak (IR) 
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Chapter 1  
Introduction 
Part of the content of this chapter has been published in: 
Coordination Chemistry Reviews (2018) with the title “Cyclometalated 
Iridium(III) Complexes For Life Science”.1  
 
1.1 Biomedical Imaging 
Biomedical imaging is the technique of producing visual representation of cells, 
tissues, organs or body parts for the use in clinical diagnosis, treatment and desease 
monitoring. The development of medical imaging techniques can be considered a 
milestone in medicine since Wilhelm Rӧntgen discovered X-rays in 1895 and was able 
to visualise the bones of a hand (Figure 1.1 - A).  
In the early 1970s, computed tomography (CT) enabled to collect for the first 
time cross-sessional images of human body (Figure 1.1 - B). Although this technique 
can improve diagnoses, limit unneeded medical procedures and enhance treatments, 
major concerns are related to the exposure of patients to ionisation radiations.2,3 
In the 1980s, magnetic resonance (MRI) revolutionised the medical diagnosis 
and biomedical research, allowing highly resolved and accurate discrimination of 
internal organs and tissues (Figure 1.1 - C). Unlike X-ray and CT, MRI is a non-
invasive technique which detects the energy released by protons in the body (most 
commonly found in water) after they have been excited by a radio frequency pulse in 
a strong magnetic field. Contrast in tissues is achieved by the different relaxation time 
of these protons, depending on their location. The improvement of the MRI image 
2 
output can be enhanced by the use of contrast agents, which are paramagnetic 
substances such as Gd3+ complexes.4–6  
Highly sensitive methods such as positron emission tomography (PET) and 
single photon emission computed tomography (SPECT) have been emerging as 
complementary to CT and MRI techniques. Both PET and SPECT use small amount 
of radioactive markers (usually 18F and 99mTc) to monitor biological activity, for 
example, the spatial distribution of blood flow and receptor concentrations, or even to 
detect tumours (Figure 1.1 – D, E). PET provides higher spatial resolution imaging 
than SPECT, due to the detection of two positrons in opposite direction emitted by the 
radioactive tracer. On the other hand, SPECT measures directly the emitted gamma 
radiation, making this technique significantly less expensive and more widely 
available than PET.7–10  
More recently, optical imaging has become a rapidly emerging area in the 
medical imaging field, with widespread applications ranging from clinical diagnosis 
to molecular biology. Noteworthy, optical imaging cannot be employed as whole body 
technique on humans as the previously discussed methods, due to limitations on the 
level of light penetration achievable and the overall contrast produced. Nevertheless, 
whole body in vivo imaging on small animals is commonly used, along with 
fluorescent image-guided surgery.11 Optical imaging is non-invasive, utilises non-
ionising radiation and can produce high resolution images at sub-cellular level.12–14 
This technique uses ultraviolet (UV) to near infrared (NIR) wavelength of light to 
excite fluorescent and phosphorescent dyes and, based on their specific emission, 
visualised molecule and biological moieties (Figure 1.1 - F). On the other hand, label-
free methods have also been developed, which allow the detection of autofluorescence 
arising from endogenous species.15–19 In this chapter, the use of phosphorescent 
probes, their advantages over fluorescent dyes for specific applications and their main 
properties will be discussed. 
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Figure 1.1 Examples of biomedical imaging techniques. A) X-ray; B) CT; C) MRI; 
D) PET; E) SPECT; F) Optical imaging. Adapted from ref20–25. 
  
A B
C D
E F
4 
1.1.1 Cellular and Tissue Optical Imaging 
Optical imaging techniques have contributed to important discoveries in molecular and 
cell biology based on studies of single cells or in vitro tissue sections.26,27 However, 
the use of optical methods in deep tissues has been limited by low penetration depth 
and strong light-scattering in the biological system, the latter being responsible for 
blurred and distorted optical signals.12,13,28–31 The development of advanced confocal 
microscopes, along with a new generation of probes (in particular for the application 
in the NIR region of the spectrum) has allowed a remarkably deeper tissue penetration, 
lower autofluorescent interference and minimal damage to the samples.32–37 
Both cells and tissues can be analysed in vivo or after a fixation process. This 
procedure can be achieved by chemical (immersion and perfusion methods) or 
physical (heat, microwave, and cryopreservation) means and aims to preserve cell and 
tissue components in an ideal “life-like state”, preventing or arresting the natural 
degenerative processes.38,39 Depending on the fixation process, different artefacts can 
be produced, due to the permeabilisation of the cellular membrane, denaturation and 
precipitation in situ of proteins, as well as, covalent cross-linking between molecules. 
On the other hand, fixed samples are necessary in the case of staining techniques as 
immunochemistry,40,41 which requires the permeabilisation of cells, or in the case of 
large number of tissue samples, which cannot be analysed in short amount of time. 
In vivo analyses, under certain situations, appear to be superior to those offered 
by the study of fixed samples. In fact, live optical imaging avoids the use of substances 
that strongly interfere with the cell or tissue structure and provides the opportunity to 
observe and track several biological functions and reactions taking place in real-
time.1,13,31,42 For this reason, luminescent probes for application in live optical imaging 
possess different properties (refer to section 1.4 of this chapter) in comparison to the 
dyes used in fixed cells or tissues, for example low cytotoxicity. 
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1.2 Probes for Optical Imaging 
1.2.1 Organic Fluorophores 
The area of organic fluorophores for cellular imaging is certainly well advanced and 
in continuous evolution, and many probes that are now of fundamental importance for 
optical imaging have been developed for various applications within a cellular 
environment.43–48 The most common organic probes can be grouped in four main 
representative platforms. Rhodamine (1) and fluorescein (2) derivatives were the first 
dyes to be reported in the end of the nineteenth century, followed by BODIPY (3) and 
cyanine dyes (4) (refer to Figure 1.2).45,49–52 
While these markers are indeed well established and essential in the field, for specific 
imaging conditions they might be associated with drawbacks that are intimately linked 
to the organic nature of these compounds. 
Typically, luminescent organic molecules have rather small Stokes shifts, often 
resulting in a significant overlap between the absorption and emission spectral 
profiles.37,50 Therefore, as the probe accumulates within a specific cellular 
compartment and its local concentration effectively increases, its brightness (defined 
as the product of molar absorptivity and photoluminescent quantum yield) can be 
reduced due to concentration quenching phenomena. 
Noteworthy, cells are inherently fluorescent due to the presence of photoactive 
endogenous compounds such as flavins, nicotinamides, and indole side groups of 
tryptophan amino acids, for example.53–58 If the excitation and emission profiles of the 
marker in use are in the same region as those of autofluorescent endogenous species, 
it might be difficult to discriminate between the two signals. 
Lastly, but potentially one of the most limiting drawbacks, is represented by 
the tendency of some organic molecules to undergo photobleaching.59–61 This process 
occurs once the compound is excited to higher energy states, from which unwanted 
reactivity can occur destroying the emissive properties of the marker. It should be 
noted that some molecular probes can undergo extensive photobleaching within a very 
short amount of time (less than one minute), limiting their usefulness for longer-time 
experiments in live cells. 
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Figure 1.2 Examples of organic fluorophores used in optical imaging; 1) Rhodamine; 
2) Fluorescein; 3) BODIPY core; 4) Cyanine. 
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1.2.2 Transition Metal Complexes 
Photoluminescent transition metal complexes of low spin d6 electronic configuration 
such a ruthenium(II), rhenium(I), and iridium(III), or d8 electronic configuration such 
as gold(I) and platinum(II),62–65 have been investigated to overcome some of the 
drawbacks associated with organic probes, as described in section 1.2.1 of this chapter. 
All these complexes display favourable chemical characteristics and advantageous 
photophysical properties (refer to section 1.3 and section 1.4) that make them ideal 
candidates for the development of probes complementary to organic fluorophores for 
applications in cellular imaging.66 Some examples of transition metal probes of Ru(II) 
(5),67 Ir(III) (6),68 Re(I) (7),69 Au(I) (8)70 and Pt(II) (9)71 developed as imaging agents 
have been depicted in Figure 1.3 
 
 
Figure 1.3 Examples of transition metal probes for biological imaging. Their 
photophysical properties and specific applications have been reported. 
8 
1.3 Photophysical Properties of Transition d6 Metal 
Complexes 
1.3.1 Fundamental Concepts 
Photoluminescence is the emission of light from molecules, after the absorption of a 
photon. The absorption of light by a molecule dissolved in a diluted solution can be 
described by the Lambert-Beer law (Equation 1.1): 
! = 	 !$	 × 10()*     (1.1) 
where I and I0 are the intensity of the transmitted and incident radiation at a given 
wavelength, respectively, ε is the molar absorptivity coefficient, b is the path length 
and c is the concentration. The molar absorptivity coefficient describes the ability of a 
compound to absorb a specific wavelength of light. 
The simplified Jablonski diagram depicted in Figure 1.4 illustrates the 
processes taking place when a molecule interacts with light (hn).  
The absorption of a photon allows the promotion of the molecule from its ground state 
(S0) to an electronically excited states (e.g.: S1, S2). For each excited state, many 
vibrational levels can be populated and vibrational relaxation (VR) can occurred 
between them. This event consists in the redistribution of the vibrational energy gained 
during the electronic transition, which allows the molecule to move to the lowest 
vibrational level of the excited state.72 Transitions between vibrational levels of 
different excited states with the same multiplicity can be also present. This process is 
known as internal conversion (IC) and, along with VR, is a rapid radiationless event 
occurring in the order of 10-13 ˗ 10-14 seconds.73 In the presence of a metal centre, from 
the excited state S1, the molecule can undertake intersystem crossing (ISC), which is 
the transition from a singlet excited state to a more stable triplet state (T1). This process 
is spin forbidden, but the spin orbit-coupling of metal complexes allows the relaxation 
of the spin selective rule (section 1.3.2) and the transition can take place.74,75 
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Decay processes from the lowest excited state (e.g.: S1 or T1) can be divided 
into two types. The non-radiative decay is directed by the overlap of the lowest 
vibrational level of the excited state and the levels of the ground state (S0). The energy 
gap law (Equation 1.2) describes the relationship between the energy of this 
overlapping and the knr: +,- = ./01∆3     (1.2) 
where knr is the non-radiative decay constant, A is the pre-exponential coefficient, α is 
a proportionality constant and ΔE is the energy gap between the two states. Equation 
1.2 states that the greater is the energy gap between the excited and the ground state, 
the slower the non-radiative decay rate.76 
The second type of process is named radiative decay and consists in the 
transition to the ground state by spontaneous emission of a photon. In the case of 
radiative decay between states of the same multiplicity, the phenomenom is described 
as fluorescence. On the other hand, a radiative transition involving a change in spin is 
known as phosphorescence, and is typical of metal complexes (Figure 1.4). 
 
Figure 1.4 Simplified Jablonski diagram illustrating fluorescence and 
phosphorescence (solid red arrows). 
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The rate of the radiative decay process can be expressed by the radiative decay 
constants kr, as previously shown for the non-radiative decay process (Equation 1.2). 
The overall decay rate of a molecule will be then described as the sum of the decay 
rates, and the excited state lifetime (τ) can be calculated as the inverse of this sum 
(Equation 1.3): 4 = 	 5678	697     (1.3) 
Therefore, the lifetime can be defined by the time the molecule spends in the excited 
state prior to return to the ground state. 
The emission quantum yield (Φ) is the ratio between the number of photons 
the molecule emits and the number of photons absorbed. It is therefore a proportion of 
the rate of radiative decay to the overall decay from the lowest excited state (Equation 
1.4): Φ	 = 	 67678	697                                                (1.4) 
The radiative (kr) and non-radiative (knr) decay constants can then be described by 
Equation 1.5 and Equation 1.6, respectively: +- = 	;<                                                         (1.5) +,- = 	 50	;<                                                    (1.6) 
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1.3.2 Selection Rules 
The probability of an electron transition to occur is directed by selection rules, which 
are associated with electronic wavefunction symmetry, overlap and multiplicity of the 
ground and excited states. Based on these rules, a transition is considered allowed or 
forbidden. 
Laporte selection rule 
The Laporte selection rule is applied to centrosymmetric species and states that 
transition between states of the same parity (gerade, g or ungerade, u) are forbidden. 
However this selection rule can be relaxed by a “vibronic coupling” process, which 
removes the centre of inversion of the molecule by asymmetric vibrations of the latter. 
As consequence, forbidden transitions can be observed, for example d-d transitions in 
octahedral metal complexes. 
Spin conservation rule 
The spin conservation rule states that transitions including a change in spin multiplicity 
(S) are forbidden. Therefore a singlet (S = 0) to singlet transition is allowed (ΔS = 0), 
whereas a singlet cannot undergo transition to a triplet (S = 1) state. Once again, the 
rule can be relaxed if the molecule contains a heavy atom. Metal complexes possess a 
strong spin-orbit coupling, which favours the mixing of states with different 
multiplicity and increases the probability of transitions that would be otherwise 
forbidden. 
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1.3.3 Electronic Structure and Transitions 
The photophysical properties of a molecule can be determined by examining its 
electronic structure. A simplified molecular orbital diagram for a low spin d6 
octahedral complex is depicted in Figure 1.5, showing some of the possible electronic 
transitions. 
 
Figure 1.5 Simplified molecular orbital diagram for a low spin d6 metal complex 
coordinated to 6 equivalent p-accepting ligands. This case represents a situation in 
which the metal centre is a second or third row transition metal and the surrounding 
ligands have low lying p* orbitals. The formation of t2g (HOMO) and t2g* (LUMO) has 
been highlighted in red. MLCT and MC transitions are noted in blue. aOnly the T2g 
combination is considered for simplicity. 
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The molecular orbital diagram depicted in Figure 1.5 is representative of complexes 
containing second or third row transition metal surrounded by p-accepting ligands, 
which cause a strong crystal field. For simplicity, in the construction of the diagram 
all of the ligands are assumed to be equivalent. 
If the complex can be approximated to an octahedral symmetry, the metal centre can 
contribute to the formation of bonds with the 5d, 6s and 6p orbitals. These orbitals are 
classified according to their symmetry in the octahedral point group. The 5d orbitals 
are represented by symmetry labels T2g and Eg, the 6s orbitals is represented as A1g, 
whereas the 6p is represented as T1u, as reported in Figure 1.5. For further simplify 
the diagram, only the p* ligand orbitals of T2g symmetry are showed to form molecular 
orbitals with the metal. The stability of low spin d6 metal complexes is highlighted in 
Figure 1.5 by the presence of totally filled bonding orbitals (a1g, eg, t1u and t2g) and 
empty anti-bonding orbitals (a1g*, eg*, t1u* and t2g*). Due to the strong crystal field of 
the ligands, which increase the metal-ligand interaction, the eg* is positioned at higher 
energy than t2g*. The higher energy of eg* is required for a metal complex to avoid the 
non-radiative decay pathways from a dark metal-centre state and thus guarantee a good 
emission intensity. The highest occupied molecular orbital (HOMO) and the lowest 
unoccupied molecular orbital (LUMO) corresponds to t2g and t2g*, respectively, and 
the relative position of t2g is determined by the presence and specific energies of the 
p* orbitals of the ligands. 
The absorption of a photon can induce different types of transitions for a metal 
complex, depending on the arrangement of electrons in the involved molecular 
orbitals. Some of the more common transitions for an octahedral metal complex have 
been highlighted in the simplified Jablonski diagram in Figure 1.6. 
The transition of an electron from the predominantly metal-based t2g (HOMO) to the 
predominantly ligand-based t2g* (LUMO) is known as metal-to-ligand charge transfer 
(MLCT). As mentioned above, in order to maximise the emission intensity of a metal 
complex, the MLCT and the dark MC state must possess sufficiently different 
energies, to avoid the thermal population of the latter. 
The promotion of an electron from the t2g orbitals to the empty antibonding eg* orbitals 
is defined as metal-centred (MC) transition. Due to the large ligand field splitting in 
octahedral metal complexes, the MC state usually lies at high energies and does not 
affect their emission properties. 
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Another possible transition occurs on the ligands themselves, and is known as 
ligand-centred (LC), intra-ligand (IL) or p-p* transition. In this case, an electron is 
transferred from the occupied p orbitals to the empty p* orbitals on the same ligand. 
Finally, if the coordinated ligands are not all equivalent, a transition of an electron 
from the p orbitals of a ligand to the empty p* orbitals of a different ligand can occur. 
This transition is called ligand-to-ligand charge transfer (LLCT), and it is not illustrate 
in Figure 1.6. 
In an illustrated representation, as showed in Figure 1.6, the absorption of a 
photon can excite the metal complex to the 1MLCT, 1LC or 1MC, depending of its 
energy.72,73 The complex can undergo vibrational relaxation (VR) and internal 
conversion (IC) to the lowest excited state 1MLCT, in concordance with Kasha’s 
rule.73 Due to the heavy atom effect, intersystem crossing (ISC) can occur between 
states of different multiplicity, allowing the transfer of the complex from 1MLCT to 
3MLCT. The complex then decay to the ground state 1GS through radiative (kr) or non-
radiative decays (knr).  
 
Figure 1.6 Simplified Jablonski diagram for an octahedral d6 metal complex with 
lowest MLCT excited state. The radiative (kr) and non-radiative (knr) rate constants 
have been reported. VR and the LLCT excited state are omitted for simplicity.  
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1.4 Properties and Requirements for Optical Imaging 
Metal Probes 
1.4.1 Stokes Shift 
The transition metal complexes listed in section 1.2.2 are triplet state emitters, which 
makes them phosphorescent, given that their ground state is of singlet spin 
multiplicity.77,78 The energy stabilisation on passing from a singlet to a triplet excited 
state, promoted by the strong spin-orbit coupling of the metal centre, ensures that the 
Stokes shift is much larger compared to fluorescent molecules. This larger shift results 
in a lack of overlap between the absorption and emission profiles, therefore limiting 
the extent of concentration quenching.79,80 
 
1.4.2 Excited State Lifetime 
As the radiative decay of transition metal complexes is forbidden by the spin selection 
rule, given the fact that there is a change in spin multiplicity on decaying from a triplet 
excited state to a singlet ground state, the characteristic excited state lifetime of these 
species is typically longer compared to organic fluorophores.81,82 Transition metal 
complexes usually decay within a time range between hundreds of nanoseconds up to 
microseconds, whereas spin-allowed fluorescence from organic species typically 
occurs within few nanoseconds. A long excited state lifetime can be exploited to 
significantly reduce unwanted background autofluorescence using time-gated 
detection associated with microscopy techniques (Figure 1.7).83,84 In fact, a time delay 
of few hundreds of nanoseconds would ensure that the luminescence signal coming 
from the cells is exclusively belonging to the metal probe, because autofluorescence 
processes are already fully completed. This aspect is especially useful when the 
excitation and emission profiles of the probe overlap with those of endogenous 
fluorescent species. 
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Figure 1.7 Diagram illustrating the lifetime of endogenous species (blue) in 
comparison to the lifetime of phosphorescent metal probes (red) during time-gated 
detection associated with macroscopy techniques. Adapted from ref85. 
 
1.4.3 Kinetic Inertness and Photostability 
Depending on the specific chemical nature of the coordinated ligands, metal 
complexes of ruthenium(II), rhenium(I), iridium(III), gold(I) and platinum(II) can be 
kinetically inert, which favours lack of reactivity through ligand exchange that can 
potentially lead to cytotoxicity. These design factors can also indeed aid in reducing 
photobleaching, thus making metal complexes viable molecular probes for longer 
timescale imaging with live cells without significant loss of 
photoluminescence.65,82,85,86 
 
1.4.4 Lipophilicity and Solubility 
Lipophilicity is a physicochemical property of principal importance in drug discovery 
and development. In fact, the affinity for a lipophilic environment facilitates the 
transport of chemicals through membranes in a biological system and the formation of 
bonds between the studied probe or drug and the receptor binding site.87 On the other 
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hand, high values of lipophilicity can affect negatively the solubility of the probe in 
aqueous environment, specifically the cellular medium employed in the analysis. 
Hence a good balance between solubility and lipophilicity must be carefully 
considered during the molecular design of a probe.82 
 
1.4.5 Tissue Penetration 
Near-infrared (NIR) light (ca. 700 – 2500 nm) can penetrate biological tissues more 
efficiently than visible light, due to the reduction of scattering and absorption by 
biological moieties at longer wavelengths.88 The use of UV radiation should be also 
avoided due to the damage caused to live tissues.89 Optimal excitation of the applied 
dye at different depths is therefore one of the requirements for the application of the 
probe in biological imaging. Three optical windows have been discovered to maximise 
the efficient excitation and detection of probes. The first and more conventionally used 
optical window is comprised between 650 and 950 nm (Figure 1.8),90 but the 
penetration depth is still limited to 1 – 2 cm due to substantial background noise caused 
by autofluorescence. This signal-to-noise ratio can be highly improved in the second 
(1100 – 1350 nm) and third (1600 – 1870 nm) optical window (Figure 1.8),88,91 
however the use of these regions is limited by the lack of compatible probes. 
 
 
Figure 1.8 Graph illustrating the three optical windows. Adapted from ref30. 
 
18 
1.4.6 Singlet Oxygen Production 
While phosphorescent transition metal complexes certainly possess advantageous 
photophysical properties, it is essential to consider their ability to sensitise singlet 
oxygen. 92–94 Molecular oxygen has two low-lying singlet excited states (1Δg and 1∑g+) 
and a triplet ground state configuration (3∑g-).95 Due to his small size, O2 can easily 
diffuse in the cellular environment and quenched the long-lived triplet excited states 
of the metal complexes through intermolecular interactions.93 The energy transfer (ET) 
between the triplet excited states of the metal complex and the triplet ground state of 
the molecular oxygen is spin-allowed, and therefore it occurs more rapidly than the 
radiative decay to the ground state of the metal (Figure 1.9). Interestingly, the 
emission of molecular oxygen from 1Δg can be easily detected in the NIR at around 
1270 nm.96 
Production of singlet oxygen within live cells can lead to extensive 
photocytotoxicity, even in cases when the metal complex is non cytotoxic when 
incubated within live cells that are kept in the dark. However, this very characteristic 
has sparked the investigation of many metal complexes from cellular markers to 
phototherapeutic agents in the field of photodynamic therapy (PDT).97–101 
 
 
Figure 1.9 Simplified Jablonski diagram illustrating the generation of singlet oxygen 
by metal complexes.  
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1.5 Iridium(III) Complexes 
Amongst the various metal complexes, cyclometalated iridium(III) species have 
received extensive investigation for applications in life science.102–108 
Typically, these complexes comprise an iridium(III) centre bound to two 
cyclometalated ligands such as phenylpyridine (ppy), and one bidentate ligand such 
as a diimine (although it is not uncommon to find two monodentate ligands). 
The chemical nature of this family of complexes can be readily tuned by chemical 
variations of the coordinated ligands, thus allowing tuning of properties such as charge, 
lipophilicity, and solubility, as well as photoluminescent characteristics. In fact, it is 
known that iridium complexes can be tuned to be emissive across the entire range of 
the visible spectrum, from blue to red, and further in the near-infrared region. Given 
this versatility, it is not surprising that a large number of iridium complexes have been 
investigated for their potential application as cellular markers and therapeutic agents. 
A broad overview of the use of iridium complexes in life science has been 
reported.1 Particular importance has been given not only to the specific chemical 
nature of the investigated cyclometalated iridium(III) complexes, but also to the 
various experimental conditions that have been used by the different research groups, 
all of which are summarised in Table 1.1. 
In structuring this section, the complexes have been grouped according to their specific 
localisation, including cytoplasm, nucleus, lysosomes, endosomes, mitochondria, 
endoplasmic reticulum and Golgi apparatus. 
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Table 1.1 Summary of data and conditions for the cyclometalated iridium(III) complexes presented in this section. 
Organelle Probe Charge Application Cell linesa Lipophilicity Incubation 
timec,d,e 
Concentration Viability 
dark 
Phototoxic 
index 
IC50 Uptake 
mechanism 
(method of 
detection) 
Ref. 
C
Y
TO
PL
A
SM
 
10 – 11 Cationic Bioimaging HeLa  
MCF-7 
HCT-8 
- 24 h  100 µM >90% - - - 
(Fluorescent 
intensity) 
109 
12 – 15 Cationic Bioimaging HeLa 
MCF-7 
HCT-8  
- 24 h  100 µM >90% - - - 
(Fluorescent 
intensity) 
102 
16 Neutral Ratiometric 
probe 
HeLa  
KB 
- 24 h 100 µM >90% - - - 
(Fluorescent 
intensity) 
110 
17 Neutral Photo-
switchable 
probe 
KB - 24 h 20 µM >80% - - - 
(Fluorescent 
intensity) 
111 
18 Neutral Bioimaging KB - 8 minsd 2 mg/mLd - - - - 
(Fluorescent 
intensity) 
112 
19a - c 
20a - b 
Neutral 
Cationic 
Bioimaging HeLa  
A549 
1.28 - 1.57 
0.56 - 0.89 
24 h 20 µMf - - 73 - 200 
50 - 120 
Energy-
dependent 
(flow 
cytometry) 
113 
21 Cationic Ratiometric HeLa - 48 h 600 mg/mL >75% - - Endocytosis 
(Fluorescent 
intensity) 
114 
22 - 24 Cationic Bioorthogonal 
probes 
CHO-K1  - 1 h 5 µMf - - 50 - 100 - 
(ICP-MS) 
 
115 
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N
U
C
LE
U
S/
 
N
U
C
LE
O
LU
S  
25 - 27 
(a - b)  
Cationic Bioimaging HeLa  
MDCK 
(live/ 
fixed) 
0.90 – 3.95 48 h 5 µMf - - 1 - 25 - 
(Fluorescent 
intensity) 
116 
28 Cationic Bioimaging HeLa 
KB 
FLS 
-0.12 48 h 100 µM >90% - - Energy-
dependent 
(ICP-AEC) 
117 
29a - g Cationic Bioimaging HeLa 
LO2 
-0.09 - 2.12 24 h 20 µM >90% - - Energy-
dependent 
(ICP-AEC) 
118 
30 - 32 Cationic Bioimaging HeLa 
(fixed) 
MCF-7 
(fixed) 
- 24 h 10 – 20 µMf - - 25 – 56 
 
- 
(Fluorescent 
intensity) 
118, 
119 
L
Y
SO
SO
M
E
S/
E
N
D
O
SO
M
E
S  
33 
34 
Neutral 
Cationic 
Bioimaging CHO - 24 h 200 µM - - >200 Energy-
dependent 
(Flow 
cytometry) 
104 
35a - i Neutral Bioimaging 4T1 -8.12 - 3.18b 1 h 0.1 µM 39 - 71% - - - 
(Flow 
cytometry) 
121 
36 - 39 Cationic PDT agents A549 
LO2 
1.97 – 2.12 15 mins 
(425 nm)e 
20 µMf - 25 - >833 
3 - 23 
- Energy-
dependent 
(Flow 
cytometry) 
105 
40 Neutral PDT agent HeLA-S3 - 90 mins 
(377 nm)e 
10 µM - 10 - 30%g - Passive 
transport 
(ICP-AEC) 
122 
41 Neutral Bioimaging HeLa - 48 h 10 µM >95% - - Energy-
independent 
(Fluorescent 
intensity) 
123 
22  
42 Cationic Bioimaging HeLa 
HEK293T 
- 0.77 48 h 0.5 µMf - - 0.39 
0.12 
Energy – 
dependent 
(ICP-MS) 
124 
43 Cationic PDT agent HeLa 0.62 1 h 
(365 nm)e 
50 µMf - 11.6 >200 Energy – 
dependent 
(ICP-MS) 
125 
M
IT
O
C
H
O
N
D
R
IA
 
44 Neutral Bioimaging 3T3 
(live/fixed) 
HeLa 
RPE 
- 12 h 10 µM 60% - - Energy-
dependent 
(Fluorescent 
intensity) 
126 
45 – 46 
(a – d) 
47c 
Cationic Bioimaging HeLa 
MCF-7 
1.40 – 2.48 48 h 50 µM - -  
1.4 - 3.8  
Endocytosis 
(ICP-MS) 
127 
48 - 49 Cationic Bioorthogonal 
probes 
CHO 5.69 – 7.14 6 h 50 µM 76 - 85% - - Passive 
diffusion 
(Fluorescent 
intensity) 
128 
50 Neutral PDT agent HeLa-S3 - 10 mins 
(465 nm)e 
10 µM - >55%g - Passive 
transport 
(ICP-AEC) 
129 
51 – 54 Cationic Ratiometric 
probe 
A549 - 12 h 10 µM >80% - - - 
(ICP-MS) 
 
130 
55a  - c Cationic PDT agents HeLa - 5 mins 
(365 nm)e 
5 µM - 3.6 – 9.2 - - 
(ICP-MS) 
131 
56a - e Cationic Bioimaging HeLa - 12 h 0.5 µM >85% - - Energy-
dependent 
(ICP-MS) 
103 
57 – 59 Cationic PDT agents HeLa 
LO2  
0.77 – 1.42 - 
(405 nm)e 
0.5 µMf - 6.5 - 75 
4.5 - 14 
- Endocytosis 
(ICP-MS) 
 
132 
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60a - c Cationic Bioimaging HeLa 0.9 – 1.5 6 h 5 µM - >80%g - Energy-
dependent 
(ICP-MS) 
133 
61 – 62 Neutral Bioimaging HOS 
(live/fixed) 
- 24 h 5 µM >80% - - - 
(Fluorescent 
intensity) 
134 
63 – 64  Cationic Anticancer 
agents 
HeLa  
A549 
(live/fixed) 
MDB-MA-
231  
PC3 
LO2 
0.23 – 2.12 48 h 10 µMf - - 0.5 - 10 
0.2 - 24 
 
0.3 - 28 
 
1.0 - >100 
1.5 - 27 
Energy-
dependent 
(ICP-MS) 
135 
65 – 66 Cationic Bioimaging HeLa - 24 h 20 µM >70% - - Energy-
dependent 
(ICP-MS) 
32 
67  Cationic Anticancer 
agents 
HeLa 
HepG2 
BEL-7402  
A549 
LO2 
- 48 h 0.5 µMf - - 0.5 
1.1 
1.5 
0.8 
2.6 
Energy-
dependent 
(ICP-MS) 
136 
68 Cationic PDT agent HeLa 
 
- 0.73 30 mins 
(365 nm)e 
300 µM - >55.6 >300 - 
(ICP-MS) 
125 
69 Cationic PDT agent HeLa 1.10 1 h 
(365 nm)e 
10 µMf - 17.2 8.6 Energy-
dependent 
(ICP-MS) 
137 
E
R
/G
O
LG
I 
A
PP
A
R
A
TU
S 70a - c 
71a - c  
Cationic 
Cationic 
Bioimaging HeLa 1.30 – 3.40 48 h 5 µMf - - 1.1 - 6.3 Endocytosis 
(Flow 
cytometry) 
138 
72 - 74 Cationic Bioimaging HeLa - 48 h  5 µMf - - 1.0 - 4.2 - 
(Fluorescent 
intensity) 
139 
24  
75 Cationic Anticancer 
agent 
HeLa 
A549 
MCF-7 
2.12 24 h 10 µMf - - 3.3 
2.0 
3.2 
- 
(Fluorescent 
intensity) 
140 
76 Neutral Ratiometric KB - 24 h 200 µM >98% - - - 
(Fluorescent 
intensity) 
141 
77 - 78 Cationic Bioimaging HeLa 
(live/fixed) 
1.66 – 2.61 48 h  2 µMf - - 1.4 – 2.1 Energy – 
dependent 
(endocytosis) 
(ICP-MS) 
142 
79 Cationic Bioorthogonal 
probe 
CHO-K1 - 20 h  20 µM >80% - - - 
(ICP-MS) 
143 
80 - 81 Cationic PDT agents MCF-7 
SKOV-3 
- 10 sece 2 µM - 5.7 - 5.9 
2.5 - 5.6 
- - 
(Fluorescent 
intensity) 
144 
82 Cationic 
 
Bioimaging HeLa  - 48 h 10 µMf - - 565.9 - 
(ICP-MS) 
145 
a Incubated within live cell lines, unless otherwise stated. 
b Theoretically calculated copying the ChemDraw structures into the structure builder on the web site http://intro.bio.umb.edu/111112/OLLM/111F98/newclogp.html. 
c Incubation time and concentration are referred to the conditions of the cytotoxicity analysis. 
d Incubation time and concentration are referred to the investigation by confocal luminescence microscopy. 
e Irradiation time; in parenthesis the excitation wavelength is reported when available. 
f Concentration is referred to the conditions of the internalisation analysis. 
g Only the cytotoxicity upon exposure to light was index. 
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1.5.1 Cytoplasm Staining 
The cytoplasm is the diffuse area enclosed between the cellular membrane and the 
nucleus. The cytoplasm hosts organelles and macromolecules, and many metabolic 
processes occur within this space, such glycolysis and protein folding.146 The transport 
of materials between organelles also occurs in the cytoplasm, due to a process called 
cytoplasmic streaming.147,148 The various interactions between organelles and 
biomolecules are highly regulated, and therefore imaging of the cytoplasm parameters 
and functions is a key component in life science.146 
A library of photoactive iridium complexes displaying cytoplasmic localisation 
is shown in Figure 1.10. The majority of complexes are cationic, and only a small 
number of neutral iridium(III) complexes have reported showing accumulation within 
the cytoplasm. As a general trend, the cytotoxicity of these probes is quite low. On 
comparing analogous neutral and cationic complexes, the neutral complexes show 
lower cytotoxicity than their corresponding cationic analogues, albeit in only one 
illustrated study.  
 
 
Figure 1.10 Examples of iridium(III) complexes with cytoplasmic localisation. 
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The first examples of cyclometalated iridium(III) probes for the staining of the 
cytoplasm in living cells were reported by Li in 2008.109 Complexes 10 and 11 present 
the same fluorinated phenylpyridine moiety (F2ppy) and different diimine ligands. The 
positive charge and the fluorination of the cyclometalated ligands, influencing the 
lipophilicity and aqueous solubility of the complexes, were argued to be the main 
factor for the internalisation of these probes within the cells. Confocal images of live 
HeLa cells incubated with 10 and 11 in DMSO/PBS (1 : 49 v/v), at a concentration of 
20 µM and for an incubation time of 10 minutes, show intense intracellular 
luminescence with high signal-to-noise ratio between the cytoplasm (Ic) and the 
background (Ib), with Ic/Ib ³ 50. Moreover, the effect of the two complexes on the 
proliferation of MCF-7 and HCT-8 cell lines was determined by MTS assay over a 
period of 24 hour incubation, showing a cellular viability greater than 90% at the 
highest tested concentration (100 µM). 
Few years later, the same group expanded on the previously presented work by 
preparing the cationic iridium(III) complexes 12, 13, and 14, whose structures are 
analogous to those of 10 and 11.102 The group also reported complex 15, where the 
two cyclometalated ligands are replaced by 2-phenylisoquinoline ligands and the 
diimine ligand is the neutral 2-(2-quinolyl)quinoxaline.149 The new complexes 12-15 
show similar biological properties in comparison to 10 and 11, albeit different 
photophysical behaviour, as it might be expected by the variation of the π conjugation 
within the various ligands. Significant emission colour tuning from blue to deep red 
was obtained (λemi from 457 to 632 nm) due to the modification of the ancillary diimine 
ligands (12-14), which was attributed to the corresponding energy variations of the 
3MLCT [dπ(Ir)→ π*diimine] and 3LLCT [πC^N → π*diimine] excited states. An increase in 
the conjugation of both cyclometalated and ancillary ligands further red-shifts the 
emission wavelength of 15 into the near-infrared region (λemi = 732 nm).149 Emission 
in the near-infrared region is particularly appealing to biological imaging as it 
facilitates signal discrimination from autofluorescence, reduces scattering, and allows 
for deeper tissue penetration of biological samples.34,150 Like the analogous complexes 
10 and 11, complexes 12-15 display predominant localisation within the cytoplasm. 
Consistently within the small library of iridium(III) complexes, for cells incubated 
with complexes 12-15, the cellular viability after 24 hours incubation time at a 
relatively high concentration (100 µM) was again ca. 90%. 
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Complex 16 is the first example of neutral iridium(III) complex proposed for cellular 
imaging, which was reported by Zhao and Li. In this complex the two cyclometalated 
ligands are 2-phenylbenzothiazole and the remaining ligand is the bidentate anionic 
O-donor acetylacetonate.110 The complex was proposed as a ratiometric luminescent 
sensor for the quantitation of cytoplasmic Hg(II) cations. In cuvette and upon addition 
of 1 equivalent of Hg(II), an acetonitrile solution of complex 16 shows a blue shift of 
ca. 40 nm that is evident in both the lowest energy absorption band and emission 
profile. The authors also illustrated how the shift is not affected by pH variations, 
within the range 2-12. When incubated within live HeLa and KB cells, complex 16 
shows low cytotoxicity with values of viability ≥ 90% using 100 µM of 16 for 24 
hours. The applicability of 16 in the ratiometric monitoring of intracellular Hg(II) was 
investigated by confocal microscopy using two optical windows: the green channel in 
the 515 ± 15 nm range, and the yellow channel in the 570 ± 10 nm range. KB cells 
were incubated with 10 µM of the complex 16 and 10 µM of Hg(II) for timeframes of 
15 minutes, 1 hour and 8 hours. As it can be seen in Figure 1.11, the ratio between the 
emission intensity at 515 and 570 nm (I515nm/I570nm) is negligible (ca. 0.1) when KB 
cells are stained with only complex 16. Upon addition of Hg(II), I515nm/I570nm increased 
up to 0.6, confirming the ratiometric behaviour of complex 16. 
 
 
Figure 1.11 Ratiometric phosphorescent images of 16 incubated in KB cells at 
concentration of 10 µM for 15 minutes. (A) KB cells qstained with 16. (B) KB cells 
incubated with 16 and then treated with 100 µM of Hg(II) for 1 hour. Reproduced with 
permission from ref110. 
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The neutral iridium(III) complex 17 was reported by Yi and Tian.111 The 
complex was designed to improve the water solubility of a previously published 
analogue, by replacing the acetylacetonato ligand with deprotonated 2-picolinic acid.35 
The MTT assay shows a cell viability greater than 80% with a concentration of 20 µM 
and 24 hour incubation time. By exploiting the reversible photoinduced ring 
opening/closing transformation of the diarylethene unit,151 the complex was proposed 
as a photoswitchable probe for live cell imaging triggered by visible light. Upon 
excitation at 488 nm of a diluted tetrahydrofuran solution containing complex 17 with 
the ligands in their open form, a yellow/orange emission with λemi at 568 nm is 
detected. Upon continuous irradiation, the emission intensity of this band gradually 
decreases as the ligands undergo a photoinduced ring closing reaction, until no 
emission is detected. On the other hand, when the non-emissive closed form of 
complex 17 is continuously excited at wavelengths longer than 600 nm, the intensity 
of the emission band at 568 nm can be slowly recovered while the ligand reverses to 
its open form. Interestingly, a similar behaviour is detected from complex 17 when 
incubated within KB cells and irradiated with 458 nm of light for 2 minutes. The 
emissive open form is quenched and then recovered to the original state upon 
irradiation over 60 minutes at 633 nm. Unfortunately, cellular damage is detected with 
these experimental conditions, limiting the exploitation of the photoswitching 
properties of this probe in live cells. 
Zhao and Li reported the neutral iridium(III) complex 18, showing enhanced 
phosphorescent emission in the solid state (EPESS).112 This complex exhibits very 
weak luminescence (Φ = 0.04%) in diluted solution, but the gradual addition of water 
causes an increase of the luminescent intensity that is ascribed to aggregation by the 
authors. Density functional theory (DFT) calculations illustrate the existence of π-π 
interactions involving the cyclometalated ligands, in support of the EPESS mechanism 
of 18. To explore the biological application of this EPESS-active complex, 18 was 
embedded in water-dispersible polymer nanoparticles with an average diameter of ca. 
190 nm and incubated in KB cells. These embedded 18-PNPs particles internalise in 
only 8 minutes within the cells and exclusively stain the cytoplasm. No cytotoxicity 
data were reported by the authors. 
Other neutral iridium(III) complexes (19a-c) were presented by Zhou,113 
together with two charged biscarbene complexes (20a-b). In both the neutral and 
cationic series, the introduction of the electron-withdrawing substituents CN and CF3 
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into the biscarbene ligand affects the emission maxima by inducing a hypsochromic 
shift in organic solvents, but an analogous clear trend was more difficult to elucidate 
from aqueous solutions. The authors showed that the lipophilicity value logPo/w is 
mainly influenced by the overall charge of the complex, and the exchange of CN for 
CF3 is not greatly affecting the lipophilicity. The neutral complexes 19a-c exhibit 
higher logPo/w values (1.28 - 1.57) in comparison to 20a-b (0.56 - 0.89), a trend that is 
expected on passing from a neutral to a cationic complex. The MTT assay towards 
HeLa and A549 cell lines also proved the lower toxicity of neutral 19a-c versus 
charged 20a-b, with average IC50 values of ca. 165 µM and ca. 85 µM for the neutral 
and charged complexes, respectively. All the complexes display cytoplasmic 
localisation and the authors determined that cellular internalisation occurred through 
energy-dependent uptake. 
The iridium(III) complex 21 was proposed by Zhao, Li and Huang for hypoxia 
bioimaging.114 Hypoxia is one of the most important features of many diseases such 
as solid tumours, inflammatory diseases and cardiac ischemia.152–154 Hence, the 
monitoring of the oxygen level within cells is essential for the advancement of 
associated diagnostic and therapeutic techniques. Complex 21 was covalently attached 
to mesoporous silica-coated and lanthanoid-doped core-shell nanoparticles 
(UCNPs@mSiO2). The use of a nanoparticle carrier for complex 21 was proposed in 
order to increase aqueous solubility and stability, as well as to facilitate the use of a 
continuous wave near-infrared (NIR) laser at 980 nm with low excitation power 
density (ca. 102 W cm-2).150 The use of this excitation source was sought to minimise 
autofluorescence and cellular photodamage. The embedded nanoparticles 21-
UCNPs@mSiO2 cannot be efficiently excited at 980 nm within cells. Nonetheless, 
upon conventional excitation at 405 nm, the probe shows responsiveness when 
incubated within cells with a gradient of O2. Additionally, the cytotoxicity was tested 
and the viability of HeLa cells results higher than 75% after 48 hours at high 
concentration (600 mg/mL). The authors showed that 21-UCNPs@mSiO2 stains the 
diffuse cytoplasm and cell membrane through a nonspecific endocytotic uptake. 
Three charged iridium(III)-based fluorogenic (turn-ON) bioorthogonal probes 
(22-24) were reported by Lo. All these complexes carry a nitrone functional group 
appended to the diimine ligand.115 The nitrone unit can selectively and rapidly react 
with modified proteins which possess the specific alkyne reaction partner.155 
Furthermore, the incorporation of the nitrone group quenches the emission of the probe 
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due to the photoisomerisation of the C=N bond, which provides a non-radiative 
deactivation pathway.156,157 After bioconjugation with the labelled proteins (bovine 
serum albumin BSA, human serum albumin HSA and holo-transferrin HTf), the 
complexes 22-24 show a remarkable enhancement of the emission intensity (I/I0 = 92.1 
- 795.1). The intracellular distribution of the bioconjugated complexes 22-24 in CHO-
K1 cell line highlights a cytoplasmic localisation. Additionally, MTT assay showed 
that the probes are essentially non-cytotoxic toward the same cell line for an incubation 
period of 1 hour (IC50 > 50 µM). 
  
 31 
1.5.2 Nucleus and Nucleolus Staining 
The nucleus is a highly specialised organelle with two main functions: storing of the 
cellular hereditary material in the form of DNA and coordination of many processes 
such as growth, intermediary metabolism, protein synthesis and cell division.158,159 The 
nucleus is surrounded by a double-membrane envelope that exhibits a two-way traffic 
to proteins and nucleic acid between nucleus and cytoplasm.160 The most prominent 
membrane-less substructure within the nucleus is the nucleolus, which is the site of 
rRNA transcription and processing, and also of ribosome assembly.161,162 
A library of iridium complexes that have been reported for the staining of the 
nucleus or the nucleolus is illustrated in Figure 1.12. Of note, all the complexes 
described are cationic and there is no neutral iridium complex proposed as a nuclear 
stain. 
 
 
Figure 1.12 Examples of iridium(III) complexes with nuclear localisation. 
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One of the first examples of nucleolar staining in live cells was proposed by 
Lan and Lo, with a series of iridium(III) dipyridoquinoxaline complexes.116 The 
modification of the chemical structure of the cyclometalated ligands (25a-27a) and the 
presence of a long chain on the dipyridoquinoxaline (25b-27b) modulates the 
lipophilicity and cytotoxicity of the complexes. Extending the conjugation of the 
ligands increases the value of logPo/w (bzq>pq>ppy)138,142 and the addition of an alkyl 
chain on the two phenyl rings of the cyclometalated ligands also results in an increment 
of the lipophilicity, especially in the case of a n-butyl substituent. The IC50 values of 
all the complexes towards HeLa and MDCK cell lines are lower than that of cisplatin, 
indicating high cytotoxicity, especially for the more lipophilic 26a-26b and 27a-27b. 
Localisation studies within the MDCK cell line revealed accumulation in the nucleus 
after 90 minutes of incubation, followed by a more specific nucleolar uptake after 120 
minutes. In particular, it was proven that the complexes bind to the hydrophobic 
pockets of proteins and intercalate with DNA. 
The group of Li developed the non-emissive iridium(III) solvato complex 28, 
bound to two molecules of DMSO in place of a diimine ligand. This complex can react 
selectively with free histidine and histidine-rich proteins with a 300-fold increase of 
its emission intensity in a fluorogenic turn-ON fashion.117 The uptake in HeLa cell line 
of 28 (10 µM, 10 minute incubation time) reveals an exclusive staining of the nucleus, 
with an energy-dependent internalisation pathway. Moreover, the MTT assay toward 
HeLa, KB and FLS cell lines showed low toxicity for complex 28, even after 48 hours, 
with values of viability greater than 90%. 
Based on the previous results, the same research group synthesised a series of 
non-emissive iridium(III) complexes (29a-g) by varying the counter ions, the 
coordinated solvent and the substituent on the phenylpyridine ligands.118 The 
structure-activity relationship studies showed how the nature of the counter ions and 
solvent ligands do not affect the behaviour of the probes within cells. On the other 
hand, the length of the appended carbon chain significantly influences the cellular 
uptake and accumulation in living cells, showing nuclei staining for the shorter chain 
29d and a diffused cytoplasmic accumulation for the longer 29f-g. 
Thomas and Smythe proposed two heterobimetallic iridium(III)-ruthenium(II) 
complexes 30-31 containing a tetrapyridophenazine unit as a bridging ligand.119 The 
probes show good water-solubility, which is often the limiting factor of many 
cyclometalated systems.163 Both complexes 30 and 31 display an unstructured red 
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emission (ca. 640 nm) and low quantum yield (Φ < 0.02%), which increases about 10 
and 24 times upon addition of DNA, respectively (Figure 1.13). Interestingly, the 
binding affinity of 31 was lower than the non-fluorinated analogue 30. This lower 
affinity for DNA was rationalised by the increased polarity of the probe. However, the 
increased lipophilicity of 31 enhances cellular uptake without loss of nuclear 
localisation (Figure 1.13). MTT assay demonstrated low cytotoxicity over a 24 hour 
incubation period for both 30 and 31 with IC50 values of 56 and 43 µM, respectively. 
 
 
Figure 1.13 (A) Co-staining of 30 (3) and 31 (4) with the nuclear stain DAPI in fixed 
HeLa cells. (B) Isolated HeLa chromosomes stained with 30 (3). Reproduced with 
permission from ref119. 
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The same authors reported complex 32120 as a more lipophilic analogue of the 
previously discussed complexes 30 and 31. The authors could therefore compare the 
behaviour of these probes upon systematic increase in lipophilicity, providing 
evidence that increasing the lipophilic character can be counterproductive for the 
uptake and the specific localisation of the probe. In fact, the incubation of complex 32 
in MCF-7 cells (10 µM, 24 hour incubation time) results in poor intracellular emission 
and lack of nuclear staining. Subsequent binding tests proved that complex 32 interacts 
more strongly with bovine serum albumin (BSA), which inhibits the targeted nuclear 
accumulation. 
  
 35 
1.5.3 Lysosomal and Endosomal Staining 
Lysosomes are acidic organelles containing a variety of hydrolytic enzymes 
capable of degrading biomacromolecules delivered by ways of phagocytosis, 
autophagy and endocytosis.164,165 Moreover, lysosomes participate in various other 
cellular processes as cell migration, intracellular transport, plasma membrane repair, 
apoptosis and exosome release.166–168 Lysosomal dysfunctions are associated with 
diverse neurodegenerative and muscular diseases, lysosomal storage disease and 
cancer.169–171 In most eukaryotic cells the internalisation, recycling, transport and 
break down of cellular and extracellular components is mediated by the highly 
dynamic lysosome-endosome system.172,173 The pH level in endosomes plays an 
important role during the endocytosis process, including the release of iron from 
transferrin, general cleavage of ligands from their receptor and, most importantly, the 
activation of lysosomal hydrolases.174 As in the case of lysosomal dysfunctions, 
endosome regulation and development is altered in a surprising range of human 
disorders, including Alzheimer’s disease, atherosclerosis and also lysosomal storage 
disease.174,175 For these reasons, luminescent probes for the tracking of these organelles 
need to possess resistance to degradation, low toxicity, high photostability, great 
penetration depth, near-infrared or longer excitation wavelengths and, more 
importantly, long-term localisation.29,176 
Examples of iridium(III) complexes reported for the staining of lysosomes and 
endosomes are shown in Figure 1.14. While both neutral and cationic complexes have 
been proposed for lysosomal and endosomal staining, the presence of protonatable 
basic substituent seems to be a common factor for this family of complexes. This is 
not surprising given the lower pH of the lysosomal and endosomal environment. 
The group of Williams published the cyclometalated iridium(III) complex 33, 
carrying a 2-pyridylbenzimidazole ligand, and its protonated analogue 34.104 
Photophysical data in dichloromethane solution show a structured emission profile in 
the green region of the spectrum for 33, and an expected red shift for 34, with emission 
centred around 590 nm. Nevertheless, the emission profiles from CHO cells incubated 
with the probes at a concentration of 10 µM for 5 minutes are essentially identical. In 
fact, the protonation equilibrium between the two complexes is a function of the local 
pH, with 33 being the predominant form within the cellular environment, which is 
regulated at pH values around 7.4. A shift is observed in acidic lysosomes, as the 
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protonation equilibrium forms the cationic complex 34. The MTT assay evidenced low 
cytotoxicity of these probes, with IC50 values > 200 µM (200 µM, 24 hour incubation) 
for both. 
 
 
Figure 1.14 Examples of iridium complexes with lysosomal and endosomal 
localisation. 
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A family of nine neutral iridium(III) complexes (35a-i) was synthesised by 
Velders. The complexes are functionalised with a different number (mono-, di-, tri-) 
and type (glycine, alanine, lysine) of amino acids on the 2-phenylpyridine (ppy) 
ligands.121 The monosubstituted complexes 35a, 35d, and 35g show a remarkable 20-
fold higher cellular uptake in 4T1 cells (10 µM, 1 hour incubation), a trend that was 
associated with the more lipophilic nature of the probes.177 This result was supported 
by the authors with the determination of the theoretical lipophilicity (ClogP), which 
shows a distribution coefficient between 2.05 and 3.18, in comparison to the negative 
values of ClogP for the di- (35b, 35e and 35h) and tri-substituted (35c, 35f and 35i) 
complexes. Analysis by flow cytometry showed a substantial reduction of the cell 
viability for the lysine derivatives (35a-c), with higher toxicity for the more substituted 
complex 35c (viability lower than 39%). The cellular distribution of complexes 35a-c 
displays different localisation, depending of the number of lysine residues, with 
nuclear staining for mono-35a, endosomes staining for bis-35b and lysosome staining 
for tris-35c. 
Four iridium(III) complexes with β-carboline ligands (36-39) were developed 
by Tan and Mao as pH-responsive tumour/lysosome-targeted photodynamic 
therapeutic (PDT) agents.105 The pH-response can be achieved with the introduction 
of the protonation sites on the imidazole and benzimidazole groups.178,179 On the other 
hand, the selectivity toward acidic environment can be enhanced by the presence of 
the β-carboline ligand.180 The complexes show similar lipophilicity values (1.97 - 
2.12), with a greater cellular penetration for the smaller imidazole-derivatives 36-37. 
Upon irradiation, they show highly selective phototoxicity against A549 cancer cells. 
In particular, complex 37 displays a phototoxicity index greater than 833. Even if all 
the complexes localise within the lysosomes, 37 is the more promising to be used to 
track the lysosomal integrity during PDT, which provides a convenient method for in 
situ monitoring of therapeutic effects. 
The group of Aoki developed a neutral iridium(III) probe 40 that can be used 
as luminescent pH-sensor and also as pH-dependent photosensitiser in live cells.122 
Photophysical analysis in degassed aqueous buffer has shown a blue-shifted emission 
maximum upon addition of 1 equivalent of acid, and an enhancement of the emission 
intensity induced by the second and third protonation of the diethylamino groups. As 
predicted, through a passive transport mechanism, complex 40 localises within the 
lysosomes of HeLa-S3 cells. Additionally, photoirradiation of 40 at 377 or 470 nm for 
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30 minutes induces necrosis-like death in HeLa-S3 cells, demonstrating the ability of 
the probe to generate 1O2 in a pH-dependent manner. 
An interesting neutral iridium(III) probe 41 for long-term lysosome tracking 
was designed by Chao.123 The water-soluble triscyclometalated iridium(III) complex 
is functionalised by morpholine moieties, which can be protonated inside the 
lysosomes181 and work as a “locker”, allowing the accumulation of 41 in these acidic 
organelles (Figure 1.15). Additionally, the electron-rich morpholine quenches the 
iridium(III) phosphorescence by photoinduced electron transfer (PeT) in basic 
condition, but upon protonation this process is suppressed, leading to an enhancement 
of the emission intensity in acidic lysosomes. The uptake of complex 41 occurs 
through an energy-dependent pathway and the probe results non-toxic for HeLa cell 
lines (10 µM, 48 hour incubation). Moreover, 41 is able to track lysosomes for a period 
of 4 days, allowing imaging and observation of most physiological activities of the 
lysosomes. 
 
 
Figure 1.15 Normalised emission intensities and images of living HeLa cells stained 
with 2 µM of 41 (Ir-lyso) and 2 µM of LysoTracker Red DND-99 (LTR) at different 
passages. Scale bar = 100 µm. Reproduced with permission from ref123. 
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A cyclometalated iridium(III) polyamine complex (42) was developed by Lo’s 
group.124 Poly(ethyleneimine) (PEI) ligands have been commonly used as DNA-
condensing and gene-delivery vectors due to their highly positive charge density and 
high proton buffer capacity over a wide range of pH.182–184 The PEI moiety plays a 
dominant role in the lipophilicity of 42, which shows a negative value of -0.73, to 
benefits its water-solubility. Moreover, the presence of the polymer doubled the uptake 
of this probe in comparison to the non-polymeric analogue, also causing an increase 
of the cytotoxicity (IC50 = 0.39 and 3.2 µM). The higher IC50 value can be probably 
due to the disruption of the cytomembrane and the mitochondrial membranes of the 
cells, as previously shown in similar PEI derivatives.185,186 Nevertheless, upon 
internalisation through an energy-requiring process, such as endocytosis, 42 
accumulated in lysosomes (0.5 µM, 2 hours). 
The same group reported an ethylenediamine iridium complex functionalised 
with polar ester substituents on the cyclometalated ligands (43)125 in order to increase 
the specificity of the probe for bovin serum albumin (BSA). Unfortunately, protein-
binding studies have highlighted minimum emission profile changes of 43 upon 
titration with BSA. However, 43 showed a marked cytotoxicity enhancement (IC50-dark 
> 200 µM, IC50-light = 17.3 µM) in HeLa cells upon irradiation at 365 nm for 1 hour, 
which allowed this probe to be eligible for PDT applications. After internalisation 
inside living cells through an energy-requiring mechanism, 43 accumulates in 
endosomes, as evidenced by colocalisation studies with Alexa Fluor 633-conjugated 
transferrin (Pearson’s coefficient = 0.88). 
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1.5.4 Mitochondrial Staining 
Mitochondria are rod-shaped organelles performing diverse functions, involving 
energy production via oxidative phosphorylation, calcium modulation, redox 
signalling, and apoptosis.187,188 Furthermore, mitochondria are dynamic organelles that 
frequently change their number, size, shape and distribution within the cytoplasm in 
response to metabolic and environmental stress.189 It is therefore not surprising that 
mitochondrial dysfunction has emerged as a key factor in a range of diseases, including 
metabolic disorders, cancer and neurodegenerative diseases, such as Alzheimer and 
Parkinson.190 
Figure 1.16 illustrates various iridium(III) complexes reported to localise 
within the mitochondria. The majority of the complexes are positively charged, with 
very limited examples of neutral species developed for the staining of mitochondria. 
In general, the presence of a positive charge facilitates mitochondrial localisation as a 
result of the mitochondrial membrane electrical potential. 
A charged iridium(III) complex carrying a phenanthroline ligand and 
functionalised with an isothiocyanate group (44) was developed to target specific 
mitochondrial proteins.126 As a previous study showed,139 the isothiocyanate unit 
allows the probe to covalently bind to amine-containing biomolecules such as lysine 
and the N-terminal of proteins, yielding luminescent bioconjugates. Interestingly, 
complex 44 accumulates only in the mitochondria of living 3T3, HeLa and RPE cells, 
while a diffuse staining is present with prefixed 3T3 cells, indicating that the process 
requires active cellular metabolism. The binding of complex 44 to mitochondrial 
proteins interferes with the function and the morphology of this organelle, as showed 
in the MTT assay. The viability of 3T3 cells decreases to 60% with concentration 
higher than 10 µM and an incubation time of 12 hours. 
Another series of bioconjugated iridium(III) complexes was proposed by Lo.127 
In this case, the complexes are appended with a β-D-glucose (45a-d) or a D-galactose 
unit (46a-d) via a polyethylene glycol (PEG) linker to the diimine ligand, while the 
degree of π conjugation was varied on the cyclometalated ligands. The general idea is 
to increase the specific cellular uptake of these sugar-appended probes in cancer cells, 
which usually show an elevated expression of glucose transporters (GLUTs) and 
hexokinases to support higher metabolic functions.191,192 
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Figure 1.16 Examples of iridium(III) complexes with mitochondrial localisation. 
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The lipophilicity was tested, highlighting that the main contributing factor was the 
nature of the cyclometalated ligands (a, c, d>>b). In fact, the complexes of the groups 
45 and 46 show similar values of lipophilicity when the cyclometalated ligands are the 
same. Overall, the lipophilicity characters of 45(a-d) and 46(a-d) are slightly lower 
than 47c, illustrating the effect of the polar carbohydrate groups. Additionally, the 
cytotoxicity toward HeLa cells (50 µM, 48 hour incubation) displays lower IC50 values 
in comparison to cisplatin for almost all the probes. Both 45a and 46a localise within 
mitochondria through an energy-dependent pathway, but only complex 45a enters the 
cells using a GLUT-mediated mechanism. 
Two charged bioorthogonal iridium(III) probes (48-49) were reported by Lo. 
The complexes are appended with a dibenzocyclooctyne moiety,128 which is capable 
of targeting different azide-labelled biomolecules.193 Lipophilicity studies of 48 and 
49 revealed very high values of 5.69 and 7.14, respectively. Both complexes exhibit 
mitochondrial localisation in CHO cells achieved through passive diffusion. 
Regardless of the higher lipophilicity of 49, complex 48 enters the cells more 
efficiently, suggesting that the smaller molecular size plays a critical role in the uptake 
of the probe. Both complexes exhibit a moderate cytotoxicity with a percentage of 
surviving CHO cell of 75.6% and 84.9%, at concentration of 50 µM for an incubation 
time of 6 hours. 
After their previous publication on pH-responsive probes,122 the group of Aoki 
synthesised a further neutral iridium(III) analogue containing three pyridyl groups at 
the 4’-position of the phenylpyridine ligand (50).129 Complex 50 exhibits a reversible 
pH-dependent emission profile based on protonation and deprotonation of the pyridine 
rings, with an intense green emission in neutral and basic conditions and a weaker red 
emission in acidic pH. Upon incubation in HeLa-S3 cells, complex 50 accumulates 
within mitochondria, potentially through a passive transport mechanism. Moreover, 
after photoirradiation at 465 nm for 10 minutes, 50 generates much more 1O2 in 
comparison to the previously published iridium(III) probe,122 thus inducing necrosis-
like cell death. 
The group of Chao developed four iridium(III) anthraquinone complexes (51-
54) that can be excited via two-photon absorption, as hypoxia-sensitive imaging 
probes.130 The anthraquinone unit is an efficient quencher of the iridium luminescence. 
However, in hypoxic conditions, it can be converted into the hydroquinone form, thus 
restoring the emission of the probe.194 In cells, the ligand can be reduced by the 
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coenzyme nicotinamide adenine reductase phosphate (NAD(P)H) in the presence of 
cellular reductase.195 Interestingly as shown in Figure 1.17, the emission intensity of 
the complexes 51-54 internalised within A549 cells rapidly increases (11- to 19-fold) 
after enzymatic reactions with NAD(P)H in hypoxic condition, without interference 
from other biological reductants. Moreover, the probes display different sensitivity 
toward oxygen, with an increment of phosphorescence at [O2] ≤ 5% for 51, and 1% or 
less for 52-54. All the probes localise in the mitochondria of A549 cells and show quite 
low cytotoxicity with viability values greater than 80% under both normoxic and 
hypoxic conditions, after 12 hour incubation at a concentration of 10 µM. 
 
Figure 1.17 Confocal images of adherent A549 cells treated with 5 µM of 51-54 (Ir1-
Ir4) under normoxic (20% O2) and different hypoxic (15, 10, 5 and 1% O2) conditions. 
Scale bar = 10 µm. Reproduced with permission from ref130. 
 
A series of photoactive iridium(III) complexes (55a-c) functionalised with a 
nitroveratryl photolabile protecting group and polyethylene glycol (PEG) chains of 
various lengths were designed by Lo.131 The PEG chain increases the water 
solubility,196 and also reduces the toxicity as the chain increases in length. In fact, 
despite similar uptake efficiency within this small family of complexes, the viability 
in the dark of HeLa cells incubated with 55a and 55b (> 80%) is higher than for 55c 
(> 60%), due to the greater biocompatibility of the longer PEG chain. Upon irradiation 
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for 5 minutes, the nitroveratryl group is cleaved and the cytotoxic iridium(III) core is 
released, showing a significant decrease of the percentage of cell survival. The 
complexes 55a-b display good accumulation within the mitochondria. 
The group of Chao synthesised five iridium(III) complexes (56a-e)103 with 
aggregation-induced emission (AIE) characteristics, showing almost no fluorescence 
in solution and high emission in the aggregated state.197 All the complexes exhibit low 
toxicity (viability > 85%) upon incubation at 500 nM for a period of 12 hours. The 
uptake in the mitochondria of HeLa cells follows a non-endocytic energy-dependent 
process. Remarkably, 56a was employed to successfully monitor a mitophagy process 
in living cells.198 
The same research group recently published a similar series of AIE-active 
iridium(III) probes (57-59), which are analogous to the family of complexes 56a-e 
with variations in the cyclometalated ligands. In line with the previously reported 
complexes, these species can also be used as two-photon absorbing agents for 
photodynamic therapy (PDT).132 In particular, complex 57 displays a significant two-
photon absorption cross-section, a high ROS (reactive oxygen species) generation 
capacity and a significant lethality at low concentration upon aggregation within 
mitochondria. 
Another family of terpyridyl iridium(III) complexes (60a-c) for the real-time 
dynamic tracking of mitophagy198 with two-photon excitation was proposed by 
Chao.133 These probes exhibit lipophilicity values logD7.4 in a range between 0.9 and 
1.5 and moderate cytotoxicity in HeLa cells, with a viability greater than 80% after 6 
hour incubation at concentration of 5 µM. Interestingly, complexes 60a-c are capable 
of localising within the mitochondria independently of the membrane potential, an 
advantageous characteristic over the commercially available mitochondrial stain 
MitoTracker™ Red (which in the absence of membrane potential distributes within 
the cytoplasm and other organelles). Moreover, complexes 60a-c show deep tissue 
penetration under two-photon excitation, enabling the visualisation of the inner 
structure of tridimensional multicellular tumour spheroids.199 
Laskar and Chowdhury designed two of the few examples of neutral 
iridium(III) probes (61-62) for the staining of mitochondria.134 As Chao’s probes,103,132 
61 and 62 exhibit aggregation induced emission with an increment of the emission 
intensity in the solid state 60 and 34 times higher than in solution, respectively. 
Additionally, these complexes show low toxicity at concentration lower than 5 µM 
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(viability > 80%) for an incubation time of 24 hours in HOS cells and specific 
mitochondrial staining. 
Mao and Tan synthesised two iridium(III) complexes (63-64) with 
chloromethyl-functionalised bipyridine as diimine ligands.135 These complexes are 
designed to react with thiol functional groups present in various mitochondrial proteins 
and immobilise the complexes inside this organelle.200 The cytotoxicity of 63-64 was 
tested against a series of cancer cell lines, showing very low IC50 values (0.2 - 27 µM) 
after treatment for 48 hours. Additionally, 63 shows a 11-fold higher selectivity for 
cancerous A459 cells over non-cancerous LO2 cells, inducing a caspase-dependent 
and ROS-mediated apoptotic cell death.201 
Complexes 65 and 66 are some of the few examples of NIR iridium(III) 
probes,32 due to the presence of phenylbenzo[g]quinoline as cyclometalated ligands.34 
These complexes display a strong emission band around ca. 750 nm, superior 
photostability and reduced pH-dependence of the phosphorescent intensity. Those 
properties, in addition to a low cytotoxicity with viability greater than 70% after 24 
hour incubation at 20 µM in HeLa cells, have allowed to track changes in the 
mitochondrial morphology during the early stage of apoptosis (Figure 1.18). 
 
 
Figure 1.18 Phosphorescent images of CCCP (carbonyl cyanide m-chlorophenyl 
hydrazone) (10 µM) treated living HeLa cells stained with 20 µM of 66 (Ir2), during 
an increasing scan time. The upper panels are the luminescence images of 66 (Ir2), the 
middle panels are the bright field (BF) images, whereas the lower panels are the 
merged images. Reproduced with permission from ref32. 
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Based on the structure of previously reported iridium(III) derivatives,103,202 the 
group of Chao synthesised a family of complexes to assess the effect of various degrees 
of fluorination on anti-proliferation.136 In particular, the complex with the highest 
degree of fluorination (67) shows high cytotoxicity against 5 different human cancer 
cell lines (IC50 values: 0.5 - 2.6 µM) with also the highest selectivity for the cisplatin-
resistant cell line A549R. 
Polyethylene glycol (PEG) moieties have shown to increase the 
biocompatibility of complexes within cells and their solubility in aqueous 
media.66,131,203 For this reason, an iridium(III) complex appended with a PEG unit (68) 
was developed by Lo’s group for application in photodynamic therapy (PDT).137 
Interestingly, 68 demonstrated to be non-toxic after incubation in HeLa cells (300 µM, 
12 hours), but its cytotoxicity was triggered by irradiation at 365 nm for 30 minutes 
(PI > 55.6). The mitochondrial accumulation of 68 facilitates efficient oxidative 
damage to these organelles, causing necrotic cell death upon photoexcitation. 
Another iridium(III) PDT agent, bearing a methyl ester substituent on the 
cyclometalated ligands was reported by the same research group.125 Complex 69 shares 
a similar chemical structure with 43, but the higher degree of conjugation of the 
quinoline ligands increases its lipophilicity (from 0.62 for 43 to 1.10 for 69) and it also 
shows a mitochondrial accumulation instead that an endosomal localisation. 
Moreover, the photoinduced cytotoxicity of 43 and 69 is comparable, but probably due 
to the mitochondrial localisation of the latter, its cytotoxicity in the dark is an order of 
magnitude higher (IC50 = 8.6 µM), making this probe less promising than 43 for 
photodynamic therapy application.  
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1.5.5 Endoplasmic Reticulum and Golgi Apparatus 
Staining 
The endoplasmic reticulum (ER) is the largest membrane-bound organelle in 
eukaryotic cells and it consists of multiple structural domains that are interconnected 
and contiguous.204 The ER serves different roles within the cell such as protein folding, 
lipid and steroid synthesis, carbohydrate metabolism as well as calcium storage and 
release.205 Importantly, a number of physiological and pathological conditions are 
known to disturb proper ER function and thereby cause ER stress, which can lead to 
unfolded protein response (UPR) or the release of calcium in the cytoplasm, followed 
by mitochondria-mediated apoptosis .206,207 Together with the ER, the Golgi apparatus 
is a central organelle in the secretory pathway, sustaining the delivery of proteins from 
their site of synthesis in the ER to their final cellular destination.208,209 During transit 
to the Golgi complex, key modifications are made to most proteins, including changes 
to their glycosylation profile, sulfation, phosphorylation and also proteolytic 
cleavage.208,210 Structural and functional alteration of this organelle have been 
recognised as a constant pathological hallmark of various neurodegenerative diseases, 
such as amyotrophic lateral sclerosis, Parkinson, Alzheimer, Huntington and prion 
diseases.209,211 
A family of iridium(III) complexes that display localisation within the 
endoplasmic reticulum and Golgi apparatus is shown in Figure 1.19. A look over these 
complexes highlights that the majority of them are cationic and exhibit acute 
cytotoxicity. On the other hand, neutral complexes with accumulation within the 
endoplasmic reticulum appear to exhibit lower cytotoxicity, even at longer incubation 
time. 
One of the first examples of ER probes was a series of charged iridium(III) 
complexes appended with an indole moiety (70a-c/71a-c).138 The binding properties 
of the indole unit with proteins such as serum albumin, which contains six specific 
substrate-binding sites,212,213 are well known. Lipophilicity measurements show 
slightly higher values for the probes with a longer spacer (70a-c), compared with their 
analogues (71a-c), and increased logD7.4 with higher conjugation of the two 
cyclometalated ligands (c>b>a). Additionally, all the probes display high levels of 
cytotoxicity toward HeLa cell, with IC50 values ranging from 1.1 to 6.3 µM at 48 hour 
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incubation time. Through an energy-requiring process such as endocytosis, 71a 
localised in the perinuclear area of cells. 
 
 
Figure 1.19 Iridium(III) complexes proposed for the staining of the endoplasmic 
reticulum and the Golgi apparatus. 
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A family of three iridium(III) complexes bound to functionalized 1,10-
phenanthroline ligands (72-74) was studied by the group of Lo.139 Complex 74 was 
the only probe in the series that can undergo bioconjugation with proteins, such as 
bovine serum albumin or human serum albumin. Surprisingly, the intracellular 
distribution of 72-74 in HeLa cells was the same, with the formation of a luminescent 
ring surrounding the nucleus. Additionally, cytotoxicity data show similar IC50 values 
(1.0 – 4.2 µM), revealing the high toxicity of these probes. 
The bathophenanthroline iridium(III) probe 75 was discovered by Fei and 
Zhou.140 The size and conjugation degree of the diimine ligand increases the 
lipophilicity and cytotoxicity of complex 75 in comparison to a previous published 
analogue.214 The greater lipophilicity causes the localisation of the probe in the 
membrane of the endoplasmic reticulum (Figure 1.20 - B), inducing ER stress and 
initiating an intrinsic apoptotic pathway,206,207 characterised by mitochondria 
fragmentation (Figure 1.20 - A). Additionally, the high cytotoxicity against HeLa, 
A549 and MCF-7 cell lines has highlighted the antitumor potential of 75, with IC50 
values of 3.3, 2.0 and 3.2 µM, respectively. 
 
 
Figure 1.20 Mitochondrial fragmentation and onset of apoptosis. (A) In the time-lapse 
confocal images of 75 (3) treated HeLa cells, ALDH-GFP (aldehyde dehydrogenase 
fused with green fluorescent proteins) labelled mitochondria became fragmented, 
resulting in small and rounded organelles. (B) Representative image of ALDH-GFP 
stained mitochondria (green) and membrane localised 75 (3, red). Scale bar = 20 µm. 
Adapted and reproduced with permission from ref140. 
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The poly(N-isopropylacrylamide) iridium(III) probe 76 was reported by Zhao 
and Huang as cellular sensor for homocysteine (Hcy) and cysteine (Cys).141 The 
chemical structure of 76 is characterised by a water-soluble polymeric moiety, which 
increases the solubility of the probe in biological environment, and two aldehyde 
groups, which are responsible to selectively react with thiol groups in Hcy and 
Cys.215,216 Upon reaction with Hcy and Cys, with consequential formation of 
thiazolidine and thiazinane groups respectively, a blue shift in the absorption spectrum 
and increase in the emission intensity was recorded. Moreover, upon incubation in KB 
cells (200 µM, 24 hours), 76 localised in the perinuclear region of the cells, showing 
a viability ≥ 98%. 
Two examples of dendritic iridium(III) polypyridine probes (77-78) were 
designed and compared to their monomeric analogues.142 As expected, due to the 
hydrophobic nature of the dendritic skeleton moiety, the lipophilicity of 77-78 was 
higher compared to the monomeric probe (1.66 - 2.61 vs 0.44 - 2.01, respectively). 
However the cellular uptake resulted similar. Upon efficient internalisation (2 µM, 2 
hours) by an energy-requiring mechanism such as endocytosis, 77 and 78 localised in 
the perinuclear area of HeLa cells. Costaining studies with fluorescent antibodies 
confirmed the localisation of these probes in the Golgi apparatus. The accumulation in 
this organelle seems to contribute to the higher cytotoxicity of the dendritic probes 
(IC50 = 1.4 - 2.1 µM) with respect to their monomeric species (IC50 = 5.5 - 26.4 µM). 
The bioorthogonal iridium(III) complex 79 containing a 1,2,4,5-tetrazine 
moiety is almost non-emissive, but its emission highly enhances upon selective 
coordination with modified bovine serum albumin (I/I0 = 1113.7).143 The cytotoxicity 
of the probe was tested by MTT assay on CHO-K1 cells and shows viability greater 
than 80% after 20 hour incubation at concentration up to 20 µM. The localisation of 
complex 79 shows a perinuclear and sharp granular cytoplasmic staining, due to the 
dynamic recycling of the probe from the endoplasmic reticulum to subcellular 
organelles for enzymatic processing.217 
Kwon, Rhee and Lim reported two bipyridine iridium(III) complexes (80-81) 
which can be used as photodynamic therapy (PDT) agents, due to their high efficiency 
in the production of ROS.144 In fact, at really low concentration (2 µM) the probes can 
be photoactivated (10 second irradiation time, 100 J cm-2 light) and reduce 
significantly the viability of SKOV-3 cancer cells, with IC50 values of 4.89/0.83 µM 
(80) and 3.61/0.63 µM (81) in the absence/presence of light. Interestingly, the 
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localisation of the probes was mainly in the endoplasmic reticulum, but the 1O2 
produced might be diffused through the ER membrane and also modify some 
mitochondrial proteins, by protein-protein cross-linking and protein oxidation 
mechanisms. 
The biological properties of PEG-appended iridium complexes can be 
modulated by changing the length of the polymeric chain.218–220 The group of Lo 
developed a new iridium(III) appended with a shorter PEG moiety (23 units)145 with 
respect to the previously discussed probe 68 (ca. 122 units). As its analogue 68, probe 
82 showed low cytotoxicity in HeLa cells (IC50= 565.9 µM) even for long period of 
time (48 hours). Moreover, 82 accumulates in the perinuclear region of the cells, likely 
binding to hydrophobic organelles such as endoplasmic reticulum or Golgi apparatus. 
 
1.5.6 State of the Art 
This section surveyed the research area of cyclometalated iridium(III) 
complexes and their use in life science.1 It is evident that this area is still incredibly 
active and it has been diversified over the years. While phosphorescent iridium(III) 
complexes were initially screened as cellular markers for optical imaging, their 
versatility has expended potential use in broader areas including therapy. Despite the 
large body of work that has appeared in the literature to date, a full rationalisation of 
structure-activity relationship is still difficult to achieve.  
Most of the design of new iridium probes and/or therapeutic agents starts with 
considerations of chemical nature such as charge, lipophilicity, solubility and 
bioconjugation to specific biological vectors. However, as illustrated in the various 
examples within this section, a systematic investigation related to a biological context 
is lacking. In fact, the various research groups have tested the iridium complexes in 
very different conditions including diverse cell lines, concentration and incubation 
time. The area, in its multidisciplinary feature bridging chemistry and biology, would 
certainly benefit for the establishment of a set of conditions to assess newly 
synthesised iridium(III) complexes and to revise currently available ones. 
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1.6 Tetrazoles and Tetrazolato Metal Complexes 
Tetrazoles are a class of five-member N-heterocyclic compounds. They are carboxylic 
acid isosteres and possess similar acidity (pKa ~ 5).221 However, tetrazoles result more 
metabolically stable in comparison to their carboxylic analogues. Hence, they are 
commonly applied in medicinal chemistry as isosteric substituents of various 
carboxylic groups in biologically active molecules. Tetrazoles and their derivatives 
have been used in a wide variety of applications as antibacterial, anti-inflammatory, 
antifungal, antiviral, antitubercolours, cyclo-oxygenase inhibitors, hypoglycemic and 
anticancer agents.222–224 
 
Figure 1.21 N1 and N2 tautomers of  protonated tetrazoles. The tetrazolic carbon (CT) 
is highlighted in blue. 
Protonated tetrazoles exist in two tautomeric forms, with the tetrazolic proton 
residing on either the N1 or N2 atom, as showed in Figure 1.21. These two tautomeric 
forms can be identified by 13C NMR, as previously described by Butler et al..225–227 
Chemical shifts of the tetrazolic carbon (CT) ranging from 152 - 156 ppm, indicate the 
predominant presence of the N1 tautomer, whereas values of 162 - 165 ppm are 
indicative of the N2 one. 
Tetrazoles have been coordinated to transition metal atom such as Ru(II),228–
230 Re(I),231–235 Ir(III),236–241 Cu(I)242–244 and Pt(II).245–248 In the metal coordination 
sphere, the tetrazole can behave as an ancillary, chelating, or bridging ligand between 
two different metal centres, as well as a substituent group on other ligands.  
These metal complexes has been utilised in a multitude of fields (Figure 1.22). 
Noteworthy, the majority of these species have found application as OLEDs (Organic 
Light Emitting Devices) or in the fabrication of LEECs (Light Emitting 
Electrochemical Cells). For example, the Ru(II) complex 83 has been developed for 
non-doped NIR light electrochemical cells,229 whereas the combination of the anionic 
(88a) and cationic (88b) Ir(III) species allowed the formation of a soft salt 
characterised by an almost pure white light emission.241 Surprisingly, tetrazolato metal 
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complexes have not been used in biological applications until 2014, when the Re(I) 
complex 89 was successfully incubated in Drosophila fat body tissue and 3T3-L1 cells 
for the staining of lipid droplets.233,249 
 
 
 
Figure 1.22 Examples of previously reported transition metal complexes 
functionalised with tetrazolate ligands. The tetrazolate moiety has been highlighted in 
red. 
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1.7 This Investigation and Scope 
In the last decades transition metal complexes of iridium(III), ruthenium(II), 
rhenium(II), platinum(II) and gold(I) have been investigated for biological 
applications, as previously highlighted in this chapter. Modulations in the chemical 
structure of these metal probes have showed to influence not only the photophysical 
properties but also the uptake mechanism, localisation and cytotoxicity within live and 
fixed cells. However, a structure-activity rationalisation has appeared to be 
challenging due to the variety of factors involved in the design of the probes. 
To further expand the knowledge in this field, this study investigates a series of 
iridium(III) complexes bearing a tetrazolate moiety as ancillary ligand (Figure 1.23). 
 
 
Figure 1.23 Structure of the target iridium(III) tetrazolato complexes in this thesis. 
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Interestingly, despite the favourable properties (antibacterial, analgesic, anti-
inflammatory, antifungal, anticonvulsant and anticancer activity)222–224,250 exhibited by 
tetrazoles, the use of tetrazolato metal complex in biology was not investigated until 
2014 (refer to complex 89 - Figure 1.22).233 Moreover, no reports of iridium(III) 
tetrazolato complexes for biological applications have been published until 2017.239 
Hence, the aim of this multidisciplinary research is to rationalise the relationship 
between the chemical structure of a family of iridium(III) tetrazolato complexes and 
the effect that modifications on both cyclometalated and ancillary ligands produce on 
solubility, lipophilicity, uptake mechanism, cytotoxicity and localisation of the probes 
in live cells and fresh/fixed tissues. 
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Chapter 2  
Synthesis and Photophysical Investigation of 
Cyano and (Iso)Quinolyl-Functionalised 
Iridium Tetrazolato Complexes 
 
The content of this chapter has been published in: 
Chemistry – A European Journal (2017) with the title “Investigating 
intracellular localisation and cytotoxicity trends for neutral and cationic iridium 
tetrazolato complexes in live cells”.239 
 
2.1 Introduction 
The interest in cyclometalated iridium(III) complexes has increased over the years 
since the discovery of the luminescent fac-Ir(ppy)3, initially found as a side product of 
the dichloro-bridged dimer [Ir(ppy)2(µ˗Cl)]2 (Figure 2.1).251–253 Many studies have 
been published on iridium complexes with formula [Ir(N^C)2(N^N)]0/+, in which N^C 
represents monoanionic cyclometalated ligands and N^N is usually a diimine unit.254–
256 A large number of [Ir(N^C)2(N^N)]0/+ complexes have been reported with 
application as light-emitting materials [Organic Light Emitting Diodes (OLEDs) or 
Light Emitting Electrochemical Cells (LEECs)],257–259 sensitisers for dye-sensitised 
solar cells,260–262 chemosensors263–265 and, more recently, as luminescent markers for 
biological imaging.32,123,144 Along with many transition metal complexes of Ru(II), 
Re(I), Au(I) and Pt(II),62,63,65 Ir(III) complexes have specific photophysical properties 
that can potentially solve many of the drawbacks associated with commonly studied 
organic fluorophores, such as enhanced photostability, large Stokes shifts and 
relatively long excited state lifetimes.66 Additionally, the chemical and photophysical 
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properties can be readily modified by altering the ancillary or cyclometalated ligands 
around the metal centre. 
 
 
Figure 2.1 Structure of the dichloro-bridged dimer [Ir(ppy)2(µ˗Cl)]2 (left) and 
fac˗Ir(ppy)3 (right). 
 
In this work, tetrazolate moieties have been chosen as ancillary ligands due to 
the intrinsic reactivity towards electrophiles,232,237,266 which can allow an easy 
methylation reaction to achieve charged analogues starting from neutral species. A 
family of five neutral complexes and five methylated analogues has been synthesised 
by modifying the functional groups on the ligands and by the extension of the p 
conjugation (Figure 2.2). A systematic investigation of the relationship between 
chemical structure and photophysical behaviour has been carried out, recording the 
emission properties of the complexes in organic, lipophilic and aqueous media, in 
order to consider their applicability in biological environment.239 
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Figure 2.2 Structure of target complexes in this investigation, illustrating neutral 
species (top) and charged analogues (bottom). 
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2.2 Synthesis of the Tetrazolato Ligands 
2.2.1 Pyridyl-Tetrazole Synthesis and Characterisation 
HTzPyCN was synthesised following the literature procedure showed in Figure 2.2. 
The ligand precursor was obtained in three steps starting from the commercially 
available 2,5-pyridinecarboxylic acid. Following a Fisher esterification to form the 
corresponding methyl ester groups,267 aminolysis with aqueous ammonia gave the 
corresponding primary amides.268 Lastly, dehydration of the amide groups yielded the 
desired nitrile moieties.269 The synthesis of HTzPyCN was carried out following a 
methodology developed by Sharpless et al.,270 in which the nitrile was reacted with 
sodium azide in presence of zinc bromide and in water at reflux. 
 
 
Figure 2.2 Scheme of the synthetic procedure for HTzPyCN. 
 
Complete separation of HTzPyCN from the ditetrazole byproduct HTzPyTz (present 
in 5 – 10% molar amount determined by NMR analysis) by selective protonation was 
challenging, and the impure HTzPyCN was used as recovered for complexation with 
iridium. The purification of the final complexes was easily achieved via column 
chromatography, as described in details in section 2.3.1. 
The main IR bands indicative of the tetrazole formation are the C=N and N–H 
stretching, observed at 1604 and 3071 cm-1, respectively. 
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As mentioned above, 1H NMR characterisation in DMSO-d6 shows the presence of a 
small percentage of HTzPyTz. Characteristic peaks are found at 9.42, 8.67 and 8.44 
ppm, which resonate at higher chemical shifts in comparison to those of the tetrazolate 
product (Figure 2.3). 
 
 
Figure 2.3 1H NMR in DMSO-d6 for HTzPyCN (red diamond) with the byproduct 
HTzPyTz (green triangle). The peaks have been assigned for the two species. 
 
The presence of the HTzPyTz is not visible in the 13C NMR spectrum, probably due 
to the negligible amount in the sample solution. On the other hand, the resonance of 
the tetrazolic carbon CT is well visible at 153.5 ppm, confirming again the formation 
of the desired final product. 
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2.2.2 Quinolyl and Isoquinolyl-Tetrazole Synthesis and 
Characterisation 
The ligands HTzQn and HTziQn were synthesised following the procedure developed 
by Koguro et al.,271 shown in Figure 2.4, where the nitrile was combined with the 
azide in presence of triethylammonium chloride in toluene at reflux to yield the desired 
product. 
 
 
Figure 2.4 Scheme of the synthetic procedure for HTzQn and HTziQn. 
 
HTzQn and HTziQn were characterised by IR, 1H NMR and 13C NMR 
spectroscopy. The IR bands present at 1600 and 1613 cm-1, for HTzQn and HTziQn 
respectively,  are associated with the stretching of the C=N, whereas the bands at 3058 
and 3063  cm-1 derive from the stretching of N–H bond. These two sets of bands are 
demonstrating the formation of the desired species. Moreover, the lack of the sharp 
nitrile band at ca. 2240 cm-1 suggests the absence of starting material. 
The spectroscopic characterisation of HTzQn and HTziQn by 1H NMR and 
13C NMR in DMSO-d6 is consistent with previous reports of these 
compounds.234,269,271 The 13C NMR of both HTzQn and HTziQn shows the 
characteristic CT peak at 155.2 and 155.0 ppm, respectively, and supports the 
predominant formation of the N1 tautomer, in agreement with Butler’s studies (refer 
to Chapter 1 – section 1.6).225,226  
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2.3 Synthesis of the Iridium(III) Complexes 
2.3.1 Synthesis and Characterisation of Neutral 
Iridium(III) Complexes 
The neutral iridium(III) complexes have been synthesised following a previously 
reported procedure.236 [Ir(ppy)2(TzPyCN)], [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] 
were prepared by reaction between [Ir(ppy)2(µ˗Cl)]2 and the corresponding pyridyl or 
(iso)quinolyl tetrazolate species, as showed in Figure 2.5. In the case of 
[Ir(F2ppy)2(TzPyCN)], the starting material was bearing 2-(2,4-
difluorophenyl)pyridine (F2ppy) as cyclometalated ligands, in place of ppy. 
 
 
Figure 2.5 Scheme of the synthetic procedures for [Ir(ppy)2(TzPyCN)], 
[Ir(F2ppy)2(TzPyCN)], [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)].  
 
The complex [Ir(ppy)2(TzPyPhCN)] was prepared via a different route, involving a 
Suzuki coupling272 of the previously reported [Ir(ppy)2(TzPyBr)]236 with 4-
cyanoboronic acid (Figure 2.6). Previous attempts to react [Ir(ppy)2(µ˗Cl)]2 with the 
pre-formed corresponding tetrazolate ligand were unsuccessful, as an inseparable 
mixture of products was obtained. 
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Figure 2.6 Scheme of the synthetic procedure for [Ir(ppy)2(TzPyPhCN)]. 
 
Chromatographic separation on neutral alumina as stationary phase was 
required for all the neutral iridium(III) complexes, in order to obtain pure final 
products with average yields around 75%. Only [Ir(ppy)2(TzQn)] was isolated with a 
slightly lower yield of 53%. 
The IR spectra display the characteristic C≡N peak around 2230 cm-1 for 
[Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)] and [Ir(ppy)2(TzPyPhCN)], in addition 
to the aromatic stretching of the tetrazolic C=N at ca. 1600 cm-1 for the whole neutral 
family. The coordination of the tetrazolate ligand to the metal centre was also 
supported by the absence of the N–H band around 3100 cm-1.  
Spectroscopic characterisation by 1H NMR shows two doublet peaks in the 
range 6.5 – 5.5 ppm (Figure 2.7), which are assigned to the protons in meta position 
with respect to the pyridine ring of ppy (or F2ppy) and are characteristic of 
cyclometalated iridium(III) complexes.126,133,273 In 13C NMR spectra the tetrazolic 
carbon CT resonating around 163.5 ppm indicates a coplanar arrangement adopted by 
the rings in the tetrazole moiety, suggestive of chelation of the ancillary ligand.236 
Consequently, the downfield shift of the CT resonance shows that the coordination 
occurred through N1 position of the tetrazolato ring. 
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Figure 2.7 1H NMR in acetone-d6 for [Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)], 
[Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)]. 1H NMR of [Ir(ppy)2(TzPyPhCN)] was 
recorded in DMSO-d6. In the spectra, the two characteristic doublet peaks of 
cyclometalated iridium complexes have been highlighted in boxes. 
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Single crystals suitable for X-ray diffraction were obtained for the neutral 
[Ir(F2ppy)2(TzPyCN)] complex. This species crystallised in the monoclinic space 
group I2/a (Figure 2.8). The coordination arrangement presents the two pyridine rings 
of the phenylpyridine ligands adopting a trans configuration, while the two 
cyclometalated phenyl rings being arranged in cis configuration. The rest of the 
coordination sphere is occupied by the two nitrogen atoms of the tetrazole and pyridine 
rings. The crystallographic data can be found in Appendix A, Table A.1 – Table A.2. 
 
 
Figure 2.8 X-ray crystal structure of [Ir(F2ppy)2(TzPyCN)], with displacement 
ellipsoids drawn at the 50% probability level. 
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2.3.2 Synthesis and Characterisation of Cationic 
Iridium(III) Complexes 
The cationic iridium(III) complexes [Ir(ppy)2(MeTzPyCN)]+, 
[Ir(F2ppy)2(MeTzPyCN)]+, [Ir(ppy)2(MeTzPyPhCN)]+, [Ir(ppy)2(MeTzQn)]+ and 
[Ir(ppy)2(MeTziQn)]+ were synthesised from their neutral analogues. Methylation of 
all the neutral species was performed by treatment with methyl 
trifluoromethanesulphonate, followed by metathesis with ammonium 
hexafluorophosphate (Figure 2.9). 
 
 
Figure 2.9 Scheme of the synthetic procedures for [Ir(ppy)2(MeTzPyCN)]+, 
[Ir(F2ppy)2(MeTzPyCN)]+, [Ir(ppy)2(MeTzPyPhCN)]+, [Ir(ppy)2(MeTzQn)]+ and 
[Ir(ppy)2(MeTziQn)]+. 
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The regioselective methylation at the N3 position of the tetrazolato ring was 
achieved by using low temperature (-50 °C), avoiding the formation of a mixture of 
N2, N3 and N4 isomers. The use of a slightly excess of methyl 
trifluoromethanesulphonate ensured the complete conversion of the neutral starting 
materials into the cationic products. All the methylated complexes could be isolated 
with acceptable purity and high yield by simple extraction from the crude mixture and 
no column chromatography work-up was required. 
The 1H NMR and 13C NMR spectra clearly indicate the presence of one methyl 
group which resonates around 4.55 and 42.5 ppm, respectively. In addition, the 
downfield shift of the tetrazolic carbon CT from ca. 163.5 ppm for neutral 
[Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)] and [Ir(ppy)2(TzPyPhCN)] to ca. 166.7 
ppm for cationic [Ir(ppy)2(MeTzPyCN)]+, [Ir(F2ppy)2(MeTzPyCN)]+ and 
[Ir(ppy)2(MeTzPyPhCN)]+ (Figure 2.10) supports the hypothesis of methylation in 
N3 position, as previously demonstrated by Stagni et al..236 In the case of 
[Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] the same phenomenon is observed, but due 
to the higher degree of conjugation of the tetrazolate ligand, the CT signal was at 
slightly higher resonance, shifting from ca. 166.0 ppm to ca. 168.0 ppm (Figure 2.11). 
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Figure 2.10 13C NMR in acetone-d6 for the neutral complex [Ir(ppy)2(TzPyCN)] (top) 
compared to the methylated analogous [Ir(ppy)2(MeTzPyCN)]+ (bottom).  
 
 
Figure 2.11 13C NMR in acetone-d6 for the neutral complex [Ir(ppy)2(TzQn)] (top) 
compared to the methylated analogous [Ir(ppy)2(MeTzQn)]+ (bottom). 
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The crystallographic analysis on [Ir(ppy)2(MeTzPyPhCN)]+ highlights again 
the tetrazolic N3 nitrogen as specific site for methylation to occur. The complex 
crystallised in monocline space group P2/n, as visible in Figure 2.12. The coordination 
sphere around the metal centre is consistent with the one obtained for the neutral 
[Ir(F2ppy)2(TzPyCN)]. The crystallographic data can be found in Appendix A, Table 
A.3 – Table A.4. 
 
Figure 2.12 X-ray crystal structure of [Ir(ppy)2(MeTzPyCN)]+, with displacement 
ellipsoids drawn at the 50% probability level. The counter anion (PF6-) is omitted for 
clarity. 
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2.4 Photophysical Investigation 
2.4.1 Absorption in Dichloromethane 
A summary of the absorption properties of the iridium(III) complexes in diluted 
dichloromethane solutions is listed in Table 2.1. 
 
Table 2.1 Absorption data of dichloromethane solutions (10-5 M) of the reported 
complexes.  
Complex 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2(TzPyCN)] 263 (6.57), 339 (1.59), 382 (1.09), 420 (0.58) 
[Ir(F2ppy)2(TzPyCN)] 256 (5.20), 364 (0.95) 
[Ir(ppy)2(TzPyPhCN)] 268 (3.95), 290 (3.64), 345 (0.58), 423 (0.27) 
[Ir(ppy)2(MeTzPyCN)]+ 266 (8.93), 376 (1.44) 
[Ir(F2ppy)2(MeTzPyCN)]+ 250 (3.56), 316 (1.28), 356 (0.58) 
[Ir(ppy)2(MeTzPyPhCN)]+ 267 (3.39), 290 (3.14), 378 (0.40) 
[Ir(ppy)2(TzQn)] 263 (8.44), 345 (1.97), 428 (0.42) 
[Ir(ppy)2(TziQn)] 260 (9.77), 340 (3.13), 424 (0.75) 
[Ir(ppy)2(MeTzQn)]+ 257 (9.29), 376 (0.95) 
[Ir(ppy)2(MeTziQn)]+ 253 (6.96), 303 (2.45), 371 (1.24) 
 
The absorption spectra from air-equilibrated dichloromethane solutions are presented 
from Figure 2.13 to Figure 2.16. All the iridium complexes show intense absorption 
bands in the UV region between 250 – 300 nm, which are associated with ligand-
centred (LC) π-π* transitions, involving the cyclometalated ppy and F2ppy ligands. 
On the other hand, the weaker and broader bands tailing off into the visible region of 
the spectra are ascribed to ligand-to-ligand (LLCT) and metal-to-ligand charge transfer 
(MLCT) transitions.236 Since the iridium metal centre possesses high spin-orbit 
coupling constant (x = 3909 cm-1),76 these bands are attributed to singlet-to-singlet and 
singlet-to-triplet LLCT/MLCT transitions, with the latter being red-shifted in the 
spectrum due to its lower energy. 
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Figure 2.13 Absorption profiles of [Ir(ppy)2(TzPyCN)] (blue), 
[Ir(F2ppy)2(TzPyCN)] (red) and [Ir(ppy)2(TzPyPhCN)] (green) in dichloromethane. 
 
 
Figure 2.14 Absorption profiles of [Ir(ppy)2(MeTzPyCN)]+ (blue), 
[Ir(F2ppy)2(MeTzPyCN)]+ (red) and [Ir(ppy)2(MeTzPyPhCN)]+ (green) in 
dichloromethane. 
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Figure 2.15 Absorption profiles of [Ir(ppy)2(TzQn)] (blue) and [Ir(ppy)2(TziQn)] 
(red) in dichloromethane. 
 
 
Figure 2.16 Absorption profiles of [Ir(ppy)2(MeTzQn)]+ (blue) and 
[Ir(ppy)2(MeTziQn)]+ (red) in dichloromethane. 
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2.4.2 Emission Properties in Dichloromethane 
All the emission properties of the iridium(III) family are summarised in Table 2.2. 
Excitation of the iridium complexes at 375 nm results in orange to red emission in air-
equilibrated dichloromethane solutions, and the emission spectra measured at 298 K 
are shown from Figure 2.17 to Figure 2.20. 
 
Table 2.2 Photophysical data of dichloromethane solutions (10-5 M) of the reported 
complexes. 
Complex 
λem 
[nm] 
τaer 
[ns]a 
τdeaer 
[ns]a 
Φaerb Φdeaerb 
[Ir(ppy)2(TzPyCN)] 618 131 529 0.055 0.397 
[Ir(F2ppy)2(TzPyCN)] 542 140 697 0.042 0.406 
[Ir(ppy)2(TzPyPhCN)] 560 114 880 0.023 0.149 
[Ir(ppy)2(MeTzPyCN)]+ 680 31 (79), 
168 (21) 
35(61), 
362 (39) 
0.012 0.014 
[Ir(F2ppy)2(MeTzPyCN)]+ 600 287 551 0.057 0.118 
[Ir(ppy)2(MeTzPyPhCN)]+ 600 184 434 0.057 0.093 
[Ir(ppy)2(TzQn)] 580 153 831 0.021 0.065 
[Ir(ppy)2(TziQn)] 535, 575, 
620 
497 6713 0.036 0.114 
[Ir(ppy)2(MeTzQn)]+ 635 218 546 0.028 0.043 
[Ir(ppy)2(MeTziQn)]+ 640 208 485 0.049 0.063 
a For the biexponential excited state lifetime (τ), the relative weights of the exponential 
curves are reported in parentheses. b Measured versus [Ru(bpy)3]2+ in H2O (Φr = 
0.028).274 
 
The neutral complexes [Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)], and 
[Ir(ppy)2(TzPyPhCN)] are characterised by broad and featureless emission bands, 
that are typical for radiative decays from excited states of charge transfer character 
(Figure 2.17).76 The [Ir(ppy)2(TzPyCN)] complex presents a red-shifted maximum at 
618 nm, which is ascribed to a stabilisation of the unoccupied π* orbitals localised on 
the TzPyCN- ligand caused by the electron-withdrawing nature of the nitrile functional 
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group.236 As expected, the addition of electron-withdrawing fluoride substituents on 
the ppy ligands causes a blue shift of the emission maximum for 
[Ir(F2ppy)2(TzPyCN)] (λem = 542 nm), as a consequence of the stabilisation of the 
occupied π orbitals of the ligands and iridium 5d orbitals composing the mixed 
LLCT(F2ppy®TzPyCN) and MLCT(Ir®TzPyCN) transition.236 The emission 
maximum of [Ir(ppy)2(TzPyPhCN)] at 560 nm is again blue-shifted with respect to 
[Ir(ppy)2(TzPyCN)], albeit to a lesser extent when compared to 
[Ir(F2ppy)2(TzPyCN)]. This trend is ascribed to the fact that the electron-withdrawing 
effect of the nitrile group on the pyridyltetrazole π* system is decreased by the addition 
of a phenyl ring spacer.  
The emission profiles of the methylated complexes [Ir(ppy)2(MeTzPyCN)]+ 
(λem = 680 nm), [Ir(F2ppy)2(MeTzPyCN)]+ (λem = 600 nm), and 
[Ir(ppy)2(MeTzPyPhCN)]+ (λem = 600 nm) are red-shifted compared to their 
corresponding neutral complexes (Figure 2.18). Once more, this red shift 
demonstrates that the π* system of the pyridyltetrazole ligand acts as an electron 
acceptor in the charge transfer transitions.236,237 When comparing the emission maxima 
of these three methylated iridium complexes, the trend for the emission properties is 
analogous to that observed for their neutral counterparts, with the most red-shifted 
emission originating from [Ir(ppy)2(MeTzPyCN)]+. 
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Figure 2.17 Normalised emission profiles of [Ir(ppy)2(TzPyCN)] (blue), 
[Ir(F2ppy)2(TzPyCN)] (red) and [Ir(ppy)2(TzPyPhCN)] (green) in dichloromethane. 
 
 
Figure 2.18 Normalised emission profiles of [Ir(ppy)2(MeTzPyCN)]+ (blue), 
[Ir(F2ppy)2(MeTzPyCN)]+ (red) and [Ir(ppy)2(MeTzPyPhCN)]+ (green) in 
dichloromethane. 
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The iridium complexes containing quinolyl and isoquinolyl-functionalised 
tetrazolate ligands, [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)], reveal emission bands 
that are similarly ranging between 500 and 750 nm (Figure 2.19). Compared to the 
previously published complex [Ir(ppy)2(TzPy)],236 where TzPy- is 5-(2’-
pyridyl)tetrazolate, displaying a structured emission band with peaks at 481 and 510 
nm, the complexes [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] present a red-shifted 
emission that is rationalised by the increased π conjugation on passing from a phenyl 
to a quinolyl or isoquinolyl substituent. The structures of these two bands appear to be 
quite different. The emission profile of [Ir(ppy)2(TzQn)] is broad and structureless, 
whereas that of [Ir(ppy)2(TziQn)] appears to be structured with a vibronic progression 
spaced around 1,300 cm-1. Furthermore, the excited state lifetime of [Ir(ppy)2(TziQn)] 
in air-equilibrated solution is significantly longer than that of [Ir(ppy)2(TzQn)], with 
even a more prominent elongation in deaerated solution, with values of 831 and 6713 
ns, respectively (Table 2.2). These results suggest the presence of a more dominating 
charge transfer character for the emission of [Ir(ppy)2(TzQn)].256 On the other hand, 
the excited state of [Ir(ppy)2(TziQn)] seems to be strongly influenced by the LC 
character, as indicated by the long excited state decay lifetime in degassed 
dichloromethane solution.256,275 For a better understanding of the different behaviour 
of these two complexes, time-dependent density functional theory (TD-DFT) analysis 
has been performed and will be discussed in section 2.4.3. 
As expected, the emission profiles of the methylated [Ir(ppy)2(MeTzQn)]+ and 
[Ir(ppy)2(MeTziQn)]+ complexes appear red-shifted, broad, and structureless, as 
depicted in Figure 2.20.  
For all the complexes, an elongation of the excited state lifetime decay (τ) and 
increase of photoluminescence quantum yield (Φ) values is observed upon degassing. 
This behaviour is indicative of the triplet spin multiplicity of the excited state.76,77  
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Figure 2.19 Normalised emission profiles of [Ir(ppy)2(TzQn)] (blue) and 
[Ir(ppy)2(TziQn)] (red) in dichloromethane. 
 
 
Figure 2.20 Normalised emission profiles of [Ir(ppy)2(MeTzQn)]+ (blue) and 
[Ir(ppy)2(MeTziQn)]+ (red) in dichloromethane. 
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The radiative (kr) and non-radiative (knr) decay constants of the majority of the 
investigated iridium(III) complexes were calculated for degassed dichloromethane 
solutions and reported in Table 2.3. Unfortunately, the kr and knr values of 
[Ir(ppy)2(MeTzPyCN)]+ could not have been evaluated due to the biexponential 
nature of the excited state lifetime of the latter.  
 
Table 2.3 Radiative (kr) and non-radiative (knr) decay constants in degassed 
dichloromethane solutions. 
Complex 
kr 
106[s-1]a 
knr 
106[s-1]b 
[Ir(ppy)2(TzPyCN)] 0.751 1.140 
[Ir(F2ppy)2(TzPyCN)] 0.583 0.852 
[Ir(ppy)2(TzPyPhCN)] 0.169 0.967 
[Ir(ppy)2(MeTzPyCN)]+ -c -c 
[Ir(F2ppy)2(MeTzPyCN)]+ 0.214 1.601 
[Ir(ppy)2(MeTzPyPhCN)]+ 0.214 2.090 
[Ir(ppy)2(TzQn)] 0.078 1.125 
[Ir(ppy)2(TziQn)] 0.021 0.128 
[Ir(ppy)2(MeTzQn)]+ 0.079 1.753 
[Ir(ppy)2(MeTziQn)]+ 0.130 1.923 
a Calculated as [Φ/τ] using measurements from deaerated dichloromethane solutions. 
b Calculated as [(1˗Φ)/τ] using measurements from deaerated dichloromethane 
solutions. c The lifetime shows a biexponential nature and so did not allowed the 
calculation of kr and knr. 
 
In general, the neutral [Ir(ppy)2(TzPyCN)], [Ir(F2ppy)2(TzPyCN)] and 
[Ir(ppy)2(TzPyPhCN)] display higher kr constants with respect to [Ir(ppy)2(TzQn)] 
and [Ir(ppy)2(TziQn)], which are associated with a less conjugation degree of the 
pyridyl-tetrazolate ligand in comparison to the (iso)quinolyl-tetrazolate moieties. 
Previous studies have shown how a more conjugated ligand can minimise the spin-
orbit coupling effect of the metal centre, reducing the intersystem crossing rate 
constant (kISC), and lowering the kr.230,276 This effect can also be highlighted by 
comparing the smaller radiative decay constant of [Ir(ppy)2(TzPyPhCN)], which 
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carries a phenyl spacer in the tetrazolate ligand, with the ones of [Ir(ppy)2(TzPyCN)] 
and [Ir(F2ppy)2(TzPyCN)], where no spacer is present.  
The cationic [Ir(F2ppy)2(MeTzPyCN)]+, [Ir(ppy)2(MeTzPyPhCN)]+, 
[Ir(ppy)2(MeTzQn)]+ and [Ir(ppy)2(MeTziQn)]+ show the same trend that their 
neutral analogues, with one order of magnitude of kr greater for the cyano-
functionalised complexes in comparison to the quinolyl and isoquinolyl-functionalised 
species. 
Furthermore, the non-radiative constants (knr) are smaller than the radiative 
decay values for almost all the complexes, with higher values for the cationic species. 
This result explains the better luminescent properties, such as higher quantum yield 
and longer excited state lifetime, for the neutral complexes with respect to their 
methylated analogues. 
 
 
2.4.3 TD-DFT Analysis 
TD-DFT analysis have been performed on [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] to 
better explain the difference in the photophysical properties of these complexes. 
The computational calculations highlight that for [Ir(ppy)2(TzQn)] in the single state, 
the HOMO-type orbitals are mainly localised on the phenyl ring of the ppy ligands 
and the iridium metal centre, while the LUMO-type orbitals are on the quinoline ring 
(LUMO) and also delocalised on the entire cyclometalated ppy ligands (LUMO+N; N 
= 1 – 5), as showed in Figure 2.21. 
In the case of [Ir(ppy)2(TziQn)], the localisation of the HOMO and LUMO 
orbitals is similar to the one of [Ir(ppy)2(TziQn)], but there is also a contribution from 
the tetrazolate ligand in the case of HOMO-4 (Figure 2.22). The HOMO-4®LUMO 
transition corresponding to a LC transition localised on the TziQn- ligand. 
Additionally, the computational calculations also confirm that the lower energy bands 
for both the complexes are mainly composed of MLCT and LLCT transitions. The full 
TD-DFT data can be found in Appendix A, Table A.5 – Table A.6. 
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Figure 2.21 Localisation of the HOMO-5 to the LUMO+5 for [Ir(ppy)2(TzQn)]. The 
simulated orbitals are spaced vertically relative to their energy. 
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Figure 2.22 Localisation of HOMO-4 to the LUMO+3 for [Ir(ppy)2(TziQn)]. The 
simulated orbitals are spaced vertically relative to their energy. 
 
  
82  
2.4.4 Absorption in Aqueous and Lipophilic Solvents 
The photophysical behaviour in aqueous and lipophilic solvents has been investigated 
to assess the applicability of the iridium(III) tetrazolato complexes in a biological 
environment. 
The aqueous media contained 0.2% DMSO to favour the solubilisation of the 
iridium complexes. These solvents have been chosen to highlight possible modulations 
of the photophysical properties of the probes in different cellular organelles. In 
particular, lysosomal pH fluid solution was used to mimic the acidic lysosomes, 
whereas PBS would resemble the cytoplasmic conditions. Moreover the choice of 
ethyl laurate was driven by the necessity to explore the photophysical properties of the 
iridium complexes in lipid-rich compartments, such as membranes, endoplasmic 
reticulum and lipid droplets. 
All the absorption data have been summarised in Table 2.4 and Table 2.5 for 
the cyano and (iso)quinolyl-substituted tetrazolato complexes, respectively. 
The absorption profiles follow the same trend that the ones presented in section 2.4.1, 
Table 2.1. All the iridium complexes display a more intense spin-allowed ligand-
centred (LC) π-π* transitions in the UV region (250 – 300 nm) and a combination of 
spin-allowed and spin-forbidden ligand-to-ligand (LLCT) and metal-to-ligand charged 
transfer (MLCT) absorption shoulders or bands in the visible region (350 – 440 nm) 
of the spectra.236 
The molar absorptivity (e) of the complexes in the different solvent systems 
does not follow a well-defined trend. In general, for aqueous media, methylated 
complexes show higher molar absorptivity coefficients in comparison to the ones in 
the lipophilic ethyl laurate. The opposite trend has been found for the neutral species, 
which display higher lipophilicity and are more likely to slightly aggregate in aqueous 
solutions. 
Absorption spectra of the neutral [Ir(F2ppy)2(TzPyCN)] and 
[Ir(ppy)2(TziQn)] and the charged [Ir(F2ppy)2(MeTzPyCN)]+ and 
[Ir(ppy)2(MeTziQn)]+ complexes have been reported, as example, from Figure 2.23 
to Figure 2.26. The absorption profiles of all the other iridium(III) complexes can be 
found in Appendix A, Figure A.1 – Figure A.6. 
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Table 2.4 Absorption data of aqueous and lipophilic solutions (10-5 M) of the reported 
cyano-substituted complexes. 
Complex Solventa 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2 
(TzPyCN)] 
H2O 253 (3.52), 377 (0.69) 
Lys. Fluid 254 (4.59), 380 (1.15) 
PBS 260 (5.21), 372 (1.47) 
Ethyl Laurate 
258 (7.67), 271 (7.35), 341 (1.98),  
378 (1.23) 
[Ir(F2ppy)2 
(TzPyCN)] 
H2O 256 (4.83), 302 (3.36), 366 (1.16) 
Lys. Fluid 259 (3.62), 300 (2.64), 362 (1.10) 
PBS 258 (3.84), 306 (2.80), 366 (1.33) 
Ethyl Laurate 262 (9.18), 307 (5.17), 371 (1.44) 
[Ir(ppy)2 
(TzPyPhCN)] 
H2O 286 (1.87), 350 (0.86), 421 (0.34) 
Lys. Fluid 262 (1.24), 319 (1.11), 372 (0.55) 
PBS 291 (1.31), 420 (0.38) 
Ethyl Laurate 266 (3.26), 355 (0.22) 
[Ir(ppy)2 
(MeTzPyCN)]+ 
H2O 260 (4.44), 373 (0.59) 
Lys. Fluid 260 (6.08), 309 (2.01), 357 (0.96) 
PBS 261 (6.03), 308 (1.98), 357 (0.93) 
Ethyl Laurate 265 (2.45), 379 (0.18) 
[Ir(F2ppy)2 
(MeTzPyCN)]+ 
H2O 260 (4.12), 309 (1.55), 353 (0.66) 
Lys. Fluid 296 (1.84), 315 (1.49), 350 (0.70) 
PBS 260 (4.88), 309 (1.69), 353 (0.72) 
Ethyl Laurate 262 (3.27), 310 (1.19), 365 (0.42) 
[Ir(ppy)2 
(MeTzPyPhCN)]+ 
H2O 264 (3.82), 390 (0.35) 
Lys. Fluid 264 (4.34), 373 (0.49) 
PBS 265 (4.35), 374 (0.54) 
Ethyl Laurate 
270 (4.95), 289 (4.54), 345 (0.91),  
387 (0.56) 
a Aqueous solvents contain 0.2% DMSO. 
  
84  
Table 2.5 Absorption data of aqueous and lipophilic solutions (10-5 M) of the reported 
(iso)quinolyl-substituted complexes. 
Complex Solventa 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2 
(TzQn)] 
H2O 266 (4.41), 350 (2.35), 425 (0.97) 
Lys. Fluid 265 (3.18), 350 (1.76), 430 (0.75) 
PBS 261 (3.19), 350 (2.07), 439 (0.89) 
Ethyl Laurate 265 (4.75), 343 (1.36), 433 (0.33) 
[Ir(ppy)2 
(TziQn)] 
H2O 268 (3.42), 350 (2.00), 435 (0.80) 
Lys. Fluid 270 (3.53), 345 (2.35), 427 (1.08) 
PBS 
257 (1.74), 293 (1.82), 352 (1.50),  
4.27 (0.93) 
Ethyl Laurate 
257 (8.09), 274 (7.78), 342 (3.21),  
431 (0.77) 
[Ir(ppy)2 
(MeTzQn)]+ 
H2O 251 (8.30), 307 (2.52), 364 (1.09) 
Lys. Fluid 251 (8.91), 310 (3.16), 365 (1.55) 
PBS 251 (8.53), 310 (3.00), 358 (1.56) 
Ethyl Laurate 255 (4.76), 306 (1.69), 350 (0.95) 
[Ir(ppy)2 
(MeTziQn)]+ 
H2O 251 (6.64), 291 (2.60), 355 (1.36) 
Lys. Fluid 251 (6.38), 295 (2.42), 350 (1.41) 
PBS 251 (5.29), 295 (2.05), 350 (1.23) 
Ethyl Laurate 255 (6.15), 298 (2.69), 355 (1.52) 
a Aqueous solvents contain 0.2% DMSO. 
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Figure 2.23 Absorption profiles of [Ir(F2ppy)2(TzPyCN)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 2.24 Absorption profiles of [Ir(F2ppy)2(MeTzPyCN)]+ in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure 2.25 Absorption profiles of [Ir(ppy)2(TziQn)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 2.26 Absorption profiles of [Ir(ppy)2(MeTziQn)]+ in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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2.4.5 Emission Properties in Aqueous and Lipophilic 
Solvents 
The emission properties in aqueous and lipophilic solvents has been listed in Table 
2.6 and Table 2.7 for cyano and (iso)quinolyl-functionalised complexes, respectively. 
The emission spectra of the neutral [Ir(F2ppy)2(TzPyCN)] and [Ir(ppy)2(TziQn)] and 
the charged [Ir(F2ppy)2(MeTzPyCN)]+ and [Ir(ppy)2(MeTziQn)]+ complexes are 
showed as reference from Figure 2.27 to Figure 2.30. The emission profiles of all the 
other iridium(III) complexes can be found in Appendix A, Figure A.7 – Figure A.11. 
The analysis of the emission bands in various solvents reveals solvatochromic 
behaviour, with a red shift of the emission maxima upon increasing the polarity of the 
solvent. The most blue-shifted emission is recorded in ethyl laurate, while the emission 
red shifts by ca. 20 – 30 nm in dichloromethane, with the exception of 
[Ir(ppy)2(MeTzPyPhCN)]+ and [Ir(ppy)2(MeTziQn)]+ for which almost no shift is 
observed. The emission bands further shift (ca. 10 – 30 nm) towards longer wavelength 
in aqueous media. There are no significant differences in the various aqueous solvents, 
apart from [Ir(ppy)2(MeTzPyPhCN)]+ that shows a 22 nm red shift on passing from 
PBS to a lysosomal pH fluid solution. The methylated complex 
[Ir(ppy)2(MeTzPyCN)]+ is found to have appreciable emission only in 
dichloromethane solution, as the complex is virtually non-emissive in aqueous and 
lipophilic solvents. In general, the methylated complexes highlight a greater degree of 
quenching in aqueous solvents with respect to their neutral analogues. While 
conclusive explanations cannot be drawn from these data, potential causes could be 
ascribed to increased non-radiative decays due to energy gap law and the higher 
solubility of the cationic complexes in aqueous solvents. In fact, a similar behaviour 
has been observed for neutral rhenium complexes, where a decrease of solubility in 
aqueous media showed an enhanced quantum yield and elongated excited state 
lifetime.232 
The majority of the iridium complexes show greater quantum yield in ethyl 
laurate, with higher emission intensity for the more lipophilic neutral species in 
comparison with their methylated analogues (refer to Chapter 3 – section 3.2.1 - Table 
3.1). [Ir(ppy)2(TzQn)] and [Ir(ppy)2(TziQn)] are exceptions, displaying comparable 
quantum yields in the lipophilic solvent with the cationic [Ir(ppy)2(MeTzQn)]+ and 
[Ir(ppy)2(MeTziQn)]+. 
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Table 2.6 Photophysical data of diluted (10-5 M) aqueous and lipophilic solutions of 
the reported cyano-substituted complexes. 
Complex Solventa 
λem 
[nm] 
τaer 
[ns]b 
Φaerc 
[Ir(ppy)2 
(TzPyCN)] 
H2O 618 123 (25), 440 (75) 0.047 
Lys. Fluid 616 152 (32), 447 (68) 0.057 
PBS 618 144 (25), 470 (75) 0.085 
Ethyl Laurate 588 156 0.209 
[Ir(F2ppy)2 
(TzPyCN)] 
H2O 552 189 (41), 628 (59) 0.057 
Lys. Fluid 560 81 (34), 384 (66) 0.049 
PBS 552 179 (39), 616 (61) 0.087 
Ethyl Laurate 520 100 (92), 216 (8) 0.159 
[Ir(ppy)2 
(TzPyPhCN)] 
H2O 580 200 (31), 728 (69) 0.055 
Lys. Fluid 580 156 (44), 605 (56) 0.039 
PBS 580 188 (39), 657 (61) 0.033 
Ethyl Laurate 540 83 (61), 371 (39) 0.100 
[Ir(ppy)2 
(MeTzPyCN)]+ 
H2O -d -d -d 
Lys. Fluid -d -d -d 
PBS -d -d -d 
 Ethyl Laurate -d -d -d 
[Ir(F2ppy)2 
(MeTzPyCN)]+ 
H2O 636 11 (76), 56 (24) 0.005 
Lys. Fluid 636 10 (71), 57 (29) 0.007 
PBS 636 11 (66), 88 (34) 0.006 
Ethyl Laurate 580 260 0.067 
[Ir(ppy)2 
(MeTzPyPhCN)]+ 
H2O 605 17 (22), 320 (88) 0.005 
Lys. Fluid 640 15 (84), 123 (16) 0.002 
PBS 618 16 (28), 320 (72) 0.002 
Ethyl Laurate 600 151 (55), 287 (45) 0.002 
a Aqueous solvents contain 0.2% DMSO. b For the biexponential excited state lifetime 
(τ), the relative weights of the exponential curves are reported in parentheses. c 
Measured versus [Ru(bpy)3]2+ in H2O (Φr = 0.028).274 d Not emissive. 
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Table 2.7 Photophysical data of dilute (10-5 M) aqueous and lipophilic solutions of 
(iso)quinolyl-substituted complexes. 
Complex Solvent 
λem 
[nm] 
τaer 
[ns]a 
Φaerb 
[Ir(ppy)2 
(TzQn)] 
H2O 600 305 (25), 928 (75) 0.039 
Lys. Fluid 600 255 (25), 820 (75) 0.033 
PBS 600 279 (27), 865 (73) 0.033 
Ethyl Laurate 566 126 (70), 258 (30) 0.027 
[Ir(ppy)2 
(TziQn)] 
H2O 590 217 (33), 531 (67) 0.018 
Lys. Fluid 590 222 (53), 652 (47) 0.008 
PBS 590 254 (45), 638 (55) 0.020 
Ethyl Laurate 
532, 572, 
622 
397 0.032 
[Ir(ppy)2 
(MeTzQn)]+ 
H2O 630 17 (39), 134 (61) 0.004 
Lys. Fluid 630 18 (40), 153 (60) 0.029 
PBS 635 22 (30), 160 (70) 0.024 
Ethyl Laurate 628 224 0.068 
[Ir(ppy)2 
(MeTziQn)]+ 
H2O 660 9 (53), 93 (47) 0.004 
Lys. Fluid 660 9 (59), 120 (41) 0.005 
PBS 670 9 (62), 85 (37) 0.005 
Ethyl Laurate 640 223 0.054 
a Aqueous solvents contain 0.2% DMSO. b For the biexponential excited state lifetime 
(τ), the relative weights of the exponential curves are reported in parentheses. c 
Measured versus [Ru(bpy)3]2+ in H2O (Φr = 0.028). 
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Figure 2.27 Normalised emission profiles of [Ir(F2ppy)2(TzPyCN)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
 
 
Figure 2.28 Normalised emission profiles of [Ir(F2ppy)2(MeTzPyCN)]+ in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
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Figure 2.29 Normalised emission profiles of [Ir(ppy)2(TziQn)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 2.30 Normalised emission profiles of [Ir(ppy)2(MeTziQn)]+ in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
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2.5 Conclusions 
In this chapter, a library of neutral iridium(III) tetrazolato complexes has been 
synthesised, displaying chemical variations in the cyclometalated phenylpyridine and 
tetrazolate ligands. Furthermore, methylation of these species has allowed facile 
access to the cationic analogues, so that a correlation between the chemical structure 
and the photophysical properties of the complexes could have been more 
systematically investigated. 
NMR and X-ray crystallography studies have confirmed the formation of only 
one isomer of the complexes, with nitrogens of the phenylpyridine in trans with respect 
to the metal centre, and the cyclometalated carbons occupying cis positions. Moreover, 
the methylation site for the charged complexes was proved to be the N3 position on 
the tetrazolato ligand, in accordance with previously reported studies.231,236  
The photophysical properties have revealed typical phosphorescent emission 
from excited state of charged transfer nature, as a mixture of 3MLCT and 3LLCT. The 
emission of the complexes was found to be general solvatochromic, with red shift 
occurring upon increase of the medium polarity. 
Based on the photophysical data summarised in this chapter, discrimination between 
organelles cannot be achieved by monitoring the shift of the emission maximum of 
this family of iridium probes. Moreover, the variation in the pH between the 
lysosomial fluid (pH = 7.4) and the PBS (pH = 4.5) highlighted the lack of pH-sensing 
activities of these probes. 
Nevertheless, the photophysical investigations in aqueous and lipophilic media have 
showed that the complexes are suitable for biological investigation, with the exception 
of [Ir(ppy)2(MeTzPyCN)]+, which displayed appreciable emission only in organic 
solvent.  
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2.6 Experimental 
2.6.1 General Procedures 
Unless otherwise stated, all reagents and solvents were purchased from Sigma Aldrich 
or Alfa Aesar and used as received without further purification. The species 
[Ir(ppy)2(µ-Cl)]2,277 [Ir(F2ppy)2(µ-Cl)]2277 and [Ir(ppy)2(TzPyBr)]236 were prepared 
according to previously published procedures.  
Nuclear magnetic resonance spectra were recorded using a Bruker Avance 400 
spectrometer (400 MHz for 1H NMR; 100 MHz for 13C NMR) at 300 K. All NMR 
spectra were calibrated to residual solvent signals. For the NMR characterisation, 
proton and carbon of all the iridium(III) tetrazolato complexes were assigned as 
pyridinic (A), phenylic (B) and tetrazolic (T), according to Figure 2.31.  
Infrared spectra were recorded using an attenuated total reflectance Perkin 
Elmer Spectrum 100 FT-IR with a diamond stage. IR spectra were recorded from 
4000–650 cm-1. The intensity of the band is reported as strong (s), medium (m), or 
weak (w), with broad (br) bands also specified.  
Melting points were determined using a BI Barnsted Electrotermal 9100 
apparatus.  
Elemental analyses were carried out on bulk samples using a Thermo Finning 
EA 1112 Series Flash; the presence of solvents was further confirmed by 1H NMR. 
Elemental analyses were performed by Robert Herman at the School of Molecular and 
Life Sciences (Curtin University) or by Dr Thomas Rodemann at the Central Science 
Laboraty (University of Tasmania). 
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Figure 2.31 NMR referencing layout. 
2.6.2 Photophysical Measurements 
Absorption spectra were recorded at room temperature using a Cary 4000 UV/Vis 
spectrometer. Uncorrected steady state emission and excitation spectra were recorded 
on an Edinburgh FLSP980-S2S2-stm spectrometer equipped with: i) a temperature-
monitored cuvette holder; ii) 450 W Xenon arc lamp; iii) double excitation and 
emission monochromators; iv) a Peltier cooled Hamamatsu R928P photomultiplier 
tube (spectral range 200-870 nm). Emission and excitation spectra were corrected for 
source intensity (lamp and grating) and emission spectral response (detector and 
grating) by a calibration curve supplied with the instrument. According to the approach 
described by Demas and Crosby,278 luminescence quantum yields (Φem) were 
measured in optically dilute solutions (O.D. < 0.1 at excitation wavelength) obtained 
from absorption spectra on a wavelength scale [nm] and compared to the reference 
emitter by the following Equation 2.1: 
"# = "% &'((*()',(*,) -((*()-,(*,) .,/.(/ 0,0(1                                     (2.1) 
where A is the absorbance at the excitation wavelength (l), I is the intensity of the 
excitation light at the excitation wavelength (l), n is the refractive index of the solvent, 
D is the integrated intensity of the luminescence and Φ is the quantum yield. The 
subscripts r and x refer to the reference and the sample, respectively. The quantum 
yield determinations were performed at identical excitation wavelength for the sample 
and the reference, therefore cancelling the I(lr)/I(lx) term in the equation. The 
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quantum yields of complexes were measured against an aqueous solution of 
[Ru(bipy)3]Cl2 (bipy = 2,2’-bipyridine; Φr = 0.028).274 Emission lifetimes (t) were 
determined with the time correlated single photon counting technique (TCSPC) with 
the same Edinburgh FLSP980-S2S2-stm spectrometer using either a pulsed 
picosecond LED (EPLED/EPL 377 nm, FHWM < 800 ps). The goodness of fit was 
assessed by minimising the reduced c2 function and by visual inspection of the 
weighted residuals. The solvents used for the preparation of the solutions for the 
photophysical investigations were of LR grade and the water was deionised. Degassing 
of the dichloromethane solutions was performed using the freeze-pump-thaw method. 
Experimental uncertainties are estimated to be ±8% for lifetime determinations, ±20% 
for quantum yields, ±2 nm and ±5 nm for absorption and emission peaks, respectively. 
2.6.3 Computational Method 
Time-dependent density functional theory (TD-DFT) calculations were performed 
with GAUSSIAN 09279 by Dr Phillip J. Wright at the Department of Chemistry, Curtin 
University. Prior to these calculations, the structures were relaxed at the B3LYP level 
of theory.280,281 The Ir atoms were treated with the Stuttgart-Dresden effective core 
potential,268 the Pople 6-311G** basis set was used for all the other atoms, and the 
effect of the solvent was mimicked with the PCM solvation model,282 with parameters 
adequate for dichloromethane. The low-lying singlet–singlet excitation energies were 
calculated at the same level of theory, and the spectra were reproduced as the 
superposition of Gaussian functions with heights proportional to calculated intensities 
and a variance of 11 nm. 
 
2.6.4 Synthesis 
HTzPyCN  
 
 
2,5-dicyanopyridine (0.100 g, 0.774 mmol), sodium azide (0.050 g, 0.769 mmol) and 
zinc bromide (0.192 g, 0.853 mmol) were dissolved in 10 mL of water. The resulting 
suspension was vigorously stirred and heated at reflux overnight. The milky reaction 
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mixture was then made basic by addition of a 0.25 M sodium hydroxide solution (7.76 
mL, 1.938 mmol) and the formed yellow precipitate was filtered. The filtrate was 
acidified to pH≈1 with 3 M hydrochloric acid. The formed white precipitate was then 
filtered and dried in air. Yield: 0.085 g (64%), M.P. 234 °C (dec). IR (ν / cm-1): 3071 
w (tetrazole N–H), 2235 w (C≡N), 1604 w (tetrazole C=N).  1H NMR (δ / ppm, 
DMSO-d6): 9.27 (s, 1H, HT6), 8.59 (d, 1H, HT4, J = 8.2 Hz), 8.38 (d, 1H, HT3, J = 8.2 
Hz). 13C NMR (δ / ppm, DMSO-d6): 154.4 (CT), 153.0 (CH6), 146.6 (CN), 142.1 
(CHT4), 122.4 (CH3), 116.5 (CT5), 110.6 (CT2). 
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HTzQn 
 
 
Triethylamine (1.9 mL, 0.030 mol) was added to toluene (25 mL) and the solution was 
cooled to 0 ºC. HCl 32% (1.6 mL, 0.030 mol) was added to the reaction mixture and 
stirred until fuming subsided. 2-quinolinecarbonitrile (0.600 g, 0.004 mol) and sodium 
azide (0.868 g, 0.018 mol) were added and heated at reflux overnight. After cooling 
down to room temperature, the mixture was extracted with water (2 × 15 mL) and the 
aqueous phase was collected and acidified to pH≈3 with HCl 32%. The formed off-
white precipitate was then filtered and dried in air. Yield: 0.722 g (94%). M.P. 197 – 
198 °C. IR (ν / cm-1): 3057 w (tetrazole N–H), 1600 w (tetrazole C=N).  1H NMR (δ / 
ppm, DMSO-d6): 8.67 (d, 1H, HT4, J = 8.5 Hz), 8.33 (d, 1H, HT3, J = 8.5 Hz), 8.19 (d, 
1H, HT9, J = 8.5 Hz), 8.13 (d, 1H, HT6, J = 8.2 Hz), 7.91 (t, 1H, HT8, J = 7.7 Hz), 7.75 
(t, 1H, HT7, J = 7.7 Hz). 13C NMR (δ / ppm, DMSO-d6): 155.2 (CT), 147.2 (CT2), 144.1 
(CT10), 138.4 (CHT4), 130.9 (CHT8), 128.9 (CHT9), 128.3 (CHT6), 128.2 (CHT7), 119.2 
(CHT3), 114.5 (CT5). 
 
HTziQn 
 
 
Triethylamine (1.9 mL, 0.030 mol) was added to toluene (25 mL) and the solution was 
cooled to 0 ºC. HCl 32% (1.6 mL, 0.030 mol) was added to the reaction mixture and 
stirred until fuming subsided. 2-quinolinecarbonitrile (0.600 g, 0.004 mol) and sodium 
azide (0.868 g, 0.018 mol) were added and heated at reflux overnight. After cooling 
down to room temperature, the mixture was extracted with water (2 × 15 mL) and the 
aqueous phase was collected and acidified to pH≈3 with HCl 32%. The formed white 
precipitate was then filtered and dried in air. Yield: 0.528 g (69%). M.P. 237 – 238 °C. 
IR (ν / cm-1): 3063 w (tetrazole N–H), 1613 w (tetrazole C=N).  1H NMR (δ / ppm, 
DMSO-d6): 9.37 (d, 1H, HT10, J = 8.3 Hz), 8.74 (d, 1H, HT9, J = 5.5 Hz), 8.16 – 8.13 
(m, 2H, HT4, HT7), 7.94 – 7.86 (m, 2H, HT5, HT6). 13C NMR (δ / ppm, DMSO-d6): 
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155.0 (CT), 143.0 (CT2), 141.8 (CHT9), 136.6 (CT3), 131.3 (CHT5), 129.3 (CHT6), 
127.5 (CHT4), 126.3 (CHT10), 125.7 (CT8), 123.6 (CHT7). 
 
 [Ir(ppy)2(TzPyCN)] 
 
 
[Ir(ppy)2(µ-Cl)]2 (0.226 g, 0.211 mmol) was combined with HTzPyCN (0.080 g, 
0.465 mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v). 
The resulting suspension was stirred at room temperature overnight. The solvents were 
concentrated and the product was purified via column chromatography using 
Brockmann I grade neutral alumina-filled as stationary phase and a 
dichloromethane/acetone (9:1 v/v) solvent system as eluent. The targeted complex 
eluted as the second fraction (yellow). Yield: 0.215 g (76%). M.P. 210 °C (dec). IR (ν 
/ cm-1): 2235 w (C≡N), 1606 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 8.55 
– 8.49 (m, 2H, HT4, HT3), 8.18 – 8.12 (m, 2H, 2HA), 8.12 (s, 1H, HT6), 7.93 – 7.88 (m, 
2H, 2HA), 7.86 (d, 2H, 2HA, J = 8.0 Hz), 7.77 (d, 1H, HB, J = 7.6 Hz), 7.58 (d, 1H, HB, 
J = 5.8 Hz), 7.17 (app. t., 1H, HB, splitting = 7.3 Hz), 7.06 – 6.99 (m, 2H, 2HA), 6.93 
– 6.88 (m, 2H, 2HB), 6.78 (app. t., 1H, HB, splitting = 7.4 Hz), 6.43 (d, 1H, HB, J = 7.5 
Hz), 6.29 (d, 1H, HB, J = 7.7 Hz). 13C NMR (δ / ppm, acetone-d6): 168.9 (CA), 168.8 
(CA), 163.7 (CT), 153.9 (CHT6), 153.5 (CN), 152.0 (CB), 150.4 (CHA), 147.4 (CB), 
145.7 (CB), 145.0 (CB), 143.5 (CHT4), 139.2 (CHA), 138.8 (CHA), 132.9 (CHB), 132.5 
(CHB), 131.0 (CHB), 130.1 (CHB), 125.7 (CHA), 125.1 (CHB), 124.3 (CHB), 123.8 
(CHB), 123.2 (2CHA), 123.1 (CHT3), 122.4 (CHB), 120.5 (CHA), 120.1 (CHA), 116.1 
(CT2), 112.3 (CT5). Anal. Calcd for [Ir(ppy)2(TzPyCN)]×0.8(acetone): C, 52.47; H, 
3.31; N, 15.67. Found: C, 52.79; H, 2.95; N, 15.71. 
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[Ir(F2ppy)2(TzPyCN)] 
 
 
[Ir(F2ppy)2(µ-Cl)]2 (0.129 g, 0.113 mmol) was combined with HTzPyCN (0.040 g, 
0.232 mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v). 
The resulting suspension was stirred at room temperature overnight. The solvents were 
concentrated and the product was purified via column chromatography using 
Brockmann I grade neutral alumina-filled as stationary phase and a 
dichloromethane/acetone (9:1 v/v) solvent system as eluent. The targeted complex 
eluted as the second fraction (yellow). Yield: 0.120 g (71%). M.P. 252 °C (dec). IR (ν 
/ cm-1): 2232 w (C≡N), 1601 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 8.61 
– 8.57 (m, 2H, HT4, HT3), 8.33 (s, 1H, HT6), 8.28 (app. t., 2H, 2HA, splitting = 8.5 Hz), 
8.00 – 7.91 (m, 3H, 3HA), 7.51 (d, 1H, HA, J = 5.8 Hz), 7.23 (app. t., 1H, HA, splitting 
= 7.4 Hz), 7.10  (app. t., 1H, HA, splitting = 7.4 Hz), 6.66 (app. t., 1H, HB, splitting = 
12.4 Hz), 6.59 (app. t., 1H, HB, splitting = 12.4 Hz), 5.84 (d, 1H, HB,  J = 8.6 Hz), 5.66 
(d, 1H, HB, J = 8.9 Hz). 13C NMR (δ, ppm, acetone-d6): 165.7 (d, 2CB, JCF = 50.4 Hz), 
165.2 (d, CB, JCF = 28.8 Hz), 165.0 (d, CB, JCF = 28.8 Hz), 163.6 (2CA), 163.2 (2CB), 
163.1 (d, 2CB, JCF = 20.0 Hz), 154.7 (CHT6), 152.8 (CN), 151.6 (d, 2CHA, JCF = 28.0 
Hz), 150.8 (d, CHA, JCF = 107.2 Hz), 144.3 (CHT4), 140.2 (d, CHA, JCF = 111.6 Hz), 
129.5 (d, CHB, JCF = 15.2 Hz), 128.9 (d, CHB, JCF = 17.6 Hz), 124.8 (CHA), 124.4 
(CHA), 124.0 (dd, CHA, JCF = 97.2 Hz), 123.4 (CHT3), 115.9 (CT2), 114.9 (dd, CHB, 
JCF = 72.0 Hz), 112.8 (CT5), 99.5 (dd, CHB, JCF = 108 Hz), 98.7 (dd, CHB, JCF = 108 
Hz); quaternary tetrazolic C peak was not visible in the spectrum. Crystals suitable for 
X-ray analysis were obtained by slow diffusion of hexane into a solution of the 
complex in dichloromethane. Anal. Calcd for [Ir(F2ppy)2(TzPyCN)]×0.2(CH2Cl2): C, 
46.39; H, 2.13; N, 14.62. Found: C, 46.36; H, 1.75; N, 14.68. 
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[Ir(ppy)2(TzPyPhCN)] 
 
 
[Ir(ppy)2(TzPyBr)] (0.150 g, 0.207 mmol), 4-cyanophenylboronic acid (0.036 g, 
0.248 mmol), and bis(triphenylphosphine)palladium(II) dichloride (0.005 g, 0.006 
mmol) were combined and dissolved in 10 mL of dry THF. The solution was stirred 
under nitrogen for 15 minutes and 1 M aqueous Na2CO3 (15 mL, 0.290 mmol) was 
added and refluxed overnight. The cooled crude mixture was washed with water and 
extracted with dichloromethane (3 × 15 mL). The combined organic phase was dried 
over MgSO4 and filtered. The product was purified via column chromatography using 
Brockmann I grade neutral alumina-filled as stationary phase and a 
dichloromethane/acetone (9:1 v/v) solvent system as eluent. The targeted complex 
eluted as the second fraction (yellow). Yield: 0.134 g (87%). M.P. 234 – 236 °C. IR (ν 
/ cm-1): 2232 w (C≡N), 1606 w (tetrazole C=N). 1H NMR (δ / ppm, DMSO-d6): 8.51 
(d, 1H, HT4, J = 8.2 Hz), 8.44 (d, 1H, HT3, J = 8.2 Hz), 8.20 (app. t., 2H, 2HA, splitting 
= 8.4 Hz), 7.94 – 7.83 (m, 6H, 2HTph, 3HB, HA), 7.77 (d, 1H, HA, J = 7.6 Hz), 7.64 – 
7.60 (m, 1H, HT6), 7.52 (d, 2H, 2HTph, J = 8.4 Hz), 7.46 (d, 1H, HA, J = 7.6 Hz), 7.19 
(app. t., 1H, HA, splitting = 7.2 Hz), 7.10 (app. t., 1H, HA, splitting = 7.2 Hz), 7.02 
(app. t., 1H, HA, splitting = 8.2 Hz), 6.93 (app. t., 2H, 2HB, splitting = 7.4 Hz), 6.79 
(app. t., 1H, HB, splitting = 7.6 Hz), 6.32 (d, 1H, HB, J = 6.4 Hz), 6.20 (d, 1H, HB, J = 
6.4 Hz). 13C NMR (δ / ppm, acetone-d6): 167.2 (CA), 167.0 (CA), 163.1 (CT), 151.5 
(CB), 149.2 (CHA), 148.9 (CHA), 147.9 (CN), 147.4 (CHB), 147.2 (CHB), 144.5 (CB), 
144.1 (CB), 139.4 (CTph), 138.5 (CHA), 138.2 (CHA), 138.0 (CHT4), 136.2 (CT2), 133.2 
(CHTph), 131.4 (CHT6), 131.5 (CHB), 130.0 (CHB), 129.1 (CHB), 128.8 (CHB), 128.7 
(CHB), 127.4 (CHTph), 124.9 (CB), 124.4 (CHTph), 123.7 (CHA), 123.4 (CHA), 122.4 
(CHTph), 122.0 (CHT3), 121.2 (CHB), 119.8 (CHA), 119.3 (CHA), 118.3 (CT5), 111.7 
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(CTph). Anal.Calcd for [Ir(ppy)2(TzPyPhCN)]×(CH2Cl2)×0.3(acetone): C, 52.15; H, 
3.19; N, 13.15. Found: C, 51.99; H, 2.82; N, 13.37. 
 
[Ir(ppy)2(MeTzPyCN)][PF6] 
 
 
[Ir(ppy)2(TzPyCN)] (0.060 g, 0.089 mmol) was dissolved in dichloromethane (10 
mL) and cooled down to –50 °C using an ethyl acetate/liquid nitrogen cool bath. 
Thereafter, a 0.1 M methyl trifluoromethanesulfonate solution in dichloromethane 
(0.022 g, 0.133 mmol) was added dropwise to the vigorously stirred solution. After 
being maintained at –50 °C for 30 minutes, the solution was warmed up at room 
temperature and left to stirred overnight. An excess of ammonium 
hexafluorophosphate (0.029 g, 0.178 mmol) was added and stirred for 45 minutes. The 
crude mixture was washed with water and extracted with dichloromethane (3 × 15 mL) 
and the combined organic phase was dried on MgSO4. The targeted complex was then 
collected after filtration and removal of the solvent as a red solid. Yield: 0.063 g (85%). 
M.P. 242 – 243 °C. IR (ν / cm-1): 2240 w (C≡N), 1609 w (tetrazole C=N).  1H NMR 
(δ / ppm, acetone-d6): 8.79 (d, 1H, HT4, J = 8.2 Hz), 8.73 (d, 1H, HT3, J = 8.2 Hz), 8.32 
(s, 1H, HT6), 8.22 (d, 2H, 2HA, J = 8.0 Hz), 8.03 – 7.96 (m, 4H, 4HA), 7.89 (d, 1H, HB, 
J = 7.7 Hz), 7.83 (d, 1H, HB, J = 7.7 Hz), 7.03 – 6.98 (m, 2H, 2HA), 7.06 (app. t, 1H, 
HB, splitting = 7.8 Hz), 6.87 – 6.80 (m, 2H, 2HB), 6.85 (app. t., 1H, HB, splitting = 7.5 
Hz), 6.34 (d, 1H, HB, J = 7.6 Hz), 6.28 (d, 1H, HB, J = 7.7 Hz), 4.57 (s, 3H, 3HTMe). 
13C NMR (δ / ppm, acetone-d6): 168.5 (CA), 168.1 (CA), 166.8 (CT), 154.9 (CHT6), 
151.2 (CHA), 151.1 (CHA), 148.6 (CN), 147.5 (CB), 145.3 (CB), 145.2 (CB), 144.9 
(CHT3), 144.0 (CB), 139.9 (CHA), 139.8 (CHA), 132.7 (CHB), 132.4 (CHB), 131.3 
(CHB), 130.6 (CHB), 126.0 (CHB), 125.6 (CHB), 125.4 (CHT4), 124.6 (CHA), 124.4 
(CHA), 124.1 (CHB), 123.5 (CHB), 121.0 (CHA), 120.6 (CHA), 115.9 (CT2), 115.5 
(CT5), 42.7 (CHTMe). Crystals were formed in the NMR tube and have been used for 
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the elemental analysis. Anal.Calcd for [Ir(ppy)2(MeTzPyCN)][PF6]×0.3(CH2Cl2) 
×0.3(acetone): C, 43.26; H, 2.88; N, 12.81. Found: C, 43.21; H, 2.57; N, 12.77. 
 
[Ir(F2ppy)2(MeTzPyCN)][PF6] 
 
 
[Ir(F2ppy)2(TzPyCN)] (0.060 g, 0.081 mmol) was dissolved in dichloromethane (10 
mL) and cooled down to –50 °C using an ethyl acetate/liquid nitrogen cool bath. A 0.1 
M methyl trifluoromethanesulfonate solution in dichloromethane (0.020 g, 0.121 
mmol) was added dropwise to the vigorously stirred solution. After being maintained 
at –50 °C for 30 minutes, the solution was warmed up at room temperature and left to 
stir overnight. An excess of ammonium hexafluorophosphate (0.026 g, 0.162 mmol) 
was added and stirred for 45 minutes. The crude mixture was washed with water and 
extracted with dichloromethane (3 × 15 mL) and the combined organic phase was dried 
on MgSO4. The targeted complex was then collected after filtration and removal of the 
solvent as a red solid. Yield: 0.092 g (88%). M.P. 293 °C (dec). IR (ν / cm-1): 2243 w 
(C≡N), 1599 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 8.84 (m, 2H, HT4, 
HT3), 8.63 (s, 1H, HT6), 8.37 (d, 2H, 2HA, J = 8.8 Hz), 8.11 – 8.06 (m, 4H, 4HA), 7.26 
– 7.21 (m, 4H, 2HA), 6.81 – 6.71 (m, 2H, 2HB), 5.79 (d, 1H, HB, J = 8.6 Hz), 5.71 (d, 
1H, HB, J = 8.7 Hz), 4.61 (s, 3H, 3HTMe). 13C NMR (δ / ppm, acetone-d6): 166.7 (CT), 
165.5 (d, CB, JCF = 12.8 Hz), 165.0 (d, CB, JCF = 12.6 Hz), 163.4 (d, CA, JCF = 13.1 Hz), 
163.0 (d, CB, JCF = 20.8 Hz), 162.9 (d, CB, JCF = 21.2 Hz), 162.4 (d, CB, JCF = 12.5 Hz), 
160.9 (d, CB, JCF = 12.9 Hz), 160.3 (d, CB, JCF = 52.0 Hz), 155.8 (CHT6), 151.7 (CHA), 
151.5 (CHA), 151.2 (d, CA, JCF = 27.6 Hz), 148.0 (CN), 145.7 (CHT4), 141.0 (2CHA), 
129.2 (d, CB, JCF = 74.0 Hz), 125.8 (CHT3), 125.1 (d, 2CHA, JCF = 30.8 Hz), 124.7 (d, 
CHA, JCF = 78.8 Hz), 124.3 (d, CHA, JCF = 80.4 Hz), 116.3 (CT2), 115.3 (CT5), 114.9 
(dd, CHB, JCF = 14.8 Hz), 114.8 (dd, CHB, JCF = 12.8 Hz), 100.4 (dd, CHB, JCF = 107.6 
Hz), 99.9 (dd, CHB, JCF = 92.0 Hz), 42.9 (CHTMe). Anal.Calcd for 
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[Ir(F2ppy)2(MeTzPyCN)][PF6]×0.3(diethyl ether): C, 40.37; H, 2.24; N, 12.15. Found: 
C, 40.20; H, 1.95; N, 11.91. 
 
[Ir(ppy)2(MeTzPyMeCN)][PF6] 
 
 
[Ir(ppy)2(TzPyPhCN)] (0.050 g, 0.067 mmol) was dissolved in dichloromethane (10 
mL) and cooled down to –50 °C using ethyl acetate/liquid nitrogen cool bath. A 0.1M 
methyl trifluoromethanesulfonate solution in dichloromethane (0.016 g, 0.100 mmol) 
was added dropwise to the vigorously stirred solution. After being maintained at –50 
°C for 30 minutes, the solution was warmed up at room temperature and left to stir 
overnight. An excess of ammonium hexafluorophosphate (0.022 g, 0.134 mmol) was 
added and stirred for 45 minutes. The crude mixture was washed with water and 
extracted with dichloromethane (3 × 15 mL) and the combined organic phase was dried 
on MgSO4. The targeted complex was then collected after filtration and removal of the 
solvent as a yellow solid. Yield: 0.044 g (73%). M.P. 222 – 224 °C. IR (ν / cm-1): 2229 
w (C≡N), 1608 w (tetrazole C=N).  1H NMR (δ / ppm, DMSO-d6): 8.70 – 8.65 (m, 2H, 
HT4, HT3), 8.24 (d, 2H, 2HA, J = 9.2 Hz), 8.00 – 7.85 (m, 8H, HT6, 4HTph, 3HA), 7.58 
(d, 3H, 3HB, J = 8.8 Hz), 7.21 – 7.14 (m, 2H, 2HA), 7.06 (app. t., 1H, HA, splitting = 
7.6 Hz), 6.99 – 6.93 (m, 2H, 2HB), 6.83 (app. t., 1H, HB, splitting = 7.6 Hz), 6.23 (d, 
1H, HB, J = 4.2 Hz), 6.16 (d, 1H, HB, J = 4.2 Hz), 4.54 (s, 3H, 3HTMe). 13C NMR (δ / 
ppm, DMSO-d6): 166.8 (CT), 166.2 (CTph), 165.6 (CTph), 150.3 (CHA), 150.1 (CHA), 
148.3 (CHT6), 147.6 (CB), 144.2 (CA), 144.1 (CA), 144.0 (CN), 143.5 (CT2), 139.1 
(CHTph), 139.0 (CHTph), 138.9 (CHTph), 138.8 (CHTph), 133.3 (CHA), 132.0 (CHB), 
131.5 (CHB), 131.4 (CHB), 130.9 (CHB), 130.3 (CHB), 129.5 (CHB), 128.8 (CB), 128.7 
(CB), 127.8 (CHB), 125.1 (CHT4), 124.6 (CHT3), 124.0 (CHA), 123.9 (CHA), 122.8 
(CHA), 122.2 (CHB), 120.1 (CHA), 119.8 (CHA), 118.2 (CT5), 112.3 (CB), 42.1 
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(CHTMe).   Crystals suitable for X-ray analysis were obtained by slow diffusion of 
hexane into a solution of the complex in dichloromethane. Anal.Calcd for 
[Ir(ppy)2(MeTzPyMeCN)][PF6]×0.2(CH2Cl2): C, 47.01; H, 2.88; N, 12.12. Found: C, 
47.14; H, 3.04; N, 12.07. 
 
[Ir(ppy)2(TzQn)] 
 
 
[Ir(ppy)2(µ-Cl)]2 (0.250 g, 0.233 mmol) was combined with HTzQn (0.115 g, 0.583 
mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v). The 
resulting suspension was stirred at room temperature overnight. The solvents were 
concentrated and the product was purified via column chromatography using 
Brockmann I grade neutral alumina-filled as stationary phase and a 
dichloromethane/acetone (8:2 v/v) solvent system as eluent. The targeted complex 
eluted as the second fraction (yellow). Yield: 0.172 g (53%). M.P. 314 – 317 °C. IR (ν 
/ cm-1): 1602 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 8.69 (d, 1H, HT4, J = 
8.2 Hz), 8.54 (d, 1H, HT3, J = 8.5 Hz), 8.14 (d, 1H, HT9, J = 8.0 Hz), 8.10 – 7.98 (m, 
4H, 4HA), 7.86 – 7.73 (m, 4H, 4HB), 7.54 (app. t., 1H, HA, splitting = 7.4 Hz), 7.33 (d, 
1H, HA, J = 6.0 Hz), 7.21 (app. t., 1H, HA, splitting = 8.0 Hz), 7.06 (app. t., 1H, HA, 
splitting = 6.8 Hz), 7.02 – 6.97 (m, 4H, HT6, HT7, HT8, HB), 6.73 (app. t., 1H, HB, 
splitting = 7.5 Hz), 6.54 (d, 1H, HB, J = 7.6 Hz), 6.16 (d, 1H, HB, J = 7.6 Hz). 13C 
NMR (δ / ppm, acetone-d6): 169.5 (CA), 168.7 (CA), 166.0 (CT), 155.5 (CB), 152.5 
(CT5), 151.3 (CHA), 149.7 (CHA), 148.7 (CT10), 145.6 (CB), 144.7 (CB), 144.6 (CB), 
141.6 (CHT4), 138.8 (CHB), 138.5 (CHB), 133.2 (CHB), 131.9 (CHB), 130.8 (CHA), 
130.2 (CHT7), 130.1 (CHT6), 129.8 (CHB), 128.9 (CHA), 128.5 (CHA), 125.7 (CHB), 
124.9 (CHB), 123.9 (CHA), 123.6 (CHA), 122.5 (CHT8), 122.4 (CHB), 120.6 (CHT3), 
120.2 (CHT9), 120.1 (CHA); quaternary tetrazolic C peak was not visible in the 
spectrum.  Anal. Calcd for [Ir(ppy)2(TzQn)]×(CH2Cl2)×0.2(acetone): C, 54.78; H, 3.71; 
N, 12.70. Found: C, 54.81; H, 3.86; N, 12.67. 
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[Ir(ppy)2(TziQn)] 
 
 
[Ir(ppy)2(µ-Cl)]2 (0.250 g, 0.233 mmol) was combined with HTzQn (0.115 g, 0.583 
mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v). The 
resulting suspension was stirred at room temperature overnight. The solvents were 
concentrated and the product was purified via column chromatography using 
Brockmann I grade neutral alumina-filled as stationary phase and a 
dichloromethane/acetone (8:2 v/v) solvent system as eluent. The targeted complex 
eluted as the second fraction (yellow). Yield: 0.235 g (72%). M.P. 272 – 275 °C. IR (ν 
/ cm-1): 1606 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 10.25 – 10.21 (m, 
1H, HT9), 8.16 – 8.12 (m, 2H, 2HA), 8.10 – 8.04 (m, 1H, HT10), 7.97 – 7.94 (m, 2H, 
HT6, HT7), 7.88 – 7.81 (m, 5H, 3HA, HT4, HT5), 7.79 – 7.75 (m, 2H, HA, HB), 7.59 (d, 
1H, HB, J = 6.0 Hz), 7.11 (app. t., 1H, HB, splitting = 6.8 Hz), 7.04 – 6.98 (m, 2H, 
2HA), 6.94 – 6.89 (m, 2H, 2HB), 6.78 (app. t., 1H, HB, splitting = 7.4 Hz), 6.67 (d, 1H, 
HB, J = 7.6 Hz), 6.35 (d, 1H, HB, J = 7.6 Hz). 13C NMR (δ / ppm, acetone-d6): 169.3 
(CA), 169.1 (CA), 166.0 (CT), 154.7 (CT8), 150.4 (CHB), 150.1 (CHB), 149.6  (CB), 
145.6 (CB), 145.1 (CB), 142.5 (CHT4), 138.8 (CHA), 138.5 (CHA), 137.7 (CT3), 133.5 
(CHT6), 132.8 (CHB), 132.7 (CHB), 131.0 (CHB), 130.4 (CHB), 130.1 (CHT7), 128.9 
(CHT9), 128.1  (CHT10), 127.3 (CB), 125.6 (CHT5), 125.1 (CHA), 125.0 (CHA), 124.1 
(CHB), 123.7 (CHA), 122.8 (CHA), 122.1 (CHB), 120.2 (CHA), 120.1 (CHA); 
quaternary tetrazolic C peak was not visible in the spectrum. Anal. Calcd for 
[Ir(ppy)2(TziQn)]×0.7(CH2Cl2): C, 52.08; H, 3.12; N, 13.01. Found: C, 52.26; H, 2.94; 
N, 13.04. 
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[Ir(ppy)2(MeTzQn)][PF6] 
 
 
[Ir(ppy)2(TzQn)] (0.050 g, 0.072 mmol) was dissolved in dichloromethane (10 mL) 
and cooled down to –50 °C using an ethyl acetate/liquid nitrogen cool bath. Thereafter, 
a 0.1 M methyl trifluoromethanesulfonate solution in dichloromethane (0.018 g, 0.108 
mmol) was added dropwise to the vigorously stirred solution. After being maintained 
at –50°C for 30 minutes, the solution was warmed up at room temperature and left to 
stirred overnight. An excess of ammonium hexafluorophosphate (0.025 g, 0.144 
mmol) was added and stirred for 45 minutes. The crude mixture was washed with 
water and extracted with dichloromethane (3 × 15 mL) and the combined organic 
phase was dried on MgSO4. The targeted complex was then collected after filtration 
and removal of the solvent as an orange solid. Yield: 0.050 g (81%). M.P. 242 – 246 
°C. IR (ν / cm-1): 1607 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 8.97 (d, 1H, 
HT4, J = 8.4 Hz), 8.66 (d, 1H, HT3, J = 8.5 Hz), 8.26 (d, 1H, HT6, J = 8.1 Hz), 8.19 – 
8.07 (m, 4H, 4HA), 7.99 (app. t., 1H, HT7, splitting = 8.2 Hz), 7.94 – 7.83 (m, 4H, 2HA, 
2HB), 7.71 (app. t., 1H, HA, splitting = 7.6 Hz), 7.35 (app. t., 1H, HA, splitting = 8.0 
Hz), 7.10 – 6.98 (m, 5H, 3HB, HT8, HT9), 6.84 (app. t., 1H, HB, splitting = 7.5 Hz), 6.43 
(d, 1H, HB, J = 7.6 Hz), 6.17 (d, 1H, HB, J = 7.7 Hz), 4.59 (s, 3H, 3HTMe). 13C NMR 
(δ / ppm, acetone-d6): 168.8 (CA), 168.6 (CA), 168.1 (CT), 152.0 (CHA), 150.8 (CB), 
150.5 (CHA), 148.9 (CB), 147.5 (CT2), 145.2 (CB), 144.7 (CB), 143.2 (CHT4), 141.0 
(CT10), 139.7 (CHA), 139.6 (CHT7), 133.1 (CHB), 132.5 (CHB), 131.9 (CHB), 131.6 
(CT5), 131.3 (CHT8), 130.7 (CHA), 130.4 (CHA), 130.3 (CHA), 129.0 (CHA), 126.1 
(CHB), 125.4 (CHB), 124.6 (CHT9), 124.1 (CHB), 123.7 (CHB), 123.6 (CHB), 120.9 
(CHT3), 120.8 (CHT6), 120.6 (CHA), 42.6 (CHTMe). Anal.Calcd for 
[Ir(ppy)2(MeTzQn)][PF6]×0.2(CH2Cl2): C, 45.74; H, 2.93; N, 11.26. Found: C, 45.71; 
H, 2.60; N, 11.13. 
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[Ir(ppy)2(MeTziQn)][PF6] 
 
 
[Ir(ppy)2(TziQn)] (0.060 g, 0.086 mmol) was dissolved in dichloromethane (10 mL) 
and cooled down to –50 °C using an ethyl acetate/liquid nitrogen cool bath. Thereafter, 
a 0.1 M methyl trifluoromethanesulfonate solution in dichloromethane (0.021 g, 0.129 
mmol) was added dropwise to the vigorously stirred solution. After being maintained 
at –50°C for 30 minutes, the solution was warmed up at room temperature and left to 
stirred overnight. An excess of ammonium hexafluorophosphate (0.028 g, 0.163 
mmol) was added and stirred for 45 minutes. The crude mixture was washed with 
water and extracted with dichloromethane (3 × 15 mL) and the combined organic 
phase was dried on MgSO4. The targeted complex was then collected after filtration 
and removal of the solvent as an orange solid. Yield: 0.044 g (60%). M.P. 215 – 218 
°C. IR (ν / cm-1): 1607 w (tetrazole C=N).  1H NMR (δ / ppm, acetone-d6): 9.58 (d, 1H, 
HT9, J = 9.8 Hz), 8.27 – 8.20 (m, 4H, 4HA), 8.15 – 8.10 (m, 2H, HT6, HT7), 8.05 (app. 
t., 2H, HA, HT10, splitting = 5.7 Hz), 7.99 – 7.92 (m, 3H, 3HA), 7.87 (d, 2H, HT4, HT5, 
J = 7.7 Hz), 7.10 – 7.06 (m, 3H, 2HA, HB), 7.03 – 6.95 (m, 2H, 2HB), 6.88 (app. t., 1H, 
HB, splitting = 7.6 Hz), 6.35 (app. t., 2H, 2HB, splitting = 7.6 Hz), 4.69 (s, 3H, 3HTMe). 
13C NMR (δ / ppm, acetone-d6): 168.8 (CA), 168.5 (CA), 168.2 (CT), 151.2 (CHT4), 
150.8 (CHT6), 150.1 (CB), 145.9 (CT8), 145.5 (CB), 145.2 (CB), 145.1 (CB), 143.0 
(CHA), 139.7 (CHA), 139.6 (CHA), 138.1 (CT3), 134.4 (CHT10), 132.8 (2CHB), 132.2 
(CHT7), 131.4 (CHB), 130.6 (CHB), 129.1 (CHA), 128.8 (CHA), 127.8 (CT2), 126.6 
(CHT9), 125.9 (CHA), 125.4 (CHT5), 124.5 (CHB), 124.4 (CHB), 123.8 (CHB), 123.3 
(CHB), 120.7 (CHA), 120.6 (CHA), 42.7 (CHTMe). Anal.Calcd for 
[Ir(ppy)2(MeTziQn)][PF6]×0.4(CH2Cl2)×0.2(H2O): C, 44.85; H, 2.95; N, 10.96. Found: 
C, 44.84; H, 2.90; N, 10.65. 
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Chapter 3  
Biological Investigation of Cyano and 
(Iso)Quinolyl-Functionalised Iridium 
Tetrazolato Complexes 
 
The content of this chapter has been published in: 
Chemistry – A European Journal (2017) with the title “Investigating 
intracellular localisation and cytotoxicity trends for neutral and cationic iridium 
tetrazolato complexes in live cells”.238 
Scientific Reports (2018) with the title “Mitochondria imaging in live cells and 
live or fixed tissues using a luminescent iridium complex”.283 
 
3.1 Introduction 
The translucent nature of cells has made detailed cellular studies hard to achieve, until 
the development of differential cell stains. This process began in 1858 when Joseph 
von Gerlach established that a dilute solution of carmine could preferentially stain the 
nuclei of brain tissues.284 However, classical dyes such as Gram or hematoxylin and 
eosin (H&E) stains (Figure 3.1 ˗ left), are generally not highly selective against 
specific biomolecules and their imaging process is based on the absorption of 
transmitted light, which does not allow 3D images.285,286  
In contrast, the development of luminescent probes has provided a new tool for 
the study of cells at subcellular level with higher sensitivity and better spatial 
resolution. Initially, these probes were based on organic fluorophores48,50 (Figure 3.1 
˗ centre), fluorescent proteins287,288 or quantum dots.289,290 Although they could 
efficiently localise within cells and accumulate in particular organelles, their 
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application was limited by inherently small Stokes shifts and short excited state 
lifetimes.291  
As alternative to the organic probes, transition metal complexes [e.g.: Re(I), 
Ru(II), Os(II), Au(I), Ir(III) and Pt(II)]64,65,80,292,293 (Figure 3.1 ˗  right) and luminescent 
lanthanide species [e.g.: Eu(III), Tb(III) and Yb(III)]291,294,295 have been explored due 
to their alternative photophysical properties, which have allowed major improvements 
in the optical imaging techniques. In particular, luminescent iridium(III) complexes 
have showed to be exceptional systems for the application in live cells imaging. Two 
main approaches have been employed for the construction of these probes. In the first 
case, small complexes have been designed to internalise and accumulate within the 
cells based on the functional groups present on the coordinated ligands.101–
104,116,139,296,297 In the second group, iridium complexes have been conjugated with 
biologically relevant moieties such as carbohydrates,126,298 biotin/avidin,107,299–301 
amino acids120 and proteins302 in an attempt to control their biospecificity. 
 
 
Figure 3.1 Different cells and tissues staining. (Left) H&E staining of lung tissue 
showing hyaline-membrane formation and pneumocyte desquamation with focal 
giant-cell formation (× 400). (Centre) Nuclei of live HeLa cells stained with NucSpot™ 
650 (Biotium). (Right) Mitochondria of live A549 cells stained with an iridium(III) 
complex (scale bar = 10 µm). Reproduced with permission from ref 303,304. 
 
In this chapter, the biological properties of the neutral and methylated iridium(III) 
complexes discussed in Chapter 2 are described, aiming to highlight the structure-
activity relationship of these probes. The biological investigation has been carried out 
in live H9c2 rat cardiomyoblast cells, and the uptake mechanism, specific localisation 
and photostability of the iridium complexes has been assessed in detailed. 
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Interesting behaviour trends have been defined, in particular related to the 
accumulation of the neutral probes in the endoplasmic reticulum (ER) and lipid 
droplets. In fact only a few examples of iridium(III) complexes applied to the stain of 
ER have been reported, and the majority of them are highly toxic.105,137–139,143,305–307  
On the other hand, the cytotoxicity analyses on the neutral cyano and (iso)quinolyl-
functionalised iridium probes have evidenced their applicability in live cells imaging. 
Moreover, only one rhenium phosphorescent dye has been developed for the specific 
localisation in lipid droplets.232,248 
Some of the methylated complexes have shown good mitochondrial 
specificity, but also high toxicity against live H2c9 cells for long term experiment. 
The staining of mitochondria in tissues relies primarily on immunochemistry 
due to the lack of probes which are able to localise in these organelles in the absence 
of membrane potential. Interestingly, the cationic [Ir(ppy)2(MeTzPyPhCN)]+, which 
had showed mitochondrial accumulation in live H9c2 cells, has also successfully 
stained mitochondria in both fresh and fixed tissues. Noteworthy, 
[Ir(ppy)2(MeTzPyPhCN)]+ represents the first example of metal probe with the ability 
of localised in these organelles in fixed tissues, suggesting a mechanism of uptake 
independent from the mitochondrial membrane potential.283 
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3.2 Biological Investigation in H9c2 cells 
3.2.1 Lipophilicity and Cellular Uptake 
Lipophilicity is one of the main factors to consider during the design of a new imaging 
probe, as previously discussed in Chapter 1, section 1.4.4. The lipophilicity of the 
investigated iridium complexes was measured by the shake-flask method described in 
this chapter (section 3.5.2), using a pH = 7.4 buffered PBS solution and n-octanol.308 
The calculated logD7.4 values are listed in Table 3.1. 
 
Table 3.1 Distribution coefficient values (logD7.4) for neutral and charged iridium 
complexes. 
Complex logD7.4 
Amount of 
complex a 
(fmol) 
Concentrationb 
(µM) 
[Ir(ppy)2(TzPyCN)] 2.09 ± 0.06 0.042 ± 0.004 21.16 ± 1.85 
[Ir(F2ppy)2(TzPyCN)] 2.01 ± 0.05 0.319 ± 0.049 159.71 ± 46.95 
[Ir(ppy)2(TzPyPhCN)] 2.68 ± 0.08 0.171 ± 0.042 85.46 ± 20.76 
[Ir(ppy)2(MeTzPyCN)]+ 0.64 ± 0.03 0.015 ± 0.002 7.35 ± 0.81 
[Ir(F2ppy)2(MeTzPyCN)]+ 1.86 ± 0.02 0.025 ± 0.007 12.74 ± 3.26 
[Ir(ppy)2(MeTzPyPhCN)]+ 1.87 ± 0.08 0.045 ± 0.005 22.74 ± 2.48 
[Ir(ppy)2(TzQn)] 2.23 ± 0.04 0.346 ± 0.070 173.03 ± 35.20 
[Ir(ppy)2(TziQn)] 2.57 ± 0.05 0.063 ± 0.011 31.61 ± 5.60 
[Ir(ppy)2(MeTzQn)]+ 1.68 ± 0.05 0.372 ± 0.038 186.24 ± 18.92 
[Ir(ppy)2(MeTziQn)]+ 1.49 ± 0.06 0.515 ± 0.085 257.29 ± 42.64 
a Average number of moles of iridium complex incubated within a H9c2 cell (see 
Experimental ˗ section 3.5.5 for incubation conditions). b The relative concentration 
was calculated assuming an average volume of H9c2 cell equal to 2 pL. 
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The values obtained are within a range that is similar to those reported previously for 
cyclometalated iridium complexes.104,112,115,126 In the case of the neutral species, the 
logD7.4 was comparable to the BODIPY family (functionalised 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene cores), which is known to localise in lipid droplets.309 
The values for the five neutral probes fall in a range between 2.01 and 2.68. 
Methylation of the iridium complexes lowers the lipophilicity, which is ascribed to the 
introduction of the cationic charge, and results in logD7.4 values occuring in the range 
1.49 ˗ 1.97. The lowest lipophilicity is observed for the complex 
[Ir(ppy)2(MeTzPyCN)]+ at 0.64. A comparison of the logD7.4 values between 
[Ir(ppy)2(TzPyCN)], [Ir(ppy)2(TzPyPhCN)], [Ir(ppy)2(TzQn)], and 
[Ir(ppy)2(TziQn)], shows that extending the conjugation of the tetrazolato ligands 
increases lipophilicity. A similar trend also holds true for the methylated analogues, 
[Ir(ppy)2(MeTzPyCN)]+, [Ir(ppy)2(MeTzPyPhCN)]+, [Ir(ppy)2(MeTzQn)]+, and 
[Ir(ppy)2(MeTziQn)]+.  
The introduction of fluoride substituents on aromatic moieties is often 
associated with an increase in logD7.4 values.131,134,310,311 However, this trend was only 
observed in the charged complexes, where logD7.4 increased from 0.64 for 
[Ir(ppy)2(MeTzPyCN)]+ to 1.86 for [Ir(F2ppy)2(MeTzPyCN)]+. In contrast, little 
change was observed in the logD7.4 value between [Ir(ppy)2(TzPyCN)] and 
[Ir(F2ppy)2(TzPyCN)], consistently with previously published cyclometalated 
iridium complexes with lipophilicity values around 2.104 
The cellular uptake for the synthesised iridium complexes was studied by 
means of ICP-MS measurements, and the results are reported in Table 3.1. The H9c2 
cells were incubated with complexes at 20 µM in cell culture medium (0.2% DMSO) 
for 30 minutes at 37 °C. The calculated cellular concentration values were obtained 
assuming an average volume of a single H9c2 cell equal to 2 pL.312 The amount of 
iridium complex accumulated within the cells is comparable with other cyclometalated 
iridium systems,127,144,296,313 even those bioconjugated with carbohydrate or biotin 
moieties, which possess lipophilicity values in a range of 2.5 and 8.2.126,298,306  
The analysis of the data does not reveal a simple trend and it could potentially 
suggest that lipophilicity is not the only factor affecting the cellular uptake of probes. 
For example, three of the neutral complexes, [Ir(F2ppy)2(TzPyCN)], 
[Ir(ppy)2(TzPyPhCN)], and [Ir(ppy)2(TzQn)] exhibit high iridium intracellular 
concentrations indicating good cellular internalisation. The remaining two complexes, 
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[Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(TziQn)], exhibit lower intracellular iridium 
concentrations although their lipophilicity fell within the range of the aforementioned 
neutral complexes. On the other hand, only the cationic iridium complexes bound to 
the quinolyl and isoquinolyl tetrazolate ligands, [Ir(ppy)2(MeTzQn)]+ and 
[Ir(ppy)2(MeTziQn)]+, exhibit efficient cellular internalisation. The lack of 
straightforward trends suggests that the mechanism of internalisation might be 
different for the various complexes.   
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3.2.2 Localisation 
The cellular localisation of the iridium complexes within H9c2 cells was investigated 
via confocal microscopy (refer to section 3.5.14). Following the same incubation 
protocol described for the ICP-MS measurements, complexes could be detected in 
cells by single photon excitation at 403 nm and were also shown to be compatible with 
two-photon imaging modalities, with optimal excitation in the range of 810 ˗ 830 nm. 
Representative lambda stack micrographs and two-photon images of live H9c2 cells 
incubated with the iridium complexes are listed in Appedix B from Figure B.1 to 
Figure B.5. 
All the complexes could be readily detected within cells in an emission interval 
of 525 ˗ 644 nm, which is consistent with the emission profiles recorded for aqueous 
solutions in cuvette and showed in Chapter 2, section 2.4.5, Table 2.6 and Table 2.7. 
The [Ir(ppy)2(MeTzPyCN)]+ complex was the only exception as it had low 
detectability within the whole instrument range (420 ˗ 740 nm), consistent with 
measurements taken in aqueous media. Thus it was omitted from co-localisation 
studies with commercially available organic dyes. 
All the neutral complexes had similar staining patterns and evidenced a diffuse 
network emanating from the nucleus and extending into the cytoplasm (Figure 3.2), 
consistent with the endoplasmic reticulum. In addition, the methylated cationic 
complex [Ir(ppy)2(MeTzQn)]+ also detected this reticular network in the perinuclear 
region (Figure 3.2).  
For a better understanding of the co-localisation of the iridium(III) tetrazolato 
probes with organic markers such as ER-Tracker™, BODIPY® 500/510 C1,C12 and 
MitoTracker®, Pearson’s correlation coefficient314 was calculated for the endoplasmic 
reticulum (ER), lipid droplets and mitochondria respectively (Table 3.2). The absence 
of the data related to [Ir(ppy)2(MeTziQn)]+ is due to the interference of this complex 
with the normal staining pattern of the commercial organic probe, which were found 
in unusual cellular structures. 
Co-staining with ER-Tracker™ revealed relatively high Pearson’s correlation 
coefficients,314 with values above 0.7, confirming that the neutral complexes and the 
methylated cationic complex [Ir(ppy)2(MeTzQn)]+ localise within the endoplasmic 
reticulum. 
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While these probes were predominately localised within the ER, their emission 
was also detected within compartments in the cytoplasm that were not labelled with 
ER-Tracker™. The morphology and localisation of these compartments resembled 
lipid droplets. Hence, BODIPY® 500/510 C1,C12, a fatty acid analogue that localises 
with lipid droplets and partially with the endoplasmic reticulum was employed for co-
localisation studies and produced strong overlapping with these complexes (Figure 
3.3). A high Pearson’s correlation coefficients314 (Table 3.2) was obtained for these 
probes and BODIPY® 500/510 C1,C12 (ranging between 0.63 and 0.92), confirming 
that these compartments were lipid droplets.  
Interestingly, it has been demonstrated that lipid droplets interact with organelles such 
as ER and mitochondria.203 In particular the ER-lipid droplets connection involves 
important physiological functions including protein and lipid trafficking, response to 
ER stress and a role in ER-associated degradation.315,316 Hence it can be hypothesised 
that part of the iridium probe that localised and accumulated in the ER, could have 
been enclosed in lipid droplets with other lipids, and then released in the cytoplasm. 
 
Table 3.2 Pearson’s correlation coefficients in live H9c2 cells. 
Complex ER-Tracker™ BODIPY
® 
500/510 C1,C12 MitoTracker
® 
[Ir(ppy)2(TzPyCN)] 0.70 ± 0.02 0.91 ± 0.01 - 
[Ir(F2ppy)2(TzPyCN)] 0.88 ± 0.03 0.85 ± 0.02 - 
[Ir(ppy)2(TzPyPhCN)] 0.79 ± 0.05 0.75 ± 0.03 - 
[Ir(F2ppy)2(MeTzPyCN)]+ N/Aa - 0.65 ± 0.04 
[Ir(ppy)2(MeTzPyPhCN)]+ - - 0.71 ± 0.05 
[Ir(ppy)2(TzQn)] 0.82 ± 0.01 0.63 ± 0.05 - 
[Ir(ppy)2(TziQn)] 0.70 ± 0.02 0.92 ± 0.01 - 
[Ir(ppy)2(MeTzQn)]+ 0.81 ± 0.01 0.81 ± 0.01 - 
a Co-localisation experiments with ER-Tracker™ could not be performed, as the 
addition of ER-Tracker™ to cells stained with this complex caused the displacement 
of the iridium species from the ER. 
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Figure 3.2 Iridium complexes interacting with endoplasmic reticulum (ER) in live 
H9c2 cells. Micrographs of H9c2 cells stained with the iridium complexes (green) and 
counter-stained with ER Tracker™ (red). Yellow/orange colour in the merge indicates 
marker co-localisation. Scale bars = 10 µm. 
  
[Ir(ppy)2(TzPyCN)]
[Ir(F2ppy)2(TzPyCN)]
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[Ir(ppy)2(MeTzQn)]
+
[Ir(ppy)2(TzQn)]
[Ir(ppy)2(TziQn)]
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Figure 3.3 Iridium complexes localise with lipid droplets in live H9c2 cells. 
Micrographs of H9c2 cells stained with the iridium complexes (green) and counter-
stained with BODIPY® 500/510 C1,C12 fatty acid analogue (red). Yellow/orange 
colour in the merge indicates marker co-localisation. Scale bars = 10 µm. 
  
[Ir(ppy)2(TzPyCN)]
[Ir(F2ppy)2(TzPyCN)]
[Ir(ppy)2(TzPyPhCN)]
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+
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The methylated complexes [Ir(F2ppy)2(MeTzPyCN)]+ and 
[Ir(ppy)2(MeTzPyPhCN)]+ localised within elongated structures throughout the 
cytoplasm, a staining pattern that is characteristic of mitochondrial association (Figure 
3.4). Co-staining with MitoTracker® Red CMXRos confirmed this interaction, with 
Pearson’s correlation coefficient314 between 0.65 and 0.71 (Table 3.2).  
In general, the positive charge favours the transport of the dye across the 
mitochondrial membrane as a consequence of the intermembrane electrical potential 
gradient. For this reason, the majority of the complexes for the staining of this 
organelle are lipophilic cations.317 Nevertheless, the uptake of 
[Ir(ppy)2(MeTzPyPhCN)]+ in H9c2 cells has been showed to be independent from the 
mitochondrial potential (refer to section 3.3.3 for the discussion). 
It is interesting to note that the complex [Ir(F2ppy)2(MeTzPyCN)]+ also 
stained what appears to be the ER along with the mitochondria, although co-staining 
between the complex and ER-Tracker™ could not be performed, due to displacement 
of the organic dye upon addition of the fluorinated iridium complex (Table 3.2). 
Despite the use of different staining protocols, the localisation of the fluorinated 
iridium probe within the cells was affected by the presence of the organic dye and 
resulted in dislocation from the ER.  
While [Ir(ppy)2(MeTziQn)]+ also co-located with MitoTracker® Red 
CMXRos, this charged complex appeared to induce apoptosis, characterised by the 
formation of cellular vacuoles and rounding of the mitochondria (Figure 3.4). In this 
case, ER-Tracker™ was also observed to co-localise with these unusual cellular 
structures. An increase of caspase activity in H9c2 cells after incubation with 
[Ir(ppy)2(MeTziQn)]+ confirmed the induction of apoptosis318 and will be discussed 
in details in section 3.2.4. 
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Figure 3.4 Iridium complexes interacting with mitochondria in live H9c2 cells. 
Micrographs of H9c2 cells stained with the iridium complexes (green) and counter-
stained with MitoTracker®Red CMXRos (red). Yellow/orange colour in the merge 
indicates co-localisation between markers. Scale bars = 10 µm. 
  
[Ir(F2ppy)2(MeTzPyCN)]
+
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+
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+
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3.2.3 Mechanism of Cellular Internalisation 
Confocal microscopy was also employed to assess the mechanism of cellular 
internalisation. The intensity of the emission from the iridium complexes was 
compared between cells incubated at 37 and 4 °C (Figure 3.5), the latter to suppress 
energy-mediated mechanisms of entrance. 
 The emission detected from each complex at 37 °C shows a good correlation 
with the average amount of iridium found in cells measured by ICP-MS (Table 3.1). 
Cells incubated with [Ir(F2ppy)2(TzPyCN)], [Ir(ppy)2(TzPyPhCN)], 
[Ir(ppy)2(TzQn)], [Ir(ppy)2(MeTzQn)]+ and [Ir(ppy)2(MeTziQn)]+ show the highest 
emission intensity, and also record the largest concentration of iridium per cell. The 
trend in emission intensity also correlates well with the quantum yield values in 
aqueous media (Chapter 2, section 2.4.5, Table 2.6 and Table 2.7). For example, the 
emission detected from [Ir(ppy)2(TzPyPhCN)] is comparable with 
[Ir(ppy)2(MeTzQn)]+ and [Ir(ppy)2(MeTziQn)]+, even though the former was 
detected at a lower concentration.  
 The emission detected from each of the cells following incubation at 4 °C was 
significantly reduced. This suggests that energy dependent pathways are 
predominantly involved in the cellular uptake of these complexes, a result that is 
consistent with previously studied cyclometalated iridium species incubated in various 
cell lines.115,117,125,254,319 Again, the lack of clear trends in Figure 3.5 suggests variable 
mechanism of entrance even for subtle chemical changes. For example, 
[Ir(ppy)2(TzQn)] is detected well upon incubation at 4 °C, but [Ir(ppy)2(TziQn)] is 
barely visible, even though the two complexes differ only by the orientation of the 
quinolyl substituents and have very similar lipophilicity values. These results reinforce 
previously reported views80,292 that conclusions based exclusively on lipophilicity 
measurements might not be adequate, even for families of complexes with very similar 
chemical structures. 
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Figure 3.5 (A) Confocal micrographs of H9c2 cells incubated with iridium complexes 
at 37 °C or 4 °C. Scale bar = 5 µm. (B) Histogram showing the emission intensity of 
iridium complexes detected from H9c2 cells when incubated at 37 °C (turquoise) or 4 
°C (green) to inhibit energy dependent cell entry. 1) [Ir(ppy)2(TzPyCN)]; 2) 
[Ir(F2ppy)2(TzPyCN)]; 3) [Ir(ppy)2(TzPyPhCN)]; 4) [Ir(ppy)2(TzQn)]; 5) 
[Ir(ppy)2(TziQn)]; 6) [Ir(ppy)2(MeTzPyCN)]+; 7) [Ir(F2ppy)2(MeTzPyCN)]+; 8) 
[Ir(ppy)2(MeTzPyPhCN)]+; 9) [Ir(ppy)2(MeTzQn)]+; 10) [Ir(ppy)2(MeTziQn)]+. 
122  
3.2.4 Cytotoxicity 
The cell viability was assessed via MTS assay to highlight cytotoxic effects of iridium 
probes in the darkness after internalisation in live cells. The MTS protocol is described 
in Experimental ˗ section 3.5.6. The H9c2 cells were incubated for either 2 hours or 
24 hours with the complexes at 20 µM or 40 µM.  
An important trend emerges from the collected results (Figure 3.6), 
highlighting the fact that while the neutral complexes only exhibit slight cytotoxicity, 
cell viability is reduced upon incubation with the corresponding cationic complexes. 
On comparing the cytotoxicity and ICP-MS data from incubated cells (Table 3.1), it 
is clear that cytotoxic effects are not exclusively dependent on the relative amount of 
iridium complexes incubated within the cells. For example, the fluorinated complex 
[Ir(F2ppy)2(TzPyCN)] does not exhibit significant cytotoxicity compared to its 
methylated analogous [Ir(F2ppy)2(MeTzPyCN)]+, even though the concentration of 
the latter is lower by an order of magnitude. These results suggest that cytotoxic effect 
for this family of iridium complexes might be strongly related to their relative cellular 
localisation. 
The only exception to the cytotoxic effect of the cationic complexes seems to 
be related to [Ir(ppy)2(MeTzPyCN)]+, which from the ICP-MS results showed 
minimal accumulation within the cells (Table 3.1). Unfortunately however, the 
localisation of this compound could not be assessed due to its non-emissive nature in 
aqueous media. 
These results demonstrate that the neutral series of iridium tetrazolato 
complexes possess very promising properties for the development of iridium-based 
markers for imaging of the ER in live cells. This is in contrast to other cationic iridium 
complexes that were previously shown to accumulate in the endoplasmic reticulum, 
but which were cytotoxic due to the triggering of Ca2+ release into the cytoplasm.139 
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Figure 3.6 Cell viability after 2 and 24 h incubation with the iridium complexes at 20 
and 40 µM. Neutral complexes are represented by blue bars, whereas cationic 
complexes are represented by green bars. 0) Control (0.2% DMSO in serum-free 
DMEM medium); 1) [Ir(ppy)2(TzPyCN)]; 2) [Ir(ppy)2(MeTzPyCN)]+; 3) 
[Ir(F2ppy)2(TzPyCN)]; 4) [Ir(F2ppy)2(MeTzPyCN)]+; 5) [Ir(ppy)2(TzPyPhCN)]; 6) 
[Ir(ppy)2(MeTzPyPhCN)]+; 7) [Ir(ppy)2(TzQn)]; 8) [Ir(ppy)2(MeTzQn)]+; 9) 
[Ir(ppy)2(TziQn)]; 10) [Ir(ppy)2(MeTziQn)]+. 
 
It is well known that phosphorescent metal complexes act as sensitisers for 
singlet oxygen.93 Previous studies by Werrett et al.230 have showed that during imaging 
via confocal microscopy, a resting time of 30 seconds reduced or eliminated the effect 
of reactive oxygen species in live cells.  
Following this protocol and imaging cells incubated for 30 minutes with a 20 
µM solution of the iridium complex, blebbing of the cell membrane was never 
observed. On the other hand, cells incubated under the same conditions (refer to 
section 3.5.7) and continuously illuminated, displayed signs of blebbing within a 30 
minutes timeframe, as reported in Table 3.3, indicating the start of apoptotic 
pathways. This result futher confirms what previously observed by Werrett et al.230 
and highlights that the protocol has been used for the staining of live cells with these 
complexes was effectively optimised.  
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Table 3.3 Live H9c2 cell response to continuous irradiation at 403 nm. 
Complex Appearance of cell blebbing (min) 
[Ir(ppy)2(TzPyCN)] 29 
[Ir(F2ppy)2(TzPyCN)] 9 
[Ir(ppy)2(TzPyPhCN)] 6 
[Ir(F2ppy)2(MeTzPyCN)]+ 12 
[Ir(ppy)2(MeTzPyPhCN)]+ 17 
[Ir(ppy)2(TzQn)] 3 
[Ir(ppy)2(TziQn)] 3 
[Ir(ppy)2(MeTzQn)]+ 9 
[Ir(ppy)2(MeTziQn)]+ 2 
 
 
During co-localisation analysis [Ir(ppy)2(MeTziQn)]+ has shown high 
cytotoxicity within the cells, expressed by changing in the morphology of 
mitochondria and formation of cellular vacuoles. In order to confirm the initiation of 
apoptotic pathways trigged by the iridium probe, a caspase assay has been performed 
(refer to section 3.5.8).318 Caspases are enzymes that play a central role in various 
phases of apoptosis. Upon activation, caspases cleave specific substrates and thereby 
mediate many of the typical biochemical and morphological changes in apoptic cells, 
such as cell shrinkage, DNA fragmentation and plasma membrane blebbing.200,320,321 
For all these reasons, the detection of caspase activity can be used as a biochemical 
marker for apoptosis.  
After incubation with 20 µM of [Ir(ppy)2(MeTziQn)]+ in H9c2 cells, the 
caspase activity was significantly increased (P < 0.0001) compared to the untreated 
control cells (Figure 3.7). This result demonstrated high toxicity of the iridium probe, 
however it is unclear why the isostructural [Ir(ppy)2(MeTzQn)]+ complex does not 
show a similar biological behaviour. 
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Figure 3.7 Caspase assay for the detection of apoptosis in H9c2 cells incubated with 
20 µM of [Ir(ppy)2(MeTziQn)]+. The released Rhodamine-110 was excited at 499 nm 
and the emission was collected at 521 nm. 0) Control (0.2% DMSO in complete 
DMEM medium); 1) [Ir(ppy)2(MeTziQn)]+. 
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3.2.5 Photostability 
Photobleaching is a severely limiting factor in biological imaging. In fact, upon 
continuous irradiation, a fluorophore can undergo irreversible conversion into a less 
or non-fluorescent species, affecting the optical studies over extended time 
periods.284,322  
To assess the photostability of the iridium probes, photobleaching experiments 
were carried out on H9c2 cells incubated with the iridium complexes at 20 µM for 30 
minutes (refer to section 3.5.9). The cells were illuminated continuously at 403 nm for 
900 seconds, and the decrease in emission intensity was compared with that from cells 
incubated with ER-Tracker™. All the complexes evaluated in cells showed better 
photostability than ER-Tracker™, with the cationic complexes exhibiting emission 
intensity above 85% of the initial values after 900 seconds irradiation (Figure 3.9). 
The neutral iridium complexes revealed to be slightly more prone to photobleaching, 
but still displayed emission above 70% of the initial emission intensity after 900 
seconds irradiation (Figure 3.8). The data clearly highlight how the cationic 
complexes exhibit better photostability than their neutral analogues.  
Results from [Ir(ppy)2(TziQn)] are not shown since the cells displayed 
tendency to detach, creating great variability in the intensity measurement. Moreover, 
[Ir(ppy)2(MeTzPyCN)]+ and [Ir(ppy)2(MeTziQn)]+ have not been tested due to low 
emission in aqueous medium and enhanced cytotoxicity in live cells, respectively. 
Unfortunately, the lack of literature regarding photobleaching analysis on 
neutral iridium probes does not permit a comparison with the data obtained for this 
series of tetrazolato complexes. On the other hand, cationic iridium species have been 
largely studied and their final emission intensity falls in a range of 60% to 99% with 
continuous irradiation at 405 nm for 120 ˗ 360 seconds.102,127,201,323 Interestingly, the 
photobleaching analysis for the tetrazolato complexes was conducted for 900 seconds, 
highlighting the superior photostability of [Ir(F2ppy)2(MeTzPyCN)]+, 
[Ir(ppy)2(MeTzPyPhCN)]+, [Ir(ppy)2(MeTzQn)]+. 
The same general trend was also observed performing the photobleaching 
experiments in cuvette, using 10-5 M PBS solutions (0.2% DMSO), excited using a 
Pen-Ray Mercury Lamp source at 365 nm (refer to section 3.5.9). 
Upon irradiation for 600 seconds, neutral iridium complexes (Figure 3.10) have 
shown a decrease of the initial intensity up to 55%, with only [Ir(ppy)2(TzPyPhCN)] 
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which resulted more photobleached, with a final emission intensity of 30% with 
respect to the starting phosphorescence. On the other hand, methylated cationic 
complexes (Figure 3.11) displayed really high photostability, with emission above 
85% of the initial emission intensity after 600 seconds of continuous irradiation. 
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Figure 3.8 Photobleaching analysis in live H9c2 cells of [Ir(ppy)2(TzPyCN)] (black), 
[Ir(F2ppy)2(TzPyCN)] (blue), [Ir(ppy)2(TzPyPhCN)] (red), [Ir(ppy)2(TzQn)] 
(green) and ER-Tracker™ (purple). 
 
 
Figure 3.9 Photobleaching analysis in live H9c2 cells of [Ir(F2ppy)2(MeTzPyCN)]+ 
(blue), [Ir(ppy)2(MeTzPyPhCN)]+ (red), [Ir(ppy)2(MeTzQn)]+ (green) and ER-
Tracker™ (purple). 
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Figure 3.10 Photobleaching analysis in PBS (0.2% DMSO) of [Ir(ppy)2(TzPyCN)] 
(black), [Ir(F2ppy)2(TzPyCN)] (blue), [Ir(ppy)2(TzPyPhCN)] (red) and 
[Ir(ppy)2(TzQn)] (green). 
 
 
Figure 3.11 Photobleaching analysis in PBS (0.2% DMSO) of 
[Ir(F2ppy)2(MeTzPyCN)]+ (blue), [Ir(ppy)2(MeTzPyPhCN)]+ (red) and 
[Ir(ppy)2(MeTzQn)]+ (green). 
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3.3 Biological Investigation in Tissue Samples 
The normal function of muscle tissue is particularly reliant on mitochondria to fulfil 
high energy demand, to regulate calcium324 and to control ROS production.325 
Mitochondrial morphology is directly linked to many important cell and tissue 
functions, and consequently significant organelle remodelling is observed in response 
to changes in energy demand and cellular environment.326,327 Moreover, changes in 
mitochondrial morphology are also observed in a range of human pathologies, 
including cardiovascular diseases and neuromuscular disorders.327–329 For this reason, 
understanding the role of mitochondria in disease pathogenesis has been greatly 
advanced by the visualisation of these organelles, using a variety of microscopy 
techniques to image affected tissues.328,329 In particular, mitochondrial imaging by 
fluorescence microscopy is often utilised in medical research, but the currently 
available mitochondrial stains have mainly been limited to uses in live samples. This 
can be problematic for pathology testing, in clinical or in large cohort studies, where 
tissue samples cannot be immediately processed for assessment, and tissue 
preservation by fixation is highly preferable before imaging. 
Mitochondrial imaging in tissue samples is primarily performed using 
fluorescence imaging by small fluorescent molecules or immunochemistry.40 The 
majority of commercially available mitochondrial dyes are organic fluorophores that 
accumulate in the mitochondrial matrix due to the organelle transmembrane potential. 
These dyes are therefore only suited for use on live samples, for example, JC-1 and 
the MitoTrackers CMTMRos and CMXRos.330,331 Commercial dyes that stain 
independently of mitochondrial polarisation tend to have an affinity for other 
mitochondrial-specific constituents (e.g. Mito-ID® Red, which specifically binds to 
cardiolipin in the inner mitochondrial membrane), but their cellular uptake is still often 
limited to live samples.40 To date, the visualisation of mitochondria in fixed samples 
has relied on immunochemistry. While antibody detection is sensitive, it is time 
consuming and requires multiple processing steps that may introduce significant 
artefacts. Moreover, issues with antibody availability can limit their use in a range of 
model species. There is, therefore, a need for small molecule imaging tools that can 
quickly and effectively image mitochondria in both live and fixed tissue samples. 
On the basis of the superior properties displayed in live cell imaging by the 
series of iridium(III) tetrazolato probes presented in this chapter, the application in the 
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staining of muscle tissues of [Ir(ppy)2(MeTzPyPhCN)]+, which has previously 
showed high specificity for mitochondria in live H9c2 rat cardiomyoblasts,238 was 
explored as well. This iridium(III) probe is now also commercially available as 
IraZolve-MitoTM.  
 
3.3.1 Localisation in Live Tissues 
The localisation of [Ir(ppy)2(MeTzPyPhCN)]+ was firstly assessed in live tissues. The 
samples were collected from the left ventricle of the heart (cardiac muscle) and the 
quadriceps (skeletal muscle) of adult ewes, and stained with 20 µM of the iridium 
complex, following the preparation and incubation protocol described in section 3.5.10 
– section 3.5.12. The complex was excited at 403 nm and clearly detected, in both 
cardiac and skeletal muscles, in cylindrical-shaped organelles, which resemble 
mitochondria (Figure 3.12 – a, a/, c, c/). These organelles were arranged in a regular 
network structure throughout the muscle fibres, in a distinctive distribution consistent 
with previous observations of mitochondrial in skeletal muscle.332,333 
To further confirm the mitochondrial localisation of 
[Ir(ppy)2(MeTzPyPhCN)]+, the distribution of NAD(P)H, which is known to be 
associated with these organelle,334 was detected by two-photon imaging microscopy. 
NAD(P)H produces a strong endogenous fluorescence at 489 nm, when exposed to 
two-photon illumination at 740 nm.18 The distribution of NAD(P)H was compatible 
with the staining pattern of the iridium probe, as shown in Figure 3.12 - b, b/, d, d/.  
Moreover the live tissue samples were also co-stained with MitoTracker® Red 
CMXRos (Figure 3.12 – e, e/ cardiac and f, f/ skeletal tissue), giving a significant high 
Pearson’s correlation coefficient of 0.84 and 0.86 (Table 3.4) for cardiac and skeletal 
muscle, respectively. 
 
Table 3.4 Pearson’s correlation coefficients in live tissues. 
Tissue MitoTracker® 
Live cardiac muscle 0.84 ± 0.01 
Live skeletal muscle 0.86 ± 0.03 
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Figure 3.12 [Ir(ppy)2(MeTzPyPhCN)]+ (IraZolve-MitoTM) detects mitochondria in 
fresh live cardiac and skeletal muscle samples. Micrographs showing mitochondria 
detected with [Ir(ppy)2(MeTzPyPhCN)]+ in cardiac (a; enlarged in a/) and skeletal (c; 
enlarged in c/) muscle samples. Endogenous NAD(P)H detected by two-photon 
microscopy in cardiac (b; enlarged in b/) and skeletal (d; enlarged in d/) muscle samples 
(excited at 740 nm and collected at 474-504 nm). Micrographs showing co-staining of 
mitochondria with [Ir(ppy)2(MeTzPyPhCN)]+ (green in e - e// and f - f//) and 
MitoTracker® Red CMXRos (red in e, e/, e/// and f, f/, f///) in cardiac (e; enlarged in e/-
e///) and skeletal (f; enlarged in f/ - f///) muscle samples. Scale bars = 20 µm (a - f) and 
5 µm (a/ - d/, e/ - e/// and f/ - f///). 
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3.3.2 Localisation in Fixed Tissues 
The localisation of [Ir(ppy)2(MeTzPyPhCN)]+ was investigated even in fixed tissue 
samples, adopting the same protocol optimised for live tissues. The cardiac and 
skeletal muscle samples were fixed in 4% paraformaldehyde for 20 hours and after a 
30 minutes washing step, were stored in PBS at 4 °C (refer to section 3.5.11).  
After incubation with the probe, the staining pattern of 
[Ir(ppy)2(MeTzPyPhCN)]+ in fixed tissues (Figure 3.13 – a, a/, c, c/) was consistent 
with the one obtained for fresh live tissues (Figure 3.12 – a, a/, c, c/) and similar to the 
mitochondrial detection obtained with antibody probing for cytochrome C protein, 
which localises to the inner membrane of mitochondria (Figure 3.13 - b, b/, d, d/). 
Unfortunately, it was impossible to perform co-staining studies with anti-
Cytochrome C antibody due to the loss in mitochondrial accumulation of the iridium 
complex, probably derived from the use of permeabilising agents required for the 
immunochemistry protocol (refer to section 3.5.12). 
Nevertheless, to confirm the localisation of [Ir(ppy)2(MeTzPyPhCN)]+, live 
tissue samples were incubated with MitoTracker® Red CMXRos and, after fixation in 
4% paraformaldehyde, co-stained with the iridium probe. In this case, the fixation 
process was performed for only 1 hour to prevent the loss of MitoTracker® Red 
CMXRos. As observed for live tissues, co-staining with MitoTracker® Red CMXRos 
confirmed the interaction of [Ir(ppy)2(MeTzPyPhCN)]+ with mitochondria (Figure 
3.13 - e, e/ cardiac and f, f/ skeletal tissue), with Pearson’s correlation coefficients of 
0.89 for both cardiac and skeletal muscle (Table 3.5).  
 
Table 3.5 Pearson’s correlation coefficients in fixed tissues. 
Tissue MitoTracker® 
Fixed cardiac muscle 0.89 ± 0.02 
Fixed skeletal muscle 0.89 ± 0.02 
  
134  
 
Figure 3.13 Staining pattern of [Ir(ppy)2(MeTzPyPhCN)]+ (IraZolve-MitoTM) in 
fixed cardiac and skeletal muscle samples. Micrographs showing subcellular 
distribution of [Ir(ppy)2(MeTzPyPhCN)]+ in 4% PFA fixed cardiac (a; enlarged in a/) 
and skeletal (c; enlarged in c/) muscle samples. Micrographs showing localisation of 
Cytochrome C detected with an anti-Cytochrome C antibody in cardiac (b enlarged in 
b/) and skeletal (d; enlarged in d/) muscle samples. Micrographs showing co-staining 
of mitochondria with [Ir(ppy)2(MeTzPyPhCN)]+ (green in e - e// and f - f//) and 
MitoTracker® Red CMXRos (red in e, e/, e/// and f, f/, f///) in cardiac (e; enlarged in e/ - 
e///) and skeletal (f; enlarged in f/ - f///) muscle samples. Scale bars = 20 µm (a - f) and 
5 µm (a/ - d/, e/ - e/// and f/ - f///). 
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3.3.3 Mechanism of Internalisation 
The compatibility of [Ir(ppy)2(MeTzPyPhCN)]+ for mitochondrial staining of fixed 
tissue suggests that the mechanism controlling the localisation is not solely based on 
its cationic nature. To confirm that the localisation of [Ir(ppy)2(MeTzPyPhCN)]+ with 
mitochondria was not dependent on membrane polarisation, the mitochondrial 
membrane potential was deregulated by using carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP).335 In H9c2 cells, FCCP treatment did not 
perturb [Ir(ppy)2(MeTzPyPhCN)]+ mitochondrial staining, as observed in Figure 
3.14 – c. By comparison MitoTracker®, which is dependent on mitochondrial 
membrane potential,330,331 exhibited dispersed cytoplasmic staining in FCCP treated 
cells (Figure 3.14 - e). Cytochrome C immunofluorescence confirmed that there were 
morphological changes in the mitochondria after FCCP treatment, which match 
[Ir(ppy)2(MeTzPyPhCN)]+ staining patterns (Figure 3.14 – f, g).  
These results suggested that unlike the majority of mitochondrial dyes, the 
localisation of [Ir(ppy)2(MeTzPyPhCN)]+ in these organelles is independent from the 
mitochondrial membrane potential, which likely accounts for its compatibility with 
fixed tissue staining. This behaviour allows the visualisation of mitochondria during 
stress conditions in live cells and tissues, which may be induced by, for example, drug 
treatments or pathological processes, as well as its ability to stain fixed tissues.  
Noteworthy, a number of similar cationic iridium complexes have shown 
membrane potential independent localisation into mitochondria (Figure 
3.15).129,132,336–339 This characteristic would indicate that this family of molecules has 
an alternative targeting mechanism, possibly via protein or lipid association. 
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Figure 3.14 Inhibition of mitochondrial membrane potential in H9c2 rat 
cardiomyoblasts does not disrupt [Ir(ppy)2(MeTzPyPhCN)]+ (IraZolve-MitoTM) 
staining. (a - a//) Micrographs showing co-staining of [Ir(ppy)2(MeTzPyPhCN)]+ 
(green in a; greyscale in a/) with MitoTracker® Red CMXRos (red in a; greyscale in 
a//) in H9c2 cells. Scale bars = 20 µm. H9c2 cells were stained with 
[Ir(ppy)2(MeTzPyPhCN)]+ (b, c), MitoTracker® Red CMXRos (d, e) or by anti-
Cytochrome C antibody (f, g) either under normal conditions (control; b, d, f) or 
following treatment with FCCP (c, e, g). Scale bars = 20 µm. 
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Figure 3.15 Example of previously reported iridium(III) probes membrane potential 
independent localisation into mitochondria.  
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3.4 Conclusions 
In this chapter, the biological investigation of the iridium(III) complexes was 
performed in live H9c2 rat cardiomyoblast cells. 
Quantification of cellular incubation via ICP-MS revealed great variability, 
with trends that cannot be simply correlated to the degree of lipophilicity and charge 
of the complexes, suggesting different mechanisms of uptake. 
The majority of the complexes were internalised into live cells and detection 
was possible via either one-photon or two-photon imaging modalities. The neutral 
species were predominantly localised within the endoplasmic reticulum and to various 
extents within lipid droplets. On the other hand, the cationic species exhibited more 
specificity for mitochondria.  
A noticeable difference between the neutral and cationic probes was found in 
terms of cytotoxicity. A remarkable low viability of cells during long term experiments 
for the charged species with respect to the neutral analogues was found. The higher 
cytotoxicity of the cationic complexes does not seem to be exclusively linked to the 
amount of complex internalised within the cells, and it is also potentially highly 
dependent on the localisation. 
This study has therefore highlighted that neutral iridium tetrazolato complexes 
are suitable building blocks for the design of ER and lipid droplets markers for cellular 
imaging on long timescales. Interestingly, the neutral iridium(III) probes presented in 
this chapter are one of the few examples of ER-markers, and most importantly, do not 
shown high cytotoxicity in live cells.105,137–139,143,305–307 On the other hand, the cationic 
iridium analogues are good candidates for the design of mitochondrial dyes.238 
However, for their application in live biological imaging their cytotoxicity needs to be 
carefully considered. 
The charged iridium(III) complex [Ir(ppy)2(MeTzPyPhCN)]+, which has 
showed a specific mitochondrial accumulation in live H9c2 cells, was also applied for 
the staining of these organelles in skeletal and cardiac tissues.283 Interestingly, the 
probe maintained the same staining pattern in both fresh and fixed tissue samples, 
suggesting that its localisation mechanism is independent of mitochondrial membrane 
polarisation. This characteristic, which was previously observed for other cationic 
iridium(III) complexes,129,132,336–339 allows [Ir(ppy)2(MeTzPyPhCN)]+ to be broadly 
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applicable for the visualisation of mitochondria during stress conditions in both live 
cell and fresh tissues. 
Moreover, this probe can be a useful alternative to immunochemistry 
commonly applied to fixed tissues, by overcoming the issues of this time consuming 
process and the risk of adding artefacts to the samples. 
Due to its superior properties, [Ir(ppy)2(MeTzPyPhCN)]+ has been patented 
(PCT/AU2015/000159 and an Australian Provisional Patent, 2016902815) and 
commercialised by Rezolve Scientific under the name of IraZolve-MitoTM. 
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3.5 Experimental 
3.5.1 Photophysical Measurements 
Photophysical measurements have been conducted as outlined in Chapter 2, section 
2.6.2, unless otherwise stated. 
 
3.5.2 Lipophilicity Analysis 
LogD7.4 values were determined by applying the shake-flask method developed by 
Kunz et al..308 Equal volumes of phosphate-buffered saline solution (PBS) and n-
octanol were stirred together for 72 hours prior to use to allow saturation of both the 
phases. For each experiment, 500 µL of PBS, 530 µL of n-octanol and 30 µL of the 
complex solution (2 mg of the analysed specie dissolved in 200 µL of DMSO) were 
combined in an Eppendorf tube and stirred for 30 minutes, follow by centrifugation (5 
minutes, 3000 rpm) to separate the two phases. UV/Vis absorption of each phase was 
recorded at 400 nm. Samples were diluted with the corresponding phase prior to 
measurement in case the absorption was exciding 1.  LogD7.4 values were calculated 
following Equation 3.1: 
23456.8 	= 	234 :;'<=>?@<A(BCC@D)∙F<=>?@<AG;'HIJ(BCC@D)∙FHIJG K                           (3.1) 
Where Aoctanol(400nm) and APBS(400nm) is the absorbance in each phase at 400 nm and foctanol 
and fPBS are the dilution factors. Given values and standard deviations were derived 
from three independent experiments. 
 
3.5.3 Cell Culture 
The biological investigation was performed in collaboration with Dr Christie A. Bader 
and Dr Alexandra Sorvina at the School of Pharmacy and Medical Sciences, 
University of South Australia. H9c2 rat cardiomyoblast cells were maintained in high-
glucose (4500 mg/L) DMEM medium (Sigma-Aldrich, USA) containing 10% fetal 
bovine serum (FBS; In Vitro Technologies, USA) and 2 mM L-glutamine (Sigma-
Aldrich, USA) at 37 ºC and 5% CO2. The H9c2 cells were cultured in 75 mm2 flasks. 
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Cells that had been passaged for no more than 18 times, were used for experiments. 
For ICP-MS, H9c2 cells were seeded at 2.7 × 104 cells/mL and grown in T25 flasks 
for 72 hours, when 80% confluence was reached. For live cell imaging and MTS assay, 
the H9c2 cells were seeded at 1 × 105 cells/mL and cultured overnight in either ibidi 
µ-slide 8 wells in a final volume of 250 µL or 96-well microtiter plate in a final volume 
of 200 µL. 
 
3.5.4 Cell Staining 
H9c2 cells were incubated with the iridium complexes at 20 µM in DMEM full culture 
medium with 0.2% DMSO (Sigma-Aldrich, St. Louis, USA) for 30 minutes at either 
37 ºC or 4 ºC. The cells were washed twice with sterile phosphate-buffered saline 
solution (PBS; Sigma-Aldrich, St. Louis, USA), before imaging in DMEM. For co-
staining experiments, the cells were then incubated with ER-Tracker™ Red, 
MitoTracker® Red CMXRos, or BODIPY® 500/510 C1,C12 (Life Technologies 
Australia Pty Ltd, Australia), following manufacturer’s instructions. 
 
3.5.5 ICP-MS 
The ICP-MS analysis was performed by Todd A. Gillam at the School of Pharmacy 
and Medical Sciences, University of South Australia. The H9c2 cells were incubated 
with the iridium complexes at 20 µM (prepared in DMEM full culture medium with 
0.2% DMSO) for 30 minutes at 37 ºC and 5% CO2 . The cells were washed three times 
with PBS, and then detached with TripLE Express reagent (Gibco, USA) for 2 minutes. 
The cells were then washed from T25 flasks with 3 mL of DMEM full culture medium, 
and pelleted by centrifugation (10 minutes, 400 rpm). The medium was removed and 
the cells were resuspended in 2 mL of PBS for cells counts. The remaining cells were 
centrifuged (10 minutes, 1000 rpm), the medium removed and the remaining stained 
cell pellets were desiccated for 3.5 hours at 95 °C. The pellets were reconstituted in 
36% HCl (400 µL) and left at 95 °C until dry, in order to digest organic material. The 
dry samples were then reconstituted in 2% HCl (2.5 mL) and sonicated for 10 minutes 
before filtering (pore diameter of 0.2 µm). The total iridium determination was 
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performed with an Agilent 8900x triple quad ICP-MS (Agilent Technologies, USA), 
using He gas (4 mL/min). 
 
3.5.6 MTS Cell Viability Assay 
The cellular NADPH-dependent redox activity was measured using CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS), according to the 
manufacturer’s instruction (Promega, USA). The H9c2 cells were stained with the 
iridium complexes at either 20 µM or 40 µM in DMEM full cell culture medium with 
0.2% DMSO, and held at 37 °C and 5% CO2 for 2 or 24 hours. As a control, H9c2 
cells were incubated for the same length of time in DMEM with 0.2% DMSO. 
Following addition of MTS, the cells were incubated for a further 2 hours in the same 
conditions. The absorbance of the formazan dye was measured by EnVision multi-
label plate reader at 490 nm. The data are reported as the mean ± SEM of three 
biological replicates for each group. 
 
3.5.7 Live Cell Response to Imaging Conditions 
Live H9c2 cells were stained with 20 µM of each iridium complex for 30 minutes. 
Cells were then imaged for 30 minutes continuously with a frame rate of 2.2 s, with 
403 nm excitation and DIC imaging concurrently. Time series were then reviewed for 
signs of cytotoxicity from the complexes, where cell blebbing was used as an indicator 
of cells entering apoptosis. The first signs of cell blebbing was recorded in Table 3.3. 
Unstained cells which were imaged using the same protocol and did not show signs of 
cell blebbing within the 30 minutes experiment. The complex [Ir(ppy)(MeTzPyCN)]+ 
was not tested as it is not emissive in cells and hence not suitable as a marker for live 
cell imaging. 
 
3.5.8 Caspase Assay for the Detection of Apoptosis 
The caspase activity was measured using Homogeneous Caspases Assay according to 
the manufacturer’s instruction (Roche, USA). H9c2 cells were incubated with 
[Ir(ppy)2(MeTziQn)]+ probe at 20 µM in a complete DMEM media (100 µL) for 30 
minutes at 37 ºC and 5% CO2. Incubation buffer was added into each well and the cells 
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were left at 37 ºC for 90 minutes. The fluorimetric measurements of released 
Rhodamine-110 induced by caspases were performed using EnVision multi-label plate 
reader (PerkinElmer, Beaconsfield, UK) with λex = 499 nm and λem = 521 nm. Data 
represents the mean ± SEM of four biological replicates for each group. 
 
3.5.9 Photobleaching Analysis 
Method in Live Cells 
Live H9c2 cells were stained with 20 μM of each complex solution for 30 minutes. 
Cells were then imaged for 900 seconds, continuously, with a frame rate of 2.2 
seconds. The relative intensity emitted from the image was then tracked overtime using 
NIS Elements V4.50 software (Nikon, Japan). For comparison, H9c2 cells stained with 
ER-Tracker™ Red were also imaged continuously for 900 seconds and the emission 
intensity was tracked and plotted against the emission traces for each of the complexes. 
 
Method in Cuvette 
3 mL of a diluted (ca. 10-5 M) PBS solution of each iridium complex was irradiated 
continuously for 600 seconds with a frame rate of 30 seconds. The irradiation source 
was a Pen-Ray® Mercury Lamp (λexc = 365 nm, 5 mW), located 3 cm from the sample. 
The emission spectra were recorded on an Edinburgh FLSP980-S2S2-stm 
spectrometer. Only those complexes tested for photostability in cells were tested for 
photostability in cuvette. 
 
3.5.10 Animal Procedure and Muscle Sample 
The experimental procedures were approved by the South Australian Health and 
Medical Research Institute Animal Ethics Committee and followed the guidelines of 
the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes developed by the National Health and Medical Research Council. The 
investigators understood the ethical principles outlined in Grundy et al.340 Animal care 
and tissue collection was performed by Stacey Holman, Lucy Flynn and Katering 
Steven at the School of Pharmacy and Medical Sciences, Sansom Institute for Health 
Research, University of South Australia. Adult pregnant ewes (4 years old; n = 4) were 
housed in an individual pen in view of other sheep in an indoor housing facility that 
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was maintained at a constant ambient temperature (20 ˗ 22 °C) and a 12 h light/dark 
cycle. Sheep were humanely killed via overdose of sodium pentobarbitone (8 g; Vibrac 
Australia, Peakhurst, Australia). Samples of cardiac muscle tissue were taken from the 
left ventricle and skeletal muscle was taken from the quadriceps. Collected tissue 
samples were placed into sterile PBS on ice, protected from light, transported to the 
imaging facility within 90 minutes and imaged within 7 hours. All experiments were 
performed on samples from a minimum of 4 animals on 3 separate days. 
 
3.5.11 Preparation of Tissue Sections 
Live Tissue Sections 
Live tissue samples were cut using a sharp scalpel to allow clean cutting and prevent 
damage associated with tearing of tissue. Sections were no more than 5 mm in 
thickness. The sectioning was performed in sterile PBS at room temperature (21 ± 2 
°C). 
 
Paraformaldehyde Fixed Tissue Sections 
After dissection, cardiac (~ 1 cm3) and skeletal muscle (~ 1 cm3) tissues were washed 
in PBS, and then submerged in 4 % paraformaldehyde (Sigma-Aldrich, St. Louis, 
USA) for 20 hours at 4 °C. Paraformaldehyde was removed and the fixed tissues were 
washed in PBS for 30 minutes at room temperature. Samples were then stored in PBS 
at 4 °C. Fixed tissue sections of ~2 mm thickness were cut by using a sharp scalpel in 
sterile PBS. Prior to staining, tissue sections were kept in PBS for 2 hours at room 
temperature. 
 
3.5.12 Tissue Staining 
The biological investigation was performed by Dr Christie A. Bader and Dr Alexandra 
Sorvina at the School of Pharmacy and Medical Sciences, University of South 
Australia. A staining solution of [Ir(ppy)2(MeTzPyPhCN)]+ was prepared from a 10 
mM stock solution in DMSO, which was diluted in sterile PBS to a final concentration 
of 20 µM. Fresh and paraformaldehyde fixed tissues were fully submerged in 1 mL of 
the staining solution in 5 mL tubes and incubated at room temperature with gentle 
agitation provided by a rocker for 30 minutes. The staining solution was aspirated and 
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tissues were then washed for 5 minutes in PBS. For mitochondrial staining by 
MitoTracker® Red CMXRos (diluted at 1:1000 in PBS) tissues were fully immersed 
in 1 mL of staining solution and incubated on ice for 15 minutes with general agitation. 
Tissues were then washed in PBS for 5 minutes. For anti-Cytochrome C antibody 
(Sapphire Bioscience, Redfern, Australia) probing, paraformaldehyde fixed tissues 
were permeabilised with 0.1% Saponin (Sigma-Aldrich, St. Louis, USA) in PBS for 2 
hours at room temperature. To block non-specific binding of the antibodies, tissues 
were submerged in 5% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, USA) 
containing 0.05% Saponin for 2 hours at room temperature. Tissues were then 
incubated with anti-Cytochrome C antibody (1 µg/mL; prepared in 5% BSA 
containing 0.05% Saponin) overnight with gentle agitation at 4 ºC. After a washing 
step, secondary anti-IgG antibody conjugated with Cy5 labels (Jackson 
ImmunoResearch Laboratories, West Grove, USA) were then added and tissues were 
incubated for 1 hour at room temperature before a final wash step was performed. 
These washing steps were performed for 2 hours at room temperature. The Hoechst 
33258 DNA stain (1:1000 in PBS; Life Technologies Australia Pty Ltd., Mulgrave, 
Australia) was performed for 1 minute and followed by a 5 minutes wash in PBS. 
 
3.5.13 Inhibition of Membrane Potential 
To investigate if cellular localisation of [Ir(ppy)2(MeTzPyPhCN)]+ was driven by 
mitochondrial membrane potential, H9c2 rat cardiomyoblast cells were treated with 
carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP; Sigma-Aldrich, St. 
Louis, USA).335 The H9c2 cells (1 x 105 cells/mL) were plated in ibidi µ-slide 8 wells 
and cultured overnight at 37 ºC and 5% CO2 in 250 µL of DMEM medium  
supplemented with 10% fetal bovine serum and 2 mM L-glutamine. The cells were 
treated with FCCP, prepared in a complete DMEM media at 100 µM concentration, 
for 30 minutes at 37 ºC and 5% CO2. Media was then aspirated and the H9c2 cells 
were either fixed in 4% PFA for 30 minutes to be used for antibody staining or stained 
with either [Ir(ppy)2(MeTzPyPhCN)]+ (20 µM) or MitoTracker (1:1000) for 30 
minutes in the presence of FCCP. After staining, the cells were washed and then 300 
µL of cell culture media was added for imaging on Nikon A1+ microscope. 
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3.5.14 Confocal Microscopy 
Cells Imaging 
Single photon live cell imaging was performed using a Nikon A1+ confocal 
microscope (Nikon, Japan) with an OKOLab Microscope Incubator (Okolab USA Inc., 
USA). The iridium complexes were excited at 403 nm and the emission was collected 
in the 525 ˗ 644 nm region; ER-Tracker™ and MitoTracker® Red were excited at 561 
nm and the emission was collected in the region 570 ˗ 620 nm. BODIPY® 500/510 
was excited at 488 nm and the emission was collected in the region 500 ˗ 550 nm. 
Image analysis including co-localisation and emission intensity was measured using 
NIS elements V4.50 software (Nikon, Japan).  
Two-photon microscopy imaging was performed using a Zeiss LSM710 META NLO 
inverted microscope supplemented with a two-photon Mai-Tai®, tunable Ti:Sapphire 
femtosecond pulse laser (710 – 920 nm, Spectra-Physics). The emission from the 
iridium complexes was detected using the following settings: two-photon excitation 
wavelength at 830 nm, beam splitter MBS 690+, emission interval 520 – 650 nm. The 
images were acquired using a Plan-APOCHROMAT 63X/ NA1.4 oil immersion 
objective. The final preparation of the images was conducted with Adobe Photoshop 
CC (Adobe Systems Inc., USA). 
 
Tissues Imaging 
Tissues were mounted with a longitudinal cross-section in contact with the imaging 
surface of the µ-slide 8 well chambers (DKSH, Hallam, Australia) and kept moist. 
Good contact between the sample and the surface was achieved by gently pressing the 
tissue down into the chamber. A dissection microscope was used to place and orientate 
the tissues. 
Once mounted, tissues were immediately imaged with no more than 30 minutes 
elapsing between mounting and image completion, as imaging beyond this time can 
lead to excessive drying of tissue samples. Stained tissues were imaged using a Nikon 
A1+ (Nikon, Japan), fitted with a LU-N4/LU-N4S 4-laser unit (403, 488, 561 and 640 
nm), the A1-DUG GaAsP Multi Detector Unit (2 GaAsP PMTs + 2 standard PMTs) 
and a 32 channel spectral detector (Nikon, Minato, Tokyo, Japan). Images for 
[Ir(ppy)2(MeTzPyPhCN)]+  were collected using a 403 nm laser set to 2 power setting 
and emission between 505 and 625 nm detected by the spectral detector, with gain set 
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to 180 for cardiac tissue and 170 for skeletal muscle tissue. The pinhole radius was 
42.1 µm. For imaging of MitoTracker® Red CMXRos, 561 nm excitation wavelength 
(0.3 power setting) was used and emission was collected at 595 nm by a GaAsP PMT 
detector (gain of PMT HV 30). For co-staining experiments the settings above were 
used in sequence to collect [Ir(ppy)2(MeTzPyPhCN)]+ and MitoTracker® Red 
CMXRos respectively, minimising any overlap in spectral profiles.  
Anti-Cytochrome C antibody staining was imaged using a 640 nm laser (7 power 
setting) and emission wavelength at 700 nm by a standard PMT (gain of PMT HV 
125). All images were captured using a 40X/WI λS DIC N2 water emersion lens. 
For the detection of NAD(P)H in fresh tissues, a Zeiss LSM710 NLO confocal 
microscope equipped with a two-photon Mai-Tai®, tunable Ti:Sapphire femtosecond 
pulse laser (Spectra-Physics, USA) was utilised. Images were collected using two-
photon excitation at 740 nm and a 474 – 504 nm emission interval.18 The laser power 
was 11% and the pinhole set to 600 µm. The pixel dwell time was set to 1.58 µs, and 
each image was averaged eight times to increase the signal-to-noise ratio. All images 
were acquired using a LD C-Apochromat 40X/NA 1.1 Water Corr UV-VIS-IR M27 
objective (Carl Zeiss, Jena, Germany). The temperature in the imaging facility was set 
to a constant 19 °C. 
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Chapter 4  
Synthesis and Photophysical Investigation of 
Amino and Nitro-Functionalised Iridium 
Tetrazolato Complexes 
 
4.1 Introduction 
The intracellular pH plays a central role in numerous biological processes, such as 
cellular proliferation, endocytosis, apoptosis, autophagy, enzymatic activity and ion 
transport.341–345 Abnormal cellular pH values are indicators of inappropriate cellular 
functions, which are often associated with many common diseases like stroke, cancer 
and Alzheimer’s disease.346–348 Therefore, sensing and monitoring the pH is essential 
for understanding the physiological and pathological processes within cells and 
tissues. For the detection of pH fluctuations, a variety of methods have been employed, 
including 31P NMR spectroscopy,349,350 electrochemical techniques using 
microelectrodes351,352 and optical microscopy.45,353,354 Among them, fluorescent and 
phosphorescent probes have gained much attention due to their high sensitivity and 
selectivity, combined with relatively low cost, fast response, facilitated detection and 
non-invasiveness.45,46,355  
During the design of the sensing system, the presence of protonatable and 
deprotonatable groups such as amino,356 carboxylic,357 hydroxyl354 or imidazole-
functionalised moieties358 has been employed to regulate the pH-response.  
Various luminescent dyes have been explored for the development of optical 
pH-sensors (refer to Figure 4.1), including organic naphthalimide (94) and rhodamine 
(95) derivatives, coumarin (96) and BODIPY (97) probes,42,43,47,199,359 as well as metal 
complexes of Ru(II), Re(I), Pt(II) and Ir(III) (98-101).354,357,360–365 
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Figure 4.1 Examples of previously reported pH-sensors with the active group(s) 
highlighted in red. 
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In this chapter, the synthesis and photophysical investigation of two amino-
functionalised iridium(III) tetrazolato complexes, [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyNH2)] (Figure 4.2 - top), will be discussed. Moreover, preliminary 
protonation and deprotonation reactions have been performed to evaluate the pH-
sensing activities of these complexes. Noteworthy, [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyNH2)] possess two different sites that can undergo protonation: the 
amino group and the tetrazolate ring.  
For a better understanding of the absorption and emission profile modifications 
between the neutral and the protonated forms, the synthesis of the cationic analogues 
[Ir(ppy)2(MeTzPyNH2)]+ and [Ir(bzq)2(MeTzPyNH2)]+ was attempted (Figure 4.2 - 
top). Unfortunately, the methylated species could not be isolated from the reaction 
mixture. For this reason, a comparative titration study was performed on 
[Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)], and their methylated equivalents 
[Ir(ppy)2(MeTzPyCN)]+ and [Ir(bzq)2(MeTzPyCN)]+ (Figure 4.2 - bottom). 
The photophysical performance of [Ir(ppy)2(TzPyNH2)] is poor in comparison 
to the emissive properties of [Ir(ppy)2(TzPyCN)], which is ascribed to the presence of 
the NH2 group on the tetrazolate ligand. In particular, the electron-donating NH2 blue 
shifts the emission maxima of the complex by increasing the energy of the emitting 
3MLCT exciting state, which lays in close proximity with the thermally available and 
dark 3MC excited state (see section 4.4.3 for details). Moreover, the emission is also 
quenched by the high energy vibrations due to the stretching of the N˗H bonds. 
Hence, in order to prove this hypothesis, the amine of [Ir(ppy)2(TzPyNH2)] 
was oxidised to an electron-withdrawing NO2 group. However, the resulting nitro-
functionalised complex [Ir(ppy)2(TzPyNO2)] (Figure 4.2 - top) has showed a total 
quenching of the emission even in organic solvent. 
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Figure 4.2 Structures of target complexes in this investigation. 
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4.2 Synthesis of the Tetrazolate Ligand 
HTzPyNH2 was synthesised following a previously reported procedure, showed in 
Figure 4.3, in which the nitrile precursor was reacted with sodium azide and 
triethylammonium chloride in toluene and heated at reflux for 24 hours.270 
 
 
Figure 4.3 Scheme of the synthetic procedure for the preparation of HTzPyNH2. 
 
HTzPyNH2 was isolated as an orange-pink precipitate and was characterised by IR, 
1H NMR and 13C NMR spectroscopy. 
The IR bands at 3334, 3160 and 1661 cm-1 are characteristic of N–H bond 
stretching and bending of the amino group, whereas the band at 1612 cm-1, associated 
with C=N stretching, is suggestive of the formation of the tetrazolate ring. 
Additionally, the lack of the nitrile band at ca. 2240 cm-1 confirms the conversion of 
the starting material in the desired product.  
 
 
Figure 4.4 1H NMR in DMSO-d6 for HTzPyNH2 with labelling of the proton peaks. 
 
The 1H NMR spectrum of HTzPyNH2 is shown in Figure 4.4. The peaks at 
8.07, 7.86 and 7.08 ppm are associated with the pyridinic protons, whereas the broad 
 153 
singlet peak resonating at 6.04 ppm is assigned to the amino substituent. The 13C NMR 
spectrum is again in agreement with the proposed structure, displaying the tetrazolic 
carbon CT at 154.9 ppm, which highlights the predominant presence of the N1 
tautomeric form of the tetrazolato ring (refer to Chapter 1 – section 1.6).225,226  
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4.3 Synthesis of the Iridium(III) Complexes 
4.3.1 Synthesis and Characterisation of Amino-
Functionalised Iridium(III) Complexes 
The synthesis of the two iridium(III) complexes [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyNH2)] was adapted from a published literature method.236,238 In this 
case, the use of triethylamine was necessary to deprotonate HTzPyNH2, in order to 
improve its low solubility in the solvent system. Once HTzPyNH2 was completely 
dissolved and converted in its anionic form TzPyNH2-, the appropriate dichloro-
bridged dimer, [Ir(ppy)2(µ-Cl)]2 or [Ir(bzq)2(µ-Cl)]2, was added and the reaction 
mixture stirred at room temperature for 16 hours. (Figure 4.5 - top). 
 
 
Figure 4.5 Scheme of the synthetic procedure for preparation of neutral 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] (top) and the attempted reaction 
scheme for the formation of the cationic [Ir(ppy)2(MeTzPyNH2)]+ and 
[Ir(bzq)2(MeTzPyNH2)]+ (bottom). 
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The synthesis of the methylated [Ir(ppy)2(MeTzPyNH2)]+ and 
[Ir(bzq)2(MeTzPyNH2)]+ (Figure 4.5 - bottom) was unsuccessful, as an inseparable 
mixture of products was obtained. The 1H NMR spectrum of the reaction mixture to 
form [Ir(ppy)2(MeTzPyNH2)]+ (Figure 4.6) displays three different species, which 
have been identified as unreacted [Ir(ppy)2(TzPyNH2)] and two methylated 
complexes. The peaks of the unreacted starting material [Ir(ppy)2(TzPyNH2)] have 
been highlighted in the spectrum (black boxes), whereas the presence of two methyl 
peaks at around 4.45 ppm (red box) is assigned to the two different methylated species. 
 
 
Figure 4.6 1H NMR spectrum in DMSO-d6 of the reaction mixture to form 
[Ir(ppy)2(MeTzPyNH2)]+. The signals of the unreacted starting material 
[Ir(ppy)2(TzPyNH2)] and the methyl peaks of two different methylated species have 
been highlighted in black and red boxes, respectively. 
 
Based on previous reports on iridium(III) tetrazolato complexes,236,238,239 the 
electrophilic addition in the N2 or N4 position of the tetrazolate ring is unlikely to 
happen. For this reason the methylation of the amino group has been investigated, 
using 5-amino-2-pyridinecarbonitrile as a model molecule and following the same 
methylation method adopted for [Ir(ppy)2(MeTzPyNH2)]+ and 
[Ir(bzq)2(MeTzPyNH2)]+. This substrate was chosen as starting material to simplify 
the studied system, by avoiding any methylation of the tetrazolato ring. As showed in 
Figure 4.7, two different species were present in the reaction crude, with a ratio of 2:1 
(based on NMR integrals). The major compound was identified as the unreacted 
starting material (green triangle), whereas the second species was represented by the 
methylated pyridine analogue (red diamond), characterised by the amino broad singlet 
around 6.40 ppm and a sharp methyl peak at ca. 4.30 ppm. On the basis of this result, 
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the methylation of the amino group using methyl trifluoromethanesulphonate has been 
discarded as possible explanation for the second methylated byproduct in the reaction 
to form [Ir(ppy)2(MeTzPyNH2)]+. 
 
 
Figure 4.7 1H NMR spectrum in DMSO-d6 of the reaction mixture for the methylation 
of 5-amino-2-pyridinecarbonitrile. In the spectrum, the peaks of the two species are 
labelled with green triangles and red diamonds for 5-amino-2-pyridinecarbonitrile and 
the methylated analogous, respectively. 
 
The presence of two methylated species in the reaction mixture showed in 
Figure 4.6 can be then attributed only to the methylation in N2 or N4 positions of the 
tetrazolato ring. In the attempt of proving this hypothesis, a preliminary investigation 
was firstly performed on HTzPyNH2, but the purification and separation of the two 
isomers via column chromatography was not achieved due to cleavage of the amino 
group and decomposition of the products. The methylation reaction was then carried 
out on 2-(1H-tetrazol-5-yl)pyridine (HTzPy) and two isomers were successfully 
synthesised and purified via column chromatography on silica gel and using an ethyl 
acetate/petroleum spirits 40-60 (9:1 v/v) solvent mixture as eluent. As depicted in 
Figure 4.8, N4-MeTzPy showed a marked downfield shift of the aromatic proton 
peaks in comparison to N3-MeTzPy, whereas the methyl groups resonated at similar 
frequency (4.42 and 4.46 ppm, respectively). Moreover, as previously reported by 
Butler et al.,226 the different isomers can be distinguished by the chemical shift of the 
tetrazolic carbon CT, which resonates in the range of 162 - 165 ppm for the N3-
substituted ring and 152 - 156 ppm for the N4 species (Figure 4.9). 
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Figure 4.8 1H NMR in DMSO-d6 for N4-MeTzPy (top) and N3-MeTzPy (bottom) 
with labelling of the proton peaks. 
 
 
Figure 4.9 13C NMR in DMSO-d6 for N4-MeTzPy (top) and N3-MeTzPy (bottom). 
In the spectra, the downfield shift of the CT is highlighted. The peak of the methyl 
carbon CMe is only visible for N4-MeTzPy. 
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Unfortunately, obtaining the 13C NMR spectrum of the reaction mixture to 
form [Ir(ppy)2(MeTzPyNH2)]+ was unsuccessful due to the presence of three species. 
Based on the 1H NMR spectra, the resonance of the methyl peaks (4.41 – 4.46 ppm) is 
comparable with the ones exhibits by N3-MeTzPy and N4-MeTzPy (4.42 -4.46 ppm). 
Furthermore, the ratio of the two methylated species in the reaction mixture was 5:1, 
which is again similar to the one obtained for N3-MeTzPy and N4-MeTzPy (4:1), 
suggesting that only a small amount of the N4-substituted product was formed. Based 
on these results, we can identify the two methylated species in Figure 4.6 as N3 and 
N4-substituted iridium(III) complexes. 
On the other hand, [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] were 
isolated with high purity and good yield by precipitation from the crude mixture with 
addition of diethyl ether and purification via column chromatography was not 
necessary. 
The IR spectroscopic characterisation highlights the bands of amino N–H 
stretching and bending at similar wavenumbers of ca. 3305, 3160 and 1640 cm-1 and, 
the tetrazolic C=N stretching at ca. 1605 cm-1 for both complexes. 
The 1H NMR spectra in DMSO-d6 showed in Figure 4.10 confirm the isolation 
of the desired products. The spectra display the characteristic doublet peaks around 6.5 
– 6.0 ppm (black boxes) assigned to cyclometalated iridium species126,133,273 and, 
slightly downshifted, the broad singlet peak of the amino substituent (red boxes). 
The 13C NMR showed the CT signals at 167.5 and 164.2 ppm for [Ir(ppy)2(TzPyNH2)] 
and [Ir(bzq)2(TzPyNH2)], respectively, confirming the coordination of the tetrazolate 
ligand to the iridium metal centre. 
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Figure 4.10 1H NMR in DMSO-d6 for [Ir(bzq)2(TzPyNH2)] (top) and 
[Ir(ppy)2(TzPyNH2)] (bottom). In the spectra, the two characteristic doublet peaks of 
cyclometalated iridium complexes and the singlet peak of the amine have been 
highlighted in black and red boxes, respectively.  
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4.3.2 Synthesis and Characterisation of Nitro-
Functionalised Iridium(III) Complex 
[Ir(ppy)2(TzPyNO2)] was synthesised by oxidation of [Ir(ppy)2(TzPyNH2)], using 
potassium iodide as catalyst and tert-butyl hydroperoxide (TBHP) as oxidating 
agent,366 as showed in Figure 4.11. 
 
 
Figure 4.11 Scheme of the synthetic procedure for the preparation of 
[Ir(ppy)2(TzPyNO2)]. 
 
Classical methods for the preparation of aromatic nitro compounds involve 
direct nitration of the aromatic ring under harsh conditions or through the formation of 
anionic intermediates.367–369 Interestingly, following the methodology discovered by 
Reddy et al.,366 direct oxidation of the amino-functionalised iridium(III) complex can 
be achieved in mild conditions, using acetonitrile as solvent and heating the reaction 
mixture at reflux for 16 hours.  
The unreacted starting material was easily separated by filtration from the 
crude mixture and recovered, whereas [Ir(ppy)2(TzPyNO2)] was purified by column 
chromatography using neutral alumina as stationary phase and isolated in good yield 
(ca. 75%). 
The IR spectrum of [Ir(ppy)2(TzPyNO2)] displays two strong absorption bands 
at 1478 and 1344 cm-1, which are associated with the asymmetric and symmetric 
stretching of the nitro group, respectively. In addition to the NO2 bands, the aromatic 
stretching of the tetrazolic C=N at 1607 cm-1 further supports the formation of the 
desired product. 
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The 1H NMR spectrum for this complex matches the proposed structure. Two 
doublets and a singlet peak at 8.83, 8.55 and 8.37 ppm are associated with the three 
pyridinic hydrogen atoms of the TzPyNO2- ligand, and resonate at higher chemical 
shift with respect to [Ir(ppy)2(TzPyNH2)] due to the oxidation of the electron-donating 
amine to an electron-withdrawing nitro group (Figure 4.12). In the 13C NMR 
spectrum, the resonance of the CT at 167.0 ppm is consistent with other cyclometalated 
iridium(III) tetrazolato species,236,238,239,370 and it is indicative of a co-planarity 
between the pyridyl and tetrazole rings of the ancillary ligand, and therefore chelation 
to the iridium metal centre. 
 
 
Figure 4.12 1H NMR in DMSO-d6 for [Ir(ppy)2(TzPyNO2)] with the tetrazolic peaks 
labelled in the spectrum. 
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4.3.3 Synthesis and Characterisation of Cyano-
Functionalised Iridium(III) Complexes 
As discussed in section 4.1 of this chapter, the photophysical behaviour of 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] in acid/base conditions has been 
investigated and compared to the one of [Ir(ppy)2(TzPyCN)] and 
[Ir(bzq)2(TzPyCN)]. To minimise the effect of the structural modifications on the 
photophysical properties, the investigation was carried out on the cyano and amino-
functionalised iridium(III) complexes bearing the same cyclometalated ligands (ppy 
or bzq).  
Based on the synthetic procedure of [Ir(ppy)2(TzPyCN)] described in Chapter 2 – 
section 2.3.1, [Ir(bzq)2(TzPyCN)] was prepared in a similar manner.236,238  
 
 
Figure 4.13 Scheme of the synthetic procedures for the preparation of the neutral 
[Ir(bzq)2(TzPyCN)] (top) and the methylated [Ir(bzq)2(MeTzPyCN)]+ (bottom) 
species. 
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The reaction is showed in Figure 4.13 (top), where the dichloro-bridge dimer 
[Ir(bzq)2(µ-Cl)]2 is combined with HTzPyCN in dichloromethane/ethanol (10:3 v/v) 
solvent system and stirred at room temperature for 16 hours to form the crude product. 
Purification via column chromatography using neutral alumina as stationary phase and 
dichloromethane/acetone (9:1 v/v) solvent system as eluent was required to yield the 
pure [Ir(bzq)2(TzPyCN)] (66%). 
The reaction of the neutral [Ir(bzq)2(TzPyCN)] with a slight excess of methyl 
trifluoromethanesulphonate, followed by metathesis with ammonium 
hexafluorophosphate led to the formation of the cationic [Ir(bzq)2(MeTzPyCN)]+ 
species as a PF6- salt (Figure 4.13 - bottom). 
The methylated complex was isolated as a red solid with good yield (ca. 75%) and 
purity by simple extraction from the reaction mixture and without further purification 
needed. 
The neutral and the methylated complexes were characterised by IR 
spectroscopy, which highlights the sharp C≡N peak around 2238 cm-1, in addition to 
the tetrazolic C=N stretching at ca. 1613 cm-1 for both the species. 
The 1H NMR spectra for [Ir(bzq)2(TzPyCN)] and [Ir(bzq)2(MeTzPyCN)]+ 
support the achieved isolation of the desired compounds, with the total peak 
integration being 19 and 22 protons, respectively. The difference in integration is due 
to the methyl sharp signal resonating at 4.50 ppm and integrating for 3 protons, which 
highlights the formation of only one methylated species for each complex (Figure 
4.14). 
To further confirm the conversion of the neutral iridium complex in the 
methylated analogous, the 13C NMR spectra of the two complexes were compared, as 
shown in Figure 4.15. In particular, the methyl peak of [Ir(bzq)2(MeTzPyCN)]+ is 
identified at 42.2 ppm and the characteristic CT resonance is downshifted from 163.0 
for [Ir(bzq)2(TzPyCN)] to 165.3 ppm for [Ir(bzq)2(MeTzPyCN)]+. A comparable 
shift of the CT signals was observed for previously published complexes,236,238,239 
supporting the hypothesis of methylation in N3 position of the tetrazolate ligand. 
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Figure 4.14 1H NMR in DMSO-d6 for the neutral complex [Ir(bzq)2(TzPyCN)] (top) 
compared to the methylated analogous [Ir(bzq)2(MeTzPyCN)]+ (bottom). 
 
 
Figure 4.15 13C NMR in DMSO-d6 for the neutral complex [Ir(bzq)2(TzPyCN)] (top) 
compared to the methylated analogous [Ir(bzq)2(MeTzPyCN)]+ (bottom). 
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4.4 Photophysical Investigation 
4.4.1 Absorption in Dichloromethane 
The absorption properties of the iridium(III) complexes in air-equilibrated 
dichloromethane solutions have been summarised in Table 4.1. 
All the neutral iridium(III) species display comparable absorption profiles (Figure 
4.16 to Figure 4.18). With reference to the absorption spectra of similar 
cyclometalated iridium(III) complexes,33,260,273,298,311,371 the absorption bands in the 
250 – 300 nm region are attributed to spin-allowed ligand-centred (LC) p-p* 
transitions, localised on the ppy and bzq ligands. The less intense absorption shoulders 
in the visible region between 300 and 400 nm are assigned to a mixture of spin-allowed 
ligand-to-ligand (LLCT) and metal-to-ligand charge transfer (MLCT) transitions. In 
addition, due to the spin-orbit coupling associated with the iridium metal centre,76 spin-
forbidden MLCT/LLCT transitions are visible as weak absorption tails at ca. 400 – 
450 nm.236 
 
Table 4.1 Absorption data of dichloromethane solutions (10-5 M) of the reported 
complexes. 
Complexes 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2(TzPyNH2)] 270 (9.45), 346 (1.79), 387 (0.89), 423 (0.53) 
[Ir(bzq)2(TzPyNH2)] 260 (9.59), 333 (3.63), 375 (1.53), 433 (0.87) 
[Ir(ppy)2(TzPyNO2)] 262 (4.60), 301 (3.40), 384 (0.86), 417 (0.50) 
[Ir(bzq)2(TzPyCN)] 262 (7.83), 290 (4.27), 351 (2.18), 426 (0.80) 
[Ir(bzq)2(MeTzPyCN)]+ 284 (3.32), 321 (2.11), 405 (0.78) 
 
A comparison between [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] 
highlights a slight blue shift of the absorption bands by changing the cyclometalated 
ligands from ppy to bzq, along with higher absorptivity values (Figure 4.16). The 
opposite behaviour was previously observed for Re(I) complexes with formula fac-
[Re(CO)3(N^N)L]+, where N^N is either bpy (2,2’-bipyridine) or phen (1,10-
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phenanthroline) and L is a para-functionalised 5-aryltetrazolate ligand. In this case, a 
red shift of the absorption bands and an increase of the molar absorptivity values were 
recorded between the phen and bpy-functionalised Re(I) complex.372 
On the other hand, a more marked red shift of MLCT/LLCT bands was 
observed in Figure 4.18 comparing [Ir(bzq)2(TzPyCN)] and [Ir(bzq)2(MeTzPyCN)]+ 
with the less conjugated [Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(MeTzPyCN)]+ 
(absorption data of these complexes are showed in Chapter 2 – section 2.4.1).115,137,301  
 
 
 
 
 
Figure 4.16 Absorption profiles of [Ir(ppy)2(TzPyNH2)] (blue) and 
[Ir(bzq)2(TzPyNH2)] (red) in dichloromethane. 
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Figure 4.17 Absorption profiles of [Ir(ppy)2(TzPyNO2)] (blue) in dichloromethane. 
 
 
Figure 4.18 Absorption profiles of [Ir(bzq)2(TzPyCN)] (solid blue), 
[Ir(bzq)2(MeTzPyCN)]+ (solid red), [Ir(ppy)2(TzPyCN)] (dash blue), 
[Ir(ppy)2(MeTzPyCN)]+ (dash red) in dichloromethane. 
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4.4.2 Emission Properties in Dichloromethane 
The photophysical properties of the iridium(III) complexes were measured in both air-
equilibrated and degassed dichloromethane solutions, and all the data are summarised 
in Table 4.2. 
Upon irradiation at 350 nm, all the complexes, with the exception of 
[Ir(ppy)2(TzPyNO2)], displayed intense green-yellow to orange-red emission for the 
amino (Figure 4.21) and cyano-functionalised complexes (Figure 4.22), respectively.  
 
Table 4.2 Photophysical data of dichloromethane solutions (10-5 M) of the reported 
complexes. 
Complex 
λem 
[nm] 
τaer 
[ns]a 
τdeaer 
[ns]a 
Φaerb Φdeaerb 
[Ir(ppy)2(TzPyNH2)] 484, 514 101 1032 0.005 0.028 
[Ir(bzq)2(TzPyNH2)] 524, 555 120 23110 0.005 0.572 
[Ir(ppy)2(TzPyNO2)] -c -c -c -c -c 
[Ir(bzq)2(TzPyCN)] 620 146 508 0.052 0.124 
[Ir(bzq)2(MeTzPyCN)]+ 690 24 (54), 
152(46) 
25 (47), 
192 (53) 
0.010 0.012 
a For the biexponential excited state lifetime (τ), the relative weights of the exponential 
curves are reported in parentheses. b Measured versus [Ru(bpy)3]2+ in H2O (Φr = 
0.028).274 c Not emissive. 
 
The emission of [Ir(ppy)2(TzPyNO2)] was too weak to be distinguishable from 
the baseline, even in an oxygen-free solution, and has not been reported. Previous 
studies on rhenium(I) and iridium(III) complexes373,374 carrying nitro groups showed 
no emission in solution at 298 K for these species, unlike their non-substituted 
analogues. In the case of fac-[Re(CO)3(5-NO2-phen)Cl] (Figure 4.19), the lack of 
emission is due to the quick conversion (ca. 10 ps) of the 3MLCT excited state into a 
close-lying intraligand (IL) 3np* excited state, whereby the electron density is excited 
from the NO2 oxygen lone pairs to the p* systems of the phen. The 3np*state is also 
short-lived and undergoes rapid non-radiative conversion to the ground state with a 
lifetime of ca. 30 – 70 ps, depending on the solvent.373 A similar assumption has been 
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applied to [Ir(ppy)2(TzPyNO2)], in order to explain why other electron-withdrawing 
groups, such as nitrile, do not show the same behaviour. 
 
Figure 4.19 Simplified Jablonski diagram (left), illustrating the excited state 
behaviour of fac-[Re(CO)3(5-NO2-phen)Cl] (right) in an acetonitrile diluted solution 
at 298 K.373 
 
The emission profiles of [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] are 
characterised by structured emission bands with a vibronic progression around 1,200 
and 1,060 cm-1, respectively, which indicate that the emissive excited state is derived 
from a mixing of ligand-centred and charge transfer character. The emission maxima 
of [Ir(bzq)2(TzPyNH2)] at 524 and 555 nm is red-shifted in comparison to the ones at 
484 and 514 nm for [Ir(ppy)2(TzPyNH2)], as showed in Figure 4.21. The expected 
red shift is ascribed to the increased conjugation of the cyclometalated bzq ligands, 
which destabilises the HOMO orbitals while stabilising the LUMO, with a resulting 
smaller HOMO-LUMO energy gap.  
In the case of [Ir(bzq)2(TzPyCN)] (Figure 4.22), the substitution of the amino 
with the electron-withdrawing nitrile group is responsible for the stabilisation of the 
unoccupied p* orbitals of the tetrazolate ligand, causing a substantial red shift of the 
emission maximum (λem = 620 nm). Interestingly, [Ir(ppy)2(TzPyCN)] (Chapter 2 – 
section 2.4.2) and [Ir(bzq)2(TzPyCN)] emits at the same wavelength, suggesting that 
the HOMO is not homogeneously localised on the cyclometalated ligands. A previous 
study by Werrett et al.372 had indeed evidenced that bpy and phen exhibit a similar 
electronic distribution, which is mainly localised on the pyridyl rings, as depicted in 
S0
1MLCT
3MLCT
T3
ISC << 1 ps
~10 ps
~30 ps
T1
S2
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Figure 4.20. For this reason, the photophysical behaviour of phen can be compared to 
that of a dimethyl-substituted bipyridine Me2bpy (Figure 4.20). 
 
 
Figure 4.20 Simplified representation of the electronic distribution on bpy and phen 
(green). On the right, the structure of Me2bpy is reported to highlight the structural 
similarity with phen.   
 
The methylated complex [Ir(bzq)2(MeTzPyCN)]+ exhibits a red-shifted 
emission maximum at 690 nm (Figure 4.22), with respect to the neutral 
[Ir(bzq)2(TzPyCN)]. As show in Chapter 2, the methylation of the tetrazolate ligand 
stabilises the p* unoccupied orbitals, demonstrating again the role of these orbitals as 
electron acceptor in the charge transfer transitions.236,237 The same trend followed by 
the neutral complexes can be observed when comparing [Ir(bzq)2(MeTzPyCN)]+ with 
[Ir(ppy)2(MeTzPyCN)]+. In this case, a shift of ca. 10 nm in the emission maximum 
is present upon increasing the conjugation from ppy to bzq. 
At different extent, all the complexes exhibit an elongation of the excited state 
lifetime decay (τ) and an increase of the photoluminescent quantum yield (Φ) values 
upon degassing the dichloromethane solution, suggesting phosphorescent decay from 
excited states of triplet spin multiplicity.107,201,237 
In particular, [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] displayed the 
major increment of excited state lifetime passing from air-equilibrated to degassed 
solutions, with values of ca. 1 and 23 µs. As previously discussed in Chapter 2 – 
section 2.4.2, the elongation of lifetime can be assigned to a stronger influence of the 
LC character of the mixed exited state, which results more pronounced for 
[Ir(bzq)2(TzPyNH2)].238 Moreover, the effect of the rigidity of the bzq ligands with 
respect to the ppy, may be also responsible for the longer excited state lifetime of 
[Ir(bzq)2(TzPyNH2)] in comparison to [Ir(ppy)2(TzPyNH2)].372  
bpy phen Me2bpy
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Figure 4.21 Normalised emission profiles of [Ir(ppy)2(TzPyNH2)] (blue) and 
[Ir(bzq)2(MeTzPyNH2)]+ (red) in dichloromethane. 
 
 
Figure 4.22 Normalised emission profiles of [Ir(bzq)2(TzPyCN)] (blue) and 
[Ir(bzq)2(MeTzPyCN)]+ (red) in dichloromethane. 
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For a better understanding of the photophysical behaviour of the reported 
iridium(III) complexes, the radiative (kr) and non-radiative (knr) decay constants were 
calculated for degassed dichloromethane solutions and are summarised in Table 4.3. 
[Ir(ppy)2(TzPyNO2)] and [Ir(bzq)2(MeTzPyCN)]+ have been excluded from this 
evaluation due to the non-emissive nature of the first species and the biexponentiality 
of the excited state lifetime of the latter. 
 
Table 4.3 Radiative (kr) and non-radiative (knr) decay constants in degassed 
dichloromethane solutions. 
Complex 
kr 
106[s-1]a 
knr 
106[s-1]b 
[Ir(ppy)2(TzPyNH2)] 0.027 0.942 
[Ir(bzq)2(TzPyNH2)] 0.025 0.019 
[Ir(ppy)2(TzPyNO2)] -c -c 
[Ir(bzq)2(TzPyCN)] 0.244 1.724 
[Ir(bzq)2(MeTzPyCN)]+ -c -c 
a Calculated as [Φ/τ] using measurements from deaerated dichloromethane solutions. 
b Calculated as [(1-Φ)/τ] using measurements from deaerated dichloromethane 
solutions. c The lifetime shows a biexponential nature, which did not allowed the 
calculation of kr and knr. 
 
The comparison of the photophysical properties of [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyNH2)] highlight comparable radiative decay constants, which are 
typical of 3LC emission, with kr << 2.0 × 105 s-1.77 This result is supported by the 
vibronically structured profile of the luminescent spectra (Figure 4.21) recorded for 
these two complexes, which demonstrates small energy separation of 3MLCT and 3LC 
levels, with a marked contribution of the 3LC excited state to the emission. On the 
other hand, a 50 fold increment of the non-radiative constant values was calculated for 
[Ir(bzq)2(TzPyNH2)] with respect to [Ir(ppy)2(TzPyNH2)]. This phenomenon is in 
agreement with the rigidity of the more conjugated bzq with respect to the ppy ligand, 
which would reduce the knr by minimising the vibrational relaxation (VR). 
[Ir(bzq)2(TzPyCN)] displays kr and knr values that are of the same order of 
magnitude as the radiative (kr = 0.751 × 106 s-1) and non-radiative decay constants (knr 
= 1.140 × 106 s-1) of [Ir(ppy)2(TzPyCN)] (Chapter 2 – section 2.4.2). In particular the 
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kr values confirm once again the emission from a MLCT excited state.77 Moreover, in 
this specific case, the higher conjugation of the cyclometalated ligands does not seem 
to extremely affect the luminescent properties of the complex. 
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4.4.3 Temperature-Dependent Luminescence Lifetime 
Measurements 
The difference in the photophysical properties between [Ir(ppy)2(TzPyNH2)] (section 
4.4.2) and [Ir(ppy)2(TzPyCN)] (Chapter 2 – section 2.4.2) have been rationalised by 
temperature-dependent luminescence lifetime measurements. 
As demonstrated by previous studies, the nature of the lowest-lying excite state 
in transition metal complexes can be 3LC (ligand-centred), 3MLCT (metal-to-ligand), 
3ILCT (intra-ligand), 3MLLCT (metal-ligand-to-ligand) or 3LLCT (ligand-to-ligand) 
charge transfer in nature.76,77,375–377 However, in some cases the presence of a dark 
3MC excited state in close proximity to the lowest-emissive excited state can lower the 
emission properties of the complex. In fact, if the energy gap between the emissive 
and the 3MC excited state is not too high, the latter becomes thermally accessible at 
room temperature. On the other hand, this thermal activation can be depressed by 
decreasing the temperature of the system and consequentially populate just the lowest 
and emissive excited state.375 
The excited state lifetimes of [Ir(ppy)2(TzPyNH2)] and [Ir(ppy)2(TzPyCN)] 
have been recorded in diluted (ca. 10-5 M) dichloromethane solutions in a range of 
temperatures between 198 and 298 K. The data have been plotted as the logarithm of 
the rate constant (kobs) against the inverse temperature (1/T), as showed in Figure 4.23. 
We can define kobs as in Equation 4.1: LMNO = 	L% +	∑ L.%	RR                                          (4.1) 
 
where kr and knr are the radiative and non-radiative decay constant, respectively. 
However, the equation can be simplified considering that the radiative transition is 
essentially governed by spin and symmetry factors,378 whereas the radiationless rate 
constant generally increases with decreasing of the excited state energy, as expected 
on the basis of the energy gap law.75 The kobs can be then described as knr by the 
Arrhenius-type Equation 4.2: L.% = S	TUVWXYZ [ + L\                                         (4.2) 
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where A is the pre-exponent coefficient, k0 is an independent-temperature factor, ΔE 
is the difference in energy between the two states, R is the gas constant (8.314 Jmol-
1K-1) and T is the temperature (K). 
 
Figure 4.23 Arrhenius plot of the rate constants of [Ir(ppy)2(TzPyNH2)] (blue) and 
[Ir(ppy)2(TzPyCN)] (red). The trendlines and the R2 values have been reported. 
 
In the case of [Ir(ppy)2(TzPyCN)], the energy gap ΔE between 3MC and the 
emissive 3MLCT excited state is high enough that the changing in temperature does 
not affect the non-radiative constant and the lifetime is maintained constant along the 
whole range of temperatures. 
On the other hand, [Ir(ppy)2(TzPyNH2)] showed a small ΔE which allowed 
thermal equilibrium between the 3LC/3MLCT lowest excited states and the 3MC state 
at room temperature, confirmed by an increase of the non-radiative decay constant. 
Moreover, lowering the temperature permits to block the thermal population of the 
3MC state, which can be verified by the elongation of the excited state lifetimes. 
Based on these results, the difference in emissive properties between 
[Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(TzPyNH2)] has been explained by the presence of 
a thermally accessible and dark 3MC excited state, which lowers the lifetime and the 
emission intensity of the latter.  
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4.4.4 Absorption in Aqueous and Lipophilic Solvents 
The photophysical behaviour of this series of complexes has been explored in aqueous 
and lipophilic solvents in order to evaluate their applicability for biological studies. 
The summary of the absorption data is listed in Table 4.4. 
Table 4.4 Absorption data of aqueous and lipophilic solutions (10-5 M) of the reported 
iridium(III) complexes. 
Complexes Solventa 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2 
(TzPyNH2)] 
H2O 273 (5.30), 388 (0.91),  422 (0.56) 
Lys. Fluid 272 (3.92), 394 (1.03),  435 (0.64) 
PBS 272 (4.56), 349 (1.76),  429 (0.60) 
Ethyl Laurate 276 (1.34), 372 (1.38),  445 (1.04) 
[Ir(bzq)2 
(TzPyNH2)] 
H2O 265 (8.08), 339 (4.04), 430 (1.19) 
Lys. Fluid 263 (2.50), 344 (1.80), 432 (0.77) 
PBS 273 (1.92), 361 (1.46), 440 (0.86) 
Ethyl Laurate 262 (2.54), 292 (2.36), 366 (1.88), 455 (0.96) 
[Ir(ppy)2 
(TzPyNO2)] 
H2O 270 (1.60), 308 (1.48), 412 (6.43) 
Lys. Fluid 273 (2.11), 306 (2.02), 410 (0.97) 
PBS 271 (2.55), 313 (2.32), 409 (1.17) 
Ethyl Laurate 270 (2.72), 301 (1.98), 388 (0.53), 425 (0.30) 
[Ir(bzq)2 
(TzPyCN)] 
H2O 266 (6.96), 294 (4.93), 355 (2.86), 431 (1.21) 
Lys. Fluid 267 (3.63), 298 (2.93), 355 (2.12), 434 (1.06) 
PBS 268 (4.07), 303 (3.34), 365 (2.50), 432 (1.53) 
Ethyl Laurate 258 (5.47), 291 (2.97), 339 (2.09), 433 (0.55) 
[Ir(bzq)2 
(MeTzPyCN)]+ 
H2O 279 (3.79), 319 (2.25), 403 (0.69) 
Lys. Fluid 279 (3.98), 317 (2.42), 406 (0.77) 
PBS 258 (5.45), 282 (3.23), 324 (1.96), 410 (0.65) 
Ethyl Laurate 262 (2.97), 351 (1.21), 436 (0.65) 
a Aqueous solvents contain 2% DMSO. 
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The choice of the solvents was driven by the necessity to establish how the 
photophysical properties could be modulated in the different cellular-type 
environments.  
A 2% of DMSO was used to dissolve the iridium(III) tetrazolate complexes in 
the aqueous media to guarantee complete dissolution of the probes. 
In general, the absorption profiles in aqueous media and ethyl laurate resemble 
the ones previously discussed for dichloromethane solutions (section 4.4.1), as showed 
from Figure 4.24 to Figure 4.28. The complexes exhibit intense spin-allowed ligand-
centre (LC) p-p* absorption features in the UV region (250 – 315 nm) and weaker 
absorption bands at λ ≥ 350 nm, which can be assigned to a mixture of spin-allowed 
ligand-to-ligand (LLCT) and metal-to-ligand charge transfer (MLCT) transitions. The 
weak absorption tailing beyond 400 nm has been assigned to spin-forbidden 
MLCT/LLCT transitions. 
Noteworthy, some of the solvents promote a slight aggregation for 
[Ir(ppy)2(TzPyNH2)] (Figure 4.24) and [Ir(bzq)2(TzPyNH2)] (Figure 4.25), 
characterised by broad and structureless absorption profiles and lower molar 
absorptivity coefficients in comparison to the data recorded in dichloromethane 
solutions. 
[Ir(ppy)2(TzPyNO2)] exhibits relatively low molar absorptivity coefficients 
for all the solvents, as depicted in Figure 4.26. This behaviour was also observed by 
Gabrielsson et al.373 for the complex fac-[Re(CO)3(5-NO2-phen)Cl], which was 
showing molar extinction coefficients of ca. 2.0 × 104 and 0.3 × 104 M-1 cm-1 for the 
p-p* LC and the MLCT transitions, respectively. 
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Figure 4.24 Absorption profiles of [Ir(ppy)2(TzPyNH2)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 4.25 Absorption profiles of [Ir(bzq)2(TzPyNH2)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure 4.26 Absorption profiles of [Ir(ppy)2(TzPyNO2)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 4.27 Absorption profiles of [Ir(bzq)2(TzPyCN)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure 4.28 Absorption profiles of [Ir(bzq)2(MeTzPyCN)]+ in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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4.4.5 Emission Properties in Aqueous Solvents 
The photophysical characterisation of the iridium(III) complexes in aqueous and 
lipophilic solvents has been summarised in Table 4.5. The emission properties of 
[Ir(ppy)2(TzPyNO2)] and [Ir(bzq)2(MeTzPyCN)]+ have been excluded due to the 
non-emissive nature of these species in the solvents used for the photophysical 
investigation. In particular, the methylated [Ir(bzq)2(MeTzPyCN)]+ follows the same 
behaviour as its analogous [Ir(ppy)2(MeTzPyCN)]+ (Chapter 2 – section 2.4.5), 
characterised by higher degree of quenching in aqueous media in comparison to 
dichloromethane solution. In this case, the quenching was so efficient that the emission 
could not be recorded. 
 
Table 4.5 Photophysical data of aqueous and lipophilic solutions (10-5 M) of the 
reported iridium(III) complexes. [Ir(ppy)2(TzPyNO2)] and [Ir(bzq)2(MeTzPyCN)]+ 
have been excluded due to their non-emissive nature in the investigated solvents. 
Complexes Solventa 
λem 
[nm] 
τear 
[ns]b 
Φaerc 
[Ir(ppy)2 
(TzPyNH2)] 
H2O 484, 508 30 (3), 466 (97) 0.012 
Lys. Fluid 484, 508 21 (6), 493 (94) 0.018 
PBS 484, 508 22 (6), 474 (94) 0.014 
Ethyl Laurate 484, 520, 
555sh 
17 (63), 89 (37) 0.010 
[Ir(bzq)2 
(TzPyNH2)] 
H2O 605 41 (31), 215 (69) 0.001 
Lys. Fluid 606 15 (17), 215 (83) 0.002 
PBS 605 41 (21), 221 (79) 0.001 
Ethyl Laurate 624 22 (14), 294 (86) 0.001 
[Ir(bzq)2 
(TzPyCN)] 
H2O 630 102 0.002 
Lys. Fluid 630 62 0.001 
PBS 630 71 0.001 
Ethyl Laurate 576 156 0.010 
a Aqueous solvents contain 2% DMSO. b For the biexponential excited state lifetime 
(τ), the relative weights of the exponential curved are reported in parentheses. c 
Measured versus [Ru(bpy)3]2+ in H2O (Φ = 0.028).274 
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The emission profiles of the two amino-functionalised complexes 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] in different solvent systems do not 
follow the same trend, implying that the change of the cyclometalated ligands from 
ppy to bzq severely affects the photophysical behaviour of these species.  
Firstly, the vibronically structured emission profile of [Ir(ppy)2(TzPyNH2)], 
shown in dichloromethane (section 4.4.2), is also maintained in the aqueous media, 
with an additional shoulder present in ethyl laurate at 555 nm (Figure 4.29). An 
increase of the relative intensity of the shoulder appears with increasing concentration 
of the complex from ca. 10-7 to 10-4 M (Appendix C, Figure C.1 – Figure C.2). 
Moreover, the excited state lifetime was measured at 484 and 555 nm, with 
significantly longer decay for the latter (refer to Appendix C – Table C.1 and Figure 
C.3). Therefore, the appearance of a shoulder at lower energy can be assigned to the 
formation of aggregates in the lipophilic solvent.379 On the other hand, 
[Ir(bzq)2(TzPyNH2)] displays broad and structureless emissions in both organic and 
aqueous solvents (Figure 4.30), indicating that the emissive excited state lost the LC 
contribution and consequently the emission originates predominantly from the CT 
excited state.136,236,238 In ethyl laurate, two different bands at 606 and 646 nm were 
visible only at high concentration (10-4 M), indicating again some level of aggregation 
of the complex379 (Appendix C – Figure C.6). 
Secondly, the emission profiles of [Ir(ppy)2(TzPyNH2)] do not reveal any 
solvatochromic behaviour, whereas [Ir(bzq)2(TzPyNH2)] shows a red shift of the 
emission maximum upon increasing the polarity of the solvent from dichloromethane 
to aqueous media. Interestingly, the emission in ethyl laurate is further red-shifted of 
ca. 20 nm, which is unusual considering the low polarity of the lipophilic solvent. For 
this reason, the excited state lifetime was recorded at 606 and 646 nm in the more 
concentrated solution (10-4 M), showing higher value for the latter. (Appendix C – 
Table C.2). These data, along with the variations in the excitation profiles in the range 
of concentrations between 10-4 and 10-7 M (Appendix C, Figure C.4 – Figure C.5), 
can be explained as a slight aggregation of [Ir(bzq)2(TzPyNH2)] in the lipophilic 
solvent.379 
The analysis of the excited state lifetimes and luminescent quantum yields for 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] highlights again the difference in the 
photophysical properties rising from the increase in the conjugation of the 
cyclometalated ligands. [Ir(ppy)2(TzPyNH2)] displays higher lifetime and quantum 
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yield values in aqueous media with respect to ethyl laurate solution, whereas 
[Ir(bzq)2(TzPyNH2)] exhibits comparable values in all the solvents (Table 4.5). 
The emission spectra of [Ir(bzq)2(TzPyCN)] in aqueous media and ethyl 
laurate are depicted in Figure 4.31. The broad and featureless profile is maintained in 
all the solvents, also revealing solvatochromic behaviour as seen for the analogous 
[Ir(ppy)2(TzPyCN)] (Chapter 2 – section 2.4.5). Excited state lifetime and quantum 
yields values are similar in aqueous environment, with average values of ca. 80 ns and 
0.001, respectively. A slight elongation of the lifetime (156 ns) and increase in 
quantum yield (0.010) is recorded in ethyl laurate. 
The photophysical properties of [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyCN)] in aqueous and lipophilic environment make them potential 
candidates for the application in cellular pH-sensing. On the other hand, 
[Ir(bzq)2(TzPyNH2)] has showed lower emission intensity along with some solubility 
issues, which can interfere during the acid/base investigation. Even if 
[Ir(bzq)2(TzPyNH2)] did not exhibit the requirements for the application as cellular 
pH-sensor, its behaviour will be evaluated as proof of concept. For this reason, the 
preliminary investigation of the protonation and deprotonation reactions of these 
complexes will be performed in dichloromethane solution. The use of the organic 
solvent was also driven by the necessity to compare the emission maxima of the 
protonated species with the one of [Ir(ppy)2(MeTzPyCN)]+ and 
[Ir(bzq)2(MeTzPyCN)]+, which are virtually not emissive in aqueous media. 
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Figure 4.29 Normalised emission profiles of [Ir(ppy)2(TzPyNH2)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
 
 
Figure 4.30 Normalised emission profiles of [Ir(bzq)2(TzPyNH2)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
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Figure 4.31 Normalised emission profiles of [Ir(bzq)2(TzPyCN)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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4.5 Protonation and Deprotonation Studies in 
Dichloromethane Solution 
The photophysical properties of octahedral d6 metal complexes are strongly influenced 
by the chosen set of coordinated ligands, which are responsible of the wide emission-
colour tunability of these species.65,81,255,380,381 In particular, previously reported 
tetrazolato-based iridium(III) complexes231,236,239 and the iridium(III) species 
discussed in this thesis238 have demonstrated the participation of the ligand containing 
the tetrazole in the composition of the emitting MLCT states. Moreover the reactivity 
of the tetrazolate ring against electrophiles has proved to be an easy method to 
modulate the photophysical properties by methylation of the neutral complexes in 
order to obtain cationic analogues.236,239,265  
Following a previously published study,231 the protonation and deprotonation 
reactions of [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] have been investigated. 
Noteworthy, the HTzPyNH2 is bearing an amino group along with a tetrazolate ring, 
which enables the complexes to have two different nucleophilic sites. In order to 
determine the protonation mechanism, and considering that the methylated 
[Ir(ppy)2(MeTzPyNH2)]+ and [Ir(bzq)2(MeTzPyNH2)]+ could not be isolated, the 
same investigation has been performed on [Ir(ppy)2(TzPyCN)] and 
[Ir(bzq)2(TzPyCN)] for comparison purposes.  
Absorption and emission spectra have been recorded after each acid or base 
addition, and for [Ir(ppy)2(TzPyNH2)] a 1H NMR spectra has been carried out as well. 
Once again, the photophysical behaviour of [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyNH2)] was completely different. It can be anticipated that 
[Ir(bzq)2(TzPyNH2)] did not show obvious changes in the absorption (Figure 4.32) 
and emission profiles (Figure 4.33), suggesting that the protonation reaction did not 
take place. Due to the extent cyclometalated ligands, the solubility of the complex in 
dichloromethane solution results lower than for [Ir(ppy)2(TzPyNH2)]. The formation 
of aggregates or partial precipitation of the complex could have protected the amino 
group and the tetrazolate ring from the electrophilic addition. 
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Figure 4.32 Absorption spectra of [Ir(bzq)2(TzPyNH2)], showing the lack of changes 
occurring upon the sequential addition of triflic acid to the complex solution. 
 
 
Figure 4.33 Emission spectra of [Ir(bzq)2(TzPyNH2)], showing the lack of changes 
occurring upon the sequential addition of triflic acid to the complex solution. 
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Upon treatment with triflic acid, the absorption profile of [Ir(ppy)2(TzPyNH2)] 
showed a decrease of the LC π-π* transitions and the formation of a band around 300 
nm (Figure 4.34). In the emission profile showed in Figure 4.35, a low energy 
shoulder appeared at ca. 555 nm after 2.0 equivalents of acid were added. This 
shoulder resembled the one discussed in section 4.4.5, in which [Ir(ppy)2(TzPyNH2)] 
exhibited the presence of a band at the same emission maximum, which was assigned 
to some level of aggregation of the complex in ethyl laurate solution.379 In order to 
evaluate this hypothesis, the excited state lifetime was measured for the initial solution 
at 484 nm and after the addition of 5 equivalents of triflic acid at both 484 and 555 nm 
(Table 4.6). As showed in Table 4.6, the lifetime decays were comparable, proving 
that no aggregation was present as a marked elongation of the excited state lifetime at 
555 nm would have been observed.379  
 
Table 4.6 Excited state lifetimes of [Ir(ppy)2(TzPyNH2)] in air-equilibrated 
dichloromethane solution, upon addition of triflic acid aliquots. 
Triflic acid aliquots 
λem 
[nm] 
τaer 
[ns] 
0.0 eq. 484 82 
5.0 eq. 
484 85 
555 85 
 
As mentioned before, [Ir(ppy)2(TzPyNH2)] possesses two different sites for 
the protonation to occur. Based on the similar basicity of the aromatic amino group 
with respect to the tetrazolate ring (pka[PhNH3+] = 4.65 ± 0.50, whereas pka[HTz] = 
4.70 ± 0.03),220 it is difficult to predict which of the two protonatable sites will react 
first. 
The 1H NMR of [Ir(ppy)2(TzPyNH2)] (Figure 4.36) suggested that the NH2 was the 
first group to be protonated and converted into NH3+ due to the lack of the broad singlet 
peak at 6.01 ppm after the addition of 0.5 equivalents of acid. The presence of the 
electron-withdrawing NH3+ did not shift the emission maxima of the complex, which 
remained at 484 and 514 nm, but affected the relative intensity of these bands. As 
showed in Figure 4.35, the emission intensity of the band at 484 nm decreased upon 
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increasing the amount of acid added to the complex solution. After the treatment with 
2.0 equivalents of triflic acid, a shoulder at 555 nm started to be visible and the total 
emission intensity of [Ir(ppy)2(TzPyNH2)] decreased, which can be ascribed to the 
protonation of the tetrazolate ring. Unfortunately, a comparison with the methylated 
[Ir(ppy)2(MeTzPyNH2)]+ was not possible to perform, but as discussed in Chapter 2 
– section 2.4.2 and in section 4.4.2 of this chapter, a decrease of the photophysical 
properties for cationic species in comparison to their neutral analogues is expected. On 
the other hand, the 1H NMR spectrum (Figure 4.36) did not displayed any major shifts 
of the peaks to support the protonation of the tetrazolate ring. Based on these data, a 
final conclusion cannot be drawn but the photophysical study of [Ir(ppy)2(TzPyCN)] 
and [Ir(bzq)2(TzPyCN)] in acid/base conditions can potentially clarify this trend. 
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Figure 4.34 Absorption spectra of [Ir(ppy)2(TzPyNH2)], showing the changes 
occurring upon the sequential addition of triflic acid to the complex solution. 
 
 
Figure 4.35 Emission spectra of [Ir(ppy)2(TzPyNH2)], showing the changes occurring 
upon the sequential addition of triflic acid to the complex solution. 
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Figure 4.36 1H NMR spectra in DMSO-d6 of [Ir(ppy)2(TzPyNH2)]. In the black box 
the amine peak (2HTamine) is highlighted. This peak disappears by treatment with triflic 
acid. 
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The complexes [Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)] were chosen for 
the preliminary studies of the effect of acid and base on the photophysical properties, 
in order to understand the behaviour of [Ir(ppy)2(TzPyNH2)]. For both the complexes, 
the methylated analogues [Ir(ppy)2(MeTzPyCN)]+ and [Ir(bzq)2(MeTzPyCN)]+ were 
isolated and their photophysical performance investigated (Chapter 2 – section 2.4.2 
and section 4.4.2 of this chapter, respectively). 
The absorption spectra of [Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)] have 
been depicted in Figure 4.37 and Figure 4.39, respectively. Upon sequential addition 
of triflic acid, the absorption profiles of both the complexes exhibit an increment in 
the extinction coefficients for the ligand-centred (LC) π-π* transitions. A similar 
increment along with a slight blue shift is also observed for the LLCT/MLCT 
transitions at ca. 400 nm, in addition to a more structured profile for 
[Ir(bzq)2(TzPyCN)] in the wavelengths region between 300 and 400 nm. 
Photoexcitation at 350 nm of [Ir(ppy)2(TzPyCN)] (Figure 4.38) and 
[Ir(bzq)2(TzPyCN)] (Figure 4.40) produced a broad and featureless orange-red 
emission centred at 620 nm for both the complexes. In this case, the protonation of the 
tetrazolate ring has showed a complete different behaviour in comparison to the one 
of [Ir(ppy)2(TzPyNH2)]. After the addition of 2.0 equivalents of triflic acid, the 
emission intensity decreased of ca. 16-fold and the emission maximum was red-shifted 
of ca. 70 nm, in accordance with the photophysical properties of 
[Ir(ppy)2(MeTzPyCN)]+ and [Ir(bzq)2(MeTzPyCN)]+ (Chapter 2 – section 2.4.2 and 
section 4.4.2 of this chapter, respectively). This behaviour can be rationalised by 
considering that the protonation of the tetrazolate ring reduced the electron density on 
the iridium metal centre, stabilising the 5d orbitals and consequentially decreasing the 
HOMO – LUMO gap.238 To further confirmed the conversion of the neutral species in 
their cationic analogues, the excited state lifetimes were measured at 620 nm for the 
initial solution, and 680 – 690 nm after the addition of 5 equivalents of acid. The results 
have been summarised in Table 4.7 and, as expected, the lifetime decays decreased 
for the final solution of the complexes in comparison to the initial ones. 
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Table 4.7 Excited state lifetimes of [Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)] in 
air-equilibrated dichloromethane solution, upon addition of triflic acid aliquots. 
Complex 
Triflic acid 
aliquots 
λem 
[nm] 
τaer 
[ns] 
[Ir(ppy)2(TzPyCN)] 
0.0 eq. 620 126 
5.0 eq. 680 45 
[Ir(bzq)2(TzPyCN)] 
0.0 eq. 620 128 
5.0 eq. 690 42 
 
The reversibility of the protonation reaction on [Ir(ppy)2(TzPyNH2)], 
[Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)] has been investigated by treatment with 
triethylamine, as depicted in Figure 4.41. All the complexes have been reconverted to 
their corresponding initial neutral species, as previously described by Werrett et al.231 
The excited state lifetime was also measured after the addition of 5 equivalents of base 
and compared to the initial value for all the complexes, in order to evaluate possible 
variation in the photophysical properties. The lifetime decays are summarised in Table 
4.8 and no major discrepancies are present, confirming that the conversion into the 
neutral complexes was achieved without any loss in the photophysical performance. 
 
Table 4.8 Excited state lifetimes of [Ir(ppy)2(TzPyNH2)], [Ir(ppy)2(TzPyCN)] and 
[Ir(bzq)2(TzPyCN)] in air-equilibrated dichloromethane solution at the start of the 
titration and after the addition of 5 equivalents of triethylamine. 
Complex 
Solution 
analysed 
λem 
[nm] 
τaer 
[ns] 
[Ir(ppy)2(TzPyNH2)] 
Initial 484 82 
Final 484 89 
[Ir(ppy)2(TzPyCN)] 
Initial 620 126 
Final 620 118 
[Ir(bzq)2(TzPyCN)] 
Initial 620 128 
Final 620 125 
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Figure 4.37 Absorption spectra of [Ir(ppy)2(TzPyCN)], showing the changes 
occurring upon the sequential addition of triflic acid to the complex solution. 
 
 
Figure 4.38 Emission spectra of [Ir(ppy)2(TzPyCN)], showing the changes occurring 
upon the sequential addition of triflic acid to the complex solution. 
  
300 400 500 600 700
Wavelength (nm)
0
2
4
6
8 0.0 eq.
0.5 eq.
1.0 eq.
1.5 eq.
2.0 eq.
2.5 eq.
3.0 eq.
3.5 eq.
4.0 eq.
4.5 eq.
5.0 eq.
M
ola
r A
bs
or
pt
ivi
ty 
(1
04
 M
-1
cm
-1
)
400 500 600 700 800
Wavelength (nm)
0
0.5
1
1.5
2
2.5
3
3.5
0.0 eq.
0.5 eq.
1.0 eq.
1.5 eq.
2.0 eq.
2.5 eq.
3.0 eq.
3.5 eq.
4.0 eq.
4.5 eq.
5.0 eq.
Em
iss
ion
 In
te
ns
ity
 (1
09
 cp
s)
 195 
 
Figure 4.39 Absorption spectra of [Ir(bzq)2(TzPyCN)], showing the changes 
occurring upon the sequential addition of triflic acid to the complex solution. 
 
 
Figure 4.40 Emission spectra of [Ir(bzq)2(TzPyCN)], showing the changes occurring 
upon the sequential addition of triflic acid to the complex solution. 
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Figure 4.41 Normalised emission spectra of [Ir(ppy)2(TzPyNH2)] (top), 
[Ir(ppy)2(TzPyCN)] (middle) and [Ir(bzq)2(TzPyCN)] (bottom) highlighting the 
changes in the emission profiles upon addition of triflic acid (left), followed by 
addition of triethylamine (right). 
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4.6 Protonation Studies in Aqueous Medium 
Eukaryotic cells contain a large number of organelles with different degrees of 
acidity.382 The range of intracellular pH falls in between the slightly alkaline 
cytoplasm, which exhibits a pH of ca. 7.4, and the acidic lysosomes and endosomes, 
where the pH is around 4.5 – 5.5.383 For an effective and precise detection of the 
intracellular H+, a probe should show changes in the fluorescence intensity, maximum 
emission wavelength or excited state lifetime in this range of intracellular 
pH.46,342,382,384,385 
In the previous paragraph (section 4.5 of this chapter), the protonation and 
deprotonation properties of [Ir(ppy)2(TzPyNH2)], [Ir(bzq)2(TzPyNH2)], 
[Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)] were investigated in organic solvent. 
Upon addition of triflic acid, [Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)] exhibit a 
red shift of the emission maximum of ca. 70 nm and a decrease of the emission 
intensity of ca. 16-fold. On the other hand, [Ir(bzq)2(TzPyNH2)] did not show any 
changes in the emission profile, probably due to the lower solubility of this complex. 
Finally, upon protonation, [Ir(ppy)2(TzPyNH2)] displays a variation in the emission 
profile, with the appearance of a shoulder at 555 nm and a more reduced decrease of 
the emission intensity (ca. 2-fold) in comparison to [Ir(ppy)2(TzPyCN)] and 
[Ir(bzq)2(TzPyCN)]. 
The possible application of these probes as cellular pH sensors was explored 
by measuring the emission spectra (Figure 4.42) and excited state lifetimes (Table 
4.9) of six PBS solutions at different pH values (4.81, 5.44, 5.92, 6.49, 6.90 and 7.45). 
The ratio between the integral of the emission profile and the maximum integral in the 
series (I/Imax) has been plotted against the pH, as showed in Figure 4.43. The pH-
titration curves showed that no major changes in the emission intensity are present, 
indicating that [Ir(ppy)2(TzPyNH2)], [Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(TzPyNH2)] 
cannot be protonated within the intracellular pH range. 
Moreover, the measurement of the lifetimes confirmed that no protonation 
reaction occurred, as a shorter excited state lifetime values would be expected for the 
cationic species, as previously demonstrated in section 4.5. 
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Figure 4.42 Emission spectra of [Ir(ppy)2(TzPyNH2)] (top), [Ir(ppy)2(TzPyCN)] 
(middle) and [Ir(bzq)2(TzPyCN)] (bottom) in PBS solutions at different pH values. 
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Figure 4.43 pH-titration curves of [Ir(ppy)2(TzPyNH2)] (black), [Ir(ppy)2(TzPyCN)] 
(blue) and [Ir(bzq)2(TzPyCN)] (red) in PBS solutions. 
 
Table 4.9 Excited state lifetimes of [Ir(ppy)2(TzPyCN)], [Ir(bzq)2(TzPyCN)] and 
[Ir(ppy)2(TzPyNH2)] in PBS solutions at different pH. 
pH 
[Ir(ppy)2(TzPyCN)] 
τ [ns]a 
[Ir(bzq)2(TzPyCN)] 
τ [ns]a 
[Ir(ppy)2(TzPyNH2)] 
τ [ns]a 
4.81 26 (10), 175 (90) 23 (15), 113 (85) 32 (10), 440 (90) 
5.44 30 (11), 187 (89) 20 (14), 105 (85) 28 (7), 476 (93) 
5.92 27 (9), 175 (91) 25 (17), 122 (83) 26 (9), 401 (91) 
6.49 30 (11), 188 (89) 28 (18), 120 (82) 21 (7), 462 (93) 
6.90 31 (11), 197 (89) 23 (15), 108 (85) 23 (7), 446 (93) 
7.45 31 (10), 187 (90) 29 (17), 126 (83) 22 (6), 475 (94) 
a For the biexponential excited state lifetime (τ), the relative weights of the exponential 
curves are reported in parentheses. 
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4.7 Conclusions 
In this chapter, two new amino-functionalised iridium(III) complexes, 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)], have been synthesised and 
characterised by IR and NMR spectroscopy, both of which confirmed the formation of 
the desired products. Unfortunately, the methylation of these neutral species was 
unsuccessful, due to the formation of multiple species which could not be separated. 
The photophysical investigation in dichloromethane highlighted a typical 
yellow-green vibronically structured emission from a mixed LC and CT excited state. 
The LC character of the emissive excited state was more pronounced for the higher 
conjugated [Ir(bzq)2(TzPyNH2)], as evidenced by the marked elongation of the 
lifetime decay in degassed solution.238,372 Moreover, temperature-dependent 
luminescence lifetime measurements on diluted dichloromethane solution of 
[Ir(ppy)2(TzPyNH2)] have confirmed the presence of a dark and thermally accessible 
3MC excited state, which is responsible of the shorter lifetime and the lower emission 
intensity of this probe in comparison to [Ir(ppy)2(TzPyCN)]. 
The applicability of [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] in 
biological field was explored by photophysical studies in different aqueous and 
lipophilic solvents. Even if the emissive performances of the complexes remains 
comparable to that in dichloromethane, some solubility issues have been encountered. 
Protonation and deprotonation reactions to evaluate the pH-sensing activity of 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] have been performed in 
dichloromethane and, due to the lack of the methylated analogues 
[Ir(ppy)2(MeTzPyNH2)]+ and [Ir(bzq)2(MeTzPyNH2)]+, compared to the acid/base 
behaviour of [Ir(ppy)2(TzPyCN)] and [Ir(bzq)2(TzPyCN)]. The cyano-functionalised 
complexes displayed a quenched and red-shifted (ca. 70 nm) emission profile upon 
addition of triflic acid, which could be reversed by treatment with triethylamine. On 
the other hand, the presence of a new shoulder at 555 nm and a decrease of the emission 
intensity was recorded for [Ir(ppy)2(TzPyNH2)], which could not be fully explained. 
Probably due to the low solubility of [Ir(bzq)2(TzPyNH2)] in dichloromethane 
solution, the protonation and deprotonation reactions did not affect the emission profile 
of this species. 
The emission properties of [Ir(ppy)2(TzPyCN)], [Ir(bzq)2(TzPyCN)] and 
[Ir(ppy)2(TzPyNH2)] were investigated in PBS solutions in the range of pH typical of 
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the cellular environment, in order to evaluate the applicability of these probes as 
cellular pH-sensors. Unfortunately, the emission profiles and excited state lifetimes 
showed no major change in the pH range of 4.8 – 7.5, implying that these probes are 
not enough sensitive to pH variation in cells, and hence they cannot be used for cellular 
sensing. 
Finally, by oxidation of [Ir(ppy)2(TzPyNH2)], [Ir(ppy)2(TzPyNO2)] was 
successfully synthesised but, due to the presence of the nitro group, the emission of 
the complex was totally quenched in all the investigated solvents. 
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4.8 Experimental 
4.8.1 General Procedures 
General procedures have been conducted as outline in Chapter 2 – section 2.6.2, unless 
otherwise stated. 
The complexes [Ir(ppy)2(µ-Cl)]2277 and [Ir(bzq)2(µ-Cl)]2386 were prepared 
according to previously reported synthetic methods. 
For the NMR characterisation, carbon and proton of all the iridium(III) 
tetrazolato species were labelled as pyridinic (A), phenylic (B), tetrazolic (T) and, 
benzoquinolynic (bzq), according to Figure 4.44.  
 
 
Figure 4.44 NMR referencing layout. 
 
4.8.2 Photophysical Measurements 
Photophysical measurements have been carried out as outlined in Chapter 2 – section 
2.6.2, unless otherwise stated.  
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4.8.3 Synthesis 
HTzPyNH2 
 
 
Triethylamine (2.1 mL, 0.015 mol) was added to toluene (15 mL) and the solution was 
cooled to 0 ºC. HCl 32% (1.3 mL, 0.015 mol) was added to the reaction mixture and 
stirred until fuming subsided. 5-amino-2-pyridinecarbonitrile (0.500 g, 0.004 mol) and 
sodium azide (1.090 g, 0.017 mol) were added and heated at reflux overnight. After 
cooling down to room temperature, the mixture was extracted with water (2 × 15 mL) 
and the aqueous phase was collected and acidified to pH≈3 with HCl 32%. The formed 
orange-pink precipitate was then filtered and dried in air. Yield: 0.280 g (41%). M.P. 
270 – 272 °C. IR (ν / cm-1): 3334 b (N–H stretch), 3160 br (N–H strech), 1661 w (N–
H bend), 1612 w (tetrazole C=N).  1H NMR (δ / ppm, DMSO-d6): 8.07 (s, 1H, HT6), 
7.86 (d, 1H, HT4, J = 8.5 Hz), 7.08 (d, 1H, HT3, J = 8.5 Hz), 6.04 (broad s, 2H, 
2HTamine). 13C NMR (δ / ppm, DMSO-d6): 154.9 (CT), 147.1 (CT2), 135.9 (CHT6), 
130.4 (CT5), 123.4 (CHT4), 119.7 (CHT3). Anal.Calcd for HTzPyNH2 ×0.5(water): C, 
42.10; H, 4.12; N, 49.10. Found: C, 42.10; H, 4.07; N, 48.95. 
 
N3-MeTzPy – N4-MeTzPy 
 
 
 
HTzPy (0.100 g, 0.680 mmol) was combine with K2CO3 (0.376 g, 2.720 mol) and 
stirred and heated at reflux in 15 mL of acetonitrile for 1 hour. Methyl iodide (0.085 
mL, 1.360 mol) was added to the resulting suspension and heated at reflux overnight. 
The white precipitated was filtered out and discarded, whereas the orange filtrate was 
collected. The solvents were concentrated and the products were purified via column 
chromatography using silica-filled as stationary phase and an ethyl acetate/petroleum 
spirits 40 - 60 (9:1 v/v) solvent system as eluent. N3-MeTzPy eluted as first fraction 
(orange) and N4-MeTzPy (yellow) as second ones.  
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N3-MeTzPy: Yield: 0.056 g (51%). M.P. 120 – 121 °C. IR (ν / cm-1): 2963, 2852, 
2923 w (C–H stretch), 1616 w (tetrazole C=N).  1H NMR (δ / ppm, DMSO-d6): 8.74 
(s, 1H, HT6), 8.12 (d, 1H, HT3, J = 8.0 Hz), 8.00 (t, 1H, HT4, J = 8.0 Hz), 7.55 (m, 1H, 
HT5), 4.46 (s, 3H, HTMe). 13C NMR (δ / ppm, DMSO-d6): 164.1 (CT), 150.1 (CHT6), 
146.2 (CT2), 137.6 (CHT4), 125.2 (CHT5), 122.3 (CHT3); the methyl C peak was not 
visible in the spectrum. 
N3-MeTzPy: Yield: 0.015 g (14%). M.P. 77 – 79 °C. IR (ν / cm-1): 2955, 2852, 2922 
w (C–H stretch), 1613 w (tetrazole C=N).  1H NMR (δ / ppm, DMSO-d6): 8.81 (s, 1H, 
HT6), 8.24 (d, 1H, HT3, J = 8.0 Hz), 8.09 (t, 1H, HT4, J = 8.2 Hz), 7.65 (m, 1H, HT5), 
4.42 (s, 3H, HTMe). 13C NMR (δ / ppm, DMSO-d6): 152.0 (CT), 149.7 (CHT6), 144.3 
(CT2), 138.1 (CHT4), 125.7 (CHT5), 124.2 (CHT3), 36.6 (CHTMe). 
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[Ir(ppy)2(TzPyNH2)] 
 
 
[Ir(ppy)2(µ-Cl)]2 (0.285 g, 0.266 mmol) was combined with HTzPyNH2 (0.108 g, 
0.666 mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v).  
Triethylamine (10 drops) was added and the resulting suspension was stirred at room 
temperature overnight. The product was precipitated with diethyl ether as a yellow 
solid, filtered and dried in air. Yield: 0.200 g (57%).  M.P. >400°C (dec). IR (ν / cm-
1): 3307 b (N–H stretch), 3163 br (N–H stretch), 1641 w (N–H bend), 1605 w (tetrazole 
C=N).  1H NMR (δ / ppm, DMSO-d6): 8.18 (app. t., 2H, HT4, HT3, splitting = 8.7 Hz), 
7.95 (d, 1H, HT6, J = 8.6 Hz), 7.90 – 7.86 (m, 3H, 3HA), 7.78 (d, 1H, HB, J = 8.0 Hz), 
7.63 (d, 1H, HA, J = 5.6 Hz), 7.21 – 7.15 (m, 3H, 3HA), 7.11 (s, 1H, HB), 6.96 (app. t., 
1H, HB, splitting = 7.5 Hz), 6.90 – 6.83 (m, 2H, 2HB), 6.74 (app. t., 1H, HB, splitting 
= 7.4 Hz), 6.21 (d, 1H, HB, J = 7.5 Hz), 6.15 (d, 1H, HB, J = 7.5 Hz), 6.01 (broad s, 
2H, 2HTamine). 13C NMR (δ / ppm, DMSO-d6): 167.5 (CT), 167.4 (CT2), 163.9 (CT5), 
152.7 (CA), 148.7 (CHA), 148.3 (CHA), 148.2 (CHA), 147.5 (CA), 144.3 (CB), 144.0 
(CB), 138.1 (CHA), 137.7 (CHA), 135.6 (CB), 135.2 (CHB), 131.4 (CHB), 131.2 (CHB), 
129.9 (CHB), 129.0 (CHB), 124.7 (CHA), 124.2 (CHB), 123.3 (2CHA), 123.0 (CHT6), 
122.2 (CB), 121.6 (CHB), 120.9 (CHB), 119.5 (CHT4), 119.3 (CHT3). Anal.Calcd for 
[Ir(ppy)2(TzPyNH2)]×0.2(CH2Cl2): C, 49.90; H, 3.18; N, 16.51. Found: C, 49.91; H, 
3.21; N, 16.54. 
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[Ir(bzq)2(TzPyNH2)] 
 
 
[Ir(bzq)2(µ-Cl)]2 (0.325 g, 0.279 mmol) was combined with HTzPyNH2 (0.120 g, 
0.699 mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v). 
Triethylamine (10 drops) was added and the resulting suspension was stirred at room 
temperature overnight. The product was precipitated with diethyl ether as a yellow 
solid, filtered and dried in air. Yield: 0.279 g (69%). M.P. >400 °C (dec). IR (ν / cm-
1): 3303 b (N–H stretch), 3158 br (N–H stretch), 1643 w (N–H bend), 1608 w (tetrazole 
C=N).  1H NMR (δ / ppm, DMSO-d6): 8.50 (d, 2H, HT4, HT3, J = 7.6 Hz), 8.09 (d, 1H, 
HT6, J = 5.2 Hz), 8.00 (d, 1H, HB, J = 8.4 Hz), 7.91 (app. t., 2H, 2Hbzq, splitting = 8.8 
Hz), 7.85 – 7.81 (m, 3H, 3Hbzq), 7.62 (d, 2H, 2Hbzq, J = 6.8 Hz), 7.49 (d, 1H, Hbzq, J 
= 7.6 Hz), 7.41 (d, 1H, Hbzq, J = 8.0 Hz), 7.20 (d, 1H, Hbzq, J = 8.8 Hz), 7.13 (app. t., 
2H, 2Hbzq, splitting = 7.6 Hz), 7.02 (app. t., 1H, Hbzq, splitting = 7.6 Hz), 6.23 (d, 1H, 
Hbzq, J = 7.2 Hz), 6.13 (d, 1H, Hbzq, J = 7.2 Hz), 5.95 (broad s, 2H, 2HTamine). 13C 
NMR (δ / ppm, DMSO-d6): 164.2 (CT), 157.0 (CT2), 156.9 (Cbzq), 149.3 (Cbzq), 148.3 
(CHbzq), 147.9 (CHT6), 147.5 (Cbzq), 144.8 (Cbzq), 140.9 (Cbzq), 140.8 (Cbzq), 137.0 
(CHT3), 136.7 (CHT4), 135.8 (CHbzq), 135.7 (CT5), 133.6 (Cbzq), 133.3 (Cbzq), 129.5 
(CHbzq), 129.4 (CHbzq), 129.5 (CHbzq), 128.7 (CHbzq), 128.6 (CHbzq), 128.5 (CHbzq), 
126.4 (Cbzq), 126.3 (Cbzq), 123.9 (CHbzq), 123.6 (CHbzq), 123.0 (CHbzq), 122.4 
(CHbzq), 122.3 (CHbzq), 122.2 (CHbzq), 119.6 (CHbzq), 118.9 (CHbzq). Anal.Calcd for 
[Ir(bzq)2(TzPyNH2)]: C, 54.15; H, 2.98; N, 15.79. Found: C, 54.19; H, 3.00; N, 15.75.  
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[Ir(ppy)2(TzPyNO2)] 
 
 
[Ir(ppy)2(TzPyNH2)] (0.100 g, 0.121 mmol) was dissolved in 5 mL of acetonitrile and 
KI (0.02 g, 5% mol) was added. An aqueous solution of tert-butyl hydroperoxide 
(70%, 0.35 mL) was added slowly in 30 minutes. The suspension was heated at the 
reflux temperature for 24 hours. The solution was then dried and 10 mL of 
dichloromethane were added. The yellow starting material was filtered and recovered 
while the filtrated was neutralised with a saturated solution of Na2SO3, (20 mL) and 
washed with water (2 × 15 mL) and brine (15 mL). The organic phase was dried over 
MgSO4 and filtered. The product was purified via alumina-filled column 
chromatography using Brockmann I grade neutral alumina-filled as stationary phase 
and ethyl acetate as eluent. The targeted complex eluted as the first fraction (orange). 
Yield: 0.062 g (74%). M.P. 247 °C (dec). IR (ν / cm-1): 1607 w (tetrazole C=N), 1478 
m (NO2 asym. stretch), 1344 m (NO2 sym. stretch).  1H NMR (δ / ppm, DMSO-d6): 
8.83 (d, 1H, HT4, J = 8.8 Hz), 8.55 (d, 1H, HT3, J = 9.6 Hz), 8.37 (s, 1H, HT6), 8.22 
(app. t., 2H, 2HA, splitting = 8.4 Hz), 7.93 – 7.87 (m, 3H, 3HA), 7.83 (d, 1H, HB, J = 
8.0 Hz), 7.76 (d, 1H, HB, J = 6.4 Hz), 7.44 (d, 1H, HA, J = 5.8 Hz), 7.19 (app. t., 1H, 
HA, splitting = 7.2 Hz), 7.08 – 7.04 (m, 2H, HA, HB), 6.96 – 6.91 (m, 2H, 2HB), 6.80 
(app. t., 1H, HB, splitting = 8.8 Hz), 6.28 (d, 1H, HB, J = 7.4 Hz), 6.14 (d, 1H, HB, J = 
7.6 Hz). 13C NMR (δ / ppm, DMSO-d6): 167.0 (CT), 166.9 (CT2), 162.0 (CT5), 152.4 
(CA), 150.4 (CA), 149.5 (CHB), 149.1 (CHA), 146.1 (CB), 145.8 (CB), 145.6 (CHT6), 
144.5 (CB), 144.0 (CB), 138.6 (CHA), 138.2 (CHA), 135.2 (CHT4), 131.4 (CHB), 131.2 
(CHB), 130.2 (CHB), 129.2 (CHB), 125.1 (CHA), 124.4 (CHB), 123.8 (CHA), 123.3 
(CHB), 122.39 (CHT3, CHA), 121.5 (CHB), 119.9 (CHA), 119.4 (CHA). Anal.Calcd for 
[Ir(ppy)2(TzPyNO2)]·0.5(ethyl acetate): C, 48.97; H, 3.15; N, 15.23. Found: C, 48.92; 
H, 3.17; N, 15.14. 
  
208  
[Ir(bzq)2(TzPyCN)] 
 
 
[Ir(bzq)2(µ-Cl)]2 (0.250 g, 0.214 mmol) was combined with HTzPyCN (0.081 g, 
0.471 mmol) and dissolved in 13 mL of a dichloromethane/ethanol mixture (10:3 v/v). 
The resulting suspension was stirred at room temperature overnight. The solvents were 
concentrated and the product was purified via column chromatography using 
Brockmann I grade neutral alumina-filled as stationary phase and a 
dichloromethane/acetone (9:1 v/v) solvent system as eluent. The targeted complex 
eluted as the second fraction (orange). Yield: 0.202 g (66%). M.P. 309 °C (dec). IR (ν 
/ cm-1): 2235 w (C≡N), 1608 w (tetrazole C=N). 1H NMR (δ / ppm, DMSO-d6): 9.01 
– 9.34 (m, 4H, 2Hbzq, HT4, HT3), 8.68 (d, 1H, HT6, J = 5.2 Hz), 8.38 – 8.22 (m, 6H, 
6Hbzq), 8.06 – 8.0013 (m, 1H, Hbzq), 7.97 – 7.94 (m, 2H, 2Hbzq), 7.62 (d, 1H, Hbzq), 
7.48 (app. t., 1H, Hbzq, splitting = 8.0 Hz), 7.03 (app. t., 1H, Hbzq, splitting = 8.0 Hz), 
6.72 (d, 1H, Hbzq, J = 7.2 Hz), 6.53 (d, 1H, Hbzq, J = 7.2 Hz). 13C NMR (δ / ppm, 
DMSO-d6): 163.0 (CT), 156.6 (CT2), 156.4 (CT5), 153.1 (CHbzq), 151.3 (Cbzq), 149.3 
(CHT6), 148.7 (CHbzq), 147.2 (CN), 143.3 (CHbzq), 142.8 (CHbzq), 140.8 (CHbzq), 
140.5 (CHbzq), 137.4 (CHT4), 137.1 (CHT3), 133.7 (Cbzq), 133.4 (Cbzq), 129.5 (CHbzq), 
129.4 (CHbzq), 129.2 (CHbzq), 128.8 (CHbzq), 128.7 (CHbzq), 128.3 (CHbzq), 126.7 
(Cbzq), 126.3 (Cbzq), 124.2 (CHbzq), 123.8 (CHbzq), 122.8 (CHbzq), 122.4 (CHbzq), 
122.3 (CHbzq), 120.3 (CHbzq), 119.4 (Cbzq), 115.7 (Cbzq), 111.4 (Cbzq). Anal.Calcd for 
[Ir(bzq)2(TzPyCN)]·0.5(acetone): C, 55.34; H, 2.96; N, 14.96. Found: C, 55.46; H, 
2.93; N, 14.89. 
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[Ir(bzq)2(MeTzPyCN)][PF6] 
 
 
[Ir(bzq)2(TzPyCN)] (0.050 g, 0.069 mmol) was dissolved in dichloromethane (10 mL) 
and cooled down to –50 °C using an ethyl acetate/liquid nitrogen cool bath. Thereafter, 
a 0.1 M methyl trifluoromethanesulfonate solution in dichloromethane (0.017 g, 0.104 
mmol) was added dropwise to the vigorously stirred solution. After being maintained 
at –50°C for 30 minutes, the solution was warmed up at room temperature and left to 
stirred overnight. An excess of ammonium hexafluorophosphate (0.022 g, 0.140 
mmol) was added and stirred for 45 minutes. The crude mixture was washed with 
water and extracted with dichloromethane (3 × 15 mL) and the combined organic 
phase was dried on MgSO4. The targeted complex was then collected after filtration 
and removal of the solvent as a red solid. Yield: 0.051 g (75%). M.P. 308 °C (dec). IR 
(ν / cm-1): 2239 w (C≡N), 1619 w (tetrazole C=N). 1H NMR (δ / ppm, DMSO-d6): 8.80 
(s, 2H, HT3, HT4), 8.62 (app. t., 2H, HT6, Hbzq, splitting =  8.4 Hz), 8.41 (d, 1H, Hbzq, 
J = 5.4 Hz), 8.33 (d, 1H, Hbzq, J = 5.4 Hz), 8.03 – 7.87 (m, 5H, 5Hbzq), 7.65 – 7.56 (m, 
3H, 3Hbzq), 7.49 (d, 1H, Hbzq, J = 7.9 Hz), 7.22 (app. t., 1H, Hbzq, splitting = 7.6 Hz), 
7.09 (app. t., 1H, Hbzq, splitting = 7.6 Hz), 6.23 (d, 1H, Hbzq, J = 7.2 Hz), 6.08 (d, 1H, 
Hbzq, J = 7.3 Hz), 4.50 (s, 3H, 3HTMe). 13C NMR (δ / ppm, DMSO-d6): 165.3 (CT), 
155.9 (CT2), 155.8 (CT5), 154.1 (CHbzq), 150.3 (CHbzq), 150.2 (CHbzq), 146.9 (CN), 
144.2 (CHT6), 143.5 (Cbzq), 140.4 (Cbzq), 140.3 (Cbzq), 139.9 (Cbzq), 138.0 (CHT4), 
137.8 (CHbzq), 133.7 (Cbzq), 133.4 (Cbzq), 129.6 (CHbzq), 129.4 (CHbzq), 129.3 
(CHbzq), 129.0 (CHbzq), 128.5 (CHbzq), 128.4 (CHbzq), 126.8 (Cbzq), 126.5 (Cbzq), 
124.4 (CHbzq), 124.3 (CHbzq), 124.0 (CHT3), 122.8 (CHbzq), 121.0 (CHbzq), 120.4 
(CHbzq), 115.3 (Cbzq), 114.5 (Cbzq), 42.2 (CHMe). Anal.Calcd for 
[Ir(bzq)2(MeTzPyCN)][PF6]: C, 46.42; H, 2.52; N, 12.74. Found: C, 46.54; H, 2.53; 
N, 12.72. 
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Chapter 5  
Synthesis and Photophysical Investigation of 
Fatty Acid-Functionalised Iridium Tetrazolato 
Complexes 
 
5.1 Introduction 
Fatty acids are found in all known living organisms, in which they play an essential 
role in membrane formation, energy storage, regulation of protein functions and 
secondary metabolite production.248,387–389  
In the case of bacteria, fatty acids are mainly localised in the cell membrane 
(Gram-positive bacteria) and also cell walls (Gram-negative species) as part of the 
lipid bylayer.390,391 On the other hand, in mammalian cells they accumulate in many 
cellular compartments and their regulation and homeostasis are strongly affected by 
environmental stress as well as the stage of the cellular life.392–394 
Most tissues, except for liver and adipose tissue, possess little capacity for de 
novo synthesis of fatty acids and depend on long-chain fatty acid uptake for their 
biological processes. Therefore, the efficient transport of these molecules through the 
cellular membrane is of vital importance.395 Noteworthy, the reduced solubility of fatty 
acids in aqueous environment (1 - 10 nM) dictates specific requirements for their 
transport and accumulation within the cells.396 After decades of studies, researchers 
have identified two main uptake mechanisms for the transport of fatty acids; a 
membrane-associated protein, recognised as FAT/CD36, which facilitates the passage 
of fatty acids through the plasma membrane, and a family of transcription factors, 
named peroxisome proliferator-activated receptors (PPAR), which can specifically 
link with fatty acids and their metabolites.397 Malfunction of FAT/CD36 and PPAR or 
  211 
general changes in the fatty acid viability can promote the development of obesity-
related chronic kidney disease, immune disorders, cancer, type-2 diabetes mellitus, as 
well as cardiovascular and neurodegenerative diseases.248,392,393,398,399 
For these reasons, the development of probes for the detection of fatty acids, 
either in their free form or as more complex lipid, is necessary. The majority of these 
dyes are organic molecules, such as Nile Red (102), Oil Red O (103) or Filipin III 
(104), which are available on the market and are routinely used for the staining of cells 
(Figure 5.1). Unfortunately, the staining protocols often require cell fixation, which 
can cause damage to the cellular ultrastructure. Other organic staining, such as 
BODIPY™ 503/512 (105), LipidTOX (106), LD540 (107) or the two dyes (108 - 109) 
synthesised by Zhao and co-workers,400 can be applied for lipid imaging in live cells 
and overcome some of the issues related to the fixation process. A rhenium(I) 
tetrazolato complex developed in 2014 by Werrett et al.232,248 and commercialised as 
ReZolve-L1™ (110) was the first example of d6 transition metal probe for the specific 
staining of polar lipids. Nevertheless, fluorescent and phosphorescent probes for fatty 
acids or lipids in general are still somewhat limited. 
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Figure 5.1 Examples of previously reported probes for the detection of lipids in fixed 
and live cells. 
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In this chapter, the synthesis and the photophysical investigation of five fatty 
acid-functionalised iridium(III) complexes (Figure 5.2) will be discussed. After the 
successful uptake and localisation of the cyano-functionalised iridium(III) tetrazolato 
complexes (described in Chapter 2 and Chapter 3) in the endoplasmic reticulum and 
lipid droplets, the addition of a fatty acids chain on the tetrazolate ligand was attempted 
to increase the specificity of these probes for lipids. Five different fatty acids (octanoic, 
palmitic, stearic, palmitoleic and oleic acid) were employed to evaluate how the chain 
length and degree of unsaturation could affect the photophysical and biological 
properties of these complexes. 
A variety of synthetic routes for the functionalisation of the tetrazolate moiety 
were attempted. However, issues with the separation and purification of the desired 
product from byproducts and unreacted starting materials were encountered. For these 
reasons, the design of a synthetic procedure using [Ir(ppy)2(TzPyNH2)] and the acyl 
chloride of the appropriate fatty acid were performed to successfully isolate 
[Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNHC18sat)], 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)] (Figure 5.2).  
The photophysical characterisation in diluted dichloromethane solutions 
highlighted yellow-green emission with relatively low intensity for the whole series, 
which is consistent with the photophysical properties of the starting material 
[Ir(ppy)2(TzPyNH2)]. The temperature-dependent luminescent lifetime 
measurements on [Ir(ppy)2(TzPyNHC16cis)] confirmed the presence of a dark and low-
lying 3MC excited state, which is thermally available at room temperature. These 
results were again consistent with the ones discussed for [Ir(ppy)2(TzPyNH2)] in 
Chapter 4 – section 4.4.3. 
Finally, the photophysical features of these family of iridium(III) complexes in 
aqueous and lipophilic solvents have been used to evaluate their applicability in 
biological environment and the possibility to discriminate their localisation within the 
cells based on their emission maxima. 
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Figure 5.2 Structure of target complexes in this investigation. 
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5.2 Synthetic Attempts for the Functionalisation of 
CNPyNH2 and HTzPyNH2 
A variety of synthetic methods was involved in the functionalisation of 5-amino-2-
pyridinecarbonitrile (CNPyNH2) and HTzPyNH2. The first attempt was the reaction 
of the nitrile and the tetrazolate substrates with a carboxylic acid, using 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) as 
coupling agent in acetonitrile (Figure 5.3).401 
 
 
Figure 5.3 Scheme of the attempted synthesis for the formation of CNPyNHC3sat and 
HTzPyNHC3sat. The different reaction conditions are summarised in Table 5.1. 
 
In order to find the optimal reaction conditions, propionic acid was utilised as 
test reaction. The synthesis was performed at different temperatures and reaction 
times, as showed in Table 5.1.  
At the start, the reactions were carried out for 24 hours at room temperature or 
heating at reflux, in order to increase the solubility of the starting materials. In general, 
the conversion of CNPyNH2 or HTzPyNH2 was higher at room temperature, although 
a byproduct236 derived from the cleavage of the amino group (HTzPy) was formed in 
all cases and the isolation of the desired products was not possible (Figure 5.4). Only 
for reaction #4 (refer to Table 5.1), the product was isolated as a fine precipitate from 
the reaction mixture in a very low yield (ca. 9%). The reaction time was then increased 
to 72 hours (#5 - #6) in an attempt to enhance the conversion of the amino substrates. 
Unfortunately, the ratio between product and byproduct (based on the NMR integrals) 
did not improve in comparison to the 24 hour heated reactions (#3 - #4) and the 
conversion of CNPyNH2 or HTzPyNH2 increased only slightly (Table 5.1).  
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Table 5.1 Summary of the reaction conditions and results for the attempted synthesis 
of CNPyNHC3sat and HTzPyNHC3sat. 
# 
Starting 
Material 
XPyNH2 
Temperature 
(°C) 
Time 
(h) 
Conversion 
(%) 
Ratioa 
product:byproduct 
Yield 
(%) 
1 CN 25 (r.t.) 24 50 1 : 5 - 
2 HTz 25 (r.t) 24 74 1 : 0 9 
3 CN 82 (reflux) 24 33 1 : 1 - 
4 HTz 82 (reflux) 24 43 2 : 1 - 
5 CN 25 (r.t.) 72 40 1 : 1 - 
6 HTz 25 (r.t) 72 48 2 : 1 - 
a The ratio is referred to the peak integration in the 1H NMR spectrum between product 
and byproduct. 
 
 
 
Figure 5.4 1H NMR spectrum in DMSO-d6 of the reaction mixture for #4, highlighting 
the peaks of the desired product HTzPyNHC3sat (red diamond), the starting material 
HTzPyNH2 (green triangle) and the byproduct HTzPy (black circle). 
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Based on these results, a different synthetic method was followed. In particular, 
the reactivity of the carboxylic acid was increased by conversion to the acyl chloride, 
using oxalyl chloride and dimethylformamide (DMF) as catalyst (Figure 5.5 - 
top).402,403,404 In this case, propionic acid was substituted with the heavier octanoic acid 
to facilitate the work up of the reaction, which consists in the removal of the solvent 
and the unreacted oxalyl chloride by evaporation under reduced pressure. Without 
further purification, octanoyl chloride was reacted with CNPyNH2 or HTzPyNH2 in 
the presence of triethylamine, and stirred in dichloromethane at room temperature for 
16 hours (Figure 5.5 - bottom).405,406 All the conditions and results are summarised in 
Table 5.2. 
 
Table 5.2 Summary of the reaction conditions and results for the synthesis of 
CNPyNHC8sat and HTzPyNHC8sat. 
# 
Starting 
Material 
XPyNH2 
Temperature 
(°C) 
Time 
(h) 
Conversion 
(%) 
Ratioa 
product:byproduct 
Yield 
(%) 
7 CN 25 (r.t.) 16 75 1 : 0 44 
8 HTz 25 (r.t) 16 51 2 : 1 - 
a The ratio is referred to the peak integration in the 1H NMR spectrum between product 
and byproduct. 
 
 
Figure 5.5 Scheme of the synthesis for the preparation of octanoyl chloride (top). On 
the bottom octanoyl chloride was reacted with CNPyNH2 or HTzPyNH2 for the 
preparation of HTzPyNHC8sat and CNPyNHC8sat, respectively. 
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At the end of the reaction, the crude was extracted with hexane and washed multiple 
times with a 0.1 M sodium hydroxide solution, before being dried and analysed by 1H 
NMR.  
The 1H NMR spectrum showed the presence of different byproducts along with 
some unreacted starting material for HTzPyNHC8sat, whereas CNPyNHC8sat was 
formed and isolated with average yield of ca. 45%, as confirmed from the N–H peak 
resonating at around 10.55 ppm (Figure 5.6). On the other hand, a variety of 
purification techniques, such as extraction, precipitation and column chromatography, 
were employed without success to isolate the pure HTzPyNHC8sat. 
 
 
Figure 5.6 1H NMR in DMSO-d6 for CNPyNHC8sat with labelling of the proton peaks. 
 
For this reason, in order to convert CNPyNHC8sat into HTzPyNHC8sat, the 
nitrile precursor was reacted with sodium azide in the presence of triethylammonium 
chloride and heated at the reflux in toluene for 24 hours (Figure 5.7).270 
Once again, the conversion of the starting material was very low (ca. 30%) and 
the product did not precipitate out from the reaction mixture by protonation of the 
tetrazolate ring. Further attempts to isolate HTzPyNHC8sat were unsuccessful, and a 
different synthetic procedure for the preparation of the fatty acid-functionalised 
iridium(III) tetrazolato complexes was explored. 
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Figure 5.7 Scheme of the attempted synthetic procedure for the preparation of 
HTzPyNHC8sat. 
  
 220
5.3 Synthesis and Characterisation of Fatty Acid-
Functionalised Iridium(III) Complexes 
The fatty acid-functionalised iridium(III) tetrazolato complexes have been synthesised 
following the same methodology that was previously applied to CNPyNH2 and 
HTzPyNH2.405,406 The advantage of performing the reaction directly on the 
iridium(III) complex was the enhanced solubility in dichloromethane and the 
consequently easier work up via column chromatography. 
Five fatty acids were investigated to evaluate the effect of the aliphatic chain 
length and the degree of unsaturation on the photophysical and biological properties 
of these iridium(III) complexes (Table 5.3). 
 
Table 5.3 Summary of the fatty acids investigated in this chapter and their structural 
characteristic. 
# Fatty acid C:Da Chemical structure 
1 Octanoic acid 8 : 0 
 
2 Palmitic acid 16 : 0 
 
3 Stearic acid 18 : 0 
 
4 Palmitoleic acid 16 : 1 
 
5 Oleic acid 18 : 1 
 
a C:D is the lipid number, where C is the number of carbon atoms in the fatty acid and 
D is the number of double bonds present in the chain. 
 
As showed in Figure 5.8 (top), five fatty acids were converted in their more reactive 
acyl chloride analogues by treatment with oxalyl chloride and DMF in an inert 
atmosphere of nitrogen and dry dichloromethane.402,403,404 The solvent and any excess 
of oxalyl chloride were removed by evaporation under reduced pressure and the acyl 
chloride was used for the following reaction without further purification. 
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[Ir(ppy)2(TzPyNH2)] (refer to Chapter 4 – section 4.8.3 for synthesis and 
characterisation) was combined with the appropriate acyl chloride species and stirred 
in dry dichloromethane for 16 hours, in the presence of triethylamine (Figure 5.8 - 
bottom). 
 
 
Figure 5.8 Scheme of the synthetic procedure for the preparation of different acyl 
chloride species (top). On the bottom, [Ir(ppy)2(TzPyNH2)] was reacted with the 
appropriate acyl chloride to form the corresponding saturated 
[Ir(ppy)2(TzPyNHCnsat)] (n = 8, 16, 18) and unsaturated [Ir(ppy)2(TzPyNHCmcis)] 
(m = 16, 18) iridium(III) complexes. 
 
At the end of the reaction, the formed triethylammonium chloride was removed 
by precipitation with diethyl ether and the filtrate was washed by a 5% aqueous 
NaHCO3 solution to eliminate the excess of fatty acids. Finally, the products were 
purified via column chromatography using basic alumina as stationary phase and a 
dichloromethane/methanol (99.5:0.5 v/v) solvent system mixture as eluent. 
The saturated [Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)] and 
[Ir(ppy)2(TzPyNHC18sat)] and the unsaturated [Ir(ppy)2(TzPyNHC16cis)] and 
[Ir(ppy)2(TzPyNHC18cis)] complexes were characterised by IR, 1H NMR and 13C 
NMR spectroscopy. 
The IR spectra of all the complexes display strong peaks at around 2920 and 
2850 cm-1 which are assigned to the C–H stretching of the aliphatic chain. Moreover, 
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the stretching of the C=O group and the tetrazolic C=N are visible at ca. 1700 and 
1600 cm-1, respectively. In addition to the aforementioned peaks, 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)] exhibit the stretching of the 
=C–H, which falls at ca. 3040 cm-1, supporting the presence of a double bond in the 
fatty acid chain.407 
Spectroscopic characterisation by 1H NMR was employed to further confirm 
the isolation of the desired products. In particular, the two doublet peaks in the range 
of 6.5 – 6.0 ppm (Figure 5.9 – red boxes), which are characteristic of cyclometalated 
iridium(III) complexes,126,133,273 have been observed for all the fatty acid-
functionalised species. Furthermore, the presence of a singlet peak resonating at ca. 
10.30 ppm is assigned to the N–H proton, which suggests the conversion of the amino 
group into an amide one (Figure 5.9 – black boxes). In the case of 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)], the unsaturation of the 
aliphatic chain was supported by the multiplet peak at ca. 5.30 ppm, which is not 
present in the 1H NMR spectra of [Ir(ppy)2(TzPyNHC8sat)], 
[Ir(ppy)2(TzPyNHC16sat)] and [Ir(ppy)2(TzPyNHC18sat)] (Figure 5.9 – top – purple 
box). Finally, all the other aliphatic protons resonate in the range between 2.5 and 1.2 
ppm, with the methyl group downshifted at ca. 0.5 ppm (Figure 5.9 – green boxes). 
In the 13C NMR spectra showed in Figure 5.10, the tetrazolic carbon CT (red 
box) resonates at around 167.5 ppm for both the saturated [Ir(ppy)2(TzPyNHC18sat)] 
and unsaturated [Ir(ppy)2(TzPyNHC18cis)] complexes, indicating a coplanar 
arrangement of the pyridyl and tetrazolate ring, as in the case of the precursor 
[Ir(ppy)2(TzPyNH2)].236 Moreover, the CO (black box) and the CH3 peak (green box) 
resonating at ca. 172.0 and 14.0 ppm, respectively, confirm the coordination of the 
fatty acids to the iridium complexes. 
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Figure 5.9 1H NMR in DMSO-d6 for [Ir(ppy)2(TzPyNHC18cis)] (top) and 
[Ir(ppy)2(TzPyNHC18sat)] (bottom). In the spectra, the boxes highlight the significant 
peaks: N–H peak (black), double peaks of cyclometalated iridium species (red), C=C 
peak of the aliphatic fatty acid chain (purple) and CH3 peak (green). 
 
 
Figure 5.10 13C NMR in DMSO-d6 for [Ir(ppy)2(TzPyNHC18cis)] (top) and 
[Ir(ppy)2(TzPyNHC18sat)] (bottom). In the spectra, the boxes highlight the significant 
peaks: CO peak (black), CT peak (red) and CH3 peak (green).  
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5.4 Photophysical Investigation 
5.4.1 Absorption in Dichloromethane 
The UV-Vis absorption spectral data of all the reported iridium(III) complexes in 
diluted dichloromethane solutions at 298 K have been summarised in Table 5.4. 
The absorption profiles of [Ir(ppy)2(TzPyNHC8sat)], 
[Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNHC18sat)], [Ir(ppy)2(TzPyNHC16cis)] and 
[Ir(ppy)2(TzPyNHC18cis)] are comparable, suggesting that the length of the fatty acid 
chains does not affect the absorption properties of the complexes (Figure 5.11), as 
expected. 
Table 5.4 Absorption data of diluted (10-5 M) dichloromethane solutions of the 
reported complexes. 
Complexes 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2(TzPyNHC8sat)] 264 (8.30), 364 (0.46), 420 (0.26) 
[Ir(ppy)2(TzPyNHC16sat)] 264 (7.91), 386 (0.29), 423 (0.15) 
[Ir(ppy)2(TzPyNHC18sat)] 264 (8.31), 386 (0.36), 422 (0.20) 
[Ir(ppy)2(TzPyNHC16cis)] 264 (8.24), 386 (0.36), 421 (0.21) 
[Ir(ppy)2(TzPyNHC18cis)] 264 (7.16), 386 (0.26), 418 (0.15) 
 
According to previous spectroscopic studies on related iridium(III) 
phenylpyridine complexes,112,124,126,139,231,311 the intense absorption bands in the UV 
region have been assigned to a spin-allowed ligand-centred (LC) p-p* transitions, 
localised on the cyclometalated ppy ligands. The less intense absorption bands in the 
visible region of the spectrum at λ > 350 nm are ascribed to spin-allowed and spin-
forbidden ligand-to-ligand (LLCT) and metal-to-ligand charge transfer (MLCT) 
transitions. In particular, the MLCT transitions are associated with transition between 
the iridium metal centre and both the tetrazolate ligand and the cyclometalated ppy, as 
previously reported in numerous studies on analogous systems.236–239 
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Figure 5.11 Absorption profiles of [Ir(ppy)2(TzPyNHC8sat)] (black), 
[Ir(ppy)2(TzPyNHC16sat)] (blue), [Ir(ppy)2(TzPyNHC18sat)] (red), 
[Ir(ppy)2(TzPyNHC16cis)] (green) and [Ir(ppy)2(TzPyNHC18cis)] (orange) in 
dichloromethane. 
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5.4.2 Emission in Dichloromethane 
The photophysical properties of the fatty acid-functionalised iridium(III) tetrazolato 
complexes were measured in both air-equilibrated and degassed dichloromethane 
solutions and the data have been reported in Table 5.5. 
 
Table 5.5 Photophysical data of diluted (10-5 M) dichloromethane solutions of the 
reported complexes. 
Complex 
λem 
[nm] 
τaer 
[ns] 
τdeaer 
[ns] 
Φaera Φdeaera 
[Ir(ppy)2(TzPyNHC8sat)] 484, 514 83 393 0.006 0.071 
[Ir(ppy)2(TzPyNHC16sat)] 484, 514 80 374 0.007 0.067 
[Ir(ppy)2(TzPyNHC18sat)] 484, 514 83 383 0.007 0.060 
[Ir(ppy)2(TzPyNHC16cis)] 484, 514 75 356 0.007 0.054 
[Ir(ppy)2(TzPyNHC18cis)] 484, 514 75 360 0.008 0.060 
a Measured versus [Ru(bpy)3]2+ in H2O (Φr= 0.028).274 
 
Photoexcitation at λex = 350 nm of the complexes resulted in a yellow-green 
emission, consistent with the emission maxima of [Ir(ppy)2(TzPyNH2)], as described 
in Chapter 4, section 4.4.2. All the complexes are characterised by a vibronically 
structured emission bands, with vibronic progression spaced around 1,200 cm-1. 
Previous studies on transition metal complexes have also demonstrated that featured 
emission profiles are typical for radiative decays from excited states derived from a 
mixture of charge transfer and ligand-centred nature (Figure 5.12).77,306,379,386 
The length and degree of unsaturation of the fatty acid chains does not affect 
the photophysical properties of these complexes when compared to their precursor 
[Ir(ppy)2(TzPyNH2)]. Interestingly, these results also suggest that the localisation of 
the LUMO-type orbitals on the pyridyl ring of the tetrazolate ligand, as shown in 
previous studies on similar systems,231,236–238,370 are not perturbed by the presence of 
the newly formed amide with respect to the amino group of the starting material. 
In general, the emission intensity of these complexes is lower compared to the 
cyano-functionalised iridium(III) probes described in Chapter 2 – section 2.4.2. 
  227 
Further investigations to describe this behaviour can be found in section 5.4.3 of this 
chapter. 
The emission of [Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)], 
[Ir(ppy)2(TzPyNHC18sat)], [Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)] 
is sensitive to the presence of molecular oxygen, confirming the assignment of the 
triplet state phosphorescence.408,409 In fact, upon deoxygenation of the 
dichloromethane solutions, an increase of the quantum yield Φ and elongation of the 
excited state lifetime τ of all the complexes was recorded. 
 
 
 
Figure 5.12 Normalised emission profiles of [Ir(ppy)2(TzPyNHC8sat)] (black), 
[Ir(ppy)2(TzPyNHC16sat)] (blue), [Ir(ppy)2(TzPyNHC18sat)] (red), 
[Ir(ppy)2(TzPyNHC16cis)] (green) and [Ir(ppy)2(TzPyNHC18cis)] (orange) in 
dichloromethane. 
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As expected, the calculation of the radiative (kr) and non-radiative (knr) decay 
constants further confirmed that the fatty acid chains affect the photophysical 
proprieties of this family of probes in a similar manner, as demonstrated by the 
comparable values for both kr and knr (Table 5.6). 
On the other hand, some discrepancies can be highlighted when the radiative 
and non-radiative constants of the fatty acid-functionalised complexes and the 
precursor [Ir(ppy)2(TzPyNH2)] (kr = 0.027 × 106 s-1; knr = 0.942 × 106 s-1) are 
compared. In particular, the radiative decay constant of [Ir(ppy)2(TzPyNH2)] results 
one order of magnitude smaller than the ones reported for the fatty acid analogues. A 
variety of factors affecting the dipole moment can be considered but, in general, the 
difference in kr values can be tentatively ascribed to a higher contribution of the LC 
character in the formation of the emissive excited state, as described in Barigelletti’s 
studies.77 
 
Table 5.6 Radiative (kr) and non-radiative (knr) decay constants in degassed 
dichloromethane solutions. 
Complexes 
kr 
106[s-1]a 
knr 
106[s-1]b 
[Ir(ppy)2(TzPyNHC8sat)] 0.181 2.364 
[Ir(ppy)2(TzPyNHC16sat)] 0.179 2.495 
[Ir(ppy)2(TzPyNHC18sat)] 0.157 2.454 
[Ir(ppy)2(TzPyNHC16cis)] 0.152 2.657 
[Ir(ppy)2(TzPyNHC18cis)] 0.167 2.611 
a Calculated as [Φ/τ] using measurements from deaerated dichloromethane solutions. 
b Calculated as [(1-Φ)/τ] using measurements from the deaerated dichloromethane 
solutions. 
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5.4.3 Temperature-Dependent Luminescent Lifetime 
Measurements 
Temperature-dependent luminescence lifetime measurements have been performed in 
order to rationalise the lower emission properties of the fatty acid-functionalised 
iridium(III) family in comparison to the cyano-functionalised iridium(III) probes 
discussed in Chapter 2, section 4.4.2. 
[Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(TzPyNH2)] have been previously analysed 
in Chapter 4 - section 4.4.3, and the investigation highlighted the presence of a dark 
and accessible 3MC excited state, which could be thermally populated at room 
temperature, increasing the non-radiative decay rate and lowering the emission 
intensity of the amino complex. On the contrary, the energy gap between the emissive 
3MLCT of [Ir(ppy)2(TzPyCN)] and the 3MC excited state was high enough to avoid 
any thermal access to the latter, consequentially showing an intense emission from the 
lowest-lying 3MLCT excited state. Hence, [Ir(ppy)2(TzPyCN)] and 
[Ir(ppy)2(TzPyNH2)] have been considered the extreme cases for this investigation. 
The excited state lifetimes of [Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNH2)] 
and [Ir(ppy)2(TzPyCN)] have been recorded in air-equilibrated dichloromethane 
solutions (ca. 10-5 M) in a range of temperatures between 198 and 298 K. The results 
have been plotted as the logarithm of the rate constant (kobs) against the inverse 
temperature (1/T) in an Arrhenius-like plot, depicted in Figure 5.13 (refer to Chapter 
4 – section 4.4.3 for detailed explanation of the equations). 
[Ir(ppy)2(TzPyNHC16sat)] and [Ir(ppy)2(TzPyNH2)] exhibit the same 
behaviour, characterised by non-radiative decay rate as function of the temperature of 
the system. Higher knr have been measured at room temperature (298 K) with respect 
to the cold dichloromethane solution (198 K), suggesting the presence of a thermally 
accessible 3MC excited state.375 On the other hand, [Ir(ppy)2(TzPyCN)] showed 
constant non-radiative decay values, which result independent from the changing in 
the temperature of the system. Thus, the emissive performances of this probe are not 
affected by the presence of the dark 3MC excited state and are comparable at all 
temperatures. 
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Figure 5.13 Arrhenius plot of the rate constants of [Ir(ppy)2(TzPyNHC16sat)] (blue), 
[Ir(ppy)2(TzPyNH2)] (red) and [Ir(ppy)(TzPyCN)] (green). The trendlines and the R2 
values have been reported.  
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5.4.4 Absorption in Aqueous and Lipophilic Solvents 
The absorption properties of [Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)], 
[Ir(ppy)2(TzPyNHC18sat)], [Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)] 
have been investigated in lipophilic and aqueous media in order to explore the possible 
modulation of the probes’ behaviour in different cellular compartments. 
All the UV-Vis absorption data have been summarised in Table 5.7 and have been 
illustrated from Figure 5.14 to Figure 5.18. 
A small percentage of DMSO (2%) was employed to increase the solubility of the fatty 
acid-functionalised iridium(III) complexes in the aqueous media, as previously 
described in Chapter 4 – section 4.4.4. 
In general, for all the complexes the absorption bands in aqueous solvents and 
ethyl laurate follow the same trend that the ones described for diluted dichloromethane 
solutions, presented in section 5.4.1 of this chapter. In particular, moderately intense 
bands are observed at 280 – 300 nm, which can be attributed to the spin-allowed 
ligand-centred (LC) p-p* transitions of the cyclometalated ppy moieties. Moreover, 
one additional weaker MLCT [dp(Ir)→p*(ppy)] and [dp(Ir)→p*(TzPyNHCx)] 
absorption band or shoulder with molar extinction coefficient on the order of 0.5 – 1.0 
× 104 M-1cm-1 (depending of the solvents) was also observed at the lower energy 
between 390 – 400 nm. Finally, the absorption band in the visible region between 410 
- 425 nm can be assigned to the spin-forbidden MLCT [dp(Ir)→p*(ppy)] and 
[dp(Ir)→p*(TzPyNHCx)] transitions, with reference to previous spectroscopic study 
of related iridium(III) tetrazolato complexes.231,236–238,370 
Notably, the complexes bearing a saturated fatty acid chain 
[Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNHC18sat)] 
showed higher solubility issues and signs of precipitation in lysosomal fluid solutions 
in comparison to the unsaturated aliphatic chain - substituted 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)]. This behaviour has not been 
observed in the PBS and water, the latter possessing a very similar pH with respect to 
the lysosomal fluid solution (pH = 7 and 7.4, respectively). 
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Table 5.7 Absorption data of aqueous and lipophilic solutions (10-5 M) of the reported 
complexes. 
Complex Solventa 
λabs [nm] 
(104 ε [M-1cm-1]) 
[Ir(ppy)2 
(TzPyNHC8sat)] 
H2O 287 (4.17), 393 (1.56), 426 (1.20) 
Lys. Fluid 294 (0.43) 
PBS 286 (2.71), 395 (0.87), 431 (0.62) 
Ethyl Laurate 285 (5.90), 413 (0.76), 457 (0.35) 
[Ir(ppy)2 
(TzPyNHC16sat)] 
H2O 280 (2.63), 392 (0.45), 433 (0.28) 
Lys. Fluid 293 (0.19) 
PBS 289 (0.92), 391 (0.44), 433 (0.40) 
Ethyl Laurate 285 (2.43),412 (0.95), 455 (0.73) 
[Ir(ppy)2 
(TzPyNHC18sat)] 
H2O 281 (5.27), 393 (2.22), 452 (1.77) 
Lys. Fluid 265 (0.13) 
PBS 281 (0.43) 
Ethyl Laurate 284 (0.89), 416 (0.56), 455 (0.49) 
[Ir(ppy)2 
(TzPyNHC16cis)] 
H2O 284 (6.38), 397 (1.33), 435 (0.84) 
Lys. Fluid 291 (1.30), 396 (0.63), 433 (0.48) 
PBS 284 (2.57), 395 (0.90), 428 (0.67) 
Ethyl Laurate 277 (2.71), 392 (0.27), 460 (0.17) 
[Ir(ppy)2 
(TzPyNHC18cis)] 
H2O 282 (6.04), 394 (1.28), 431 (0.85) 
Lys. Fluid 287 (1.19), 395 (0.58), 436 (0.43) 
PBS 285 (2.67), 394 (0.88), 433 (0.60) 
Ethyl Laurate 278 (3.73), 395 (0.45), 436 (0.27) 
a Aqueous solvents contain 2% DMSO. 
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Figure 5.14 Absorption profiles of [Ir(ppy)2(TzPyNHC8sat)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 5.15 Absorption profiles of [Ir(ppy)2(TzPyNHC16sat)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure 5.16 Absorption profiles of [Ir(ppy)2(TzPyNHC18sat)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure 5.17 Absorption profiles of [Ir(ppy)2(TzPyNHC16cis)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure 5.18 Absorption profiles of [Ir(ppy)2(TzPyNHC18cis)] in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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5.4.5 Emission in Aqueous and Lipophilic Solvents 
The photophysical characterisation in aqueous and lipophilic solvents for the reported 
fatty acid-functionalised iridium(III) tetrazolato complexes has been listed in Table 
5.8. 
Table 5.8 Photophysical data of aqueous and lipophilic solutions (10-5 M) of the 
reported complexes. 
Complex Solventa 
λem 
[nm] 
τaer 
[ns]b 
Φaerc 
[Ir(ppy)2 
(TzPyNHC8sat)] 
H2O 493, 520 55 (81), 277 (19) 0.004 
Lys. Fluid 500, 530 72 (77), 422 (23) 0.042 
PBS 493, 520 52 (79), 321 (21) 0.009 
Ethyl Laurate 493, 523 48 (52), 116 (48) 0.023 
[Ir(ppy)2 
(TzPyNHC16sat)] 
H2O 495, 526 53 (43), 197 (57) 0.009 
Lys. Fluid 500, 530 45 (50), 214 (50) 0.024 
PBS 495, 526 44 (45), 179 (55) 0.013 
Ethyl Laurate 495, 526 78 (65), 243 (35) 0.015 
[Ir(ppy)2 
(TzPyNHC18sat)] 
H2O 498, 530 195 (57), 999 (43) 0.024 
Lys. Fluid 502, 526 121 (67), 509 (33) 0.101 
PBS 498, 530 187 (63), 734 (37) 0.082 
Ethyl Laurate 498, 530 173 (70), 873 (30) 0.086 
[Ir(ppy)2 
(TzPyNHC16cis)] 
H2O 496, 548 70 (25), 946 (75) 0.009 
Lys. Fluid 496, 548 51 (66), 466 (34) 0.013 
PBS 496, 548 59 (55), 462 (45) 0.014 
Ethyl Laurate 489, 521 96 0.059 
[Ir(ppy)2 
(TzPyNHC18cis)] 
H2O 496, 547 34 (59), 339 (41) 0.005 
Lys. Fluid 493, 537 36 (68), 249 (32) 0.015 
PBS 493, 520 58 (79), 321 (21) 0.011 
Ethyl Laurate 493, 523 48 (52), 116 (48) 0.049 
a Aqueous solvents contain 2% DMSO. b For the biexponential excited state lifetime 
(τ), the relative weights of the exponential curves are reported in parentheses. c 
Measured versus [Ru(bpy)3]2+ in H2O (Φr = 0.028).274 
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[Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)] and 
[Ir(ppy)2(TzPyNHC18sat)] (Figure 5.19 - Figure 5.21) maintained the same 
vibronically structured emission profile in aqueous and lipophilic solvents, as 
previously recorded for the dichloromethane solutions (section 5.4.2 of this chapter), 
which is typical of emission from a combination of 3MLCT and 3LC excited states.77,238 
The analysis of the emission bands in various solvents highlights a solvatochromic 
behaviour, characterised by ca. 10 – 15 nm bathochromic shift upon increasing the 
polarity of the system from dichloromethane to the aqueous media. Interestingly, 
emission in ethyl laurate was red-shifted with respect to the dichloromethane solution, 
despite the low polarity of the lipophilic medium. In general, no significant differences 
were recorded between the various solvents, in particular the three aqueous media. 
Therefore, the emission maxima of these complexes cannot be used to discriminate the 
different environments within cells. 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)] (Figure 5.22 - 
Figure 5.23) displayed a different trend in comparison to [Ir(ppy)2(TzPyNHC8sat)], 
[Ir(ppy)2(TzPyNHC16sat)] and [Ir(ppy)2(TzPyNHC18sat)], implying that the 
unsaturation present in the fatty acid chains can play a role in lipophilic and aqueous 
media, in opposition to what has been observed in dichloromethane solutions.  
Firstly, the emission profiles of both [Ir(ppy)2(TzPyNHC16cis)] and 
[Ir(ppy)2(TzPyNHC18cis)] in aqueous solvents appear different in comparison to the 
ones in dichloromethane and ethyl laurate, in terms of intensity and shape, as depicted 
in Figure 5.22 and Figure 5.23. While in the case of saturated species, the intensity 
and shape of the two bands were relatively similar (refer to Figure 5.19 - Figure 5.21), 
in the case of the unsaturated species the band at longer wavelength shows the double 
of the intensity and the profile is broader with respect to the band at ca. 490 nm. These 
results suggest that the emission in aqueous environment showed a smaller LC 
contribution than the one in dichloromethane and ethyl laurate.256,275  
Secondly, a bathochromic shift is recorded for the aqueous media in 
comparison to the organic solvent, with a more marked shift of the band at 514 nm 
(ca. 10 – 15 nm) in comparison to the band at 484 nm (ca. 15 – 30 nm). Moreover, the 
emission from ethyl laurate solution is ca. 20 nm blue-shifted in comparison to the 
aqueous media. This characteristic can be potentially used to discriminate the emission 
of the probes in aqueous and lipophilic compartment, when uptake inside the cells. 
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The excited state lifetimes are comparable for all the iridium(III) complexes 
and also for both the aqueous and lipophilic solvents, with values of ca. 100 ns for the 
shorter component and around 400 – 600 ns for the longer one. A simple trend for the 
luminescent quantum yield values was difficult to rationalise, but in general slightly 
higher Φ have been recorded for ethyl laurate solutions. 
 
 
 
Figure 5.19 Normalised emission profiles of [Ir(ppy)2(TzPyNHC8sat)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
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Figure 5.20 Normalised emission profiles of [Ir(ppy)2(TzPyNHC16sat)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
 
 
Figure 5.21 Normalised emission profiles of [Ir(ppy)2(TzPyNHC18sat)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
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Figure 5.22 Normalised emission profiles of [Ir(ppy)2(TzPyNHC16cis)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange). 
 
 
Figure 5.23 Normalised emission profiles of [Ir(ppy)2(TzPyNHC18cis)] in 
dichloromethane (black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate 
(orange).  
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5.5 Conclusions 
In this chapter, a family of five fatty acid-functionalised iridium(III) complexes, 
[Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNHC18sat)], 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)], have been discussed. 
A variety of synthetic routes has been employed in the attempt of functionalise 
CNPyNH2 or HTzPyNH2 with the appropriate fatty acid chain, but issues during the 
purification process have made impossible the separation of the desired products from 
the unreacted starting material and byproducts. However, due to the enhanced 
solubility of [Ir(ppy)2(TzPyNH2)] in dichloromethane, the reaction with the different 
acyl chloride species was successfully achieved and the purification via column 
chromatography allowed the isolation of the final fatty acid-functionalised complexes. 
The photophysical investigation in dichloromethane solution showed a yellow-
green emission for all the complexes, derived from a mixture of 3MLCT and 3LC 
excited state and which is comparable with the emission maxima exhibits by the 
starting material [Ir(ppy)2(TzPyNH2)]. This result suggests that the LUMO-type 
orbitals on the pyridyl ring of the tetrazolate ligand are not affected by the substitution 
of the amino group to an amide one. Moreover, the temperature-dependent lifetime 
measurements on [Ir(ppy)2(TzPyNHC16cis)] have confirmed the presence of a lower-
lying 3MC excited state, which can be thermally populated and is responsible of the 
reduced emission intensity of the fatty acid-functionalised complexes in comparison 
to [Ir(ppy)2(TzPyCN)]. 
The photophysical properties of this family of complexes have been explored 
in aqueous and lipophilic solvents to evaluate their applicability in biological 
environment. In general, the emission was red-shifted upon increase of the medium 
polarity, with a more marked solvatochromic behaviour for [Ir(ppy)2(TzPyNHC16cis)] 
and [Ir(ppy)2(TzPyNHC18cis)] in comparison to [Ir(ppy)2(TzPyNHC8sat)], 
[Ir(ppy)2(TzPyNHC16sat)] and [Ir(ppy)2(TzPyNHC18sat)]. Moreover, the unsaturation 
of the appended fatty acid chains affects the emission profile in aqueous media for 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)], which becomes broader, 
suggesting the smaller contribution from the 3LC excited state to the emission. 
Interestingly, this behaviour was not recorded in dichloromethane solution, 
where the different degree of saturation of the fatty acids did not affect neither the 
emission maxima nor the profile. 
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A lack of major variations between water, lysosomial fluid and PBS have been 
recorded, excluding these probes from the application in cellular pH-sensing field. 
Nevertheless, due to the emissive nature of these probes in all the assessed solvents for 
the photophysical investigation, this new family of fatty acid-functionalised 
iridium(III) probes can be tested for biological imaging applications.  
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5.6 Experimental 
5.6.1 General Procedures 
General procedures have been conducted as outline in Chapter 2 – section 2.6.1, unless 
otherwise stated. 
The complex [Ir(ppy)2(TzPyNH2)] was prepared according to the synthetic 
method discussed in Chapter 4 – section 2.6.4. 
For the NMR characterisation, carbon and proton of all the iridium(III) 
tetrazolato species were labelled as pyridinic (A), phenylic (B), tetrazolic (T) and, 
alifatic (F), according to Figure 5.24. 
 
 
Figure 5.24 NMR referencing layout. 
 
5.6.2 Photophysical Measurements 
Photophysical measurements have been carried out as outlined in Chapter 2 – section 
2.6.2, unless otherwise stated. 
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5.6.3 Synthesis 
CNPyNHC8sat 
 
 
5-Amino-2-pyridinecarbonitrile (0.150 g, 0.126 mmol) and triethylamine (0.26 mL, 
1.882 mmol) were combined in 10 mL of dry dichloromethane in inert atmosphere of 
N2. Octanoyl chloride (0.22 mL, 1.260 mmol) was dissolved in 3 mL of dry 
dichloromethane, added dropwise to the reaction mixture and stirred at room 
temperature overnight. The solution was concentrated and diethyl ether was added. A 
white precipitate was formed and filtered. The solvent was evaporated under reduce 
pressure and the solid suspended in hexane (10 mL) and washed with NaOH aqueous 
solution (0.1 M).  The aqueous phase was discarded and the off-white solid collected 
by vacuum filtration. Yield: 0.138 g (45%). M.P. 100 – 102 °C. IR (ν / cm-1): 2926 s, 
2854 s (CH stretch saturated C–C), 2227 w (C≡N), 1680 w (C=O functionalised 
stretch). 1H NMR (δ / ppm, DMSO-d6): 10.55 (s, 1H, HTamide), 8.86 (s, 1H, HT6), 8.27 
(d, 1H, HT4, J = 8.6 Hz), 7.96 (d, 1H, HT3, J = 8.8 Hz), 1.62 – 1.59 (m, 2H, 2HF), 1.29 
(broad s, 10H, 10HF), 0.87 (t, 3H, 3HFMe, J = 6.0 Hz). 13C NMR (δ / ppm, DMSO-d6): 
172.6 (CO), 141.7 (CHT6), 139.1 (CN), 129.6 (CHT4), 125.6 (CT2), 125.5 (CHT3), 
117.7 (CT5), 36.3 (CHF), 31.1 (CHF), 28.5 (CHF), 28.4 (CHF), 24.7 (CHF), 22.0 (CHF), 
13.9 (CHFMe). Anal.Calcd for CNPyNHC8sat·0.3(diethyl ether): C, 68.20; H, 8.34; N, 
15.56. Found: C, 67.24; H, 8.48; N, 15.57.  
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[Ir(ppy)2(TzPyNHC8sat)] 
 
 
[Ir(ppy)2(TzPyNH2)] (0.100 g, 0.152 mmol) and triethylamine (0.32 mL, 2.270 mmol) 
were combined in 10 mL of dry dichloromethane. Octanoyl chloride (0.26 mL, 1.520 
mmol) was dissolved in 3 mL of dry dichloromethane, added dropwise to the reaction 
mixture and stirred at room temperature overnight. The solution was concentrated and 
diethyl ether was added. A white precipitate was formed and filtered. The filtrate was 
washed with NaHCO3 5% solution (3 × 15 mL). The organic phase was dried over 
MgSO4 anhydrous and the product was purified via column chromatography using 
Brockmann I grade basic alumina-filled as stationary phase and a 
dichloromethane/methanol (99.5:0.5 v/v) solvent system mixture as eluent. The 
targeted complex eluted as the second fraction (yellow). Yield: 0.091 g (76%). M.P. 
252 – 254 °C. IR (ν / cm-1): 2924 s, 2853 s (CH stretch saturated C–C), 1699 w (C=O 
functionalised stretch), 1606 w (tetrazole C=N). 1H NMR (δ / ppm, DMSO-d6): 10.31 
(s, 1H, HTamide), 8.34 (d, 1H, HT4, J = 8.7 Hz), 8.27 (d, 1H, HT3, J = 8.8 Hz), 8.20 – 
8.17 (m, 2H, 2HA), 8.14 (s, 1H, HT6), 7.89 – 7.84 (m, 3H, 3HA), 7.79 (d, 1H, HB, J = 
7.7 Hz), 7.62 (d, 1H, HB, J = 5.6 Hz), 7.39 (d, 1H, HB, J = 5.6 Hz), 7.18 – 7.11 (m, 2H, 
2HA), 6.97 (app. t., 1H, HA, splitting = 7.4 Hz), 6.91 – 6.84 (m, 2H, 2HB), 6.75 (app. 
t., 1H, HA, splitting = 7.4 Hz), 6.21 (d, 1H, HB, J = 7.5 Hz), 6.13 (d, 1H, HB, J = 7.5 
Hz), 2.23 (t, 2H, 2HF, J = 7.5 Hz), 1.52 – 1.45 (m, 2H, 2HF), 1.22 (broad s, 24H, 
24HF), 0.84 (t, 3H, 3HFMe, J = 7.2 Hz). 13C NMR (δ / ppm, DMSO-d6): 172.0 (CO), 
167.4 (CT), 167.3 (CT2), 163.4 (CA), 151.6 (CB), 148.7 (2CHB), 147.4 (CB), 144.2 
(CB), 144.0 (CB), 142.5 (CT5), 140.8 (CHT6), 138.3 (CHA), 138.2 (CHA), 137.9 (CA), 
131.3 (2CHB), 129.9 (CHB), 129.1 (CHB), 128.8 (CHT4), 124.8 (CHA), 124.2 (CHB), 
123.4 (CHA), 123.3 (CHA), 121.8 (CHA), 121.1 (CHB), 119.6 (CHA), 119.4 (CHA), 
36.1 (CHF), 31.1 (CHF), 28.5 (CHF), 28.4 (CHF), 24.7 (CHF), 22.0 (CHF), 13.9 
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(CHFMe). Anal.Calcd for [Ir(ppy)2(TzPyNHC8sat)]: C, 54.88; H, 4.48; N, 14.22. 
Found: C, 54.83; H, 4.53; N, 14.18. 
 
[Ir(ppy)2(TzPyNHC16sat)] 
 
 
[Ir(ppy)2(TzPyNH2)] (0.100 g, 0.152 mmol) and triethylamine (0.32 mL, 2.270 mmol) 
were combined in 10 mL of dry dichloromethane. Palmitoyl chloride (0.46 mL, 1.520 
mmol) was dissolved in 3 mL of dry dichloromethane, added dropwise to the reaction 
mixture and stirred at room temperature overnight. The solution was concentrated and 
diethyl ether was added. A white precipitate was formed and filtered. The filtrate was 
washed with NaHCO3 5% solution (3 × 15 mL). The organic phase was dried over 
MgSO4 anhydrous and the product was purified via column chromatography using 
Brockmann I grade basic alumina-filled as stationary phase and a 
dichloromethane/methanol (99.5:0.5 v/v) solvent system mixture as eluent. The 
targeted complex eluted as the second fraction (yellow). Yield: 0.107 g (78%). M.P. 
321 – 314 °C. IR (ν / cm-1): 2923 s, 2849 s (CH stretch saturated C–C), 1703 w (C=O 
functionalised stretch), 1607 w (tetrazole C=N). 1H NMR (δ / ppm, DMSO-d6): 10.31 
(s, 1H, HTamide), 8.33 (d, 1H, HT4, J = 8.8 Hz), 8.27 (d, 1H, HT3, J = 8.7 Hz), 8.20 – 
8.17 (m, 2H, 2HA), 8.14 (s, 1H, HT6), 7.89 – 7.83 (m, 3H, 3HA), 7.79 (d, 1H, HB, J = 
7.9 Hz), 7.62 (d, 1H, HB, J = 5.2 Hz), 7.39 (d, 1H, HB, J = 5.2 Hz), 7.17 – 7.11 (m, 2H, 
2HA), 6.97 (app. t., 1H, HA, splitting = 7.5 Hz), 6.91 – 6.84 (m, 2H, 2HB), 6.75 (app. 
t., 1H, HA, splitting = 7.4 Hz), 6.21 (d, 1H, HB, J = 8.8 Hz), 6.13 (d, 1H, HB, J = 8.8 
Hz), 2.22 (t, 2H, 2HF, J = 7.5 Hz), 1.49 – 1.43 (m, 2H, 2HF), 1.22 (broad s., 24H, 
24HF), 0.84 (t, 3H, 3HFMe, J = 6.8 Hz). 13C NMR (δ / ppm, DMSO-d6): 172.0 (CO), 
167.4 (CT), 167.3 (CT2), 163.5 (CA), 151.7 (CB), 148.7 (2CHB), 147.4 (CB), 144.2 
(CB), 144.0 (CB), 142.5 (CT5), 140.8 (CHT6), 138.3 (CHA), 138.2 (CHA), 137.9 (CA), 
131.3 (2CHB), 129.9 (CHB), 129.1 (CHB), 128.8 (CHT4), 124.8 (CHA), 124.3 (CHB), 
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123.4 (CHA), 123.3 (CHA), 122.6 (CHT3), 121.9 (CHA), 121.1 (CHB), 119.6 (CHA), 
119.4 (CHA), 36.1 (CHF), 31.3 (2CHF), 29.0 (2CHF), 28.9 (2CHF), 28.8 (CHF), 28.7 
(2CHF), 28.6 (CHF), 24.7 (CHF), 22.1 (2CHF), 14.0 (CHFMe). Anal.Calcd for 
[Ir(ppy)2(TzPyNHC16sat)]·0.5(dichloromethane): C, 56.70; H, 5.56; N, 11.89. Found: 
C, 56.70; H, 5.60; N, 11.87. 
 
[Ir(ppy)2(TzPyNHC18sat)] 
 
 
[Ir(ppy)2(TzPyNH2)] (0.100 g, 0.152 mmol) and triethylamine (0.32 mL, 2.270 mmol) 
were combined in 10 mL of dry dichloromethane. Stearoyl chloride (0.51 mL, 1.520 
mmol) was dissolved in 3 mL of dry dichloromethane, added dropwise to the reaction 
mixture and stirred at room temperature overnight. The solution was concentrated and 
diethyl ether was added. A white precipitate was formed and filtered. The filtrate was 
washed with NaHCO3 5% solution (3 × 15 mL). The organic phase was dried over 
MgSO4 anhydrous and the product was purified via column chromatography using 
Brockmann I grade basic alumina-filled as stationary phase and a 
dichloromethane/methanol (99.5:0.5 v/v) solvent system mixture as eluent. The 
targeted complex eluted as the second fraction (yellow). Yield: 0.097 g (69%). M.P. 
308 – 310 °C. IR (ν / cm-1): 2922 s, 2849 s (CH stretch saturated C–C), 1703 w (C=O 
functionalised stretch), 1607 w (tetrazole C=N). 1H NMR (δ / ppm, DMSO-d6): 10.31 
(s, 1H, HTamide), 8.34 (d, 1H, HT4, J = 8.7 Hz), 8.27 (d, 1H, HT3, J = 8.7 Hz), 8.22 – 
8.17 (m, 2H, 2HA), 8.14 (s, 1H, HT6), 7.91 – 7.82 (m, 3H, 3HA), 7.79 (d, 1H, HB, J = 
8.9 Hz), 7.62 (d, 1H, HB, J = 7.2 Hz), 7.39 (d, 1H, HB, J = 7.2 Hz), 7.18 – 7.10 (m, 2H, 
2HA), 6.97 (app. t., 1H, HA, splitting = 8.1 Hz), 6.91 – 6.84 (m, 2H, 2HB), 6.75 (app. 
t., 1H, HA, splitting = 8.1 Hz), 6.21 (d, 1H, HB, J = 7.5 Hz), 6.13 (d, 1H, HB, J = 7.5 
Hz), 2.22 (t, 2H, 2HF, J = 7.2 Hz), 1.51 – 1.44 (m, 2H, 2HF), 1.22 (broad s., 28H, 
28HF), 0.83 (t, 3H, 3HFMe, J = 6.4 Hz). 13C NMR (δ / ppm, DMSO-d6): 172.0 (CO), 
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167.4 (CT), 167.3 (CT2), 163.5 (CA), 151.7 (CA), 148.7 (2CHB), 147.4 (CB), 144.2 
(CB), 144.0 (CB), 142.5 (CT5), 140.8 (CHT6), 138.3 (2CHA), 137.9 (CB), 131.3 (2CHB), 
130.0 (CHB), 129.1 (CHT4), 128.8 (CHB), 124.8 (2CHA), 124.3 (CHB), 123.4 (CHA), 
122.6 (CHT3), 121.9 (CHA), 121.1 (CHB), 119.6 (CHA), 119.4 (CHA), 36.2 (CHF), 
31.3 (CHF), 30.7 (2CHF), 29.0 (3CHF), 28.9 (2CHF), 28.8 (CHF), 28.7 (2CHF), 28.6 
(CHF), 28.5 (CHF), 24.7 (CHF), 22.1 (CHF), 14.0 (CHFMe). Anal.Calcd for 
[Ir(ppy)2(TzPyNHC18sat)]·0.5(methanol): C, 59.15; H, 6.08; N, 11.87. Found: C, 
59.16; H, 5.96; N, 11.81.  
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[Ir(ppy)2(TzPyNHC16cis)] 
 
 
[Ir(ppy)2(TzPyNH2)] (0.100 g, 0.152 mmol) and triethylamine (0.32 mL, 2.270 mmol) 
were combined in 10 mL of dry dichloromethane. Palmitoleoyl chloride (0.46 mL, 
1.520 mmol) was dissolved in 3 mL of dry dichloromethane, added dropwise to the 
reaction mixture and stirred at room temperature overnight. The solution was 
concentrated and diethyl ether was added. A white precipitate was formed and filtered. 
The filtrate was washed with NaHCO3 5% solution (3 × 15 mL). The organic phase 
was dried over MgSO4 anhydrous and the product was purified via column 
chromatography using Brockmann I grade basic alumina-filled as stationary phase and 
a dichloromethane/methanol (99.5:0.5 v/v) solvent system mixture as eluent. The 
targeted complex eluted as the second fraction (yellow). Yield: 0.085 g (62%). M.P. 
194 – 196 °C. IR (ν / cm-1): 3006 w (=C–H stretch), 2922 s, 2851 s (CH stretch 
saturated C–C), 1703 w (C=O functionalised stretch), 1607 w (tetrazole C=N).  1H 
NMR (δ / ppm, DMSO-d6): 10.31 (s, 1H, HTamide), 8.34 (d, 1H, HT4, J = 8.8 Hz), 8.27 
(d, 1H, HT3, J = 8.7 Hz), 8.20 – 8.19 (m, 2H, 2HA), 8.13 (s, 1H, HT6), 7.89 – 7.83 (m, 
3H, 3HA), 7.79 (d, 1H, HB, J = 7.9 Hz), 7.62 (d, 1H, HB, J = 5.2 Hz), 7.39 (d, 1H, HB, 
J = 5.2 Hz), 7.18 – 7.10 (m, 2H, 2HA), 6.97 (app. t., 1H, HA, splitting = 7.5 Hz), 6.91 
– 6.84 (m, 2H, 2HB), 6.75 (app. t., 1H, HA, splitting = 7.4 Hz), 6.21 (d, 1H, HB, J = 8.8 
Hz), 6.13 (d, 1H, HB, J = 8.8 Hz), 5.32 – 5.30 (m, 2H, 2HFCH=CH), 2.22 (t, 2H, 2HF, J 
= 7.5 Hz), 1.99 – 1.94 (m, 3H, 3HF), 1.51 – 1.46 (m, 2H, 2HF), 1.23 (broad s., 15H, 
15HF), 0.85 – 0.80 (m, 3H, 3HFMe). 13C NMR (δ / ppm, DMSO-d6): 172.0 (CO), 167.4 
(CT), 167.3 (CT2), 163.5 (CA), 151.7 (CB), 148.7 (2CHB), 147.4 (CB), 144.3 (CB), 
144.0 (CB), 142.5 (CT5), 140.8 (CHT6), 138.4 (CHA), 138.3 (CHA), 137.9 (CA), 131.3 
(2CHB), 130.0 (CHB), 129.7 (CHFCH=CH), 129.6 (CHFCH=CH), 129.1 (CHB), 128.9 
(CHT4), 124.8 (CHA), 124.3 (CHB), 123.4 (CHA), 123.3 (CHA), 122.6 (CHT3), 121.9 
(CHA), 121.1 (CHB), 119.6 (CHA), 119.4 (CHA), 36.2 (CHF), 31.1 (2CHF), 29.1 
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(CHF), 28.6 (2CHF), 28.5 (CHF), 28.2 (CHF), 26.6 (CHF), 24.7 (CHF), 22.1 (2CHF), 
13.9 (CHFMe). Anal.Calcd for [Ir(ppy)2(TzPyNHC16cis)]: C, 58.84; H, 5.50; N, 12.48. 
Found: C, 59.04; H, 5.55; N, 12.27. 
 
[Ir(ppy)2(TzPyNHC18cis)] 
 
 
[Ir(ppy)2(TzPyNH2)] (0.100 g, 0.152 mmol) and triethylamine (0.32 mL, 2.270 mmol) 
were combined in 10 mL of dry dichloromethane. Oleoyl chloride (0.50 mL, 1.520 
mmol) was dissolved in 3 mL of dry dichloromethane, added dropwise to the reaction 
mixture and stirred at room temperature overnight. The solution was concentrated and 
diethyl ether was added. A white precipitate was formed and filtered. The filtrate was 
washed with NaHCO3 5% solution (3 × 15 mL). The organic phase was dried over 
MgSO4 anhydrous and the product was purified via column chromatography using 
Brockmann I grade basic alumina-filled as stationary phase and a 
dichloromethane/methanol (99.5:0.5 v/v) solvent system mixture as eluent. The 
targeted complex eluted as the second fraction (yellow). Yield: 0.085 g (61%). M.P. 
186 – 189 °C. IR (ν / cm-1): 3004 w (=C–H stretch), 2922 s, 2852 s (CH stretch 
saturated C–C), 1700 w (C=O functionalised stretch), 1606 w (tetrazole C=N).  1H 
NMR (δ / ppm, DMSO-d6): 10.31 (s, 1H, HTamide), 8.35 (d, 1H, HT4, J = 8.8 Hz), 8.27 
(d, 1H, HT3, J = 8.7 Hz), 8.19 – 8.17 (m, 2H, 2HA), 8.13 (s, 1H, HT6), 7.89 – 7.83 (m, 
3H, 3HA), 7.79 (d, 1H, HB, J = 7.9 Hz), 7.62 (d, 1H, HB, J = 5.2 Hz), 7.39 (d, 1H, HB, 
J = 5.2 Hz), 7.18 – 7.10 (m, 2H, 2HA), 6.96 (app. t., 1H, HA, splitting = 8.0 Hz), 6.91 
– 6.84 (m, 2H, 2HB), 6.75 (app. t., 1H, HA, splitting = 8.0 Hz), 6.21 (d, 1H, HB, J = 8.8 
Hz), 6.13 (d, 1H, HB, J = 8.8 Hz), 5.32 – 5.30 (m, 2H, 2HFCH=CH), 2.22 (t, 2H, 2HF, J 
= 7.5 Hz), 1.99 – 1.94 (m, 4H, 4HF), 1.51 – 1.46 (m, 2H, 2HF), 1.18 (broad s, 20H, 
20HF), 0.83 – 0.80 (m, 3H, 3HFMe). 13C NMR (δ / ppm, DMSO-d6): 171.9 (CO), 167.4 
(CT), 167.3 (CT2), 163.4 (CA), 151.6 (CB), 148.7 (CHB), 148.6 (CHB), 147.4 (CB), 
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144.2 (CB), 144.0 (CB), 142.5 (CT5), 140.8 (CHT6), 138.3 (CHA), 138.2 (CHA), 137.9 
(CA), 131.3 (2CHB), 129.9 (CHA), 129.6 (CHFCH=CH), 129.5 (CHFCH=CH), 129.0 
(CHB), 128.8 (CHT4), 124.8 (CHB), 124.2 (CHB), 123.3 (CHA), 123.2 (CHA), 122.5 
(CHT3), 121.8 (CHA), 121.1 (CHB), 119.6 (CHA), 119.4 (CHA), 36.1 (CHF), 31.2 
(CHF), 29.1 (CHF), 29.0 (CHF), 28.8 (CHF), 28.6 (2CHF), 28.5 (2CHF), 28.4 (CHF), 
26.5 (2CHF), 24.7 (CHF), 22.0 (CHF), 13.9 (CHFMe). Anal.Calcd for 
[Ir(ppy)2(TzPyNHC18cis)]·0.3(methanol): C, 59.40; H; 5.85; N, 11.96. Found: C, 
59.49; H, 5.85; N, 12.00.
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Chapter 6  
Preliminary Biological Investigation of Amino 
and Fatty Acid-Functionalised Iridium 
Tetrazolato Complexes 
 
6.1 Introduction 
During the design of organic and transition metal probes, the subcellular localisation 
or the binding affinity of these luminescent species with specific biological targets are 
essential properties to be considered.49,62,291,385 A variety of strategies has been applied 
to the development of probes with high specificity, which includes the addition of 
protonatable-deprotonatable groups, cleavage or formation of covalent bonds, 
complexation and conjugation with biologically relevant 
vectors.63,107,114,120,126,263,300,354,356–358,410–413  
Due to the important role of fatty acids and lipids in many aspects of cells 
biology such as membrane architecture, intracellular trafficking, signalling, hormone 
regulation, energy storage and secondary metabolite production, the interest in these 
species has attracted the researchers’ attention during the years.248,393–395,397  
In particular, a plateau of organic fluorophores (Figure 6.1 – Left and centre – 
111, 112)414–417 and few transition metal species of Ir(III), Re(I), Ru(II) and 
Pt(II)298,418–423 (Figure 6.1 – Right – 113) have been appended with fatty acids or long 
alkyl chains in order to mimic the biological behaviour of lipids and increase the 
biospecificity for these targeted moieties. Unfortunately, the investigation of lipid-rich 
organelles and the monitoring of processes involving fatty acids have been limited by 
the availability of probes that can specifically visualise lipids in live cells. In fact, as 
previously mentioned in Chapter 5 – section 5.1, the majority of these dyes can be 
applied only in fixed cells, due to issues related to membrane permeability or high 
cytotoxicity against live cells.232,248 
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Figure 6.1 Different staining pattern (bottom) of dyes appended with fatty acids or 
long alkyl chains (top). (Left) Lipid droplets of fixed hepatocytes of wild-types mice 
stained with 111 (Scale bar = 10 µm). (Centre) Plasma membrane staining of HeLa 
cells with 0.1 µM of 112 (Scale bar = 20 µm). (Right) Plasma membrane localisation 
of 113 in HeLa cell (Scale bar = 20 µm). Reproduced with permission from 
ref415,416,422. 
 
In this chapter, the preliminary biological investigation on amino and fatty 
acid-functionalised iridium(III) complexes will be discussed. Normal epithelial 
prostatic cell line PNT2 were employed instead of H9c2 rat cardiomyoblast cells, due 
to their bigger size (which allows better visualisation of the probes within the cells) 
and higher concentration of lipids. 
The probes have been successfully internalised in live PNT2 cells and different 
concentrations of these dyes have been evaluated in order to assess the uptake 
mechanism and in the attempt to solve solubility issues. It can be anticipated that all 
the probes have accumulated within the cells, but the detection of few of them was 
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minimal, probably due to a combination of low emissive properties in aqueous 
environment and precipitation in the culture medium. The cytotoxicity and 
photostability of this family of probes has been assessed, highlighting the potential of 
this class of complexes for the development of lipid probes in live cells. 
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6.2 Preliminary Biological Investigation 
6.2.1 Lipophilicity 
Lipophilicity is often closely correlated with the permeability and solubility profile of 
a compound. In general, the permeability coefficient of a molecule improves with 
higher values of lipophilicity. On the other hand, an excessive increase of this 
parameter may contribute to a substantial decrease of the solubility of the compound 
in biological environment.86 For this reason, during the design of new imaging and 
therapeutic agents, the lipophilicity is one of the crucial properties to be considered, 
along with charge, solubility and bioconjugation to specific biological vectors.1 
Fatty acids possess amphipathic character due to the presence of an ionisable 
headgroup and a hydrophobic aliphatic chain, which is responsible for the low 
solubility in water of these species.387 Previous works on metallosurfactants have 
shown remarkable self-assembling features of these complexes in aqueous solutions, 
with the formation of micellar systems.379,424–427 
The fatty acid-functionalised iridium(III) complexes, described in Chapter 5, 
exhibit a similar architecture given the polar iridium(III) core and hydrophobic 
aliphatic chain, which should increase the lipophilicity value of this family of probes 
with respect to the amino-functionalised iridium(III) precursor (refer to Chapter 4). 
The lipophilicity of [Ir(ppy)2(TzPyNH2)] , [Ir(bzq)2(TzPyNH2)] , 
[Ir(ppy)2(TzPyNHC8sat)], [Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNHC18sat)], 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)] has been measured by the 
shake-flask method, using a pH= 7.4 buffered PBS solution and n-octanol, as outlined 
in Chapter 3 – section 3.5.2.308  
All the logD7.4 values have been summarised in Table 6.1. 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] possess lipophilicity values (1.99 and 
1.87, respectively) which are within the range of previously reported iridium(III) 
cyclometalated species.104,115,120,126,134,238 Surprisingly, increasing the conjugation of 
the cyclometalated ligands from a phenylpyridine (ppy) to a benzoquinoline (bzq) 
does not increase the logD7.4 values, as observed from other reported data.126,137 
As expected, by introducing a long and hydrophobic aliphatic chain on the 
tetrazolate ligand, the lipophilicity of the fatty acid-functionalised iridium(III) probes 
(logD7.4 = 2.26 – 2.84) increase in comparison to their precursor [Ir(ppy)2(TzPyNH2)] 
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(logD7.4 = 1.99).418,428 Moreover, along the whole series, the lower lipophilicity is 
observed for [Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)], with values of 
2.31 and 2.26, respectively. This behaviour may derive from the presence of the 
unsaturation on the fatty acid, which increases the rigidity of the chain and modulates 
the geometry of the whole system in aqueous solution.426 Interestingly, the length of 
the fatty acid chain does not affect the lipophilicity of these probes, even when 
comparing [Ir(ppy)2(TzPyNHC8sat)] (logD7.4 = 2.66) with [Ir(ppy)2(TzPyNHC18sat)] 
(logD7.4 = 2.63), bearing 8 and 18-carbon chains, respectively. 
 
Table 6.1 Distribution coefficient values (logD7.4) for the amino and fatty 
acidfunctionalised iridium(III) complexes. 
Complexes logD7.4 
[Ir(ppy)2(TzPyNH2)] 1.99 ± 0.04 
[Ir(bzq)2(TzPyNH2)] 1.87 ± 0.03 
[Ir(ppy)2(TzPyNHC8sat)] 2.66 ± 0.07 
[Ir(ppy)2(TzPyNHC16sat)] 2.84 ± 0.08 
[Ir(ppy)2(TzPyNHC18sat)] 2.63 ± 0.06 
[Ir(ppy)2(TzPyNHC16cis)] 2.31 ± 0.06 
[Ir(ppy)2(TzPyNHC18cis)] 2.26 ± 0.06 
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6.2.2 Localisation and Internalisation 
The cellular localisation of the fatty acid (Figure 6.2) and amino-functionalised 
iridium(III) probes (Figure 6.3) within PNT2 cells was investigated via confocal 
microscopy, using single photon excitation at 403 nm. 
Given the lower solubility in aqueous solutions of these probes in comparison 
to the cyano and (iso)quinolyl-functionalised complexes described in Chapter 3 – 
section 3.2.2, the staining protocol was modified. In particular, the amount of DMSO 
used for the solubilisation of the complexes in the RPMI-1640 culture medium was 
increased from 0.2 to 2%. Moreover, prolonged sonication of the solutions was 
required for each dilution step to ensure complete dissolution of the probes. 
In general, precipitation issues were encountered with whole series of fatty 
acid-functionalised iridium(III) probes and with the more conjugated amino-
substituted species [Ir(bzq)2(TzPyNH2)]. The presence of the precipitated probes is 
evident in Figure 6.2 and Figure 6.3, even after multiple washings with PBS. 
Live PNT2 cells were incubated with the iridium complexes at 5 and 10 µM 
for 20 minutes at 37 °C. Longer incubation time (3 hours) and higher concentrations 
(20 – 40 µM) were also attempted, showing analogous results. For this reason, only 
the data derived from the short incubation analysis will be discussed. 
The successful uptake of all the probes has been confirmed by recording the 
emission intensity deriving from the stained cells at different wavelength intervals. As 
depicted from Figure 6.4 to Figure 6.6, the emission intensity of the probes has been 
recorded in spectral mode with maximum around 504 – 513 nm, which is consistent 
with the photophysical data in aqueous solutions discussed in Chapter 4 – section 4.4.5 
and Chapter 5 – section 5.4.5 for the amino and fatty acid-functionalised iridium(III) 
complexes, respectively. In the case of [Ir(bzq)2(TzPyNH2)], the emission maximum 
is slightly red-shifted around 524 – 533 nm, which is ascribed to the presence of the 
more conjugated cyclometalated ligands with respect to the other complexes in the 
series. Moreover, higher is the intensity in the interval of wavelengths 444 – 453 nm, 
higher is the contribution of the endogenous species to the recorded emission. The lack 
of emission in the interval 484 – 493 nm is ascribed to the use of a filter. 
The internalisation within cells and detection of [Ir(ppy)2(TzPyNHC8sat)], 
[Ir(ppy)2(TzPyNHC16cis)], [Ir(ppy)2(TzPyNHC18cis)] (only for 5 µM), 
[Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] (only for 5 µM) was successfully 
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achieved. In case of [Ir(ppy)2(TzPyNHC16sat)] and [Ir(ppy)2(TzPyNHC18sat)], a 
combination of low solubility and low phosphorescence in aqueous environment was 
probably responsible for the negligible detectability of these species within the cells. 
The majority of these probes was found to accumulate in the perinuclear area of live 
PNT2 cells, with staining patterns resembling the endoplasmic reticulum, as 
previously observed in Chapter 3 – section 3.2.2.238 To confirm the intracellular 
localisation of the complexes in this lipid-rich organelle, co-localisation analyses with 
ER-Tracker™ need to be performed to complete the biological investigation.  
Interestingly, the internalisation of this family of probes appeared to occur 
through two distinctive mechanisms. The accumulation of [Ir(ppy)2(TzPyNH2)] 
increases at higher concentration (Figure 6.3 – column B), suggesting a potential 
passive diffusion mechanism across the cellular membrane, driven by the 
concentration gradient. On the other hand, [Ir(ppy)2(TzPyNHC8sat)] and 
[Ir(ppy)2(TzPyNHC16cis)] (Figure 6.2) did not show any significant variations in the 
cellular uptake upon increase of concentration, which may suggest a mediated 
transport. Finally, the higher concentration of [Ir(ppy)2(TzPyNHC18cis)] and 
[Ir(bzq)2(TzPyNH2)] (Figure 6.2 and Figure 6.3, respectively) inhibited cellular 
entry. The mechanism of internalisation of [Ir(ppy)2(TzPyNHC16sat)] and 
[Ir(ppy)2(TzPyNHC18sat)] has not been evaluated due to their poor detectability. 
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Figure 6.2 Micrographs of live PNT2 cells stained with 5 µM ( column A) and 10 µM 
(column B) of the fatty acid-functionalised iridium(III) complexes. Scale bar = 20 µm. 
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Figure 6.3 Micrographs of live PNT2 cells stained with 5 µM (column A) and 10 µM 
(column B) of the amino-functionalised iridium(III) complexes. Scale bar = 20 µm. 
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Figure 6.4 Emission profiles of [Ir(ppy)2(TzPyNHC8sat)] (top), 
[Ir(ppy)2(TzPyNHC16sat)] (middle) and [Ir(ppy)2(TzPyNHC18sat)] (bottom) 
incubated in live PNT2 cells (5 µM). The maximum emission (black star) and the 
emission from endogenous species (red star) are highlighted. Scale bar = 20 µm. 
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Figure 6.5 Emission profiles of [Ir(ppy)2(TzPyNHC16cis)] (top) and 
[Ir(ppy)2(TzPyNHC18cis)] (bottom) incubated in live PNT2 cells (5 µM). The 
maximum emission (black star) and the emission from endogenous species (red star) 
are highlighted. Scale bar = 20 µm. 
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Figure 6.6 Emission profiles of [Ir(ppy)2(TzPyNH2)] (top) and [Ir(bzq)2(TzPyNH2)] 
(bottom) incubated in live PNT2 cells (5 µM). The maximum emission (black star) 
and the emission from endogenous species (red star) are highlighted. Scale bar = 20 
µm. 
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6.2.3 Cytotoxicity 
The cytotoxicity of the fatty acid-functionalised iridium(III) complexes toward PNT2 
cells has been evaluated via MTS assay, as described in section 6.4.5 of this chapter.  
Unfortunately, cytotoxicity data of [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] 
have not been evaluated due to time constraints. 
The cells were incubated for either 2 or 24 hours with concentration of the 
complexes at 20 or 40 µM. All the complexes exhibited low toxicity even at the longest 
incubation time and the highest concentration, with viability values ≥85% for 
[Ir(ppy)2(TzPyNHC8sat)] and [Ir(ppy)2(TzPyNHC18sat)], as depicted in Figure 6.7. 
Even greater cell survival rate was recorded for [Ir(ppy)2(TzPyNHC16sat)], 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC18cis)]. 
 
 
Figure 6.7 Cell viability after 2 and 24 h incubation with iridium complexes at 20 and 
40 µM. Saturated fatty acid chain-substituted iridium complexes are represented by 
blue bars, whereas unsaturated fatty acid chain-substituted iridium complexes are 
represented by green bars. 0) Control (2% DMSO in serum-free RPMI-1640 medium); 
1) [Ir(ppy)2(TzPyNHC8sat)]; 2) [Ir(ppy)2(TzPyNHC16sat)]; 3) 
[Ir(ppy)2(TzPyNHC18sat)]; 4) [Ir(ppy)2(TzPyNHC16cis)]; 5) 
[Ir(ppy)2(TzPyNHC18cis)].  
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Only few examples of metal complexes appended with fatty acid or simple 
alkyl chains have been investigated for biological applications. When reported, the 
cytotoxicity studies of related Ir(III), Re(I) and Ru(II) probes (Figure 6.8) showed 
moderate to high cytotoxicity in live cells. 298,418–423 In particular, the two iridium 
complexes bearing a long alkyl chain in their ancillary bipyridine ligand (115a-b) 
exhibit higher toxicity (IC50 = 12.0 and 2.0 µM, respectively) than cisplatin (IC50 = 
18.1 µM) in the same experimental conditions. Only the Pt(II) complex 113 exhibits 
low cytotoxicity against live HeLa cells with a viability of ca. 90% after 25 hours of 
incubation.422 
Based on these results, the low cytotoxicity of the fatty acid-functionalised 
iridium(III) probes makes them good building block for biological imaging 
application. 
 
 
Figure 6.8 Examples of previously reported probes functionalised with fatty acids or 
long alkyl chains.  
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6.2.4 Photostability 
Transition metal complexes for the application in biological imaging have frequently 
showed an improved photostability compared to conventional organic fluorophores, 
which is advantageous when continuous monitoring of biological processes is required 
or for real-time tracking applications.113,122,132,336,339 During these analyses, the probe 
is continuously irradiated and can undergo photodegradation or conversion in species 
with lower emissive properties. For this reason, the photostability of imaging agents is 
one of the major requirements, along with low cytotoxicity, high localisation 
specificity and good solubility in aqueous environment.1,65,384 
The photostability of amino and fatty acid-functionalised iridium(III) 
complexes has been assessed, as described in Chapter 3 – section 3.5.9. 
The iridium species have been dissolved in PBS solution (2% DMSO) and 
irradiated using a Pen-Ray Mercury Lamp source at 365 nm for 900 seconds. The 
variation in emission intensity has been recorded with a time frame of 30 seconds. 
Both the amino and fatty acid-appended complexes exhibit high resistance to 
photobleaching, as reported in Figure 6.9 and Figure 6.10. 
From the evaluation of the photostability in cuvette, [Ir(ppy)2(TzPyNHC8sat)], 
[Ir(ppy)2(TzPyNHC16sat)], [Ir(ppy)2(TzPyNHC18sat)], [Ir(ppy)2(TzPyNHC16cis)], 
[Ir(ppy)2(TzPyNHC18cis)] and [Ir(bzq)2(TzPyNH2)] display emission intensity above 
60% of the initial values after 900 seconds of continuous irradiation. 
[Ir(ppy)2(TzPyNH2)] exhibits greater photostability with respect to the other 
investigated complexes, with final emission intensity up to 75% the initial value. 
As previously mentioned, the photostability of neutral iridium complexes has 
not been explored in literature and thus the only possible comparison is with the cyano 
and (iso)quinolyl tetrazolato complexes described in Chapter 3 – section 3.2.5.238  
The photostability of [Ir(bzq)2(TzPyNH2)] and the fatty acid-functionalised probes is 
similar to the one measured for [Ir(F2ppy)2(TzPyCN)], with a final value of 55% 
(Chapter 3 – section 3.2.5 - Figure 3.10). On the other hand, the more photostable 
[Ir(ppy)2(TzPyNH2)] has showed higher resistance to photobleaching, comparable 
with [Ir(ppy)2(TzPyCN)] and [Ir(ppy)2(TzQn)] (Chapter 3 - Figure 3.10).  
The good photostability in cuvette of these series of probes indicates the need 
for further testing, in order to assess if this property can also be maintained in cellular 
environment.  
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Figure 6.9 Photobleaching analysis in PBS (2% DMSO) of [Ir(ppy)2(TzPyNH2)] 
(blue) and [Ir(bzq)2(TzPyNH2)] (red). 
 
 
Figure 6.10 Photobleaching analysis in PBS (2% DMSO) of [Ir(ppy)2(TzPyNHC8sat)] 
(black),  [Ir(ppy)2(TzPyNHC16sat)] (blue), [Ir(ppy)2(TzPyNHC18sat)] (red), 
[Ir(ppy)2(TzPyNHC16cis)] (green) and [Ir(ppy)2(TzPyNHC18cis)] (purple).  
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6.3 Conclusions 
In this chapter, a preliminary biological investigation of the fatty acid and amino-
functionalised iridium(III) probes in live PNT2 cell lines has been carried out. 
The evaluation of the lipophilicity of this family of compounds has been 
performed, highlighting higher values for the fatty acid-appended complexes in 
comparison to the precursor [Ir(ppy)2(TzPyNH2)]. Interestingly, regardless of the 
lipophilicity showed by these complexes, solubility issues in aqueous environment 
have been encountered for the whole series. For this reason, the staining protocol 
previously applied to the cyano and (iso)quinolyl-functionalised iridium(III) probes 
(Chapter 3 –section 3.5.4) has been modified. 
The majority of the probes has been internalised within PNT2 cells, 
accumulating in the perinuclear area, with a staining pattern resembling the 
endoplasmic reticulum. However co-localisation analysis will be required to confirm 
the accumulation of the probes in this organelle. [Ir(ppy)2(TzPyNHC16sat)] and 
[Ir(ppy)2(TzPyNHC18sat)] have showed low detectability within the cells, probably 
due to poor solubility, which decreases the uptake, and also low emission in aqueous 
media. 
Interestingly, internalisation tests varying the concentration of the probes have 
suggested different mechanism of uptake. In particular [Ir(ppy)2(TzPyNH2)] seems to 
be internalised through a potential passive diffusion mechanism, whereas 
[Ir(ppy)2(TzPyNHC8sat)] and [Ir(ppy)2(TzPyNHC16cis)] undergo a mediated 
transport. Finally, the cellular entry of [Ir(ppy)2(TzPyNHC18cis)] and 
[Ir(bzq)2(TzPyNH2)] at higher concentration is inhibited, possibly due to precipitation 
of the probes. 
The cytotoxicity assay showed good cellular viability (≥ 85%) at high 
concentration and long incubation time. Moreover, the length of the chains or the 
degree of unsaturation of the appended fatty acids does not affect the toxicity of the 
complexes. These derivatives, along with few Pt(II) species,421,422 are also ones of the 
few examples in literature of low toxic probes functionalised with fatty acids or long 
alkyl chains.  
Finally, high photostability in cuvette has been recorded for the whole series 
of iridium(III) complexes. 
  269 
Based on these results, upon minor modifications on the chemical structure to 
overcome the solubility issues, these series of probes can be used as scaffold for the 
synthesis of other fatty acids-functionalised analogues. In particular, as showed in 
previous works, the introduction of a PEG moieties could potentially increase the 
water-solubility of the complexes, without major effects on the localisation within the 
cells.429 
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6.4 Experimental 
6.4.1 Photophysical Measurements 
Photophysical measurements have been conducted as outlined in Chapter 2, section 
2.6.2, unless otherwise stated. 
 
6.4.2 Lipophilicity Analysis 
LogD7.4 values were determined by applying the shake-flask method developed by 
Kunz et al..308 The analysis has been described in detailed in Chapter 3, section 3.5.2.  
 
6.4.3 Cell Culture 
The biological investigation was performed in collaboration with Dr Christie A. Bader 
and Dr Alexandra Sorvina at the School of Pharmacy and Medical Sciences, 
University of South Australia. Normal epithelial prostatic cell line PNT2 were 
maintained in FBS-free (fetal bovine serum) RPMI-1640 culture medium (Sigma-
Aldrich, USA) at 37 ºC and 5% CO2. The PNT2 cells were cultured in 75 mm2 flasks. 
Cells that had been passaged for no more than 18 times, were used for experiments. 
For live cell imaging and MTS assay, the PNT2 cells were seeded at 1 × 105 cells/mL 
and cultured overnight in either ibidi µ-slide 8 wells in a final volume of 250 µL or 
96-well microtiter plate in a final volume of 200 µL. 
 
6.4.4 Cell Staining 
PNT2 cells were incubated with the iridium complexes at 5, 10, 20 and 40 µM in FBS-
free RPMI-1640 culture medium with 2% DMSO (Sigma-Aldrich, St. Louis, USA) 
for 20 minutes at 37 ºC and 5% CO2. The cells were washed twice with sterile 
phosphate-buffered saline solution (PBS; Sigma-Aldrich, St. Louis, USA), before 
imaging in RPMI-1640.  
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6.4.5 MTS Cell Viability Assay 
The cellular NADPH-dependent redox activity was measured using CellTiter 96® 
AQueous Non-Radioactive Cell Proliferation Assay (MTS), according to the 
manufacturer’s instruction (Promega, USA). The PNT2 cells were stained with the 
iridium complexes at either 20 µM or 40 µM in FBS-free RPMI-1640 culture medium 
with 2% DMSO, and held at 37 °C and 5% CO2 for 2 or 24 hours. As a control, PNT2 
cells were incubated for the same length of time in FBS-free RPMI-1640 with 2% 
DMSO. Following addition of MTS, the cells were incubated for a further 2 hours in 
the same conditions. The absorbance of the formazan dye was measured by EnVision 
multi-label plate reader at 490 nm. The data are reported as the mean ± SEM of three 
biological replicates for each group.  
 
6.4.6 Photobleaching Analysis 
The photobleaching analysis has been performed following the method in cuvette 
delineated in Chapter 3, section 3.5.9. 
 
6.4.7 Confocal Microscopy 
Single photon live cell imaging was performed using a Nikon A1+ confocal 
microscope (Nikon, Japan) with an OKOLab Microscope Incubator (Okolab USA Inc., 
USA). The iridium complexes were excited at 403 nm and the emission was collected 
in the 400 ˗ 750 nm region. Image analysis was measured using NIS elements V4.50 
software (Nikon, Japan). The final preparation of the images was conducted with 
Adobe Photoshop CC (Adobe Systems Inc., USA). 
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Chapter 7  
Conclusions and Future Work 
The research presented in this thesis was intended to explore the structure-activity 
relationship of a series of iridium tetrazolato complexes. Modifications on the 
chemical structure of both the cyclometalated and the tetrazolate ancillary ligands were 
systematically made in order to assess how the photophysical and biological properties 
of the complexes would be affected. 
This aim was dictated by the lack of literature regarding a methodical 
rationalisation between the chemical structure of complexes and their photophysical 
and biological behaviour, which would be extremely beneficial for the design of a new 
advanced generation of iridium probes for applications in life science. Moreover, due 
to their favourable emissive properties and easy tunability, iridium(III) tetrazolato 
complexes have been previously studied and applied in light emitting devices but their 
use in biological imaging was still unexplored. 
The first series of iridium(III) complexes (Figure 7.1) discussed in this 
thesis238 followed the interesting discovery of a rhenium tetrazolato complex with 
formula fac-[Re(CO)3(phen)(TzPhCN)], which represented the first metal probe to 
localise in lipid droplets.232,248 The functionalisation of the tetrazolate ligand with a 
nitrile group was then apply to the iridium(III) series in order to investigate the 
possibility of a similar internalisation within live cells. Small chemical modifications 
in the structure of the complexes were made in order to modulate emission maxima, 
lipophilicity and charge. In fact, to evaluate the role played by the charge, all the 
neutral complexes have been methylated to obtain the cationic analogues for a 
systematic comparison. Interestingly, only few examples of neutral iridium(III) probes 
have been reported in literature.82,103,109–112,120–122,125,128,133 Quinolyl (HTzQn) and 
isoquinolyl-tetrazolate (HTziQn) ligands were also studied in the place of the nitrile 
pyridyl-tetrazolato ligand (HTzPyCN), to evaluate the effect of the increased 
conjugation on the lipophilicity of the complexes. Photophysical measurements in 
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organic, lipophilica and aqueous media showed a solvatochromic emission of MLCT 
nature, with a red shift of the cationic species with respect to their neutral analogues. 
The internalisation within live H9c2 cells highlighted endoplasmic reticulum 
accumulation, in addition to the staining of lipid droplets, for the neutral complexes 
and [Ir(ppy)2(MeTzQn)]+, whereas the two charged probes [Ir(F-
2ppy)2(MeTzPyCN)]+ and [Ir(ppy)2(MeTzPyPhCN)]+ localised in mitochondria. 
Moreover, the cytotoxicity assay revealed high toxicity of the charged complexes in 
comparison to the neutral species, probably due to a combination of cellular uptake 
and intracellular localisation. In fact, the high cytotoxicity of iridium(III) complexes 
for the staining of mitochondrial is a common trend in previously reported 
publications.124,126,130,132,134–136 On the other hand, the neutral cyano and (iso)quinolyl-
functionalised iridium(III) probes represent the first example of non-toxic metal 
complexes for the staining of endoplasmic reticulum.238 
 
 
Figure 7.1 Structures of the investigated cyano (top) and (iso)quinolyl-functionalised 
iridium(III) complexes (bottom). 
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[Ir(ppy)2(MeTzPyPhCN)]+, which exhibits mitochondrial accumulation in live cells, 
was also tested in fresh and frozen tissues.283 Interestingly, the imaging of fixed tissue 
samples mostly relies on immunochemistry, which is time-consuming and can produce 
artefacts, due to fixation processes. Remarkably, [Ir(ppy)2(MeTzPyPhCN)]+ could 
accumulate within the mitochondria of both the fresh and fixed muscle tissues, 
suggesting an internalisation mechanism which is independent of mitochondrial 
membrane polarisation. 
In the second family of iridium complexes the nitrile group on the tetrazolato 
ligand was substituted with an amino group (Figure 7.2) for the investigation of 
protonation/deprotonation reactions. Variation on the cyclometalated ligands were 
achieved by replacing ppy with the more conjugated bzq. [Ir(ppy)2(TzPyNH2)] and 
[Ir(bzq)2(TzPyNH2)] showed lower emission properties in all the investigated 
solvents in comparison to the previously discussed family of complexes. Temperature-
dependent luminescent lifetime measurements highlighted the presence of a thermally 
available and dark 3MC excited state, which is responsible of the increase of non-
radiative decay pathways and hence the poor emission of these species. The NH2 group 
was also oxidised to a NO2 group, but the emission of [Ir(ppy)2(TzPyNO2)] was 
completely quenched even in oxygen-free dichloromethane solution. Nevertheless, the 
pH-sensing activity of [Ir(ppy)2(TzPyNH2)] and [Ir(bzq)2(TzPyNH2)] was tested in 
organic solution, showing decrease of the emission intensity and appearance of a 
shoulder at ca. 555 nm upon protonation for [Ir(ppy)2(TzPyNH2)]. On the other hand, 
probably due to the low solubility of [Ir(bzq)2(TzPyNH2)] in dichloromethane 
solution, the acid-base titration did not affect the emission profile of this species. The 
applicability as cellular pH-sensor of [Ir(ppy)2(TzPyNH2)] was evaluated by 
performing the titration in aqueous environment in a pH range of 4.8 – 7.5. 
Unfortunately, no changes were recorded, implying that the emission of the probes is 
not sensitive enough to small cellular pH variations. 
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Figure 7.2 Structures of the investigated amino-functionalised iridium(III) complexes. 
 
Finally, [Ir(ppy)2(TzPyNH2)] was reacted with different fatty acid chains to 
form the fatty acid-functionalised iridium(III) series (Figure 7.3). The photophysical 
properties of this family of complexes were not affected by the degree of unsaturation 
and the length of the aliphatic chains, resulting in a yellow-green emission and low 
quantum yield (Φaer < 1), as displayed by the starting material [Ir(ppy)2(TzPyNH2)]. 
Temperature-dependent luminescent lifetime measurement on 
[Ir(ppy)2(TzPyNHC16cis)] confirmed the presence of a low-lying 3MC excited state, 
which can be easily populated at room temperature, reducing the emission intensity of 
the probe. The emission in aqueous and lipophilic solvents was recorded, highlighting 
a solvatochromic red shift (ca. 10 – 15 nm) of the emission maxima upon increase of 
the medium polarity. Interestingly, the emission profiles of the unsaturated species 
[Ir(ppy)2(TzPyNHC16cis)] and [Ir(ppy)2(TzPyNHC16cis)] become broader, suggesting 
the smaller contribution of the 3LC excited state to the emission. 
A preliminary biological investigation for the amino and fatty acid-
functionalised iridium(III) complexes was performed using live PNT2 cells. As 
expected, upon addition of long hydrophobic chains, the lipophilicity of the fatty acid-
functionalised family was higher than the amino-functionalised complexes. Moreover, 
solubility issues in aqueous media were encountered for the whole series, requiring 
modifications in the protocol with respect to the one used for the previously discussed 
cyano and (iso)quinolyl-functionalised probes. All the complexes were internalised in 
live cells, showing different mechanisms of uptake, such as passive diffusion or 
mediated transport. [Ir(ppy)2(TzPyNHC16sat)] and [Ir(ppy)2(TzPyNHC18sat)] showed 
low detectability within the cells, probably due to a combination of low emissive 
properties in aqueous media and precipitation issues. The cytotoxicity analyses 
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showed cellular viability higher than 85% at 40 µM and 24 hour incubation time, 
which was independent of the length and unsaturation of the appended fatty acid 
chains. Interestingly, these fatty acid complexes represent a rare examples of non-toxic 
probes bearing long aliphatic chains, along with few Pt(II) species.421,422 
 
 
Figure 7.3 Structures of the investigated fatty acid-functionalised iridium(III) 
complexes. 
 
 The data presented in this thesis have showed the relationship between charge 
and cytotoxicity of the investigated iridium(III) complexes, highlighting the low 
toxicity of neutral species in comparison with their cationic analogues. Further 
research on neutral complexes for applications in biological imaging may be of 
interest, especially due to presence of only few examples of neutral complexes in the 
field. 82,103,109–112,120–122,125,128,133 In addition, the role of the positive charge may be 
further investigated by modifying the tetrazolate ligand with an aliphatic chain 
appended with a phosphonium moiety, in the proposed structures presented in Figure 
7.4. This study is currently undergoing in Massi’s research group. 
 The results in this thesis also suggest that further research efforts in the 
systematic study of the structure-activity relationship on iridium(III) complexes may 
be beneficial for the development of a superior generation of imaging and therapeutic 
agents. 
 The biological investigation of amino and fatty acid-functionalised iridium(III) 
probes needs to be completed. Co-localisation analyses with organic dyes may provide 
more evidence about the specific accumulation of the complexes within the cells. Another 
useful technique would be ICP-MS, which may determine the amount of complex present 
in the different organelles. 
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 Finally, further studies to enhance the poor solubility of the amino and fatty acid-
functionalised iridium(III) complexes may be of interested. In particular, the conjugation 
of these complexes with water-soluble moieties, such as PEG, may increase their solubility 
in aqueous media, without affecting their cytotoxicity and localisation within the cells. 
 
 
Figure 7.4 Proposed structures of iridium(III) complexes appended with a positively 
charged phosphonium moiety. 
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Appendix A 
Table A.1 Crystal data and structure refinement for [Ir(F2ppy)2(TzPyCN)].  
Identification code  [Ir(F2ppy)2(TzPyCN)] 
Empirical formula  C30.50H18Cl3F4IrN8 
Formula weight  871.08 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  I2/a 
Unit cell dimensions a = 19.3193(4) Å 
 b = 10.42280(10) Å 
 c = 31.7649(6) Å 
 β = 106.177(2)° 
Volume 6142.96(19) Å3 
Z 8 
Density (calculated) 1.884 Mg/m3 
 4.670 mm˗1 
Crystal size 0.30 x 0.19 x 0.055 mm3 
θ range for data collection 2.065 to 33.049°. 
Index ranges ˗25<=h<=28, ˗15<=k<=12, ˗47<=l<=46 
Reflections collected 38758 
Independent reflections 10992 [R(int) = 0.0507] 
Completeness to θ = 31.00° 100.0 %  
Absorption correction Semi˗empirical from equivalents 
Max./min. transmission 1.000/0.873 
Refinement method Full˗matrix least˗squares on F2 
Data / restraints / parameters 10992 / 672 / 598 
Goodness˗of˗fit on F2 1.038 
Final R indices [I>2σ(I)] R1 = 0.0421, wR2 = 0.0857 
R indices (all data) R1 = 0.0648, wR2 = 0.0948 
Largest diff. peak and hole 2.125 and ˗1.357 e.Å˗3 
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Table A.2 Selected Bond lengths [Å] and angles [°] for [Ir(F2ppy)2(TzPyCN)]. 
Ir(1)˗C(21)  2.000(4) 
Ir(1)˗N(11)  2.034(3) 
Ir(1)˗N(31)  2.042(3) 
Ir(1)˗C(41)  2.066(17) 
Ir(1)˗N(51)  2.107(3) 
Ir(1)˗N(61)  2.22(3) 
  
C(21)˗Ir(1)˗N(11) 80.51(14) 
C(21)˗Ir(1)˗N(31) 95.27(14) 
N(11)˗Ir(1)˗N(31) 172.93(12) 
C(21)˗Ir(1)˗C(41) 92.4(6) 
N(11)˗Ir(1)˗C(41) 97.7(5) 
N(31)˗Ir(1)˗C(41) 76.8(5) 
C(21)˗Ir(1)˗N(51) 96.84(13) 
N(11)˗Ir(1)˗N(51) 91.50(12) 
N(31)˗Ir(1)˗N(51) 94.65(12) 
C(41)˗Ir(1)˗N(51) 168.0(6) 
C(21)˗Ir(1)˗N(61) 173.4(7) 
N(11)˗Ir(1)˗N(61) 98.3(9) 
N(31)˗Ir(1)˗N(61) 86.5(9) 
C(41)˗Ir(1)˗N(61) 94.2(9) 
N(51)˗Ir(1)˗N(61) 76.7(7) 
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Table A.3 Crystal data and structure refinement for [Ir(ppy)2(MeTzPyPhCN)]+. 
Identification code  [Ir(ppy)2(MeTzPyPhCN)]+ 
Empirical formula  C37.38H28.75Cl2.75F6IrN8P 
Formula weight  1024.59 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P2/n 
Unit cell dimensions a = 22.1244(4) Å 
 b = 12.7352(2) Å 
 c = 30.7626(4) Å 
 β = 108.760(2)° 
Volume 8207.2(2) Å3 
Z 8 
Density (calculated) 1.658 Mg/m3 
 8.889 mm˗1 
Crystal size 0.250 x 0.151 x 0.029 mm3 
θ range for data collection 2.968 to 67.348°. 
Index ranges ˗19<=h<=26, ˗15<=k<=15, ˗36<=l<=35 
Reflections collected 51875 
Independent reflections 14634 [R(int) = 0.0509] 
Completeness to θ = 67.348° 99.2 %  
Absorption correction Analytical 
Max. and min. transmission 0.731 and 0.195 
Refinement method Full˗matrix least˗squares on F2 
Data / restraints / parameters 14634 / 197 / 1057 
Goodness˗of˗fit on F2 1.052 
Final R indices [I>2σ(I)] R1 = 0.0541, wR2 = 0.1480 
R indices (all data) R1 = 0.0717, wR2 = 0.1637 
Largest diff. peak and hole 1.581 and ˗1.016 e.Å˗3 
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Table A.4 Selected Bond lengths [Å] and angles [°] for [Ir(ppy)2(MeTzPyPhCN)]+. 
Ir(1)˗C(121)  1.994(6) 
Ir(1)˗C(141)  2.005(7) 
Ir(1)˗N(111)  2.022(7) 
Ir(1)˗N(131)  2.031(7) 
Ir(1)˗N(151)  2.147(6) 
Ir(1)˗N(161)  2.175(5) 
  
C(121)˗Ir(1)˗C(141) 90.3(3) 
C(121)˗Ir(1)˗N(111) 80.8(3) 
C(141)˗Ir(1)˗N(111) 95.0(3) 
C(121)˗Ir(1)˗N(131) 95.2(3) 
C(141)˗Ir(1)˗N(131) 81.1(3) 
N(111)˗Ir(1)˗N(131) 174.4(3) 
C(121)˗Ir(1)˗N(151) 99.8(2) 
C(141)˗Ir(1)˗N(151) 169.9(2) 
N(111)˗Ir(1)˗N(151) 87.1(3) 
N(131)˗Ir(1)˗N(151) 97.5(2) 
C(121)˗Ir(1)˗N(161) 175.1(2) 
C(141)˗Ir(1)˗N(161) 94.6(2) 
N(111)˗Ir(1)˗N(161) 98.3(2) 
N(131)˗Ir(1)˗N(161) 86.0(2) 
N(151)˗Ir(1)˗N(161) 75.4(2) 
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Table A.5 Calculated low energy transitions for [Ir(ppy)2(TzQn)]. 
Wavelength Intensity Levels Character 
405.42 nm 0.0806 HOMO → LUMO+1 96.7% 
379.99 nm 0.0366 HOMO˗1 → LUMO 91.9% 
359.83 nm 0.0879 HOMO˗3 → LUMO 
HOMO˗2 → LUMO 
51.5% 
40.4% 
351.48 nm 0.0335 HOMO˗3 → LUMO 
HOMO˗2 → LUMO  
42.0% 
53.3% 
343.21 nm 0.0270 HOMO˗1 → LUMO+1 85.8% 
341.68 nm 0.0390 HOMO → LUMO+3 89.2% 
328.98 nm 0.0665 HOMO˗1 → LUMO+2 
HOMO → LUMO+5 
51.5% 
18.1% 
327.97 nm 0.0275 HOMO˗3 → LUMO+1 
HOMO˗2 → LUMO+1 
HOMO → LUMO+5 
19.4% 
12.1% 
60.3% 
326.62 nm 0.0416 HOMO˗4 → LUMO 94.1% 
322.77 nm 0.0443 HOMO˗2 → LUMO+1 
HOMO˗1 → LUMO+2 
HOMO → LUMO+5 
44.9% 
25.8% 
12.4% 
321.34 nm 0.0333 HOMO˗3 → LUMO+2 
HOMO˗2 → LUMO+2 
51.6% 
29.5% 
316.56 nm 0.0152 HOMO˗5 → LUMO 
HOMO˗3 → LUMO+1 
HOMO˗2 → LUMO+1 
15.8% 
45.0% 
13.5% 
314.95 nm 0.1188 HOMO˗6 → LUMO 
HOMO˗5 → LUMO 
26.5% 
45.0% 
312.65 nm 0.1398 HOMO˗6 → LUMO 
HOMO˗5 → LUMO 
HOMO˗2 → LUMO+2 
47.6% 
24.9% 
11.3% 
311.27 nm 0.2456 HOMO˗6 → LUMO 
HOMO˗3 → LUMO+2 
HOMO˗2 → LUMO+2 
10.1% 
28.4% 
44.0% 
304.99 nm 0.0513 HOMO˗7 → LUMO 80.4% 
297.72 nm 0.0689 HOMO˗4 → LUMO+1 62.5% 
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Table A.6 Calculated low energy transitions for [Ir(ppy)2(TziQn)]. 
Wavelength Intensity Levels Character 
408.40 nm 0.0896 HOMO → LUMO+1 96.8% 
384.25 nm 0.0453 HOMO˗1 → LUMO 90.8% 
364.16 nm 0.1632 HOMO˗3 → LUMO 
HOMO˗2 → LUMO 
22.9% 
65.9% 
335.49 nm 0.1799 HOMO˗5 → LUMO 
HOMO˗4 → LUMO  
13.3% 
74.7% 
328.51 nm 0.0879 HOMO˗3 → LUMO+1 
HOMO˗2 → LUMO+1 
HOMO˗1 → LUMO+1 
12.4% 
29.9% 
42.6% 
322.39 nm 0.0583 HOMO˗3 → LUMO+2 
HOMO˗2 → LUMO+2 
HOMO˗1 → LUMO+2 
25.9% 
39.8% 
19.4% 
321.40 nm 0.0410 HOMO˗2 → LUMO+1 
HOMO˗2 → LUMO+2 
HOMO˗1 → LUMO+2 
45.3% 
17.1% 
15.2% 
311.83 nm 0.0526 HOMO˗3 → LUMO+1 
HOMO˗2 → LUMO+1 
HOMO˗1 → LUMO+2 
73.2% 
7.3% 
4.0% 
307.34 nm 0.1940 HOMO˗3 → LUMO+2 
HOMO˗2 → LUMO+2 
HOMO˗1 → LUMO+2 
HOMO˗1 → LUMO+3 
58.7% 
28.1% 
2.0% 
4.0% 
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Figure A.1 Absorption profiles of [Ir(ppy)2(TzPyCN)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure A.2 Absorption profiles of [Ir(ppy)2(TzPyPhCN)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure A.3 Absorption profiles of [Ir(ppy)2(MeTzPyCN)]+ in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
 
Figure A.4 Absorption profiles of [Ir(ppy)2(MeTzPyPhCN)]+ in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure A.5 Absorption profiles of [Ir(ppy)2(TzQn)] in dichloromethane (black), H2O 
(blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure A.6 Absorption profiles of [Ir(ppy)2(MeTzQn)]+ in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure A.7 Emission profiles of [Ir(ppy)2(TzPyCN)] in dichloromethane (black), H2O 
(blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
 
Figure A.8 Emission profiles of [Ir(ppy)2(TzPyPhCN)] in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure A.9 Emission profiles of [Ir(ppy)2(MeTzPyPhCN)]+ in dichloromethane 
(black), H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
 
 
Figure A.10 Emission profiles of [Ir(ppy)2(TzQn)] in dichloromethane (black), H2O 
(blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Figure A.11 Emission profiles of [Ir(ppy)2(MeTzQn)]+ in dichloromethane (black), 
H2O (blue), lys. fluid (red), PBS (green) and ethyl laurate (orange). 
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Appendix B 
 
 
Figure B.1 (Top) Representative lambda stack micrographs of live H9c2 cells using 
META detection module, sampling emission over the visible spectrum with 38.9 nm 
wavelength intervals. The complexes were excited with two-photon laser. Scale bar = 
15 µm. (Bottom) Two-photon microscopy image (lex = 830 nm) of live H9c2 cells 
stained with [Ir(ppy)2(TzPyCN)] (20 µM, 30 mins). Scale bar = 30 µm. 
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Figure B.2 (Top) Representative lambda stack micrographs of live H9c2 cells using 
META detection module, sampling emission over the visible spectrum with 38.9 nm 
wavelength intervals. The complexes were excited with two-photon laser. Scale bar = 
15 µm. (Bottom) Two-photon microscopy images (lex = 830 nm) of live H9c2 cells 
stained with [Ir(F2ppy)2(TzPyCN)] (left) and [Ir(F2ppy)2(MeTzPyCN)]+ (right) (20 
µM, 30 mins). Scale bar = 30 µm. 
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Figure B.3 (Top) Representative lambda stack micrographs of live H9c2 cells using 
META detection module, sampling emission over the visible spectrum with 38.9 nm 
wavelength intervals. The complexes were excited with two-photon laser. Scale bar = 
15 µm. (Bottom) Two-photon microscopy images (lex = 820 nm) of live H9c2 cells 
stained with [Ir(ppy)2(TzPyPhCN)] (left) and [Ir(ppy)2(MeTzPyPhCN)]+ (right) (20 
µM, 30 mins). Scale bar = 30 µm. 
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Figure B.4 (Top) Representative lambda stack micrographs of live H9c2 cells using 
META detection module, sampling emission over the visible spectrum with 38.9 nm 
wavelength intervals. The complexes were excited with two-photon laser. Scale bar = 
15 µm. (Bottom) Two-photon microscopy images (lex = 830 nm) of live H9c2 cells 
stained with [Ir(ppy)2(TzQn)] (left) and [Ir(ppy)2(MeTzQn)]+ (right) (20 µM, 30 
mins). Scale bar = 30 µm. 
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Figure B.5 (Top) Representative lambda stack micrographs of live H9c2 cells using 
META detection module, sampling emission over the visible spectrum with 38.9 nm 
wavelength intervals. The complexes were excited with two-photon laser. Scale bar = 
15 µm. (Bottom) Two-photon microscopy images (lex = 810 nm) of live H9c2 cells 
stained with [Ir(ppy)2(TziQn)] (left) and [Ir(F2ppy)2(MeTziQn)]+ (right) (20 µM, 30 
mins). Scale bar = 30 µm.
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Appendix C 
 
 
Figure C.1 Normalised emission profile of [Ir(ppy)2(TzPyNH2)] in ethyl laurate at 
different concentration: 10-4 M (black), 10-5 M (blue), 10-6 M (red) and 10-7 M (green). 
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Figure C.2 Emission profile of [Ir(ppy)2(TzPyNH2)] in ethyl laurate at different 
concentration: 10-4 M (black), 10-5 M (blue), 10-6 M (red) and 10-7 M (green). 
  
400 500 600 700 800
Wavelength (nm)
0
2
4
6
8
10
12
14
16
18
Em
iss
ion
 In
te
ns
ity
 (1
04
 cp
s)
 320
Table C.1 Excited state lifetimes of [Ir(ppy)2(TzPyNH2)] in diluted (10-4 M) ethyl 
laurate solution, measured at different maxima emission wavelengths. 
λem 
[nm]a 
τ 
[ns]b 
484 17 (63), 89 (37) 
555 41 (32), 258 (68) 
a Maximum emission wavelength (λem) at which the excited state lifetime (τ) was 
measured. b For the biexponential excited state lifetime (τ), the relative weights of the 
exponential curves are reported in parentheses. 
 
 
 
 
 
 
Figure C.3 Excited state lifetime profiles of [Ir(ppy)2(TzPyNH2)] in ethyl laurate, 
measured at λem = 484 nm (blue) and λem = 555 nm (red). 
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Figure C.4 Normalised excitation profile of [Ir(bzq)2(TzPyNH2)] in ethyl laurate at 
different concentration: 10-4 M at λemi = 606 nm (black), 10-4 M at λemi = 646 nm (grey), 
10-5 M (blue), 10-6 M (red) and 10-7 M (green). 
 
 
Figure C.5 Excitation profile of [Ir(bzq)2(TzPyNH2)] in ethyl laurate at different 
concentration: 10-4 M at λemi = 606 nm (black), 10-4 M at λemi = 646 nm (grey), 10-5 M 
(blue), 10-6 M (red) and 10-7 M (green). 
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Figure C.6 Emission profile of [Ir(bzq)2(TzPyNH2)] in ethyl laurate at different 
concentration: 10-4 M (black), 10-5 M (blue), 10-6 M (red) and 10-7 M (green). 
 
Table C.2 Excited state lifetimes of [Ir(bzq)2(TzPyNH2)] in diluted (10-4 M) ethyl 
laurate solution, measured at different maxima emission wavelengths. 
λem 
[nm]a 
τ 
[ns]b 
606 83 
646 169 
a Maximum emission wavelength (λem) at which the excited state lifetime (τ) was 
measured. 
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